
<html lang="en"     class="pb-page"  data-request-id="b7609b72-3603-44c5-b533-af812edef149"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2017.60.issue-19;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.7b00745"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine" /></meta><meta name="dc.Creator" content="Niklas M.  Walter" /></meta><meta name="dc.Creator" content="Heike K.  Wentsch" /></meta><meta name="dc.Creator" content="Mike  Bührmann" /></meta><meta name="dc.Creator" content="Silke M.  Bauer" /></meta><meta name="dc.Creator" content="Eva  Döring" /></meta><meta name="dc.Creator" content="Svenja  Mayer-Wrangowski" /></meta><meta name="dc.Creator" content="Adrian  Sievers-Engler" /></meta><meta name="dc.Creator" content="Nicole  Willemsen-Seegers" /></meta><meta name="dc.Creator" content="Guido  Zaman" /></meta><meta name="dc.Creator" content="Rogier  Buijsman" /></meta><meta name="dc.Creator" content="Michael  Lämmerhofer" /></meta><meta name="dc.Creator" content="Daniel  Rauh" /></meta><meta name="dc.Creator" content="Stefan A.  Laufer" /></meta><meta name="dc.Description" content="We recently reported 1a (skepinone-L) as a type I p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo. However, as a type I inhibitor, it is entirely ATP-comp..." /></meta><meta name="Description" content="We recently reported 1a (skepinone-L) as a type I p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo. However, as a type I inhibitor, it is entirely ATP-comp..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="September 7, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.7b00745" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00745" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.7b00745" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.7b00745" /></link>
        
    
    

<title>Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.7b00745" /></meta><meta property="og:title" content="Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0024.jpeg" /></meta><meta property="og:description" content="We recently reported 1a (skepinone-L) as a type I p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo. However, as a type I inhibitor, it is entirely ATP-competitive and shows just a moderate residence time. Thus, the scope was to develop a new class of advanced compounds maintaining the structural binding features of skepinone-L scaffold like inducing a glycine flip at the hinge region and occupying both hydrophobic regions I and II. Extending this scaffold with suitable residues resulted in an interference with the kinase’s R-Spine. By synthesizing 69 compounds, we could significantly prolong the target residence time with one example to 3663 s, along with an excellent selectivity score of 0.006 and an outstanding potency of 1.0 nM. This new binding mode was validated by cocrystallization, showing all binding interactions typifying type I1/2 binding. Moreover, microsomal studies showed convenient metabolic stability of the most potent, herein reported representatives." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.7b00745"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.7b00745">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.7b00745&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.7b00745&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.7b00745&amp;href=/doi/10.1021/acs.jmedchem.7b00745" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 19</span><span class="cit-fg-pageRange">, 8027-8054</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/19" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.7b00631" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.7b00780" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Biological Evaluation of Novel Type I<sup>1</sup>/<sub>2</sub> p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Niklas+M.++Walter">Niklas M. Walter</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Heike+K.++Wentsch">Heike K. Wentsch</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mike++B%C3%BChrmann">Mike Bührmann</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol "><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Silke+M.++Bauer">Silke M. Bauer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Eva++D%C3%B6ring">Eva Döring</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Svenja++Mayer-Wrangowski">Svenja Mayer-Wrangowski</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Adrian++Sievers-Engler">Adrian Sievers-Engler</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicole++Willemsen-Seegers">Nicole Willemsen-Seegers</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Guido++Zaman">Guido Zaman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rogier++Buijsman">Rogier Buijsman</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++L%C3%A4mmerhofer">Michael Lämmerhofer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Rauh">Daniel Rauh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0002-1970-7642" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Stefan+A.++Laufer">Stefan A. Laufer</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-6952-1486" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard-Karls-Universitaet Tuebingen, Auf der Morgenstelle 8, 72076 Tuebingen, Germany</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Faculty of Chemistry and Chemical Biology, Technische Universitaet Dortmund, Otto-Hahn-Strasse 4a, 44227 Dortmund, Germany</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">Netherlands Translational Research Center B.V. (NTRC), Pivot Park, RE1210, Molenstraat 110, 5342 CC Oss, The Netherlands</span></div><div class="corresp-info"><strong>*</strong>Phone: +49 7071 2972459. E-mail: <a href="/cdn-cgi/l/email-protection#07747362616669296b66726162754772696e2a737262656e69606269296362"><span class="__cf_email__" data-cfemail="3340475655525d1d5f524655564173465d5a1e474656515a5d54565d1d5756">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00745&amp;href=/doi/10.1021%2Facs.jmedchem.7b00745" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 19</span><span class="cit-pageRange">, 8027–8054</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 23, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>19 May 2017</li><li><span class="item_label"><b>Published</b> online</span>7 September 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 October 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.7b00745" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00745</a></div><div class="article_header-article-copyright"><strong>Copyright © 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D8027%26pageCount%3D28%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DNiklas%2BM.%2BWalter%252C%2BHeike%2BK.%2BWentsch%252C%2BMike%2BB%25C3%25BChrmann%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D19%26contentID%3Dacs.jmedchem.7b00745%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BNovel%2BType%2BI1%252F2%2Bp38%25CE%25B1%2BMAP%2BKinase%2BInhibitors%2Bwith%2BExcellent%2BSelectivity%252C%2BHigh%2BPotency%252C%2Band%2BProlonged%2BTarget%2BResidence%2BTime%2Bby%2BInterfering%2Bwith%2Bthe%2BR-Spine%26numPages%3D28%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D8054%26publicationDate%3DOctober%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.7b00745"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2398</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">15</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.7b00745" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Niklas&quot;,&quot;last_name&quot;:&quot;M. Walter&quot;},{&quot;first_name&quot;:&quot;Heike&quot;,&quot;last_name&quot;:&quot;K. Wentsch&quot;},{&quot;first_name&quot;:&quot;Mike&quot;,&quot;last_name&quot;:&quot;Bührmann&quot;},{&quot;first_name&quot;:&quot;Silke&quot;,&quot;last_name&quot;:&quot;M. Bauer&quot;},{&quot;first_name&quot;:&quot;Eva&quot;,&quot;last_name&quot;:&quot;Döring&quot;},{&quot;first_name&quot;:&quot;Svenja&quot;,&quot;last_name&quot;:&quot;Mayer-Wrangowski&quot;},{&quot;first_name&quot;:&quot;Adrian&quot;,&quot;last_name&quot;:&quot;Sievers-Engler&quot;},{&quot;first_name&quot;:&quot;Nicole&quot;,&quot;last_name&quot;:&quot;Willemsen-Seegers&quot;},{&quot;first_name&quot;:&quot;Guido&quot;,&quot;last_name&quot;:&quot;Zaman&quot;},{&quot;first_name&quot;:&quot;Rogier&quot;,&quot;last_name&quot;:&quot;Buijsman&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Lämmerhofer&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Rauh&quot;},{&quot;first_name&quot;:&quot;Stefan&quot;,&quot;last_name&quot;:&quot;A. Laufer&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;09&quot;,&quot;day&quot;:&quot;07&quot;,&quot;issue&quot;:&quot;19&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;8027-8054&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.7b00745&quot;},&quot;abstract&quot;:&quot;We recently reported 1a (skepinone-L) as a type I p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo. However, as a type I inhibitor, it is entirely ATP-competitive and shows just a moderate residence time. Thus, the scope was to develop a new class of advanced compounds maintaining the structural binding features of skepinone-L scaffold like inducing a glycine flip at the hinge region and occupying both hydrophobic regions I and II. Extending this scaffold with suitable residues resulted in an interference with the kinase’s R-Spine. By synthesizing 69 compounds, we could significantly prolong the target residence time with one example to 3663 s, along with an excellent selectivity score of 0.006 and an outstanding potency of 1.0 nM. This new binding mode was validated by cocrystallization, showing all binding interactions typifying type I1/2 binding. Moreover, microsomal studies showed convenient metabolic stability of the most potent, herein reported representatives.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00745&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00745" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00745&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00745" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.7b00745&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00745" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.7b00745&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.7b00745&amp;href=/doi/10.1021/acs.jmedchem.7b00745" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.7b00745" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.7b00745" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.7b00745%26sid%3Dliteratum%253Aachs%26pmid%3D28834431%26genre%3Darticle%26aulast%3DWalter%26date%3D2017%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BNovel%2BType%2BI1%252F2%2Bp38%25CE%25B1%2BMAP%2BKinase%2BInhibitors%2Bwith%2BExcellent%2BSelectivity%252C%2BHigh%2BPotency%252C%2Band%2BProlonged%2BTarget%2BResidence%2BTime%2Bby%2BInterfering%2Bwith%2Bthe%2BR-Spine%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D19%26spage%3D8027%26epage%3D8054%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291011" title="High-performance liquid chromatography">High-performance liquid chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291594" title="Silica">Silica</a>,</li><li><a href="/action/doSearch?ConceptID=292234" title="Chromatography">Chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/19" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/jmcmar.2017.60.issue-19/20171012/jmcmar.2017.60.issue-19.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0024.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00745&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We recently reported <b>1a</b> (skepinone-L) as a type I p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo. However, as a type I inhibitor, it is entirely ATP-competitive and shows just a moderate residence time. Thus, the scope was to develop a new class of advanced compounds maintaining the structural binding features of skepinone-L scaffold like inducing a glycine flip at the hinge region and occupying both hydrophobic regions I and II. Extending this scaffold with suitable residues resulted in an interference with the kinase’s R-Spine. By synthesizing 69 compounds, we could significantly prolong the target residence time with one example to 3663 s, along with an excellent selectivity score of 0.006 and an outstanding potency of 1.0 nM. This new binding mode was validated by cocrystallization, showing all binding interactions typifying type I<sup>1</sup>/<sub>2</sub> binding. Moreover, microsomal studies showed convenient metabolic stability of the most potent, herein reported representatives.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11147" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11147" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Since the first protein kinase inhibitor imatinib<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> was launched in 2002, protein kinases have increasingly attracted attention in drug research and discovery. 518 human genes encoding for protein kinases have been discovered by now,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> and approximately 180 protein kinases are directly associated with human diseases.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> By transferring a phosphoryl group from ATP to their molecular target, protein kinases control essential physiological processes such as regulation of signal transduction cascades. Therefore, kinases play an important role in the generation of inflammations, cancer, autoinflammatory afflictions, and neurodegenerative diseases.<a onclick="showRef(event, 'ref4 ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref6 ref7">(4-7)</a> The p38α mitogen-activated protein (MAP) kinase plays a key role in regulating the biosynthesis of proinflammatory cytokines like interleukin 1β, tumor necrosis factor α (TNFα), and the oncogenic activating transcription factor 2 (ATF-2),<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> which are capable of inducing severe diseases.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Thus, p38α has emerged as an important target in medicinal chemistry and pharmaceutical research. A well-established therapeutic approach to address directly kinase-related diseases is based on the inhibition of dysfunctioning or misregulated kinases with small molecule inhibitors.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Currently, about 32 protein kinase inhibitors have been approved by the FDA.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> However, no inhibitor of the p38α MAP kinase has been accepted for market introduction. This has several reasons, e.g., organ toxicity<a onclick="showRef(event, 'ref4 ref12 ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref4 ref12 ref13 ref14">(4, 12-14)</a> and insufficient or the drug candidates’ complete loss of efficacy in vivo.<a onclick="showRef(event, 'ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16">(14-16)</a> Generally, these inhibitors target the kinase ATP-binding cleft which is located between the C-terminal and an N-terminal subdomain, connected by the so-called hinge region.</div><div class="NLM_p">Protein kinase inhibitors can be divided into different classes with regard to the adopted binding mode within the active site and the addressed conformational state of the enzyme (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). This categorization is connected to their corresponding selectivity profile, potency range, and binding kinetics.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Important hallmarks for noncovalent kinase inhibitor assignment are the occupied areas within the active site as well as the DFG motif and the α-helix C orientation.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Comparison of type I, type II, and type III kinase inhibitors based on representative cocrystal structures in complex with corresponding p38α MAP kinase inhibitors. (A) <b>1a</b> (white, type I) addressing the kinase’s active DFG-“in between” conformation, occupying the adenine binding site (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QUE">3QUE</a>). (B) <b>13b</b> (yellow, type II) bound to the kinase’s inactive DFG-out conformation, occupying both the adenine binding site and the deep pocket (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV2">1KV2</a>). (C) <b>13c</b> (green, type III) addressing the kinase’s inactive DFG-out conformation, occupying the deep pocket (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HV7">3HV7</a>). Hydrogen bonds are shown as yellow dots.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00745&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Type I inhibitors represent the majority of kinase inhibitors. They typically bind to the ATP pocket, forming polar interactions with the hinge region by mimicking the cosubstrate adenine structure, thereby being strictly ATP-competitive. Following the described binding mode, these ligands are able to interact with the hinge-flanking hydrophobic region I and/or region II (HRI and HRII) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>A).<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Commonly, type I inhibitors address the kinases’ DFG-in conformation which is defined by a rotation of the corresponding Phe169 side chain toward the α-helix C, opening up the ATP-binding cleft. However, this behavior is not clearly observed for one of the most prominent examples for p38α MAP kinase type I inhibitors, 4-(4-(4-fluorophenyl)-2-(4-(methylsulfinyl)phenyl)-1<i>H</i>-imidazol-5-yl)pyridine <b>13a</b> (SB203580<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a>), which rather depicts a DFG-“in between” orientation of the corresponding motif. Type I inhibition generally enables high potency but at the same time intrinsically implicates shortcomings in selectivity due to the highly conserved nature of the active site within the kinase family. To overcome these drawbacks, novel classes of kinase inhibitors arose making use of structurally unique elements of specific kinases. The success of imatinib as a type II inhibitor stimulated the research toward type II binders targeting p38α MAP kinase. 1-(3-(<i>tert</i>-Butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)-3-(4-(2-morpholinoethoxy)naphthalen-1-yl)urea <b>13b</b> (BIRB 769<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a>) is a potent representative that emerged from these efforts and reached phase IIa in clinical studies. Type II inhibitors can be seen as extended type I inhibitors binding to the hinge region and HRI/HRII and beyond that additionally extending to the less conserved so-called deep pocket (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>B). This cavity opens up as a consequence of Phe169 rotation away from the α-helix C, defining the inactive DFG-out conformation. For the p38α type II inhibitor <b>13b</b>, it has been shown that the formation of polar interactions within the deep pocket results in an increased target residence time (TRT) at the enzyme combined with very good potency.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> However, <b>13b</b> shows poor selectivity over other kinases and failed in clinical trials.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22, 23)</a> In contrast, type III inhibitors represent a completely different binding mode than type I and type II inhibitors, as they do not form any hydrogen bonds to the hinge region and thus act entirely ATP-independently. The selectivity of type III inhibitors is comparably high because they address binding sites that are uniquely associated with particular kinases.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> This is typically achieved by targeting allosteric sites in contrast to the ATP binding pocket, particularly the deep pocket (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>C). Hence, as described for <b>13b</b> fragments like 1-(3-(<i>tert</i>-butyl)-1-(<i>p</i>-tolyl)-1<i>H</i>-pyrazol-5-yl)-3-(naphthalen-1-yl)urea <b>13c</b> (RL38<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a>), DFG-out conformation is required for the ligands to access the deep pocket in p38α. The discovery of type III inhibitors is yet quite coincidental as detailed knowledge about the three-dimensional structure of a kinase is required for a target-oriented design.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a></div><div class="NLM_p">Concerning the importance of p38α MAP kinase, our group first started its work on selective p38α inhibition based on the improvement of substituted isoxazoles<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and diarylpurinones<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> as well as the development of dibenzepinones toward a novel class of p38α MAP kinase inhibitors.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> These efforts resulted in the discovery of (<i>R</i>)-2-((2,4-difluorophenyl)amino)-7-(2,3-dihydroxypropoxy)-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulen-5-one <b>1a</b> (skepinone-L<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a>) as an exceptionally potent type I inhibitor and a selective high quality probe for p38α MAP kinase. The excellent selectivity of <b>1a</b> is achieved by inducing a glycine flip at the hinge region and addressing both HRI and HRII (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>A). The glycine flip in p38α is described by a 180° rotation of Gly110, induced upon binding of specific inhibitors only.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> However, this compound is still a fully ATP-competitive type I binder, consequently prompting us to undertake optimization studies, regarding the combination of the favorable properties of <b>1a</b>-type templates with features of type II inhibitors, characterized by being nearly ATP-independent due to long TRTs as shown by <b>13b</b>.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> These attempts resulted in the development of a novel class of p38α inhibitors recently described by Fischer et al.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and Baur et al.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> Analysis of the accordingly published cocrystal structure of compound (<i>R</i>)-<i>N</i>-(5-((7-(2,3-dihydroxypropoxy)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulen-2-yl)amino)-2-fluorophenyl)benzamide <b>1b</b><a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> surprisingly revealed a binding mode not entirely following the typical features of DFG-out type II binders as we initially assumed (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Assembly of the R-Spine. Crystal structures of p38α MAP kinase in complex with (A) compound <b>1b</b> targeting the active DFG-in conformation with assembled R-Spine (green) and (B) <b>13b</b> addressing the inactive DFG-out conformation with nonassembled R-Spine (white and red surfaces) (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV2">1KV2</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UVQ">3UVQ</a>). Hydrogen bonds are shown as yellow dots; regions relevant for inhibitor binding are highlighted in the background: HRII (beige), HRI (brown), deep pocket (red).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00745&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The reported inhibitor <b>1b</b> forms hydrogen-bond-mediated contact to the hinge region and induces a glycine flip; the fluorophenyl moiety occupies HRI, while the polar diol moiety targets HRII and displaces water.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Certainly, the more important interactions are represented by two hydrogen bonds formed between the amide linker of <b>1b</b> and Glu71 located at the α-helix C and Asp168 of the DFG-motif, respectively. In contrast to our initial design approach of incorporating structural features inspired by type II inhibitors, <b>1b</b> stabilizes the active DFG-in conformation of the kinase by forming an edge-to-face Ar–Ar interaction between the terminal benzamide moiety and Phe169. Of particular note is that the inhibitor binds to the kinase in DFG-in conformation while showing almost no loss in potency in the presence of increasing concentrations of competing ATP, indicating a particularly high affinity toward the enzyme.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Thus, the ligand is apparently not able to reach into the deep pocket of the kinase and is consequently not inducing the DFG-out conformation. Surface plasmon resonance (SPR) measurements revealed a contrasting kinetic profile to <b>13b</b> (<b>1b</b>, <i>k</i><sub>on</sub> [M<sup>–1</sup> s<sup>–1</sup>] of 1.10 × 10<sup>6</sup>; <i>k</i><sub>off</sub> [s<sup>–1</sup>] of 1.29 × 10<sup>–2</sup>; <b>13b</b>, <i>k</i><sub>on</sub> [M<sup>–1</sup> s<sup>–1</sup>] of 4.30 × 10<sup>3</sup>; <i>k</i><sub>off</sub> [s<sup>–1</sup>] of 5.16 × 10<sup>–5</sup>), demonstrating further differences to type II inhibitors. Moreover, <b>1b</b> was shown to be less ATP-competitive than <b>13a</b>,<a onclick="showRef(event, 'ref31 ref33'); return false;" href="javascript:void(0);" class="ref ref31 ref33">(31, 33)</a> underlining that <b>1b</b> is not related to either type I or type II inhibitors. The combination of type I and type II features is coined the definition of type I<sup>1</sup>/<sub>2</sub> inhibition.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> This binding type was discovered and termed in 2010 and is characterized by a unique combination of interactions formed within a kinase active site representing a promising approach to overcome the limitations related to the highly flexible mechanism of kinase inhibition.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Among others, possible shortcomings of current kinase inhibitors revolve around a missing selectivity over the humane kinome causing cross-reactiveness and poor binding kinetics expressed in a comparably short TRT at the enzyme. The prolongation of the TRT has several advantages as it can help to overcome selectivity deficiencies, increase compound efficacy in vitro and in vivo, and reduce undesired side effects.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35, 36)</a> It also contributes to sustain the pharmacodynamic effects of the inhibitor after its clearance from the bloodstream.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Furthermore, a particularly long TRT can also be assigned to a decreased ATP-competition, as it binds tighter to the target, exemplified by (pseudo)irreversible binding of kinase inhibitors.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><div class="NLM_p">One way to effectively prolong TRT of ligands at a protein, besides utilizing structurally unique regions and binding sites for selective targeting, is provided by the conformational stabilization of substructures within the enzyme.<a onclick="showRef(event, 'ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref39 ref40">(39, 40)</a> As observed for compound <b>1b</b>, type I<sup>1</sup>/<sub>2</sub> inhibitors are able to reach toward the DFG motif and stabilize a certain conformational activity state of a kinase.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> In addition, Phe169 of the DFG motif serves as a member of a hydrophobic backbone spine too. Two of those spines were recently discovered in kinases, labeled as the regulatory spine (R-Spine) and the catalytic spine (C-spine).<a onclick="showRef(event, 'ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref41 ref42 ref43">(41-43)</a> The R-Spine is assembled by four highly conserved lipophilic amino acids, A1–A4, originating from crucial regions of the kinase and is a signature of every kinase.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> In the case of p38α, A1 refers to His148 of the HRD-motif, A2 represents Phe169 of the DFG-motif, and A3 and A4 are two leucines from α-helix C and β4-strand.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> When the kinase is activated upon diphosphorylation of Thr180 and Tyr182 by MAPKK3/6, the change of charge triggers a chain reaction: Phe169 flips by 180° from DFG-out to DFG-in conformation, thereby leading to an assembly of the R-Spine (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A). To substantiate the importance of the R-Spine, Bukhtiyarova et al. showed that a mutation of Phe169 in p38α MAP kinase caused a nearly complete loss of catalytic function.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> We hypothesized that skepinone-derived type I<sup>1</sup>/<sub>2</sub> inhibitors as exemplified by the dibenzosuberone compound <b>1b</b> could putatively serve to gain selectivity via stabilization of the assembled R-Spine. This is caused by the observed interaction with Phe169 in DFG-in state, supposedly leading to an increased TRT at the kinase and higher affinity due to the additional interaction.</div><div class="NLM_p">Here, we present the structure-based design and chemical synthesis of a focused library of dibenzepinones, following up on the previously reported <b>1a</b>-derived p38α MAP kinase type I<sup>1</sup>/<sub>2</sub> inhibitor <b>1b</b>.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Biochemical evaluation was conducted by means of direct activity-based assays on the isolated kinase domain as well as using a whole blood TNFα release test system. Selected compounds that arose from these measurements were further characterized as representatives for type I<sup>1</sup>/<sub>2</sub> inhibitors regarding TRT and binding mode employing SPR experiments and protein crystallography, respectively. Finally, we aimed to demonstrate the metabolic stability in microsomal studies, paving the way for type I<sup>1</sup>/<sub>2</sub> inhibitors to serve as powerful in vivo probes or potent and selective clinical drug candidates.</div><div id="sec1-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Structure-Based Design</h3><div class="NLM_p">Starting from the aforementioned findings, we pursued a structure-based design approach to transfer and improve the newly discovered concept of type I<sup>1</sup>/<sub>2</sub> inhibition with respect to p38α MAP kinase. On the basis of the conclusions deduced from the X-ray structure of compound <b>1b</b> in complex with p38α (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A), we pursued an optimization program of both dibenzooxepinone and dibenzosuberone scaffolds to improve affinity and activity toward the kinase as well as their influence on metabolic stability and elucidate the impact on type I<sup>1</sup>/<sub>2</sub> inhibition. The developed synthetic strategy should lead to a diverse range of dibenzepinones, which are able to induce a glycine flip due to the rigidized carbonyl group present in these scaffolds and furthermore effectively target HRI and HRII, combined with moieties interfering with the R-Spine by targeting the DFG-motif to increase potency and residence time. All these properties were considered for our conceptual ligands as they proved to be important for selective and potent inhibitor design.<a onclick="showRef(event, 'ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref31 ref32">(31, 32)</a> Concerning the glycine flip, this property is used to form additional interactions within the enzyme’s binding site, essential to the hinge region plus gaining selectivity over other kinases that are not able to perform the glycine flip. Only 46 kinases of the human kinase genome are reported to undergo this conformational adaptation upon ligand binding.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Both HRI and HRII are surrounding the hinge region and allow for selective targeting by specific pharmacophores. The small and solvent-exposed HRII supports the introduction of a wide range of chemical moieties, thus allowing a certain influence on solubility of the inhibitor. A further gain in potency can be achieved with suitable residues displacing water molecules in the periphery of the binding site to increase entropy. The access to HRI is limited by the gatekeeper amino acid Thr106 and is mainly addressed by aromatic and hydrophobic interactions. Introduction of various methylated and fluorinated aromatic moieties at this position might contribute to increased binding affinity and inhibitory activity.</div><div class="NLM_p">Following this design approach, we decided to equip our new series of type I<sup>1</sup>/<sub>2</sub> inhibitors with an amide targeting HRII (R<sup>1</sup>) in contrast to the previously used ether substitution (compound <b>1b</b>), thereby offering the advantage of a faster synthesis of a diverse set of analogs.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> HRI should be addressed with a conjugated (L<sup>1</sup>), substituted (R<sup>2</sup> and R<sup>3</sup>) aromatic system. Notably, our designed dibenzepinones should feature the previously described R-Spine stabilization, as we believed it would contribute to prolonged TRTs. Therefore, a suitable hydrophobic moiety was attached via another linker (L<sup>2</sup>), namely, an amide and an inverse amide, respectively, to potentially form interactions with the DFG-motif and thereby interfere with the R-Spine (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Planned design of type I<sup>1</sup>/<sub>2</sub> dibenzepinone inhibitors interfering with the R-Spine. The core template of <b>1a</b> is equipped with an additional hydrophobic moiety (HM), reaching into the R-Spine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00745&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65115" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65115" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Due to the intended optimization of both the dibenzooxepinone and dibenzosuberone scaffolds, the nomenclature and substitution pattern differ between the two scaffolds. The scheme below illustrates the numbering following IUPAC rules and is valid for the compounds presented in this paper. As listed below, scaffold <b>A</b> is further named dibenzosuberone and scaffold <b>B</b> dibenzooxepinone, together hereinafter referred to as dibenzepinones (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0028.jpeg" id="GRAPHIC-d237e818-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Numbering Pattern of the Two Scaffolds:<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00745&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Scaffold <b>A</b>: dibenzooxepinone. Scaffold <b>B</b>: dibenzosuberone.</p></p></figure><div class="NLM_p">Chemical synthesis of the proposed type I<sup>1</sup>/<sub>2</sub> inhibitors was realized by initial preparation of the bare scaffolds, suitable for following derivatization. Moieties that were designed to occupy HRI and to interact with the DFG-motif targeting the R-Spine (R<sup>1</sup>) were synthesized via Buchwald–Hartwig cross-couplings while the implementation of suitable residues for HRII was accomplished by amide coupling (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of the Dibenzepinones<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00745&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and reaction conditions: (i) (1) MeMgBr, THF<sub>dry</sub>, 0 °C, (2) <i>n</i>-BuLi,-78 °C, (3) dry ice, −40 °C; (ii) H<sub>2</sub>SO<sub>4</sub>, MeOH, reflux; (iii) LDA, THF<sub>dry</sub>, −78 °C; (iv) NBS, AIBN, CCl<sub>4</sub>, reflux; (v) K<sub>2</sub>CO<sub>3</sub>, Me<sub>2</sub>CO, reflux; (vi) KOH, MeOH/H<sub>2</sub>O, reflux; (vii) (1) SOCl<sub>2</sub>, DCM, reflux, (2) AlCl<sub>3</sub>, room temperature; (viii) H<sub>2</sub>SO<sub>4</sub>, MeOH, reflux; (ix) (1) CDI/TBTU, DMF, 50 °C, (2) methylamine/2-morpholin-4-ethan-1-amine, 50 °C; (x) substituted aniline derivative, Cs<sub>2</sub>CO<sub>3</sub>, X-Phos, Pd(OAc)<sub>2</sub>, 1,4-dioxane, <i>t</i>-BuOH, reflux; (xi) KOH, MeOH/H<sub>2</sub>O, reflux; (xii) CDI/TBTU, corresponding amine, DMF/DCM, 50 °C. For the nature of R<sup>1</sup>–R<sup>6</sup>, see <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>.</p></p></figure><div class="NLM_p">For the synthesis of the dibenzepinone scaffolds, the commercially available starting material 3-bromo-4-methylbenzoic acid <b>14</b> was deprotonated with methylmagnesium bromide, followed by halogen–lithium exchange using <i>n</i>-BuLi (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The organometallic intermediate was quenched with dry ice to obtain 4-methylisophthalic acid <b>15</b> in 85% yield.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> This approach is an optimization of the conditions used earlier in the synthesis of <b>15</b>.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> The subsequent steps (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>, ii, iii, vi, and vii) for synthesis of the dibenzosuberone scaffold have already been published by Fischer et al.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> For synthesis of the corresponding dibenzooxepinones, the central oxygen was introduced via Wohl–Ziegler bromination of the methyl group in position 6 yielding intermediate <b>18</b>, followed by Williamson ether synthesis with 3-chlorophenol <b>19</b> to yield compound <b>21</b>. The corresponding acids <b>22</b> and <b>23</b> were obtained by hydrolysis of the esters using KOH. The resulting acids were subsequently activated with thionyl chloride and treated with dry aluminum chloride to achieve the respective dibenzepinone scaffold <b>24</b>/<b>25</b> via intramolecular Friedel–Crafts acylation. This synthesis led to the desired scaffolds with a carboxylic acid in position 3 of the dibenzosuberones and position 9 in the dibenzooxepinones, respectively. This facilitated a fast introduction of a broad variety of aliphatic and functionalized moieties on the A-ring. The chlorine in position 8 of the dibenzosuberone scaffold and in position 3 of the dibenzooxepinone scaffold enabled the introduction of suitable residues via Buchwald–Hartwig cross-coupling for potential DFG-motif interaction. For compounds with a free carboxylic acid function, Buchwald–Hartwig coupling was unsuccessful or accompanied by low yields. Therefore, compounds <b>24</b> and <b>25</b> were esterified with methanol to generate compounds <b>26</b> and <b>27</b> or were directly converted with 2-morpholine-4-ylethylamine or methylamine to give compounds <b>28</b> and <b>29</b>. To investigate the interaction potential with the DFG motif, we introduced a simple methylamine moiety in position 7 of the dibenzosuberone scaffold, assumingly preventing any interaction with HRII (<b>2</b>; <b>3a</b>–<b>c</b>; <b>4a</b>–<b>d</b>; <b>5a</b>–<b>d</b>,<b>k</b>; <b>8d</b>,<b>k</b>; <b>9a</b>,<b>b</b>; <b>10a</b>,<b>b</b>; <b>11a</b>,<b>b</b>; <b>12</b>). The residues for the proposed DFG-motif interaction were synthesized according to <a class="ref internalNav" href="#sch3" aria-label="Schemes 3">Schemes 3</a> and <a class="ref internalNav" href="#sch4" aria-label="4">4</a>.</div><div class="NLM_p">Both amides and inverse amides were introduced as linker systems on the B-ring of the dibenzepinone scaffolds (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The inverse amides <b>37a</b>–<b>d</b> and <b>38a</b>–<b>d</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>) were synthesized in good to acceptable yields by the activation with oxalyl chloride or thionyl chloride of the respective benzoic acid derivatives and subsequent conversion with the amine followed by reduction of the nitro group with palladium on activated carbon. The synthesis of the regular amide residues <b>39</b>; <b>40a</b>,<b>b</b>; <b>41a</b>–<b>g</b>; <b>42a</b>–<b>d</b>; <b>43</b>; <b>44</b>; <b>45a</b>,<b>b</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) was conducted by starting with the respective aniline derivatives being converted with the corresponding acid chloride in the presence of sodium hydride yielding up to 70% of the described target compounds. If the corresponding acid chloride was not commercially available, the respective carboxylic acids were activated with thionyl chloride and subsequently underwent nucleophilic substitution with the described amines. The resulting nitro compounds were reduced using hydrogen and palladium on activated carbon or stannous chloride to obtain the desired residues bearing an amino function suitable for Buchwald–Hartwig cross-coupling. After reduction, the corresponding anilines could be implemented in position 8 of the dibenzosuberone scaffold and position 3 of the dibenzooxepinone scaffold as coupling partners for the Buchwald–Hartwig reaction using standard coupling conditions (<b>2</b>; <b>3a</b>–<b>c</b>; <b>4a</b>–<b>d</b>; <b>5</b><b>a</b>–<b>f</b>,<b>m</b>; <b>6a</b>,<b>b</b>,<b>f</b>,<b>g</b>,<b>k</b>,<b>l</b>,<b>q</b>; <b>7a</b>; <b>8a</b>,<b>b</b>,<b>g</b>; <b>9a</b>,<b>b</b>; <b>10a</b>,<b>b</b>; <b>11a</b>,<b>b</b>; <b>12</b>).<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Upon coupling, the resulting ester compounds were hydrolyzed prior to introduction via amide coupling of suitable residues putatively occupying HRII. On the basis of the analysis of the known crystal structure, we selected positions and substituents for this interaction; polar (poly)alcohols and basic residues seemed to match these criteria.<a onclick="showRef(event, 'ref31 ref50'); return false;" href="javascript:void(0);" class="ref ref31 ref50">(31, 50)</a> Activation of the carboxylic acid with CDI or TBTU and conversion with the respective amines led to the test compounds <b>5</b><b>g</b>–<b>l</b>,<b>n</b>,<b>o</b>; <b>6</b><b>c</b>–<b>e</b>,<b>h</b>–<b>j</b>,<b>m</b>–<b>p</b>,<b>r</b>–<b>v</b>; <b>7b</b>,<b>c</b>; <b>8c</b>–<b>f</b>,<b>i</b>–<b>n</b>; <b>9a</b>.</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of the Inverse Amides <b>37a</b>–<b>d</b> and <b>38a</b>–<b>d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00745&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and reaction conditions: (i) C<sub>2</sub>O<sub>2</sub>Cl<sub>2</sub>/SOCl<sub>2</sub>, triethylamine, DCM, room temperature; (ii) H<sub>2</sub>, Pd/C, EtOAc, room temperature. For the nature of R<sup>1</sup>–R<sup>3</sup>, see <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>.</p></p></figure><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of the Regular Amides <b>39</b>, <b>40a</b>,<b>b</b>, <b>41a</b>–<b>g</b>, <b>42a</b>–<b>d</b>, <b>43</b>, <b>44</b>, <b>45a</b>,<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00745&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and reaction conditions: (i) (1) NaH, THF<sub>dry</sub>, room temperature, (2) acid chloride, 0 °C; (ii) (1) acid, SOCl<sub>2</sub>, reflux, (2) amine, NaH, THF<sub>dry</sub>/DMF, room temperature, (3) 1 + 2, 0 °C; (iii) H<sub>2</sub>, Pd/C, EtOAc, room temperature; (iv) SnCl<sub>2</sub>, EtOH, reflux. For the nature of R<sup>1</sup>–R<sup>3</sup> see <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_80081" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_80081" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Biological Evaluation</h3><div class="NLM_p">The successfully synthesized library of designed type I<sup>1</sup>/<sub>2</sub> inhibitors was evaluated using two different enzyme-linked immunosorbent assays (ELISAs). The effect on kinase activity was tested in an isolated p38α enzyme assay using a monoclonal antiphospho-ATF-2 peroxidase-conjugated antibody and <b>13a</b> as reference compound.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> The experimental setup of this assay limited the detection range to >3 nM. Additionally, compounds that showed promising IC<sub>50</sub> values with respect to p38α MAP kinase were also tested in a human whole blood TNFα-release system.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Due to various influencing factors, like solubility, plasma protein binding, cell–cell interaction, transporters, and ATP concentration, the results obtained from this human whole blood TNFα-release assay deviated from the results of the isolated enzyme assay. Moreover, results depended on interindividual variations by blood from different donors.</div><div class="NLM_p">Herein, we characterized our synthesized library of diverse derivatives of lead compound <b>1b</b> designed as type I<sup>1</sup>/<sub>2</sub> inhibitors.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> We further used the latest version of ZINC15 database to virtually test all final compounds for structural elements representing pan-assay interference compounds (PAINS). We did not get any PAIN hit from this database search.</div><div class="NLM_p">First, we compared inhibitors that carried <i>N</i>-isopropyl and <i>N</i>-cyclopropyl substituents (R<sup>4</sup>), respectively, designed to reach into the R-Spine. Introduction of <i>N</i>-isopropyl residues led to compounds with decreased biological activity on the isolated enzyme (<b>2</b> and <b>3a</b>–<b>c</b>) compared to the lead compound <b>1b</b> (IC<sub>50</sub>(p38α) = 1.0 nM). The loss of activity could be explained by the isopropyl residue of <b>2</b>, <b>3a</b>–<b>c</b>, which is not able to form any charge transfer or π–π-interactions with Phe169 of the DFG-motif and is therefore unable to interfere with the hydrophobic spine of the enzyme. Deletion of the methyl group of the R<sup>4</sup> substituent in <b>2</b> by a hydrogen (<b>3a</b>) resulted in a 20-fold improved activity. This indicated the importance of the additional hydrogen bond interaction to Glu71 of the N-lobe of the enzyme (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>A). With a change of R<sup>4</sup> from an isopropyl moiety <b>3c</b> to a cyclopropyl residue <b>4d</b>, an aromatic-alike structure, the biological activity increased up to 16-fold.<a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53, 54)</a> The decoration of the aniline (C-ring) seemed to be important when using a methyl as substituent. The methyl group in ortho position <b>4a</b> resulted in an increased inhibitory activity compared to the para-substituted compound <b>4b</b>, whereas this deviation in activity was not observed for a fluorine substitution (<b>4c</b> vs <b>4d</b>). In contrast to the ortho-fluorine substitution we assume that the ortho-methyl substitution enforces the aniline ring to be more out of the plane of the tricyclic structure, therefore leading to a better occupied HR I. The most active compound <b>4a</b> in the kinase assay was also tested regarding its inhibition of TNFα-release in human whole blood; however, it revealed a relatively low IC<sub>50</sub> value of 903.2 nM.</div><div class="NLM_p">All dibenzosuberone compounds (scaffold <b>A</b>, X = CH<sub>2</sub>) depicted in <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> showed activities on the enzyme in the low nanomolar range down to 2 nM (<b>5h</b>, <b>5j</b>, and <b>5k</b>, <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). The chemical rearrangement of the amide structure R<sup>4</sup> from amides to reverse amides led to further improvement of the inhibitory activity in both assays. On the basis of the determined potencies of <b>4a</b>–<b>d</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) compared to <b>5a</b>–<b>d</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>), it is most likely that the regiochemistry of the amide linker bond R<sup>4</sup> is relevant for the inhibitory activity. Considering the introduction of a methyl group on the C-ring, the decoration of the aniline, as already noted (<b>4a</b> vs <b>4b</b>), is important (<b>5a</b> vs <b>5b</b>) for an adequate potency of the compounds. However, introduction of fluorine on the C-ring of the dibenzosuberone scaffold as R<sup>2</sup> and/or as R<sup>3</sup> led to increased inhibition compared to a methyl substitution (e.g., <b>5b</b> vs <b>5d</b>). These observations led us to the decoration of fluorine as preferred substituents on the C-ring for all following designs. The dibenzooxepinone compounds (scaffold <b>B</b>, X = O) <b>5m</b>–<b>o</b> showed IC<sub>50</sub> values in the low double-digit range on the enzyme level. However, the IC<sub>50</sub> value of the dibenzosuberone compound <b>5i</b> (IC<sub>50</sub>(p38α) = 5.4 nM) was almost 5-fold higher in comparison to the corresponding dibenzooxepinone compound <b>5n</b> (IC<sub>50</sub>(p38α) = 23.8 nM). This factor is even increased to more than 60 in the TNFα-release assay (<b>5i</b> vs <b>5n</b>). The most potent compound of <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a> was <b>5i</b> showing a remarkable IC<sub>50</sub> value of 25.1 nM in human whole blood (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>).</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Biological Data of the Substituted p38α MAP Kinase Dibenzosuberone Inhibitors <b>2</b>–<b>4d</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0009.gif" alt="" id="GRAPHIC-d237e1673-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0010.gif" alt="" id="GRAPHIC-d237e1674-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">Results from three experiments.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Results from four experiments.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">n.d.: not determined.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Biological Data of the Substituted p38α MAP Kinase Dibenzosuberone Inhibitors <b>5a</b>–<b>l</b> and p38α-MAP Kinase Dibenzooxepinone Inhibitors <b>5m</b>–<b>o</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0011.gif" alt="" id="GRAPHIC-d237e1708-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0012.gif" alt="" id="GRAPHIC-d237e1709-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">Results from three experiments.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Results from four experiments.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">n.d.: not determined.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">IC<sub>50</sub> value below the detection limit of the assay; IC<sub>50</sub> < 3 nM.</p></div></div><div></div></div><div class="NLM_p">All listed compounds in <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>, apart from compound <b>6p</b>, showed excellent potencies on the enzyme with IC<sub>50</sub> values below the detection limit of the assay (3 nM), which confirmed the assumption that an aromatic or an aromatic-alike structure is needed for interaction with Phe169 of the DFG-motif. The significantly high value of <b>6p</b> in this series indicates the importance of the free amide hydrogen. There is no significant difference between the dibenzosuberone and the dibenzooxepinone compounds observed on the enzyme level. However, the TNFα values in part provided remarkably higher potencies for the dibenzosuberone compounds when compared to the dibenzooxepinone compounds. Considering the IC<sub>50</sub> values of compound <b>6e</b> vs <b>6o</b> and <b>6g</b> vs <b>6r</b>, the corresponding dibenzosuberone compounds are up to 4-fold better in its whole blood TNFα-release activity. However, the dibenzooxepinone compounds still displayed moderate IC<sub>50</sub> values down the low three-digit nanomolar range <b>6v</b>. Compounds <b>6b</b>, <b>6c</b>, <b>6e</b>, and <b>6j</b> were the most potent ones in the TNFα-release assay with IC<sub>50</sub> values below 40 nM.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Biological Data of the Substituted p38α MAP Kinase Dibenzosuberone Inhibitors <b>6a</b>–<b>j</b> and p38α-MAP Kinase Dibenzooxepinone Inhibitors <b>6k</b>–<b>v</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0013.gif" alt="" id="GRAPHIC-d237e1807-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0014.gif" alt="" id="GRAPHIC-d237e1808-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0015.gif" alt="" id="GRAPHIC-d237e1809-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">Results from three experiments.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Results from four experiments.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">n.d.: not determined.</p></div><div class="footnote" id="t3fn4"><sup>Table d</sup><p class="last">IC<sub>50</sub> value below the detection limit of the assay; IC<sub>50</sub> < 3 nM.</p></div></div><div></div></div><div class="NLM_p">Another set of dibenzooxepinones was synthesized in order to study the effect of the substitution pattern of the thiophene and the combination of a fluorine substitution with a methyl substitution on the C-ring (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Obviously, there was no big difference in the inhibitory activity on the isolated enzyme between a 3-thiophene and a 2-thiophene for R<sup>4</sup>. The corresponding IC<sub>50</sub> value in the kinase assay of <b>6u</b> was marginally lower than <b>7b</b>. A comparison of the IC<sub>50</sub> values of the different substitution patterns on the C-ring of <b>6o</b> (R<sup>2</sup> = H), <b>6t</b> (R<sup>2</sup> = F), and <b>7c</b> (R<sup>2</sup> = CH<sub>3</sub>) illustrates the adverse role of a methyl substitution. However, the evaluated TNFα values of the dibenzooxepinones (scaffold <b>B</b>) <b>7a</b>–<b>c</b> were again comparably high, underlining the advantage of the dibenzosuberones (scaffold <b>A</b>).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Biological Data of the Substituted p38α MAP Kinase Dibenzooxepinone Inhibitors <b>7a</b>–<b>c</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0016.gif" alt="" id="GRAPHIC-d237e1904-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0017.gif" alt="" id="GRAPHIC-d237e1905-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last">Results from three experiments.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">Results from four experiments.</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">n.d.: not determined.</p></div><div class="footnote" id="t4fn4"><sup>Table d</sup><p class="last">IC<sub>50</sub> value below the detection limit of the assay; IC<sub>50</sub> < 3 nM.</p></div></div><div></div></div><div class="NLM_p">Next, we investigated the benzamide substitution inspired by the lead compound <b>1b</b>. The corresponding inhibitors <b>8a</b>–<b>n</b> exhibited an excellent biochemical activity in the p38α MAP kinase assay below the detection limit of the enzyme assay. This was also observed regarding the determined IC<sub>50</sub> values in the TNFα-release assay. Evaluated values in human whole blood testing system represented again the superiority of the dibenzosuberone scaffold compared to the dibenzooxepinones scaffold. The dibenzooxepinones (scaffold <b>A</b>) <b>8l</b>–<b>n</b> were in fact as potent as the dibenzosuberones (scaffold <b>B</b>) <b>8a</b>–<b>k</b> in the enzyme assay, but when comparing the dibenzooxepinone compound <b>8m</b> with its direct dibenzosuberone equivalent <b>8b</b>, the difference in a whole blood system became evident. Once again, the introduction of an aromatic residue as an amide for proposed interaction with the DFG motif in combination with a fluorine substitution on the C-ring led to very low IC<sub>50</sub> values on the enzyme level down to the picomolar range.</div><div class="NLM_p">Substitution of the benzamide structure with different halogen and methoxy groups in ortho- and para-position displayed inhibitors with excellent IC<sub>50</sub> values down to picomolar activities on the isolated enzyme. Thus, there was no obvious difference to the unsubstituted benzamide inhibitors depicted in <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>, <b>8a</b>–<b>k</b>.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Biological Data of the Substituted p38α MAP Kinase Dibenzosuberone Inhibitors <b>8a</b>–<b>k</b> and p38α-MAP Kinase Dibenzooxepinone Inhibitors <b>8l</b>–<b>n</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0018.gif" alt="" id="GRAPHIC-d237e2009-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0019.gif" alt="" id="GRAPHIC-d237e2010-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>Table a</sup><p class="last">Results from three experiments.</p></div><div class="footnote" id="t5fn2"><sup>Table b</sup><p class="last">Results from four experiments.</p></div><div class="footnote" id="t5fn3"><sup>Table c</sup><p class="last">n.d.: not determined.</p></div><div class="footnote" id="t5fn4"><sup>Table d</sup><p class="last">IC<sub>50</sub> value below the detection limit of the assay; IC<sub>50</sub> < 3 nM.</p></div></div><div></div></div><div class="NLM_p last">To obtain a more detailed insight based on the presented biochemical data, we selected a few compounds for further characterization by means of SPR measurements, X-ray crystallography, and metabolic studies. These compounds were not chosen primarily based on especially low IC<sub>50</sub>-value activities determined in both assays. The selected inhibitors showcased suitable representatives by means of the shown structure–activity-relationships and would allow us to make as many conclusions as possible about the other nontested compounds in order to shed a light on the mechanisms and details of type I<sup>1</sup>/<sub>2</sub> inhibition. With this selection, we wanted to further investigate the impact on binding kinetics, the binding mode, and metabolic stability of the compounds of the regiochemistry of the amide linker R<sup>4</sup>, the attached moiety for interaction with the R-Spine R<sup>4</sup>, the different scaffolds <b>A</b> and <b>B</b>, and the metabolic stability of the additional residues for DFG interaction and HRII interaction.</div></div><div id="sec3-2" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Binding Kinetics</h3><div class="NLM_p">The kinetic constants of the aforementioned selected p38α MAP kinase inhibitors were determined by surface plasmon resonance (SPR) measurement (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>) to investigate the impact of type I<sup>1</sup>/<sub>2</sub> inhibition on a compound’s binding kinetics.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> Equilibrium dissociation constants (<i>K</i><sub>D</sub>) were determined by measuring the association (<i>k</i><sub>a</sub>) and dissociation rates (<i>k</i><sub>d</sub>) of the individual inhibitors, and binding affinities in the low nanomolar range (1.3–43.5 nM) were obtained. The inhibitors selected from our synthesized library were tested against a small panel of reference compounds consisting of literature-described type I and type II p38α MAP kinase inhibitors. <b>13b</b>, a prototypical type II inhibitor, showed the lowest <i>K</i><sub>D</sub> with 0.123 nM. 3-(3-Bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1(2<i>H</i>)-yl)-<i>N</i>,4-dimethylbenzamide <b>13d</b> (PH-797804<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a>), a type I inhibitor and clinical candidate from Pfizer, had an affinity (2.5 nM) similar to most of the dibenzosuberone and dibenzooxepinone compounds. Comparing the TRTs of the reference inhibitors with our type I<sup>1</sup>/<sub>2</sub> series showed an improved TRT of the dibenzosuberones <b>6b</b>, <b>6e</b>, <b>6g</b>, <b>6j</b>, <b>6l</b>, and <b>8b</b> (τ = 259–3660 s) compared to the classical type I inhibitors such as <b>13d</b> (τ = 36 s) and <b>13a</b> (τ = 4.6 s). The longest TRTs in the dibenzosuberone series were observed for compounds containing an additional fluorine group at position 2 (e.g., <b>8b</b> and <b>8e</b>). Worthy of note is that the improved TRT of this series correlated with a high potency in the human whole blood cellular assay (<b>8b</b>, IC<sub>50</sub> = 31 nM; <b>8e</b>, IC<sub>50</sub> = 34 nM). The dibenzooxepinone series generally showed a less pronounced improvement in TRT. However, an important exception to this trend was observed regarding <b>6q</b>, which showed the highest TRT among all tested inhibitors (τ = 4099 s).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Biological Data of the Substituted p38α MAP Kinase Dibenzosuberone Inhibitors <b>9a</b>,<b>b</b>, <b>10a</b>,<b>b</b>, <b>11a</b>,<b>b</b>, <b>12</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0020.gif" alt="" id="GRAPHIC-d237e2198-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0021.gif" alt="" id="GRAPHIC-d237e2199-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>Table a</sup><p class="last">Results from three experiments.</p></div><div class="footnote" id="t6fn2"><sup>Table b</sup><p class="last">Results from four experiments.</p></div><div class="footnote" id="t6fn3"><sup>Table c</sup><p class="last">n.d.: not determined.</p></div><div class="footnote" id="t6fn4"><sup>Table d</sup><p class="last">IC<sub>50</sub> value below the detection limit of the assay; IC<sub>50</sub> < 3 nM.</p></div></div><div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Binding Kinetics of Testing Compounds <b>6b</b>, <b>6e</b>, <b>6g</b>, <b>6j</b>, <b>6l</b>, <b>6o</b>, <b>6q</b>, <b>8b</b>, and <b>8m</b> to Active p38α MAP Kinase<a class="ref internalNav" href="#tbl7-fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center">p38α MAP kinase</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">inhibitor type</th><th class="colsep0 rowsep0" align="center"><i>k</i><sub>a</sub> [1/M s]</th><th class="colsep0 rowsep0" align="center"><i>k</i><sub>d</sub> [1/s]</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>D</sub> [nM]</th><th class="colsep0 rowsep0" align="center">τ [s]</th><th class="colsep0 rowsep0" align="center"><i>t</i><sub>1/2</sub> [s]</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13a</b></td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">1.00 × 10<sup>7</sup></td><td class="colsep0 rowsep0" align="left">2.18 × 10<sup>–1</sup></td><td class="colsep0 rowsep0" align="left">21.7</td><td class="colsep0 rowsep0" align="left">4.6</td><td class="colsep0 rowsep0" align="left">3.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13d</b></td><td class="colsep0 rowsep0" align="left">I</td><td class="colsep0 rowsep0" align="left">1.08 × 10<sup>7</sup></td><td class="colsep0 rowsep0" align="left">2.75 × 10<sup>–2</sup></td><td class="colsep0 rowsep0" align="left">2.5</td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="left">25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13b</b></td><td class="colsep0 rowsep0" align="left">II</td><td class="colsep0 rowsep0" align="left">1.21 × 10<sup>4</sup></td><td class="colsep0 rowsep0" align="left">1.00 × 10<sup>–5</sup></td><td class="colsep0 rowsep0" align="left">0.123</td><td class="colsep0 rowsep0" align="left">>10<sup>5</sup></td><td class="colsep0 rowsep0" align="left">>69300</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6b</b></td><td class="colsep0 rowsep0" align="left">I<sup>1</sup>/<sub>2</sub></td><td class="colsep0 rowsep0" align="left">5.32 × 10<sup>5</sup></td><td class="colsep0 rowsep0" align="left">2.08 × 10<sup>–3</sup></td><td class="colsep0 rowsep0" align="left">3.9</td><td class="colsep0 rowsep0" align="left">480</td><td class="colsep0 rowsep0" align="left">333</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6e</b></td><td class="colsep0 rowsep0" align="left">I<sup>1</sup>/<sub>2</sub></td><td class="colsep0 rowsep0" align="left">8.32 × 10<sup>5</sup></td><td class="colsep0 rowsep0" align="left">2.00 × 10<sup>–3</sup></td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">499</td><td class="colsep0 rowsep0" align="left">346</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6g</b></td><td class="colsep0 rowsep0" align="left">I<sup>1</sup>/<sub>2</sub></td><td class="colsep0 rowsep0" align="left">6.15 × 10<sup>4</sup></td><td class="colsep0 rowsep0" align="left">2.73 × 10<sup>–4</sup></td><td class="colsep0 rowsep0" align="left">4.4</td><td class="colsep0 rowsep0" align="left">3663</td><td class="colsep0 rowsep0" align="left">2538</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6j</b></td><td class="colsep0 rowsep0" align="left">I<sup>1</sup>/<sub>2</sub></td><td class="colsep0 rowsep0" align="left">5.82 × 10<sup>5</sup></td><td class="colsep0 rowsep0" align="left">7.53 × 10<sup>–4</sup></td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">1329</td><td class="colsep0 rowsep0" align="left">921</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6l</b></td><td class="colsep0 rowsep0" align="left">I<sup>1</sup>/<sub>2</sub></td><td class="colsep0 rowsep0" align="left">4.11 × 10<sup>6</sup></td><td class="colsep0 rowsep0" align="left">3.22 × 10<sup>–2</sup></td><td class="colsep0 rowsep0" align="left">7.8</td><td class="colsep0 rowsep0" align="left">31</td><td class="colsep0 rowsep0" align="left">22</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6o</b></td><td class="colsep0 rowsep0" align="left">I<sup>1</sup>/<sub>2</sub></td><td class="colsep0 rowsep0" align="left">1.61 × 10<sup>6</sup></td><td class="colsep0 rowsep0" align="left">1.17 × 10<sup>–2</sup></td><td class="colsep0 rowsep0" align="left">7.3</td><td class="colsep0 rowsep0" align="left">86</td><td class="colsep0 rowsep0" align="left">59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6q</b></td><td class="colsep0 rowsep0" align="left">I<sup>1</sup>/<sub>2</sub></td><td class="colsep0 rowsep0" align="left">1.09 × 10<sup>5</sup></td><td class="colsep0 rowsep0" align="left">2.44 × 10<sup>–4</sup></td><td class="colsep0 rowsep0" align="left">2.2</td><td class="colsep0 rowsep0" align="left">4099</td><td class="colsep0 rowsep0" align="left">2840</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8b</b></td><td class="colsep0 rowsep0" align="left">I<sup>1</sup>/<sub>2</sub></td><td class="colsep0 rowsep0" align="left">1.23 × 10<sup>6</sup></td><td class="colsep0 rowsep0" align="left">3.86 × 10<sup>–3</sup></td><td class="colsep0 rowsep0" align="left">3.14</td><td class="colsep0 rowsep0" align="left">259</td><td class="colsep0 rowsep0" align="left">180</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8m</b></td><td class="colsep0 rowsep0" align="left">I<sup>1</sup>/<sub>2</sub></td><td class="colsep0 rowsep0" align="left">1.75 × 10<sup>6</sup></td><td class="colsep0 rowsep0" align="left">3.09 × 10<sup>–2</sup></td><td class="colsep0 rowsep0" align="left">17.7</td><td class="colsep0 rowsep0" align="left">32</td><td class="colsep0 rowsep0" align="left">22</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl7-fn1"><div class="footnote" id="tbl7-fn1"><sup>a</sup><p class="last"><i>k</i><sub>a</sub>, association rate constant; <i>k</i><sub>d</sub>, dissociation rate constant; <i>K</i><sub>D</sub>, equilibrium dissociation constant; τ, residence time; <i>t</i><sub>1/2</sub>, half-life.</p></div></div></div></div><div id="sec3-3" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Binding Mode</h3><div class="NLM_p">To validate our conceptual design concept of type I<sup>1</sup>/<sub>2</sub> kinase inhibitors, we proceeded with the cocrystallization of a small selection from our library. Consequently, the complex structures of <b>6j</b> and <b>8m</b> were successfully solved (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). As conceived, the following compounds complied with the binding mode of our lead compound <b>1b</b> that was essentially maintained for both cocrystallized compounds due to their analogous scaffolds and substitution patterns. In agreement with our working hypothesis, upon variation of the scaffold from dibenzosuberone to dibenzooxepinone as well as the solubilizing group on the A-ring reaching into HRII and the fluorination pattern on the C-ring addressing HRI, the crucial main interactions with the kinase were kept. Namely, the formation of two hydrogen bonds to Met109 and Gly110 of the hinge region inducing the glycine flip and an efficient occupancy of HRI and HRII were part of the compliance. Most importantly, two hydrogen bonds from the amide linker to Glu71 of α-helix C and Asp168 of the DFG-motif leading to the quality of the compounds to bind the kinase in a DFG-in conformation were also found in both cases. The aromatic thiophene (<b>6j</b>) and phenyl (<b>8m</b>) systems, respectively, were forming an edge-to-face interaction with the side chain of Phe169. Thereby, the kinase R-Spine was stabilized in its assembled form, presumably leading to the by now most efficient interaction enabling very low IC<sub>50</sub> values and long TRTs.</div><figure id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cocrystal structure of type I<sup>1</sup>/<sub>2</sub> inhibitors in complex with p38α MAP kinase. (A) Detailed binding mode of <b>6j</b> (cyan) and (B) <b>8m</b> (yellow) in the kinases active site. Hydrogen bonds shown as yellow dots. (C) Overlay of the inhibitors occupying HRI (brown) and HRII (beige) (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MTY">5MTY</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MTX">5MTX</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00745&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3-4" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> In Vitro Metabolism</h3><div class="NLM_p">In order to examine if and to what extent the variety of residues influences metabolic stability, the in vitro biotransformation of selected dibenzosuberone and dibenzooxepinone inhibitors was investigated in male rat liver microsomes (RLMs). Furthermore, the hypothesis of the potentially blocked metabolic position of the dibenzosuberone scaffold <b>A</b> with the introduction of an oxygen leading to the dibenzooxepinone scaffold <b>B</b> was investigated. Therefore, the compounds profiled (<a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>) reflected the structural diversity and revealed remarkable results in the RLM assay.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Metabolic Stability of Selected Dibenzosuberone Inhibitors <b>4d</b>, <b>5a</b>,<b>g</b>, <b>6</b><b>b</b>,<b>g</b>–<b>j</b>, <b>8b</b>,<b>d</b> and Dibenzooxepinone Inhibitors <b>6t</b> and <b>8m</b> after 180 min Incubation with Rat Liver microsomes</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0022.gif" alt="" id="GRAPHIC-d237e2772-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0023.gif" alt="" id="GRAPHIC-d237e2773-autogenerated" /></img><div></div></div><div class="NLM_p">All tested substances appear to undergo metabolic degradation and reveal metabolite formation. An exception is represented by <b>5g</b> not showing any metabolites. The introduction of the cyclopropyl residue as an anilide (<b>5a</b>) led to an increased metabolic stability compared to the reverse amide (<b>4d</b>). In addition, the insertion of a diolamine moiety showed decreased substrate degradation (<b>5g</b>) and a significant suppression of metabolite formation. To our surprise, the insertion of a heteroatom to the scaffold <b>A</b> led to decreased metabolic stability and increased metabolite formation when compared with its dibenzosuberone equivalent (<b>8b</b> vs <b>8m</b>). In comparison to the corresponding phenylbenzamides (<b>8b</b>, <b>8m</b>), the introduction of the 2-thiopheneanilide residue (<b>6b</b>, <b>6g</b>) seems to support the substrate stability (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). Fortunately, compounds <b>8b</b>–<b>m</b> were not metabolized to the possible 1,4-iminioquinone-like metabolites.</div><figure id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Substrate degradation and metabolite formation of compounds <b>6b</b>, <b>8b</b>, and <b>8m</b>. (A) Overview of the analyte decrease during 180 min incubation with RLM. (B) Percentage of all formed metabolites during 180 min incubation. Incubations were carried out in triplicates, and average mean values with standard deviation are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00745&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3-5" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> Kinase Selectivity Profiling</h3><div class="NLM_p last">The high potency and long TRTs of the compounds encouraged us to investigate the influence of the additional interaction on kinome-wide selectivity. To examine the impact of very potent but yet chemically different compounds, <b>8b</b> and <b>6g</b> were chosen as representatives for type I<sup>1</sup>/<sub>2</sub> inhibitors. Compound <b>8b</b> was screened against a panel of 451 kinases and only showed CSNK1E as off-target at a 1000 nM concentration,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> and compound <b>6g</b> (τ = 3663 s, <a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>) was screened against a panel of 320 wild type kinases and showed no off-target at a 500 nM concentration.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> This indicates that the additional R-Spine interaction has no negative influence on selectivity. The affinity of type I<sup>1</sup>/<sub>2</sub> toward p38 MAP kinases seems to be specifically increased.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i23">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63556" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63556" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we presented the conceptual design and successful synthesis of a new generation of skepinones as exceptionally potent p38α MAP kinase inhibitors. A focused compound library comprising a total number of 69 compounds following the type I<sup>1</sup>/<sub>2</sub> concept was generated. From this set we determined biochemical data imposingly showing effective inhibition of TNFα-release in human whole blood reflected by IC<sub>50</sub> values down in the low nanomolar range. We subsequently selected a structurally diverse set of compounds for characterization regarding binding kinetics and binding mode via SPR and X-ray studies, respectively. The corresponding results showed a significant improvement in TRT caused by direct interaction with the kinase’s R-Spine leading to its stabilization, providing explanations for the high observed potency of our ligands. This observed R-Spine interaction even increased the already high selectivity of <b>1a</b> down to a selectivity score of 0.006 for compound <b>6g</b>. Furthermore, we could show that despite an extension of the scaffolds, the metabolic stability of the molecules was maintained. This novel class of p38α MAP kinase inhibition opens a new chapter in the book of anti-inflammatory drug design and will be further investigated and optimized toward kinase selectivity and drug efficacy.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i24">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56078" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56078" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5-1-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Synthesis</h3><div class="NLM_p">All reagents and (anhydrous) solvents are commercially available and were used without further purification.</div><div class="NLM_p"><i>NMR</i>. <sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained with Bruker Avance 200 or with Bruker Avance 400. The spectra were obtained in the indicated solvent and calibrated against the residual proton peak of the deuterated solvent. Chemical shifts (δ) are reported in parts per million.</div><div class="NLM_p"><i>Mass Spectrometry</i>. Mass spectra were obtained by DC-MS (ESI) and from the Mass Spectrometry Department (FAB-MS; EI-MS), Institute of Organic Chemistry, Eberhard-Karls-Universitaet Tübingen or from the Institute of Sciences, Department of Pharmaceutical Analytics and Bioanalytics. GC/MS analyses were carried out on a Hewlett-Packard HP 6890 series GC system equipped with a HP-5MS capillary column (0.25 μm film thickness, 30 m × 250 μm) and a HP 5973 mass selective detector (EI ionization). Helium was used as carrier gas in the following temperature program: start at 100 °C and hold for 1 min, then increase to 160 °C and hold for 5 min, then increase to 250 °C and hold for 8 min. High resolution, high accuracy mass spectrometry (ESI-HRMS) was performed on an Sciex (Ontario, Canada) TripleTof 5600+ mass spectrometer with a Duospray source, coupled to a 1290 UHPLC from Agilent (Waldbron, Germany) equipped with an PAL-HTS autosampler from CTC (Zwingen, Switzerland). For chromatographic separation, samples were dissolved in MeOH. Separation was performed on a Phenomenex (Torrance, CA, USA) Kinetex C18 2.8 μm, 100 mm × 3 mm 100 Å core shell technology column for optimal chromatographic resolution using the following gradient profile: 0–1 min 5% B, 1–10 min 5–100% B, 5–15 100% B. Solvent A was MS-Grade H<sub>2</sub>O with 0.1% formic acid, and solvent B was Ultra-MS-Grade acetonitrile (Carl Roth, Karlsruhe, Germany) with 0.1% formic acid. Flow was set to 500 μL/min and column temperature to 20 °C. Mass analysis was run in ESI+ mode. Settings were as follows: curtain gas 30 psi, nebulizer gas 40, drying gas 50, source temperature 400 °C, ion source floating voltage +5500 V. Analysis was run as information dependent acquisition; i.e., every cycle consisted of a TOF survey scan from 100 to 2000 <i>m</i>/<i>z</i>, and subsequent fragmentation scans were triggered automatically by acquisition software. To ensure MSMS spectra generation of synthesized compounds, IDA was supplied with an inclusion list containing the respective [M + H<sup>+</sup>]<sup>+</sup><i>m</i>/<i>z</i> ratios. Collision energy was set to 27 V.</div><div class="NLM_p"><i>TLC</i>. Analyses were performed on fluorescent silica gel 60 F<sub>254</sub> plates (Merck) and visualized under UV illumination at 254 and 366 nm.</div><div class="NLM_p"><i>Column Chromatography</i>. Column chromatography was performed on Davisil LC60A 20–45 μm silica from Grace Davison and Geduran Si60 63–200 μm silica from Merck for the precolumn using an Interchim PuriFlash 430 automated flash chromatography system.</div><div class="NLM_p"><i>HPLC</i>. The purity of all compounds is, unless otherwise stated, >95% and was determined via reverse phase high performance liquid chromatography on Hewlett-Packard HP 1090 series II LC equipped with a UV diode array detector (DAD, detection at 230 and 254 nm). The chromatographic separation was performed on a Phenomenex Luna 5u C8 column (150 mm × 4.6 mm, 5 μm) at 35 °C oven temperature. The injection volume was 5 μL, and the gradient of the used method was the following (flow, 1.5 mL/min), with 0.01 M KH<sub>2</sub>PO<sub>4</sub>, pH 2.3 (solvent A), methanol (solvent B): from 40% B to 85% B in 8 min, 85% B for 5 min, from 85% to 40% B in 1 min, 40% B for 2 min, stop time 16 min.</div><div class="NLM_p"><i>Melting Points</i>. Büchi melting point B-545 with thermodynamic correction was used. Melting points were determined after the compound was completely melted.</div><div class="NLM_p last"><i>Visualization</i>. For visualization and generation of pharmacophore models, PyMOL molecular graphics system (version 1.3, Schrödinger, LLC) and Schrödinger release 2015-2 Maestro (version 10.2, Schrödinger, LLC, New York, NY, 2015) were used.</div></div><div id="sec5-2" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> General Procedure Ia: Preparation of the Inverse Amide Intermediates <b>30a</b>–<b>d</b> and <b>31a</b>–<b>d</b></h3><div class="NLM_p last">The respective carboxylic acid was activated at first. The acid (1.0 equiv) was dissolved in DCM (0.3 M) and catalytic amounts of DMF. Oxalyl chloride (1.0 equiv) was added dropwise, and the mixture was allowed to stir at ambient temperature for 1 h under argon atmosphere. Afterward, a solution of the respective amine derivative (1.1 equiv) and triethylamine (4.0 equiv) in DCM (0.1 M) was prepared. The activated carboxylic acid was added dropwise and the reaction mixture was stirred at ambient temperature under argon atmosphere until the reaction was completed. Then it was poured into H<sub>2</sub>O, extracted with DCM, dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed under reduced pressure. The extract was further purified by flash chromatography (silica gel, petroleum ether/ethyl acetate).</div></div><div id="sec5-3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> General Procedure Ib: Amide Synthesis of the Intermediates <b>32a</b>–<b>d</b></h3><div class="NLM_p last">Sodium hydride (1.0 equiv) was suspended in THF<sub>dry</sub> (0.3 M), and the respective aniline (1.0 equiv) was added dropwise. The reaction mixture was allowed to stir under argon atmosphere at ambient temperature until the implementation was completed. Afterward, a solution of the cyclopropanecarbonyl chloride (1.0 equiv) in THF<sub>dry</sub> (0.1 M) was prepared. The acid chloride was added dropwise at 0 °C under argon atmosphere in 30 min. The reaction mixture was allowed to stir until the conversion is completed. The reaction mixture was poured into H<sub>2</sub>O, extracted with ethyl acetate, dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo. The extract was further purified using flash chromatography (silica gel, petroleum ether/ethyl acetate).</div></div><div id="sec5-4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> General Procedure Ic: Amide Synthesis of the Intermediates <b>33a</b>, <b>34c</b>, <b>35b</b></h3><div class="NLM_p last">Sodium hydride (1.0 equiv) was suspended in THF<sub>dry</sub> (0.1 M), and the respective aniline (1.0 equiv), dissolved in THF<sub>dry</sub> (0.1 M), was added dropwise. The reaction mixture was allowed to stir under argon atmosphere at ambient temperature until the deprotonation was completed (1–2 h). At the same time, the corresponding acid (1.1 equiv) was dissolved in SOCl<sub>2</sub> (10.0 equiv) and was refluxed for 1 h. After cooling to room temperature, the excess SOCl<sub>2</sub> was removed in vacuo and the resulting acid chloride was directly dissolved in THF<sub>dry</sub>. (0.1 M). The acid chloride was added dropwise at 0 °C under argon atmosphere in 30 min. The reaction mixture was allowed to stir until the conversion was completed (3–10 h). The reaction mixture was poured into H<sub>2</sub>O, extracted with ethyl acetate, dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed under reduced pressure. The extract was further purified using flash chromatography (silica gel, petroleum ether/ethyl acetate).</div></div><div id="sec5-5" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> General Procedure Id: Amide Synthesis of the Intermediates <b>33b</b>, <b>34</b>, <b>34d</b>, <b>36a</b>–<b>g</b></h3><div class="NLM_p last">The aniline (1.0 equiv) was dissolved in THF<sub>dry</sub> (0.1 M), and sodium hydride (1.0 equiv) was added. After 1 h of stirring, the cyclopropyl acid chloride/benzoyl chloride (1.1 equiv) was added at 0 °C. The reaction mixture was allowed to stir at ambient temperature. After complete conversion, the reaction mixture was diluted with water, neutralized with diluted HCl, and extracted with ethyl acetate. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated under reduced pressure. The crude product was purified by recrystallization in hexane/ethyl acetate.</div></div><div id="sec5-6" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> General Procedure II: Nitration <b>34a</b> and <b>35a</b></h3><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0025.gif" alt="" id="dgr1" /></img><div class="NLM_p last">Concentrated nitric acid (10% V/V) was added dropwise over 20 min to a stirred solution of the corresponding substituted aniline in concentrated sulfuric acid (0.75 M) at −10 °C. The mixture was stirred under 5 °C for 30 min and then poured on ice and the pH was set to 13 with solid NaOH. Temperature was regulated under 80 °C. After cooling to room temperature, the nitrated aniline was extracted three times with diethyl ether. The extract was further purified by flash chromatography (silica gel, petroleum ether/ethyl acetate).</div></div><div id="sec5-7" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> General Procedure IIIa: Reduction Using Pd on Activated Carbon Preparing Residues <b>37a</b>–<b>d</b>, <b>38a</b>–<b>d</b>, <b>39</b>, <b>40a</b>,<b>b</b>, and <b>41a</b>–<b>g</b></h3><div class="NLM_p last">The nitro compound (1.0 equiv) was dissolved in ethyl acetate (0.3 M), and 10 wt % palladium on activated carbon was added. The resulting suspension was stirred under hydrogen atmosphere at ambient temperature. Afterward, the mixture was filtered and the solvent was removed under reduced pressure. The residue was further purified using flash chromatography (silica gel, petroleum ether/ethyl acetate).</div></div><div id="sec5-8" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> General Procedure IIIb: Reduction Using SnCl<sub>2</sub> Preparing Residues <b>42a</b>–<b>d</b>, <b>43</b>, <b>44m</b>, and <b>45a</b>,<b>b</b></h3><div class="NLM_p last">The nitro compound (1.0 equiv) was dissolved in a three-necked flask in ethanol or methanol (0.075 M) and was heated to reflux. The corresponding amount of stannous chloride (5.0 equiv) was added in small portions followed by stirring for 3–6 h. After complete conversion (monitored by TLC and HPLC), sodium hydrogen carbonate was added carefully and the alcohol was removed in a rotary evaporator. The remainder was suspended in ethyl acetate followed by stirring for 15 min and filtering over Celite. After washing generously with ethyl acetate, the solvent was removed in vacuo. The crude product was purified by flash chromatography (silica gel, petroleum ether/ethyl acetate).</div></div><div id="sec5-9" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> General Procedure IV: Ester Hydrolysis to Compounds <b>49</b>–<b>60</b></h3><div class="NLM_p last">For hydrolysis, the ester (1.0 equiv) was dissolved in methanol (0.05 M) and some water and was heated to 50 °C. After complete solvation, potassium hydroxide (1.0–2.5 equiv) was added and the mixture was refluxed for 4 h. When the reaction was completed (monitored by TLC), the solvent was evaporated in vacuo and the remainder was suspended in water. The aqueous layer was set to pH 3 with HCl, and the acid was extracted three times with EtOAc. The solvent was then removed in vacuo to yield the product. In some cases, the acid had to be purified by flash chromatography (DCM/methanol/formic acid).</div></div><div id="sec5-10" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> General Procedure Va: Buchwald–Hartwig Coupling <b>46</b>, <b>47</b>, <b>48</b>, <b>2</b>, <b>3a</b>–<b>c</b>, <b>4a</b>–<b>d</b>, <b>5a</b>–<b>d</b>,<b>m</b>, <b>6a</b>,<b>f</b>,<b>k</b>,<b>p</b>,<b>q</b>, <b>7a</b>, <b>8a</b>,<b>d</b>,<b>k</b>,<b>l</b></h3><div class="NLM_p last">For preparation of the diarylamine, the respective amine (1.1 equiv) was dissolved under inert gas atmosphere in a three-necked flask. A mixture of 1,4-dioxane and <i>tert</i>-butanol (10:2, 0.075 M) was used. The mixture was heated to 60 °C, and Cs<sub>2</sub>CO<sub>3</sub> (1.5 equiv), Pd(OAc)<sub>2</sub> (0.1 equiv), X-Phos ((2-(dicyclohexylphosphino)-2′,4′,6′-triisopropylbiphenyl) (0.3 equiv), and the corresponding chlorodibenzepinone (1.0 equiv) were added. The reaction was refluxed 1–6 h until TLC showed complete conversion. After cooling to room temperature, the suspension was filtered and washed with DCM, methanol, and ethyl acetate. The combined organic layers were removed in vacuo. The remainder was purified using flash chromatography (silica gel, petroleum ether/ethyl acetate, DCM/methanol, ethyl acetate/petroleum ether/DCM).</div></div><div id="sec5-11" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> General Procedure Vb: Buchwald–Hartwig Coupling <b>9a</b>,<b>b</b>, <b>10a</b>,<b>b</b>, <b>11a</b>,<b>b</b>, <b>12</b></h3><div class="NLM_p last">For preparation of the diarylamine, the respective amine (1.2 equiv), K<sub>2</sub>CO<sub>3</sub> (3.0 equiv), BrettPhos G3 precatalyst (0.02 equiv), and the corresponding chlorodibenzepinone (1.0 equiv) was solved in 1,4-dioxane (0.1–0.2 M) under inert gas atmosphere in a three-necked flask. The reaction was stirred at 90 °C until the reaction was completed. After cooling to room temperature, an ammonium chloride solution was added and the product extracted with ethyl acetate. The combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed in vacuo before purification using flash chromatography (silica gel, petroleum ether/ethyl acetate, DCM/methanol).</div></div><div id="sec5-12" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> General Procedure VI: Amide Coupling <b>5e</b>–<b>l</b>,<b>n</b>,<b>o</b>, <b>6b</b>–<b>e</b>,<b>g</b>–<b>j</b>,<b>l</b>–<b>o</b>,<b>r</b>–<b>v</b>, <b>7b</b>,<b>c</b>, <b>8b</b>,<b>c</b>,<b>e</b>–<b>j</b>,<b>m</b>,<b>n</b></h3><div class="NLM_p last">For synthesis of the amide, the arylcarboxylic acid (1.0 equiv) was dissolved in DMF (0.02 M) under inert gas atmosphere, and CDI (2.0 equiv) or DIPEA (2.5 equiv) and TBTU (1.5 equiv) were added. The mixture was stirred at 50 °C for 1–3 h. An excess of the corresponding amine (2.5 equiv) was added, and stirring continued for 1–12 h (monitored by TLC and HPLC). Afterward the mixture was poured into water and extracted with ethyl acetate/DCM. The crude product was purified by flash chromatography (silica gel, petroleum ether/ethyl acetate, DCM/methanol).</div></div><div id="sec5-12-1" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> 8-((5-(Isopropyl(methyl)carbamoyl)-2-methylphenyl)amino)-<i>N</i>-methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>2</b>)</h3><div class="NLM_p last">Compound <b>2</b> was prepared according to general procedure Va. The compound was purified by flash chromatography (silica gel, gradient petroleum ether/ethyl acetate 70:30) to afford 0.11 g (0.23 mmol, 31.0%) of the title compound <b>2</b>. Melting point, 168.6 °C. HPLC, 6.62 min. IR (ATR) [cm<sup>–1</sup>] 3255, 2370, 2076, 1785, 1646, 1554, 1500, 1351, 1261, 1085, 786, 450. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.58–8.49 (m, 1H), 8.37 (s, 1H), 8.34–8.29 (m, 1H), 8.01 (d, <i>J</i> = 8.7 Hz, 1H), 7.95–7.84 (m, 1H), 7.44–7.28 (m, 2H), 7.18 (s, 1H), 7.12–6.98 (m, 1H), 6.83–6.72 (m, 1H), 6.68–6.60 (m, 1H), 4.10–3.83 (m, 1H), 3.15–2.95 (m, 4H), 2.77 (m, 6H), 2.23 (s, 3H), 1.11 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.1, 169.6, 166.0, 149.8, 146.9, 145.4, 144.5, 141.0, 139.0, 138.9, 135.8, 133.56, 132.8, 132.5, 131.3, 130.2, 129.1, 128.9, 126.75, 113.8, 112.5, 39.52, 35.5, 33.8, 26.3, 17.8. ESI-HRMS [M – H]<sup>+</sup> calculated: 470.2438. Found: 470.2434.</div></div><div id="sec5-12-2" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 8-((5-(Isopropylcarbamoyl)-2-methylphenyl)amino)-<i>N</i>-methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>3a</b>)</h3><div class="NLM_p last">Compound <b>3a</b> was prepared according to general procedure Va. The compound was purified by flash chromatography (silica gel, gradient petroleum ether/ethyl acetate 30:70) to afford 0.18 g (0.40 mmol, 47.4%) of the title compound <b>3a</b>. Melting point, 233.1 °C. HPLC, 6.10 min. IR (ATR) [cm<sup>–1</sup>] 3304, 2938, 2356, 1730, 1644, 1522, 1519, 1398, 1157, 960, 785, 719, 626, 512, 418. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.59–8.48 (m, 1H), 8.39 (s, 1H), 8.36–8.30 (m, 1H), 8.20–8.13 (m, 1H), 8.01 (d, <i>J</i> = 8.8 Hz, 1H), 7.90 (dd, <i>J</i> = 7.9, 1.3 Hz, 1H), 7.78–7.72 (m, 1H), 7.64–7.57 (m, 1H), 7.44–7.31 (m, 2H), 6.78–6.67 (m, 1H), 6.60–6.54 (m, 1H), 4.15–3.98 (m, 1H), 3.19–2.97 (m, 4H), 2.78 (d, <i>J</i> = 4.3 Hz, 3H), 2.23 (s, 3H), 1.14 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.2, 165.9, 164.7, 150.2, 145.4, 144.5, 139.0, 138.8, 135.8, 133.6, 133.5, 132.8, 130.8, 130.2, 129.1, 128.9, 126.5, 123.4, 123.0, 113.5, 112.1, 40.9, 40.8, 40.4, 39.9, 39.5, 39.5, 39.1, 38.7, 38.3, 35.5, 33.8, 26.3, 22.3, 17.8. ESI-HRMS [M – H]<sup>+</sup> calculated: 456.2282. Found: 456.229.</div></div><div id="sec5-12-3" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 8-((2-Fluor-5-(isopropylcarbamoyl)phenyl)amino)-<i>N</i>-methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>3b</b>)</h3><div class="NLM_p last">Compound <b>3b</b> was prepared according to general procedure Va. The compound was purified by flash chromatography (silica gel, gradient petroleum ether/ethyl acetate 30:70) to afford 0.28 g (0.61 mmol, 67%) of the title compound <b>3b</b>. Melting point, 162.6 °C. HPLC, 6.15 min. IR (ATR) [cm<sup>–1</sup>] 3312, 2969, 2360, 2342, 1738, 1633, 1575, 1589, 1416, 1354, 1267, 1203, 1115, 1036, 965, 835, 781, 701, 668, 563, 456. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 8.74 (s, 1H), 8.60–8.48 (m, 1H), 8.36 (s, 1H), 8.26 (d, <i>J</i> = 7.8 Hz, 1H), 8.03 (d, <i>J</i> = 8.9 Hz, 1H), 7.92 (d, <i>J</i> = 7.8 Hz, 2H), 7.72–7.60 (m, 1H), 7.45–7.31 (m, 2H), 6.89 (d, <i>J</i> = 8.9 Hz, 1H), 6.76 (s, 1H), 4.19–3.95 (m, 1H), 3.21–3.00 (m, 4H), 2.89–2.71 (m, 3H), 1.19–1.11 (m, 6H). <sup>13</sup>C NMR (50 MHz, CDCl3) δ 191.0, 166.3, 164.5, 157.0 (d, <i>J</i> = 249.7 Hz), 148.9, 145.2 (d, <i>J</i> = 31.6 Hz), 139.2, 133.6, 133.2, 132.1 (d, <i>J</i> = 3.1 Hz), 130.7, 129.4 (d, <i>J</i> = 6.4 Hz), 128.8, 128.6, 128.1, 124.0 (d, <i>J</i> = 7.4 Hz), 123.5, 123.5, 116.5 (d, <i>J</i> = 19.9 Hz), 114.9, 113.3, 35.7, 34.2, 26.6, 22.6. ESI-HRMS [M – H]<sup>+</sup> calculated: 460.2031. Found: 460.2034.</div></div><div id="sec5-12-4" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 8-((4-Fluor-3-(isopropylcarbamoyl)phenyl)amino)-<i>N</i>-methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>3c</b>)</h3><div class="NLM_p last">Compound <b>3c</b> was prepared according to general procedure Va. The compound was purified by flash chromatography (silica gel, gradient petroleum ether/ethyl acetate 20:80) to afford 0.40 g (0.87 mmol, 74.6%) of the title compound <b>3a</b>. Melting point, 210.3 °C. HPLC, 6.27 min. IR (ATR) [cm<sup>–1</sup>] 3292, 2976, 2937, 1737, 1651, 1539, 1435, 1327, 1269, 1138, 966, 852, 814, 775, 668, 522, 461, 424. <sup>1</sup>H NMR (200 MHz, DMSO) δ 8.90 (s, 1H), 8.62–8.47 (m, 1H), 8.38–8.32 (m, 1H), 8.16 (d, <i>J</i> = 8.7 Hz, 1H), 8.03 (d, <i>J</i> = 8.7 Hz, 1H), 7.91 (dd, <i>J</i> = 7.9, 1.9 Hz, 1H), 7.48–7.37 (m, 1H), 7.36–7.19 (m, 3H), 7.01–6.89 (m, 1H), 6.87–6.77 (m, 1H), 4.15–3.94 (m, 1H), 3.20–3.01 (m, 4H), 2.85–2.73 (m, 3H), 1.15 (d, <i>J</i> = 6.6 Hz, 6H). <sup>13</sup>C NMR (50 MHz, DMSO) δ 190.4, 165.9, 162.6, 154.3 (d, <i>J</i> = 243.7 Hz), 148.4, 145.4, 144.5, 138.9, 137.3 (d, <i>J</i> = 2.6 Hz), 133.6, 132.8, 130.3, 129.0 (d, <i>J</i> = 7.5 Hz), 127.5, 125.4 (d, <i>J</i> = 16.4 Hz), 123.0 (d, <i>J</i> = 8.5 Hz), 120.9, 120.8, 116.9 (d, <i>J</i> = 25.5 Hz), 114.1, 112.7, 41.1, 35.4, 33.8, 26.3, 22.2. ESI-HRMS [M – H]<sup>+</sup> calculated: 460.2031. Found: 460.2028.</div></div><div id="sec5-12-5" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 8-((5-(Cyclopropylcarbamoyl)-2-methylphenyl)amino)-<i>N</i>-methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulen-3-carboxamide (<b>4a</b>)</h3><div class="NLM_p last">Compound <b>4a</b> was prepared according to general procedure Va. The compound was purified by flash chromatography (silica gel, gradient petroleum ether/ethyl acetate 30:70) to afford 0.09 g (0.20 mmol, 30.0%) of the title compound <b>3a</b>. Melting point, 235.6 °C. HPLC, 5.79 min. IR (ATR) [cm<sup>–1</sup>] 3344, 3290, 2920, 2850, 1641, 1560, 1485, 1436, 1404, 1207, 1020, 961, 895, 642, 624, 501, 433. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.59–8.49 (m, 1H), 8.42–8.36 (m, 2H), 8.35–8.25 (m, 1H), 8.00 (d, <i>J</i> = 8.8 Hz, 1H), 7.93–7.86 (m, 1H), 7.73 (s, 1H), 7.59–7.52 (m, 1H), 7.43–7.32 (m, 2H), 6.76–6.69 (m, 1H), 6.61–6.53 (m, 1H), 3.15–2.98 (m, 4H), 2.87–2.80 (m, 1H), 2.80–2.73 (m, 3H), 2.23 (s, 3H), 0.71–0.61 (m, 2H), 0.61–0.49 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.2, 166.9, 165.9, 150.1, 145.3, 144.4, 139.0, 138.8, 135.8, 133.5, 133.1, 132.8, 130.9, 130.1, 129.1, 128.8, 126.6, 123.3, 122.8, 113.5, 112.1, 35.5, 33.8, 30.6, 26.2, 17.8, 5.6. ESI-HRMS [M – H]<sup>+</sup> calculated: 454.2125. Found: 454.2121.</div></div><div id="sec5-12-6" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 8-((3-(Cyclopropylcarbamoyl)-4-methylphenyl)amino)-<i>N</i>-methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulen-3-carboxamide (<b>4b</b>)</h3><div class="NLM_p last">Compound <b>4b</b> was prepared according to general procedure Va. The compound was purified by flash chromatography (silica gel, gradient petroleum ether/ethyl acetate 30:70) to afford 0.15 g (0.33 mmol, 34%) of the title compound <b>4b</b>. Melting point, 229.2 °C. HPLC, 5.54 min. IR (ATR) [cm<sup>–1</sup>] 3326, 3264, 3091, 1601, 1552, 1492, 1403, 1341, 1216, 1118, 1031, 937, 863, 825, 701, 606, 526, 418. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.76 (s, 1H), 8.58–8.52 (m, 1H), 8.52–8.45 (m, 1H), 8.35 (s, 1H), 8.02 (d, <i>J</i> = 8.8 Hz, 1H), 7.95–7.85 (m, 2H), 7.65–7.58 (m, 1H), 7.42–7.33 (m, 2H), 6.89 (d, <i>J</i> = 8.8 Hz, 1H), 6.75 (s, 1H), 3.17–3.02 (m, 4H), 2.87–2.75 (m, 4H), 0.72–0.64 (m, 2H), 0.58–0.52 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 192.5, 172.8, 167.0, 166.9, 150.4, 145.1, 144.9, 143.1, 138.9, 138.2, 133.1, 133.0, 132.3, 131.7, 131.0, 129.8, 129.3, 123.6, 123.1, 122.8, 120.7, 35.1, 34.00, 26.7, 17.8, 7.6. ESI-HRMS [M – H]<sup>+</sup> calculated: 454.2125. Found: 454.2128.</div></div><div id="sec5-12-7" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 8-((5-(Cyclopropylcarbamoyl)-2-fluorphenyl)amino)-<i>N</i>-methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>4c</b>)</h3><div class="NLM_p last">Compound <b>4c</b> was prepared according to general procedure Va. The compound was purified by flash chromatography (silica gel, gradient petroleum ether/ethyl acetate 20:80) to afford 0.36 g (0.79 mmol, 78.3%) of the title compound <b>4c</b>. Melting point, 146.7 °C. HPLC, 5.85 min. IR (ATR) [cm<sup>–1</sup>] 3223, 1639, 1574, 1520, 1362, 1273, 1137, 1019, 928, 840, 760, 621, 418. <sup>1</sup>H NMR (400 MHz, DMSO) δ 8.76 (s, 1H), 8.58–8.52 (m, 1H), 8.52–8.45 (m, 1H), 8.35 (s, 1H), 8.02 (d, <i>J</i> = 8.8 Hz, 1H), 7.95–7.85 (m, 2H), 7.65–7.58 (m, 1H), 7.42–7.33 (m, 2H), 6.89 (d, <i>J</i> = 8.8 Hz, 1H), 6.75 (s, 1H), 3.17–3.02 (m, 4H), 2.87–2.75 (m, 4H), 0.72–0.64 (m, 2H), 0.58–0.52 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO) δ 190.9, 166.5, 166.2, 156.9 (d, <i>J</i> = 249.6 Hz), 148.7, 145.3, 144.7, 139.0, 133.5, 133.1, 131.6 (d, <i>J</i> = 2.8 Hz), 130.5, 129.2 (d, <i>J</i> = 9.6 Hz), 128.6 (d, <i>J</i> = 12.3 Hz), 128.0, 123.8 (d, <i>J</i> = 8.2 Hz), 123.1, 123.1, 116.3 (d, <i>J</i> = 20.4 Hz), 114.8, 113.2, 40.2, 35.5, 34.0, 3.5, 23.3, 5.9. ESI-HRMS [M – H]<sup>+</sup> calculated: 458.1874. Found: 458.1878.</div></div><div id="sec5-12-8" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 8-((3-(Cyclopropylcarbamoyl)-2-fluorphenyl)amino)-<i>N</i>-methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>4d</b>)</h3><div class="NLM_p last">Compound <b>4d</b> was prepared according to general procedure Va. The compound was purified by flash chromatography (silica gel, gradient petroleum ether/ethyl acetate 20:80) to afford 0.33 g (0.72 mmol, 64.0%) of the title compound <b>4d</b>. Melting point, 226.9 °C. HPLC, 5.92 min. IR (ATR) [cm<sup>–1</sup>] 3313, 3089, 2956, 1633, 1492, 1327, 1268, 1136, 1036, 927, 786, 702, 612, 453, 414. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.02 (s, 1H), 8.83 (s, 1H), 8.63–8.48 (m, 1H), 8.34 (s, 1H), 8.08–7.97 (m, 1H), 7.93–7.75 (m, 2H), 7.46–7.28 (m, 1H), 7.32–7.13 (m, 1H), 7.00–6.90 (m, 2H), 6.83 (s, 1H), 3.16–3.00 (m, 4H), 2.85–2.71 (m, 3H), 2.07–2.00 (m, 1H), 0.84–0.72 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 206.3, 145.3, 144.4, 138.8, 137.3, 133.5, 132.8, 131.7, 130.2, 128.9 (d, <i>J</i> = 12.0 Hz), 127.5, 123.2 (d, <i>J</i> = 7.4 Hz), 120.7, 120.7, 117.0, 116.8, 114.1, 112.6, 35.3, 33.8, 26.2, 22.9, 5.7. ESI-HRMS [M – H]<sup>+</sup> calculated: 458.1874. Found: 458.1869.</div></div><div id="sec5-12-9" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 8-((3-(Cyclopropanecarboxamido)-4-fluorophenyl)amino)-<i>N</i>-methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>5a</b>)</h3><div class="NLM_p last">Compound <b>5a</b> was prepared according to general procedure Va. The compound was purified by flash chromatography (silica gel, gradient petroleum ether/ethyl acetate 20:80) to afford 0.39 g (0.85 mmol, 85.0%) of the title compound <b>5a</b>. Melting point, 193.9 °C. HPLC, 5.90 min. IR (ATR) [cm<sup>–1</sup>] 3315, 1615, 1538, 1486, 1403, 1317, 1199, 1039, 950, 809, 760, 589, 483, 451. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.02 (s, 1H), 8.83 (s, 1H), 8.63–8.48 (m, 1H), 8.34 (s, 1H), 8.08–7.97 (m, 1H), 7.93–7.75 (m, 2H), 7.46–7.28 (m, 1H), 7.32–7.13 (m, 1H), 7.00–6.90 (m, 2H), 6.83 (s, 1H), 3.16–3.00 (m, 4H), 2.85–2.71 (m, 3H), 2.07–2.00 (m, 1H), 0.84–0.72 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO) δ 190.3, 172.2, 170.3, 165.9, 149.9, 148.7 (d, <i>J</i> = 239.9 Hz), 145.3, 144.4, 138.9, 137.0 (d, <i>J</i> = 2.0 Hz), 133.4, 132.8, 130.2, 128.9 (d, <i>J</i> = 19.5 Hz), 127.1, 126.8 (d, <i>J</i> = 12.7 Hz), 116.0 (d, <i>J</i> = 6.7 Hz), 115.8, 115.6 (d, <i>J</i> = 7.8 Hz), 113.9, 112.5, 35.4, 33.8, 26.2, 14.0, 7.5. ESI-HRMS [M – H]<sup>+</sup> calculated: 458.1874. Found: 458.1879.</div></div><div id="sec5-12-10" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 8-((5-(Cyclopropancarboxamido)-2-fluorphenyl)amino)-<i>N</i>-methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>5b</b>)</h3><div class="NLM_p last">Compound <b>5b</b> was prepared according to general procedure Va. The compound was purified by flash chromatography (silica gel, gradient petroleum ether/ethyl acetate 20:80) to afford 0.38 g (0.83 mmol, 83.0%) of the title compound <b>5b</b>. Melting point, 219.8 °C. HPLC, 6.40 min. IR (ATR) [cm<sup>–1</sup>] 3281, 1602, 1525, 1505, 1503, 1353, 1360, 1194, 1114, 955, 810, 785, 611, 521, 451. <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.02 (s, 1H), 8.83 (s, 1H), 8.63–8.48 (m, 1H), 8.34 (s, 1H), 8.08–7.97 (m, 1H), 7.93–7.75 (m, 2H), 7.46–7.28 (m, 1H), 7.32–7.13 (m, 1H), 7.00–6.90 (m, 2H), 6.83 (s, 1H), 3.16–3.00 (m, 4H), 2.85–2.71 (m, 3H), 2.07–2.00 (m, 1H), 0.84–0.72 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO) δ 190.6, 171.6, 165.9, 150.5 (d, <i>J</i> = 240.9 Hz), 148.5, 145.1, 144.5, 138.9, 136.00 (d, <i>J</i> = 2.3 Hz), 133.2, 132.8, 130.3, 129.0 (d, <i>J</i> = 7.8 Hz), 128.3 (d, <i>J</i> = 12.6 Hz), 127.5, 116.1 (d, <i>J</i> = 20.5 Hz), 114.6, 114.5, 113.7, 113.0, 35.3, 33.7, 26.3, 14.5, 7.1.ESI-HRMS [M – H]<sup>+</sup> calculated: 458.1874. Found: 458.1878.</div></div><div id="sec5-12-11" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 8-((5-(Cyclopropancarboxamido)-2-methylphenyl)amino)-<i>N</i>-methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>5c</b>)</h3><div class="NLM_p last">Compound <b>5c</b> was prepared according to general procedure Va. The compound was purified by flash chromatography (silica gel, gradient petroleum ether/ethyl acetate 30:70) to afford 0.34 g (0.75 mmol, 75.0%) of the title compound <b>5c</b>. Melting point, 209.7 °C. HPLC, 6.11 min. IR (ATR) [cm<sup>–1</sup>] 3291, 1633, 1574, 1519, 1403, 1353, 1263, 1196, 1114, 954, 821, 785, 760, 611, 451. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.15 (s, 1H), 8.59–8.51 (m, 1H), 8.34 (s, 1H), 8.28 (s, 1H), 8.01 (d, <i>J</i> = 8.9 Hz, 1H), 7.90 (d, <i>J</i> = 7.7 Hz, 1H), 7.61 (s, 1H), 7.38 (d, <i>J</i> = 7.7 Hz, 1H), 7.32–7.24 (m, 1H), 7.20–7.13 (m, 1H), 6.78 (d, <i>J</i> = 8.9 Hz, 1H), 6.64 (s, 1H), 3.14–2.96 (m, 4H), 2.87–2.71 (m, 3H), 2.14 (s, 3H), 1.80–1.65 (m, 1H), 0.83–0.68 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.2, 171.5, 166.1, 150.1, 145.3, 144.4, 139.1, 138.9, 138.0, 133.5, 132.8, 131.0, 130.1, 129.1, 128.8, 126.4, 126.4, 115.3, 114.3, 113.7, 112.4, 35.6, 33.84, 4.4, 17.2, 14.0, 7.0. ESI-HRMS [M – H]<sup>+</sup> calculated: 454.2128. Found: 454.2125.</div></div><div id="sec5-12-12" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 8-((3-(Cyclopropancarboxamido)-4-methylphenyl)amino)-<i>N</i>-methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>5d</b>)</h3><div class="NLM_p last">Compound <b>5d</b> was prepared according to general procedure Va. The compound was purified by flash chromatography (silica gel, gradient petroleum ether/ethyl acetate 30:70) to afford 0.20 g (0.44 mmol, 44.0%) of the title compound <b>5d</b>. Melting point, 205.9 °C. HPLC, 5.95 min. IR (ATR) [cm<sup>–1</sup>] 3238, 2358, 1639, 1603, 1525, 1504, 1445, 1395, 1354, 1267, 1113, 1029, 889, 852, 780, 616, 455. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.46 (s, 1H), 8.79 (s, 1H), 8.62–8.47 (m, 1H), 8.38–8.28 (m, 1H), 8.01 (d, <i>J</i> = 8.5 Hz, 1H), 7.95–7.86 (m, 1H), 7.48–7.33 (m, 2H), 7.15 (d, <i>J</i> = 8.5 Hz, 1H), 7.01–6.81 (m, 3H), 3.17–2.97 (m, 4H), 2.84–2.72 (m, 3H), 2.20 (s, 3H), 2.01–1.81 (m, 1H), 0.84–0.72 (m, 4H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.5, 172.1, 166.3, 149.2, 145.7, 144.8, 139.3, 139.0, 137.4, 133.9, 133.1, 131.2, 130.6, 129.4, 129.2, 127.1, 124.9, 116.9, 116.7, 114.2, 112.9, 35.8, 34.1, 26.6, 17.6, 14.4, 7.4. ESI-HRMS [M – H]<sup>+</sup> calculated: 454.2128. Found: 454.2125.</div></div><div id="sec5-12-13" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 8-((5-(Cyclopropancarboxamido)-2-fluorophenyl)amino)-<i>N</i>-(2-morpholinoethyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>5e</b>)</h3><div class="NLM_p last">Compound <b>5e</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.10 g (0.18 mmol, 30.0%) of the title compound <b>5e</b>. Melting point, 148.7 °C. HPLC, 4.50 min. IR (ATR) [cm<sup>–1</sup>] 3272, 2923, 1634, 1580, 1530, 1435, 1403, 1262, 1114, 1030, 955, 858, 785, 613, 455. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.23 (s, 1H), 8.67 (s, 1H), 8.58–8.44 (m, 1H), 8.07–7.97 (m, 1H), 7.91 (d, <i>J</i> = 7.7 Hz, 1H), 7.79–7.68 (m, 1H), 7.42 (d, <i>J</i> = 7.7 Hz, 1H), 7.32–7.16 (m, 2H), 6.93–6.85 (m, 1H), 6.77 (s, 1H), 3.57 (s, 4H), 3.44–3.37 (m, 2H), 3.15–3.02 (m, 4H), 2.47 (s, 2H), 2.42 (s, 3H), 1.78–1.67 (m, 1H), 0.81–0.75 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.8, 171.7, 165.6, 150.8 (d, <i>J</i> = 240.8 Hz), 148.7, 145.2, 144.7, 139.1, 136.2 (d, <i>J</i> = 2.3 Hz), 133.3, 133.1, 130.6, 129.2, 129.1, 128.5 (d, <i>J</i> = 13.1 Hz), 127.7, 116.3 (d, <i>J</i> = 20.7 Hz), 114.8, 114.0, 114.0, 113.2, 66.3, 57.5, 5.4, 36.7, 35.6, 33.9, 1487, 7.3. ESI-HRMS [M – H]<sup>+</sup> calculated: 557.2559. Found: 557.2553.</div></div><div id="sec5-12-14" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 8-((3-(Cyclopropancarboxamido)-4-fluorophenyl)amino)-<i>N</i>-(2-morpholinoethyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>5f</b>)</h3><div class="NLM_p last">Compound <b>5f</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.07 g (0.13 mmol, 17.0%) of the title compound <b>5f</b>. Melting point, 203.0 °C. HPLC, 4.59 min. IR (ATR) [cm<sup>–1</sup>] 2816, 1636, 1577, 1488, 1398, 1354, 1261, 1213, 1143, 1112, 1024, 950, 860, 782, 567, 418. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.99 (s, 1H), 8.82 (s, 1H), 8.51 (t, <i>J</i> = 5.3 Hz, 1H), 8.31 (s, 1H), 8.00 (d, <i>J</i> = 8.2 Hz, 1H), 7.94–7.78 (m, 2H), 7.40 (d, <i>J</i> = 8.2 Hz, 1H), 7.28–7.12 (m, 1H), 7.00–6.85 (m, 2H), 6.85–6.72 (m, 1H), 3.61–3.51 (m, 4H), 3.44–3.34 (m, 2H), 3.19–2.96 (m, 4H), 2.45 (s, 2H), 2.43–2.34 (m, 4H), 0.81–0.73 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.3, 172.2, 165.4, 151.2 (d, <i>J</i> = 223.1 Hz), 148.7, 146.6, 145.3, 144.5 (d, <i>J</i> = 1.9 Hz), 138.9, 137.0, 133.4, 132.8, 130.3, 129.0, 128.8, 127.0, 126.8 (d, <i>J</i> = 12.4 Hz), 116.1 (d, <i>J</i> = 9.6 Hz), 115.7 (d, <i>J</i> = 20.8 Hz), 113.9, 112.5, 66.1, 57.3, 53.2, 36.5, 35.4, 33.7, 14.0, 7.4. ESI-HRMS [M – H]<sup>+</sup> calculated: 557.2559. Found: 557.2558.</div></div><div id="sec5-12-15" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 8-((3-(Cyclopropanecarboxamido)-4-fluorophenyl)amino)-<i>N-</i>(2,3-dihydroxypropyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>5g</b>)</h3><div class="NLM_p last">Compound <b>5g</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.03 g (0.06 mmol, 23.0%) of the title compound <b>5g</b>. Melting point, 163.9 °C. HPLC, 3.19 min. IR (ATR) [cm<sup>–1</sup>] 3302, 2929, 1601, 1531, 1487, 1402, 1354, 1263, 1215, 1113, 953, 859, 784, 760, 521, 454. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.99 (s, 1H), 8.82 (s, 1H), 8.51 (t, <i>J</i> = 5.3 Hz, 1H), 8.31 (s, 1H), 8.00 (d, <i>J</i> = 8.2 Hz, 1H), 7.94–7.78 (m, 2H), 7.40 (d, <i>J</i> = 8.2 Hz, 1H), 7.28–7.12 (m, 1H), 7.00–6.85 (m, 2H), 6.85–6.72 (m, 1H), 3.61–3.51 (m, 4H), 3.44–3.34 (m, 2H), 3.19–2.96 (m, 4H), 2.45 (s, 2H), 2.43–2.34 (m, 4H), 0.81–0.73 (m, 4H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.3, 172.2, 165.9, 148.8, 145.3, 144.5, 138.9, 137.0 (d, <i>J</i> = 2.4 Hz), 133.4, 132.8, 130.39, 129.2, 128.8, 127.1, 126.8 (d, <i>J</i> = 12.6 Hz), 116.1 (d, <i>J</i> = 7.8 Hz), 115.8, 115.6 (d, <i>J</i> = 7.8 Hz).114.0, 112.5, 70.4, 63.9, 43.0, 35.5, 33.8, 14.0, 7.5. ESI-HRMS [M – H]<sup>+</sup> calculated: 518.2086. Found: 518.2081.</div></div><div id="sec5-12-16" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 8-((5-(Cyclopropanecarboxamido)-2,4-difluorophenyl)amino)-<i>N</i>-(2-morpholinoethyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>5h</b>)</h3><div class="NLM_p last">Compound <b>5h</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.08 g (0.14 mmol, 55.6%) of the title compound <b>5h</b>. Melting point, 120.4 °C. HPLC, 4.58 min. IR (ATR) [cm<sup>–1</sup>] 3015, 2696, 1739, 1637, 1538, 1436, 1365, 1216, 1112, 859, 785, 527 <sup>1</sup>H NMR (400 MHz, Acetone<i>-d6</i>) δ 10.05 (s, 1H), 8.62 (s, 1H), 8.53 (t, <i>J</i> = 5.6 Hz, 1H), 8.35–8.28 (m, 1H), 7.99 (d, <i>J</i> = 8.8 Hz, 1H), 7.96–7.88 (m, 2H), 7.48–7.37 (m, 2H), 6.79 (d, <i>J</i> = 8.9 Hz, 1H), 6.66 (s, 1H), 3.59–3.53 (m, 4H), 3.41–3.37 (m, 2H), 3.14–3.01 (m, 4H), 2.48–2.44 (m, 2H), 2.41 (s, 4H), 1.98–1.94 (m, 1H), 0.83–0.77 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.5, 172.2, 165.4, 149.1, 145.2, 144.5, 138.9, 133.2, 132.9, 130.4, 129.0, 128.9, 127.2, 124.0 (dd, <i>J</i> = 12.4, 3.2 Hz), 122.9 (dd, <i>J</i> = 12.6, 3.5 Hz), 119.5, 113.9, 112.4, 104.8 (t, <i>J</i> = 25.3 Hz), 66.2, 57.3, 53.3, 36.5, 35.4, 33.7, 13.9, 7.4. ESI-HRMS [M – H]<sup>+</sup> calculated: 575.2464 found: 575.2459.</div></div><div id="sec5-12-17" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 8-((5-(Cyclopropanecarboxamido)-2,4-difluorophenyl)amino)-<i>N</i>-(2-hydroxyethyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>5i</b>)</h3><div class="NLM_p last">Compound <b>5i</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.05 g (0.10 mmol, 92.6%) of the title compound <b>5i</b>. Melting point, 130.2 °C. HPLC, 6.32 min. IR (ATR) [cm<sup>–1</sup>] 3271, 1633, 1603, 1537, 1403, 1266, 1193, 1114, 1062, 857, 758, 516 <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.04 (s, 1H), 8.61 (s, 1H), 8.57–8.49 (m, 1H), 8.39–8.26 (m, 1H), 8.07–7.85 (m, 3H), 7.51–7.34 (m, 2H), 6.84–6.72 (m, 1H), 6.67–6.56 (m, 1H), 4.80–4.66 (m, 1H), 3.58–3.45 (m, 3H), 3.38–3.36 (m, 2H), 3.20–2.94 (m, 4H), 2.03–1.85 (m, 1H), 0.85–0.70 (m, 4H). ESI-HRMS [M – H]<sup>+</sup> calculated: 506.1886 found: 506.1892.</div></div><div id="sec5-12-18" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> 8-((5-(Cyclopropanecarboxamido)-2,4-difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>5j</b>)</h3><div class="NLM_p last">Compound <b>5j</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.04 g (0.09 mmol, 57.3%) of the title compound <b>5j</b>. Melting point, 243.4 °C. HPLC, 6.20 min. IR (ATR) [cm<sup>–1</sup>] 3324, 3270, 3184, 1662, 1580, 1496, 1404, 1388, 1314, 1275, 1221, 1119, 1061, 863, 784, 617, 529. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.05 (s, 1H), 8.61 (s, 1H), 8.35 (s, 1H), 8.07 (s, 1H), 8.01–7.88 (m, 3H), 7.52–7.34 (m, 3H), 6.78 (d, <i>J</i> = 9.0 Hz, 1H), 6.66 (s, 1H), 3.17–3.01 (m, 4H), 2.02–1.92 (m, 1H), 0.84–0.73 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.5, 172.2, 167.2, 149.0, 145.1, 144.6, 138.9, 133.2, 132.6, 130.6, 129.5, 128.8, 127.3, 124.0 (dd, <i>J</i> = 12.9, 2.8 Hz), 122.9 (dd, <i>J</i> = 12.6, 3.5 Hz), 119.5, 113.9, 112.4, 104.8 (t, <i>J</i> = 25.1 Hz), 35.3, 33.7, 13.9, 7.4. ESI-HRMS [M – H]<sup>+</sup> calculated: 462.1624 found: 462.1639.</div></div><div id="sec5-12-19" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> 8-((5-(Cyclopropanecarboxamido)-2,4-difluorophenyl)amino)-<i>N</i>-methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>5k</b>)</h3><div class="NLM_p last">Compound <b>5k</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.03 g (0.03 mmol, 42.3%) of the title compound <b>5k</b>. Melting point, 240.0 °C. HPLC, 6.65 min. IR (ATR) [cm<sup>–1</sup>] 3408, 3311, 3051, 1669, 1563, 1435, 1360, 1218, 1106, 1030, 931, 826, 719, 679, 625, 503, 462. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.07 (s, 1H), 8.62 (s, 1H), 8.59–8.53 (m, 1H), 8.31 (s, 1H), 7.98 (d, <i>J</i> = 8.8 Hz, 1H), 7.95–7.85 (m, 2H), 7.49–7.39 (m, 2H), 6.78 (d, <i>J</i> = 10.0 Hz, 1H), 6.65 (s, 1H), 3.15–3.02 (m, 4H), 2.81–2.73 (m, 3H), 2.01–1.91 (m, 1H), 0.83–0.76 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.6, 172.3, 166.0, 149.1, 145.2, 144.5, 138.9, 133.3, 132.8, 130.3, 129.0, 129.0, 127.3, 124.1, 123.0, 119.6, 113.9, 112.4, 104.8, 35.4, 33.8, 26.3, 14.0, 7.5. ESI-HRMS [M – H]<sup>+</sup> calculated: 475.1707 found: 475.1727.</div></div><div id="sec5-12-20" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 8-((5-(Cyclopropancarboxamido)-2,4-difluorphenyl)amino)-<i>N</i>-(2,3-dihydroxypropyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulen-3-carboxamid (<b>5l</b>)</h3><div class="NLM_p last">Compound <b>5l</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.05 g (0.10 mmol, 44.9%) of the title compound <b>5h</b>. Melting point, 149.0 °C. HPLC, 7.45 min. IR (ATR) [cm<sup>–1</sup>] 2359, 2934, 1665, 1568, 1504, 1404, 1316, 1354, 1201, 1158, 1112, 1052, 923, 786, 706, 576, 456. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.40–8.35 (m, 2H), 8.11–8.02 (m, 2H), 7.97–7.85 (m, 4H), 7.42–7.32 (m, 2H), 7.13 (t, <i>J</i> = 10.4 Hz, 2H), 6.89–6.81 (m, 2H), 6.72 (s, 2H), 4.36–4.27 (m, 2H), 4.13–4.03 (m, 2H), 3.81–3.67 (m, 2H), 3.57–3.48 (m, 4H), 3.20–3.05 (m, 8H), 1.92–1.80 (m, 2H), 0.99–0.92 (m, 4H), 0.92–0.80 (m, 5H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 193.3, 169.8, 150.9, 147.2, 147.0, 140.8, 134.9, 134.0, 131.7, 130.6, 130.2, 129.1, 126.1 (dd, <i>J</i> = 11.1, 4.2 Hz), 123.8 (dd, <i>J</i> = 12.2, 3.3 Hz), 121.0, 115.3, 114.0, 110.6, 105.4 (t, <i>J</i> = 25.1 Hz), 76.0, 68.3, 43.5, 37.0, 35.6, 15.3, 8.3. ESI-HRMS [M – H]<sup>+</sup> calculated: 536.1991. Found: 536.2005.</div></div><div id="sec5-12-21" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Methyl 3-((3-(Cyclopropanecarboxamido)-4-fluorophenyl)amino)-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxylate (<b>5m</b>)</h3><div class="NLM_p last">Compound <b>5m</b> was prepared according to general procedure Va to afford 0.04 g (0.08 mmol, 28.8%) of the title compound <b>5m</b>. Melting point, 237.9 °C. HPLC, 7.00 min. IR (ATR) [cm<sup>–1</sup>] 3254, 2921, 1724, 1607, 1556, 1505, 1434, 1262, 1122, 1093. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.26 (s, 1H), 8.88 (s, 1H), 8.37 (s, 1H), 8.16 (d, <i>J</i> = 7.7 Hz, 1H), 8.04 (d, <i>J</i> = 8.9 Hz, 1H), 7.72 (dd, <i>J</i> = 18.0, 6.9 Hz, 2H), 7.24 (dd, <i>J</i> = 23.3, 13.2 Hz, 2H), 6.76 (d, <i>J</i> = 8.7 Hz, 1H), 6.44 (s, 1H), 5.29 (s, 2H), 3.89 (s, 3H), 1.77–1.67 (m, 1H), 0.78 (d, <i>J</i> = 5.7 Hz, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 186.0, 171.6, 165.4, 162.8, 151.3, 149.4, 140.6, 140.1, 136.1, 133.4, 132.6, 130.1, 129.8, 128.8, 127.7, 116.6, 116.1, 115.2, 114.1, 110.6, 102.6, 72.4, 52.4, 14.5, 7.1. ESI-HRMS [M – H]<sup>+</sup> calculated: 461.1507. Found: 461.1511.</div></div><div id="sec5-12-22" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> 3-((3-(Cyclopropanecarboxamido)-4-fluorophenyl)amino)-<i>N-</i>(2-hydroxyethyl)-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxamide (<b>5n</b>)</h3><div class="NLM_p last">Compound <b>5n</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 90:10) to afford 0.05 g (0.12 mmol, 87.7%) of the title compound <b>5n</b>. Melting point, 217.2 °C. IR (ATR) [cm<sup>–1</sup>] 3271, 2945, 2854, 1633, 1606, 1525, 1383, 1257, 1229, 1124, 1031, 955. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.33 (d, <i>J</i> = 43.4 Hz, 1H), 8.85 (s, 1H), 8.66 (s, 1H), 8.31 (s, 1H), 8.05 (t, <i>J</i> = 8.5 Hz, 2H), 7.95 (s, 1H), 7.73 (t, <i>J</i> = 17.5 Hz, 1H), 7.62 (d, <i>J</i> = 7.7 Hz, 1H), 7.37–7.12 (m, 2H), 6.83–6.65 (m, 1H), 6.45 (s, 1H), 5.29 (d, <i>J</i> = 25.6 Hz, 2H), 4.76 (t, <i>J</i> = 5.2 Hz, 1H), 3.53 (d, <i>J</i> = 5.6 Hz, 2H), 1.73 (d, <i>J</i> = 5.1 Hz, 1H), 1.19 (dd, <i>J</i> = 26.2, 6.5 Hz, 2H), 1.05 (t, <i>J</i> = 7.0 Hz, 1H), 0.79 (s, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 186.8, 171.6, 165.4, 162.7, 162.3, 151.2, 149.4, 139.9, 138.3, 136.1, 135.1, 133.2, 130.9, 128.2, 127.8, 127.7, 116.8, 116.3, 116.1, 115.1, 114.1, 110.5, 102.6, 72.4, 59.7, 14.5, 7.1. ESI-HRMS [M – H]<sup>+</sup> calculated: 494.1886. Found: 494.1881.</div></div><div id="sec5-12-23" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> 3-((3-(Cyclopropanecarboxamido)-4-fluorophenyl)amino)-<i>N-</i>(1,3-dihydroxypropan-2-yl)-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxamide (<b>5o</b>)</h3><div class="NLM_p last">Compound <b>5o</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 90:10) to afford 0.036 g (0.14 mmol, 53,0%) of the title compound <b>5o</b>. Melting point, 234.1 °C. HPLC, 4.75 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.26 (s, 1H), 8.84 (s, 1H), 8.31 (s, 1H), 8.21 (d, <i>J</i> = 7.9 Hz, 1H), 8.05 (dd, <i>J</i> = 14.2, 8.4 Hz, 2H), 7.74 (d, <i>J</i> = 5.9 Hz, 1H), 7.62 (d, <i>J</i> = 7.8 Hz, 1H), 7.24 (dd, <i>J</i> = 23.0, 12.9 Hz, 2H), 6.76 (d, <i>J</i> = 8.8 Hz, 1H), 6.44 (s, 1H), 5.26 (s, 2H), 4.68 (s, 2H), 3.98 (dd, <i>J</i> = 12.9, 6.0 Hz, 1H), 3.52 (d, <i>J</i> = 4.3 Hz, 4H), 1.72 (dd, <i>J</i> = 12.0, 6.0 Hz, 1H), 1.23 (s, 1H), 0.78 (d, <i>J</i> = 5.8 Hz, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 186.9, 171.6, 165.3, 162.7, 151.2, 139.9, 138.2, 136.0, 135.3, 133.1, 131.1, 128.1, 127.9, 116.8, 116.3, 116.1, 115.2, 114.1, 110.4, 102.6, 72.4, 60.4, 54.0, 14.5, 7.1. FAB (<i>m</i>/<i>z</i>): 520.3 [M – H]<sup>+</sup>.</div></div><div id="sec5-12-24" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Methyl 8-((4-Fluoro-3-(thiophene-2-carboxamido)phenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxylate (<b>6a</b>)</h3><div class="NLM_p last">Compound <b>6a</b> was prepared according to general procedure Va to afford 0.06 g (0.12 mmol, 60%) of the title compound <b>6a</b>. Melting point, 98.3 °C. HPLC, 7.55 min. IR (ATR) [cm<sup>–1</sup>] 3330, 2916, 1601, 1555, 1515, 1435, 1414, 1383, 1353, 1217, 1109, 954, 881, 853, 736, 701, 520. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 8.66–8.60 (m, 1H), 8.19 (dd, <i>J</i> = 6.9, 2.7 Hz, 1H), 8.12 (d, <i>J</i> = 8.8 Hz, 1H), 8.07–7.96 (m, 2H), 7.66 (dd, <i>J</i> = 3.8, 1.1 Hz, 1H), 7.56 (dd, <i>J</i> = 5.0, 1.1 Hz, 1H), 7.15–7.07 (m, 1H), 7.05–6.96 (m, 1H), 6.93–6.82 (m, 2H), 6.71 (d, <i>J</i> = 2.2 Hz, 1H), 6.45 (s, 1H), 3.90 (s, 3H), 3.22–2.94 (m, 4H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 191.4, 166.7, 159.9, 148.7 (d, <i>J</i> = 240.2 Hz), 148.4, 146.6, 145.4, 139.7, 138.7, 137.2 (d, <i>J</i> = 2.8 Hz), 134.2, 132.4 (d, <i>J</i> = 9.7 Hz), 131.6, 129.0, 129.0, 128.8, 128.6, 128.1, 126.8 (d, <i>J</i> = 11.3 Hz), 116.8 (d, <i>J</i> = 7.4 Hz), 115.5 (d, <i>J</i> = 20.4 Hz), 114.9, 114.7, 113.4, 77.2, 52.2, 35.9, 34.8. ESI-HRMS [M + H]<sup>+</sup> calculated: 501.1279. Found: 501.1277.</div></div><div id="sec5-12-25" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> <i>N-</i>(2-Fluoro-5-((7-((2-morpholinoethyl)carbamoyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulen-2-yl)amino)phenyl)thiophene-2-carboxamide (<b>6b</b>)</h3><div class="NLM_p last">Compound <b>6b</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.03 g (0.05 mmol, 64.0%) of the title compound <b>6b</b>. Melting point, °C. HPLC, 6,93 min, IR (ATR) [cm<sup>–1</sup>] 3290, 2920, 1633, 1530, 1504, 1442, 1416, 1258, 1213, 1144, 1111, 1068, 913, 854, 719, 493, 524, 450, 426. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 9.17 (s, 1H), 8.34 (s, 2H), 8.13–7.85 (m, 10H), 7.85–7.70 (m, 3H), 7.41–7.30 (m, 2H), 7.23–7.11 (m, 4H), 7.08–6.97 (m, 4H), 6.93 (s, 2H), 3.57 (s, 9H), 3.53–3.46 (m, 4H), 3.20–3.08 (m, 8H), 2.59–2.51 (m, 4H), 2.43 (s, 8H), 2.00–1.99 (m, 8H). <sup>13</sup>C NMR (100 MHz, acetone-<i>d</i><sub>6</sub>) δ 205.7, 191.2, 166.6, 146.4, 145.7, 143.2, 140.4, 140.3, 138.5, 138.5, 138.5, 134.57, 134.4, 132.5, 131.3, 129.9, 129.8, 129.2, 128.8, 116.7, 116.5, 115.3, 115.2, 113.9, 113.9, 109.8, 67.5, 58.4, 54.5, 37.5, 36.7, 35.2. ESI-HRMS [M – H]<sup>+</sup> calculated: 599.2117. Found: 599.2123.</div></div><div id="sec5-12-26" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> <i>N-</i>(2-Fluoro-5-((7-((2-hydroxyethyl)carbamoyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulen-2-yl)amino)phenyl)thiophene-2-carboxamide (<b>6c</b>)</h3><div class="NLM_p last">Compound <b>6c</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 96:04) to afford 0.03 g (0.05 mmol, 33.0%) of the title compound <b>6c</b>. Melting point, 106.2 °C. HPLC, 5.70 min IR (ATR) [cm<sup>–1</sup>] 1715, 1652, 1530, 1436, 1348, 1261, 1067, 965, 857, 844, 828, 751, 696, 534, 478, 441. <sup>1</sup>H NMR (200 MHz, acetone-<i>d</i><sub>6</sub>) δ 9.24 (s, 1H), 8.41 (d, <i>J</i> = 1.6 Hz, 1H), 8.15–8.06 (m, 2H), 8.06–7.92 (m, 4H), 7.81 (d, <i>J</i> = 4.9 Hz, 1H), 7.42–7.33 (m, 1H), 7.28–7.16 (m, 2H), 7.16–6.89 (m, 4H), 3.77–3.66 (m, 2H), 3.59–3.49 (m, 2H), 3.24–3.07 (m, 4H). <sup>13</sup>C NMR (50 MHz, acetone-<i>d</i><sub>6</sub>) δ 206.3, 191.3, 167.4, 161.0, 151.0 (d, <i>J</i> = 240.9 Hz), 148.6, 146.5, 145.9, 140.4, 140.3, 138.5 (d, <i>J</i> = 2.7 Hz), 134.7, 134.3, 132.7, 131.4, 130.0, 130.0 (d, <i>J</i> = 13.6 Hz), 129.1, 128.9, 128.5, 127.5 (d, <i>J</i> = 12.6 Hz), 118.3 (d, <i>J</i> = 7.3 Hz), 117.6, 117.6, 116.7 (d, <i>J</i> = 20.9 Hz), 115.3, 113.9, 62.0, 43.7, 36.8, 35.3. ESI-HRMS [M – H]<sup>+</sup> calculated: 530.1543. Found: 530.1544.</div></div><div id="sec5-12-27" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> <i>N-</i>(5-((7-Carbamoyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulen-2-yl)amino)-2-fluorophenyl)thiophene-2-carboxamide (<b>6d</b>)</h3><div class="NLM_p last">Compound <b>6d</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.03 g (0.04 mmol, 68.0%) of the title compound <b>6d</b> (0.025 g, 68%). Melting point, 65.4 °C. HPLC, 5.73 min. IR (ATR) [cm<sup>–1</sup>] 3305, 2920, 2850, 1651, 1600, 1576, 1525, 1416, 1394, 1260, 1168, 1109, 922, 853, 768, 451. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 9.24 (s, 1H), 8.49–8.43 (m, 1H), 8.15–8.05 (m, 2H), 8.05–7.97 (m, 3H), 7.83–7.77 (m, 1H), 7.70–7.61 (m, 1H), 7.41–7.36 (m, 1H), 7.24–7.16 (m, 2H), 7.11–7.01 (m, 2H), 6.96 (s, 1H), 6.72 (s, 1H), 3.23–3.09 (m, 4H). <sup>13</sup>C NMR (100 MHz, acetone-<i>d</i><sub>6</sub>) δ 191.3, 168.5, 160.9, 150.9 (d, <i>J</i> = 240.8 Hz), 149.8, 146.4, 146.0, 140.4, 140.4, 138.5 (d, <i>J</i> = 2.2 Hz), 134.6, 133.8, 132.6, 131.6, 130.6, 130.0, 129.8, 129.2, 128.8, 127.5 (d, <i>J</i> = 12.7 Hz), 118.28 (d, <i>J</i> = 7.3 Hz), 117.6, 116.6 (d, <i>J</i> = 21.1 Hz), 115.3, 113.9, 36.7, 35.3, 29.8. ESI-HRMS [M – H]<sup>+</sup> calculated: 486.1287. Found: 486.1282.</div></div><div id="sec5-12-28" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> <i>N-</i>(5-((7-((2,3-Dihydroxypropyl)carbamoyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulen-2-yl)amino)-2-fluorophenyl)thiophene-2-carboxamide (<b>6e</b>)</h3><div class="NLM_p last">Compound <b>6e</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.03 g (0.05 mmol, 49.0%) of the title compound <b>6e</b>. Melting point, 67.3 °C. HPLC, 5.73 min. IR (ATR) [cm<sup>–1</sup>] 3303, 2921, 2852, 1731, 1632, 1575, 1586, 1353, 1213, 1035, 853, 719, 520. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 9.22 (s, 1H), 8.43 (s, 1H), 8.15–7.92 (m, 6H), 7.81 (s, 1H), 7.40 (s, 1H), 7.20 (s, 2H), 7.11–6.94 (m, 3H), 3.86–3.71 (m, 2H), 3.68–3.52 (m, 4H), 3.25–3.11 (m, 4H). <sup>13</sup>C NMR (100 MHz, acetone-<i>d</i><sub>6</sub>) δ 190.3, 167.2, 160.0, 150.0 (d, <i>J</i> = 240.9 Hz), 148.9, 145.5, 145.1, 139.5, 139.4, 137.6 (d, <i>J</i> = 2.4 Hz), 133.7, 133.0, 131.6, 130.5, 129.2, 129.0, 129.0, 128.2, 127.9, 126.6 (d, <i>J</i> = 12.4 Hz), 117.4 (d, <i>J</i> = 7.4 Hz), 116.6, 115.7 (d, <i>J</i> = 20.9 Hz), 114.4, 113.0, 71.3, 63.8, 43.0, 35.8, 34.3. ESI-HRMS [M – H]<sup>+</sup> calculated: 530.1543. Found: 530.1544.</div></div><div id="sec5-12-29" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Methyl 8-((2,4-Difluoro-5-(thiophene-2-carboxamido)phenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxylate (<b>6f</b>)</h3><div class="NLM_p last">Compound <b>6f</b> was prepared according to general procedure Va to afford 0.12 g (0.23 mmol, 69.9%) of the title compound <b>6f</b>. Melting point, 97.4 °C. HPLC, 7.53 min. IR (ATR) [cm<sup>–1</sup>] 3307, 1947, 1633, 162, 1582, 1530, 1434, 1416, 1353, 1192, 1120, 1036, 949, 786, 719, 649, 509, 456. <sup>1</sup>H NMR (200 MHz, CDCl<sub>3</sub>) δ 8.64 (d, <i>J</i> = 1.8 Hz, 1H), 8.52–8.37 (m, 1H), 8.18 (d, <i>J</i> = 8.7 Hz, 1H), 8.05 (dd, <i>J</i> = 7.7, 1.8 Hz, 1H), 7.89–7.80 (m, 1H), 7.70–7.54 (m, 2H), 7.30 (s, 1H), 7.20–7.07 (m, 1H), 7.07–6.86 (m, 2H), 6.83–6.74 (m, 1H), 6.00 (s, 1H), 3.92 (s, 3H), 3.32–3.11 (m, 4H). <sup>13</sup>C NMR (50 MHz, CDCl<sub>3</sub>) δ 207.2, 191.7, 166.7, 160.0, 150.7 (dd, <i>J</i> = 244.5, 9.3 Hz), 148.5 (dd, <i>J</i> = 244.3, 12.2 Hz), 145.3, 139.6, 138.5, 134.1, 132.6, 132.3, 131.6, 129.3, 129.1 (d, <i>J</i> = 2.4 Hz), 128.8, 128.1, 125.1 (dd, <i>J</i> = 12.2, 3.5 Hz), 122.37 (dd, <i>J</i> = 11.4, 3.8 Hz), 120.1, 117.9, 116.2, 115.1, 113.7, 104.3 (t, <i>J</i> = 24.7 Hz), 52.2, 35.8, 34.9. ESI-HRMS [M + H]<sup>+</sup> calculated: 519.1185. Found: 519.1189.</div></div><div id="sec5-12-30" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> <i>N-</i>(2,4-Difluoro-5-((7-((2-morpholinoethyl)carbamoyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulen-2-yl)amino)phenyl)thiophene-2-carboxamide (<b>6g</b>)</h3><div class="NLM_p last">Compound <b>6g</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol and 1%NH<sub>3</sub> 95:05) to afford 0.03 g (0.05 mmol, 84.5%) of the title compound <b>6g</b>. Melting point, 104.7 °C. HPLC, 4.18 min. IR (ATR) [cm<sup>–1</sup>] 3271, 2921, 2851, 1698, 1633, 1530, 1434, 1353, 1260, 1207, 1067, 914, 859, 786, 719, 622, 507, 457. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.46 (t, <i>J</i> = 8.4 Hz, 1H), 8.30 (d, <i>J</i> = 1.4 Hz, 1H), 8.18 (d, <i>J</i> = 8.7 Hz, 1H), 8.01–7.92 (m, 1H), 7.88 (s, 1H), 7.62 (dd, <i>J</i> = 28.8, 4.1 Hz, 2H), 7.30 (d, <i>J</i> = 7.9 Hz, 1H), 7.17–7.12 (m, 1H), 7.05–6.96 (m, 1H), 6.96–6.87 (m, 2H), 6.81 (s, 1H), 6.06 (s, 1H), 3.86–3.69 (m, 4H), 3.63–3.52 (m, 2H), 3.22–3.08 (m, 4H), 2.63–2.59 (m, 2H), 2.51 (s, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 191.7, 166.9, 159.9, 150.6 (dd, <i>J</i> = 248.3, 8.5 Hz), 147.4, 147.0 (d, <i>J</i> = 11.1 Hz), 145.5, 145.3, 139.2, 138.6, 134.3, 133.2, 131.6, 131.4, 129.5, 129.1, 128.6, 128.1, 125.3 (dd, <i>J</i> = 11.7, 3.1 Hz), 122.7 (dd, <i>J</i> = 11.1, 3.7 Hz), 115.7, 115.3, 114.0, 104.2 (d, <i>J</i> = 24.5 Hz), 104.1, 77.2, 67.1, 57.2, 53.6, 36.4, 36.0, 34.8. ESI-HRMS [M – H]<sup>+</sup> calculated: 617.2029. Found: 617.2018.</div></div><div id="sec5-12-31" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> <i>N-</i>(5-((7-Carbamoyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulen-2-yl)amino)-2,4-difluorophenyl)thiophene-2-carboxamide (<b>6h</b>)</h3><div class="NLM_p last">Compound <b>6h</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.03 g (0.06 mmol, 84.5%) of the title compound <b>6h</b>. Melting point, 139.6 °C. HPLC, 5.75 min. IR (ATR) [cm<sup>–1</sup>] 3293, 2920, 1652, 1580, 1525, 1416, 1397, 1353, 1265, 1110, 1037, 974, 857, 767, 603, 508, 445. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 9.28 (s, 1H), 8.45 (s, 1H), 8.16–8.05 (m, 2H), 8.03–7.93 (m, 2H), 7.85–7.76 (m, 2H), 7.71–7.50 (m, 1H), 7.43–7.36 (m, 1H), 7.30–7.18 (m, 2H), 7.01–6.95 (m, 1H), 6.90 (s, 1H), 6.72–6.52 (m, 1H), 3.22–3.11 (m, 4H). <sup>13</sup>C NMR (100 MHz, acetone-<i>d</i><sub>6</sub>) δ 201.3, 178.4, 170.8, 159.4, 155.9, 155.7, 149.9, 149.8, 143.3, 142.2, 141.3, 140.3, 139.7, 139.5, 139.0, 138.5, 135.5 (dd, <i>J</i> = 12.2, 3.0 Hz), 135.4, 135.4, 132.8, 131.0, 125.0, 123.54, 115.1 (t, <i>J</i> = 25.0 Hz), 114.9, 46.2, 44.8, 39.5. ESI-HRMS [M – H]<sup>+</sup> calculated: 504.1188. Found: 504.118.</div></div><div id="sec5-12-32" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> <i>N-</i>(5-((7-((2,3-Dihydroxypropyl)carbamoyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulen-2-yl)amino)-2,4-difluorophenyl)thiophene-2-carboxamide (<b>6i</b>)</h3><div class="NLM_p last">Compound <b>6i</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.03 g (0.05 mmol, 90.3%) of the title compound <b>6i</b>. Melting point, 68.1 °C. HPLC, 5.43 min. IR (ATR) [cm<sup>–1</sup>] 3123, 3019, 2911, 2696, 1735, 1627, 1538, 1445, 1353, 1260, 1146, 1054, 930, 825, 736, 617, 418. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 9.28 (s, 1H), 8.45 (s, 1H), 8.16–8.05 (m, 2H), 8.03–7.93 (m, 2H), 7.85–7.76 (m, 2H), 7.71–7.50 (m, 1H), 7.43–7.36 (m, 1H), 7.30–7.18 (m, 2H), 7.01–6.95 (m, 1H), 6.90 (s, 1H), 6.72–6.52 (m, 1H), 3.22–3.11 (m, 4H). <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 190.9, 166.2, 160.4, 149.3, 145.6, 144.9, 139.2, 139.1, 133.7, 133.2, 132.5, 130.8, 130.1, 129.6, 129.2, 128.5, 127.7, 124.6, 122.8, 122.0, 114.3, 112.8, 70.7, 64.3, 43.4, 35.7, 34.1. ESI-HRMS [M – H]<sup>+</sup> calculated: 578.1556. Found: 578.1551.</div></div><div id="sec5-12-33" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> <i>N-</i>(2,4-Difluoro-5-((7-((2-hydroxyethyl)carbamoyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulen-2-yl)amino)phenyl)thiophene-2-carboxamide (<b>6j</b>)</h3><div class="NLM_p last">Compound <b>6j</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.03 g (0.06 mmol, 75.0%) of the title compound <b>6j</b>. Melting point, 220.4 °C. HPLC, 5.65 min. IR (ATR) [cm<sup>–1</sup>] 3043, 2935, 1623, 1577, 1507, 1433, 1356, 1267, 1199, 1119, 1088, 978, 826, 763, 678, 566, 446, 413. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 9.32 (s, 1H), 8.44–8.35 (m, 1H), 8.12–8.02 (m, 2H), 8.02–7.93 (m, 3H), 7.85–7.77 (m, 2H), 7.37 (d, <i>J</i> = 7.9 Hz, 1H), 7.29–7.18 (m, 2H), 7.01–6.93 (m, 1H), 6.88 (s, 1H), 3.76–3.69 (m, 2H), 3.59–3.51 (m, 2H), 3.21–3.09 (m, 4H). <sup>13</sup>C NMR (100 MHz, acetone-<i>d</i><sub>6</sub>) δ 191.6, 167.4, 161.0, 149.7, 146.2, 145.8, 140.2, 140.2, 134.4, 134.2, 132.6, 131.4, 130.1, 130.0, 129.9, 129.6, 128.8, 125.9 (dd, <i>J</i> = 12.8, 3.3 Hz), 123.3 (dd, <i>J</i> = 12.6, 3.7 Hz), 121.1, 121.0, 115.5, 114.0, 105.5 (dd, <i>J</i> = 42.9, 17.9 Hz), 62.0, 43.7, 36.6, 35.2. ESI-HRMS [M – H]<sup>+</sup> calculated: 548.1450. Found: 548.1459.</div></div><div id="sec5-12-34" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Methyl 3-((4-Fluoro-3-(thiophene-2-carboxamido)phenyl)amino)-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxylate (<b>6k</b>)</h3><div class="NLM_p last">Compound <b>6k</b> was prepared according to general procedure Va to afford 0.10 g (0.20 mmol, 40.0%) of the title compound <b>6k</b>. Melting point, 184.5 °C. HPLC, 7.44 min. IR (ATR) [cm<sup>–1</sup>] 3301, 2925, 2852, 1573, 1526, 1241, 1116, 851, 715, 529. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.16 (s, 1H), 9.09 (s, 1H), 8.37 (s, 1H), 8.16 (d, <i>J</i> = 7.8 Hz, 1H), 8.04 (dd, <i>J</i> = 12.3, 6.0 Hz, 2H), 7.88 (d, <i>J</i> = 4.6 Hz, 1H), 7.68 (t, <i>J</i> = 10.5 Hz, 1H), 7.48 (dd, <i>J</i> = 10.8, 6.5 Hz, 1H), 7.30 (t, <i>J</i> = 9.5 Hz, 1H), 7.26–7.19 (m, 1H), 7.11–7.03 (m, 1H), 6.80 (d, <i>J</i> = 9.0 Hz, 1H), 6.56 (s, 1H), 5.29 (s, 2H), 4.56 (s, 1H), 3.89 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 208.3, 185.8, 165.4, 163.0, 159.9, 151.4, 140.6, 140.1, 138.9, 133.6, 132.5, 132.1, 130.2, 129.8, 129.7, 128.8, 128.1, 118.9, 118.7, 116.5, 116.3, 110.4, 101.8, 72.4, 29.6. ESI-HRMS [M + H]<sup>+</sup> calculated: 503.1071. Found: 503.1071.</div></div><div id="sec5-12-35" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 3-((4-Fluoro-3-(thiophene-2-carboxamido)phenyl)amino)-<i>N-</i>(2-morpholinoethyl)-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxamide (<b>6l</b>)</h3><div class="NLM_p last">Compound <b>6l</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.024 g (0.06 mmol, 69,6%) of the title compound <b>6l</b>. HPLC, 4.39 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.17 (s, 1H), 9.07 (s, 1H), 8.57 (d, <i>J</i> = 49.7 Hz, 1H), 8.28 (s, 1H), 8.03 (s, 3H), 7.88 (s, 1H), 7.60 (t, <i>J</i> = 20.3 Hz, 1H), 7.48 (s, 1H), 7.37–7.18 (m, 2H), 7.07 (s, 1H), 6.80 (d, <i>J</i> = 7.4 Hz, 1H), 6.56 (s, 1H), 5.26 (s, 2H), 3.56 (s, 4H), 3.40 (s, 2H), 2.48–2.44 (m, 2H), 2.41 (s, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 186.6, 165.2, 162.9, 159.96, 151.3, 140.0, 138.9, 138.4, 136.6, 135.1, 133.4, 132.1, 130.8, 129.7, 128.2, 128.1, 127.7, 118.8, 118.7, 116.6, 116.3, 110.3, 101.8, 72.4, 66.2, 57.2, 53.2, 36.6. ESI-HRMS [M – H]<sup>+</sup> calculated: 601.1915. Found: 601.1911.</div></div><div id="sec5-12-36" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> 3-((4-Fluoro-3-(thiophene-2-carboxamido)phenyl)amino)-<i>N-</i>(2-hydroxyethyl)-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxamide (<b>6m</b>)</h3><div class="NLM_p last">Compound <b>6m</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.010 g (0.07 mmol, 26.3%) of the title compound <b>5n</b>. Melting point, 201.8 °C. HPLC, 5.45 min. IR (ATR) [cm<sup>–1</sup>] 3016, 2924, 2853, 1738, 1634, 1568, 1441, 1416, 1365, 1217. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.14 (d, <i>J</i> = 21.9 Hz, 1H), 9.07 (s, 1H), 8.65 (s, 1H), 8.30 (s, 1H), 8.05 (d, <i>J</i> = 8.7 Hz, 3H), 7.86 (d, <i>J</i> = 19.2 Hz, 1H), 7.62 (d, <i>J</i> = 7.2 Hz, 1H), 7.48 (s, 1H), 7.28 (dd, <i>J</i> = 21.3, 11.9 Hz, 2H), 7.03 (d, <i>J</i> = 40.7 Hz, 1H), 6.77 (t, <i>J</i> = 14.5 Hz, 1H), 6.53 (d, <i>J</i> = 23.6 Hz, 1H), 5.26 (s, 2H), 4.82 (d, <i>J</i> = 49.5 Hz, 1H), 3.52 (s, 2H), 1.35–1.18 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 186.6, 162.9, 160.0, 139.9, 138.9, 138.3, 135.1, 133.4, 132.1, 130.9, 129.7, 128.1, 127.8, 118.7, 116.5, 110.3, 101.8, 72.4, 59.6, 42.3. ESI-HRMS [M – H]<sup>+</sup> calculated: 532.1337. Found: 532.1342.</div></div><div id="sec5-12-37" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> 3-((4-Fluoro-3-(thiophene-2-carboxamido)phenyl)amino)-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxamide (<b>6n</b>)</h3><div class="NLM_p last">Compound <b>6n</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.02 g (0.04 mmol, 40.6%) of the title compound <b>6n</b>. HPLC, 6.02 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.15 (s, 1H), 9.07 (s, 2H), 8.63 (t, <i>J</i> = 5.3 Hz, 1H), 8.27 (s, 1H), 8.04 (t, <i>J</i> = 7.8 Hz, 2H), 7.97 (d, <i>J</i> = 7.7 Hz, 2H), 7.61 (t, <i>J</i> = 7.2 Hz, 2H), 7.53 (t, <i>J</i> = 7.3 Hz, 3H), 7.29 (t, <i>J</i> = 9.5 Hz, 1H), 7.12–7.00 (m, 1H), 6.80 (d, <i>J</i> = 9.0 Hz, 1H), 6.56 (s, 1H), 5.25 (s, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 186.6, 186.6, 165.50, 165.5, 165.2, 162.9, 162.9, 151.3, 150.1, 140.0, 138.4, 135.1, 133.9, 133.4, 131.9, 130.8, 128.4, 128.2, 127.8, 127.7, 126.3, 118.6, 116.5, 110.2, 101.7, 72.4, 66.2, 57.2, 53.2, 36.6. ESI-HRMS [M – H]<sup>+</sup> calculated: 488.1075. Found: 488.1045.</div></div><div id="sec5-12-38" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> <i>N-</i>(2,3-Dihydroxypropyl)-3-((4-fluoro-3-(thiophene-2-carboxamido)phenyl)amino)-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxamide (<b>6o</b>)</h3><div class="NLM_p last">Compound <b>6o</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.03 g (0,05 mmol, 87.0%) of the title compound <b>6o</b>. Melting point, 173.8 °C. HPLC, 5.16 min. IR (ATR) [cm<sup>–1</sup>] 3289, 2922, 1633, 1537, 1531, 1455, 1385, 1260, 1120. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.17 (d, <i>J</i> = 15.8 Hz, 1H), 9.04 (s, 1H), 8.59 (s, 1H), 8.30 (s, 1H), 8.13–8.00 (m, 3H), 7.88 (d, <i>J</i> = 3.9 Hz, 1H), 7.69–7.53 (m, 1H), 7.45 (d, <i>J</i> = 22.4 Hz, 1H), 7.35–7.19 (m, 2H), 7.13–7.00 (m, 1H), 6.80 (d, <i>J</i> = 7.2 Hz, 1H), 6.52 (d, <i>J</i> = 32.4 Hz, 1H), 5.27 (s, 2H), 4.81 (s, 1H), 4.57 (d, <i>J</i> = 3.8 Hz, 1H), 3.66 (s, 1H), 3.23 (d, <i>J</i> = 4.0 Hz, 2H), 1.21 (ddd, <i>J</i> = 40.1, 30.9, 11.3 Hz, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 186.6, 165.6, 162.9, 160.0, 151.3, 139.9, 138.9, 138.4, 136.6, 135.1, 133.4, 132.0, 130.9, 129.7, 128.1, 127.9, 118.7, 116.6, 110.3, 101.8, 72.4, 70.3, 64.0, 43.1. ESI-HRMS [M – H]<sup>+</sup> calculated: 562.1443. Found: 562.1443.</div></div><div id="sec5-12-39" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> <i>N-</i>(2-Fluoro-5-((9-(morpholine-4-carbonyl)-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepin-3-yl)amino)phenyl)thiophene-2-carboxamide (<b>6p</b>)</h3><div class="NLM_p last">Compound <b>6p</b> was prepared according to general procedure <b>Va.</b> The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.03 g (0.05 mmol, 57.0%) of the title compound <b>6p</b>. Melting point, 195.1 °C. HPLC, 6.05 min. IR (ATR) [cm<sup>–1</sup>] 3293, 2917, 2852, 1573, 1519, 1435, 1269, 1111, 1026, 846, 714, 573. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.16 (s, 1H), 9.06 (s, 1H), 8.04 (d, <i>J</i> = 8.8 Hz, 2H), 7.88 (d, <i>J</i> = 4.7 Hz, 1H), 7.79 (s, 1H), 7.63 (dd, <i>J</i> = 14.6, 7.6 Hz, 2H), 7.49 (d, <i>J</i> = 6.2 Hz, 1H), 7.35–7.18 (m, 2H), 7.06 (d, <i>J</i> = 8.4 Hz, 1H), 6.79 (d, <i>J</i> = 8.9 Hz, 1H), 6.56 (s, 1H), 5.25 (s, 2H), 4.35 (s, 2H), 3.71–3.39 (m, 8H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 185.5, 167.1, 162.0, 158.9, 150.2, 138.9, 137.8, 135.9, 135.4, 135.0, 132.4, 130.9, 129.5, 128.5, 127.1, 126.9, 126.3, 124.6, 117.3, 115.2, 109.0, 100.3, 70.8, 64.4, 60.3. ESI-HRMS [M – H]<sup>+</sup> calculated: 558.1493. Found: 558.1498.</div></div><div id="sec5-12-40" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> Methyl 3-((2,4-difluoro-5-(thiophene-2-carboxamido)phenyl)amino)-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxylate (<b>6q</b>)</h3><div class="NLM_p last">Compound <b>6q</b> was prepared according to general procedure Va to afford 0.25 g (0.48 mmol, 61.1%) of the title compound <b>6q</b>. Melting point, 194.0 °C. HPLC, 6.10 min. IR (ATR) [cm<sup>–1</sup>] 2357, 2341, 1715, 1607, 1574, 1525, 1508, 1417, 1244, 1117, 1087. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.22 (s, 1H), 8.82 (d, <i>J</i> = 60.2 Hz, 1H), 8.37 (s, 1H), 8.08 (d, <i>J</i> = 50.2 Hz, 3H), 7.87 (s, 1H), 7.78–7.40 (m, 3H), 7.22 (s, 1H), 6.72 (s, 1H), 6.31 (d, <i>J</i> = 45.6 Hz, 1H), 5.29 (s, 2H), 3.88 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 186.0, 165.4, 162.9, 160.0, 151.8, 140.6, 140.0, 138.7, 133.5, 132.6, 132.1, 130.1, 129.8, 129.8, 128.8, 128.1, 123.9, 122.8, 121.9, 116.6, 110.1, 105.6, 105.3, 105.1, 102.0, 72.4, 52.4. ESI-HRMS [M + H]<sup>+</sup> calculated: 521.0977. Found: 521.0967.</div></div><div id="sec5-12-41" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> 3-((2,4-Difluoro-5-(thiophene-2-carboxamido)phenyl)amino)-<i>N-</i>(2-morpholinoethyl)-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxamide (<b>6r</b>)</h3><div class="NLM_p last">Compound <b>6r</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.02 g (0.03 mmol, 62.8%) of the title compound <b>6r</b>. HPLC, 4.49 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.20 (s, 1H), 8.86 (s, 1H), 8.64 (s, 1H), 8.28 (s, 1H), 8.14–7.95 (m, 3H), 7.88 (d, <i>J</i> = 3.6 Hz, 1H), 7.68–7.49 (m, 3H), 7.19 (d, <i>J</i> = 36.2 Hz, 1H), 6.67 (t, <i>J</i> = 26.2 Hz, 1H), 6.36 (s, 1H), 5.26 (s, 2H), 3.57 (s, 4H), 3.40 (s, 2H), 2.48–2.45 (m, 2H), 2.41 (s, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 186.8, 165.1, 162.8, 160.0, 151.6, 139.9, 138.7, 138.4, 135.1, 133.3, 132.1, 130.9, 129.7, 128.2, 128.1, 127.7, 122.8, 116.7, 109.9, 102.0, 72.4, 66.2, 57.2, 53.2, 36.6. ESI-HRMS [M – H]<sup>+</sup> calculated: 619.1821. Found: 619.1911.</div></div><div id="sec5-12-42" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> 3-((2,4-Difluoro-5-(thiophene-2-carboxamido)phenyl)amino)-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxamide (<b>6s</b>)</h3><div class="NLM_p last">Compound <b>6s</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.02 g (0.04 mmol, 60.1%) of the title compound <b>6s</b>. HPLC, 5.44 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.23 (d, <i>J</i> = 19.4 Hz, 1H), 8.85 (s, 1H), 8.30 (s, 1H), 8.16 (s, 1H), 8.11–7.97 (m, 3H), 7.87 (d, <i>J</i> = 4.9 Hz, 1H), 7.66–7.42 (m, 4H), 7.23 (dd, <i>J</i> = 5.8, 2.8 Hz, 1H), 6.70 (d, <i>J</i> = 9.0 Hz, 1H), 6.35 (s, 1H), 5.25 (s, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 186.8, 166.9, 162.8, 160.0, 151.6, 139.9, 138.7, 138.5, 134.8, 133.3, 132.1, 131.1, 129.7, 128.2, 122.8, 116.7, 110.0, 102.0, 72.4. ESI-HRMS [M – H]<sup>+</sup> calculated: 506.0981. Found: 506.0984.</div></div><div id="sec5-12-43" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> 3-((2,4-Difluoro-5-(thiophene-2-carboxamido)phenyl)amino)-<i>N-</i>(2,3-dihydroxypropyl)-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxamide (<b>6t</b>)</h3><div class="NLM_p last">Compound <b>6t</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.01 g (0.02 mmol, 43.7%) of the title compound <b>6t</b>. HPLC, 5.14 min. <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.34 (s, 1H), 8.25 (s, 1H), 8.11 (dd, <i>J</i> = 9.0, 3.1 Hz, 1H), 8.02 (d, <i>J</i> = 7.7 Hz, 1H), 7.76 (dd, <i>J</i> = 18.0, 9.8 Hz, 1H), 7.60 (dd, <i>J</i> = 12.4, 11.2 Hz, 1H), 7.53 (dd, <i>J</i> = 5.0, 2.8 Hz, 2H), 7.28–7.12 (m, 1H), 6.72 (d, <i>J</i> = 8.9 Hz, 1H), 6.45 (s, 1H), 5.20 (d, <i>J</i> = 2.4 Hz, 2H), 3.64 (s, 2H), 3.56 (dd, <i>J</i> = 5.0, 2.0 Hz, 2H), 3.43 (dd, <i>J</i> = 12.8, 6.3 Hz, 1H). <sup>13</sup>C NMR (100 MHz, MeOD) δ 187.9, 168.2, 163.7, 152.3, 140.4, 139.3, 136.5, 135.0, 133.4, 130.7, 129.68, 127.9, 126.5, 126.3, 122.1, 117.2, 110.1, 104.5, 102.3, 72.8, 70.7, 63.8, 42.8. ESI-HRMS [M – H]<sup>+</sup> calculated: 580.1348. Found: 580.1337.</div></div><div id="sec5-12-44" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> 3-((2,4-Difluoro-5-(thiophene-2-carboxamido)phenyl)amino)-<i>N-</i>(1,3-dihydroxypropan-2-yl)-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxamide (<b>6u</b>)</h3><div class="NLM_p last">Compound <b>6u</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.01 g (0.02 mmol, 87.4%) of the title compound <b>6u</b>. HPLC, 5.23 min: <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.35 (s, 1H), 8.10 (dd, <i>J</i> = 8.9, 4.9 Hz, 1H), 8.07–7.99 (m, 1H), 7.89 (s, 1H), 7.78–7.66 (m, 2H), 7.56–7.47 (m, 1H), 7.27–7.13 (m, 2H), 6.71 (d, <i>J</i> = 8.8 Hz, 1H), 6.44 (s, 1H), 5.19 (d, <i>J</i> = 4.8 Hz, 2H), 4.24–4.11 (m, 1H), 3.75 (d, <i>J</i> = 4.2 Hz, 4H). <sup>13</sup>C NMR (100 MHz, MeOD) δ 187.9, 167.9, 167.9, 163.7, 163.7, 161.7, 161.7, 152.2, 140.3, 139.2, 138.1, 135.2, 133.4, 131.5, 130.8, 129.5, 128.0, 127.8, 127.6, 122.1, 117.2, 110.0, 104.5, 102.3, 72.8, 60.7, 53.9. ESI-HRMS [M – H]<sup>+</sup> calculated: 580.1348. Found: 580.1355.</div></div><div id="sec5-12-45" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> 3-((2,4-Difluoro-5-(thiophene-2-carboxamido)phenyl)amino)-<i>N-</i>(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxamide (<b>6v</b>)</h3><div class="NLM_p last">Compound <b>6v</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.03 g (0.05 mmol, 69.2%) of the title compound <b>6v</b>. HPLC, 5.10 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.21 (s, 1H), 8.85 (s, 1H), 8.21 (s, 1H), 8.04 (d, <i>J</i> = 8.9 Hz, 1H), 8.00 (s, 2H), 7.88 (d, <i>J</i> = 4.9 Hz, 1H), 7.64–7.43 (m, 4H), 7.23 (dd, <i>J</i> = 6.0, 2.7 Hz, 1H), 6.68 (t, <i>J</i> = 14.5 Hz, 1H), 6.32 (d, <i>J</i> = 24.1 Hz, 1H), 5.26 (s, 2H), 4.74 (s, 3H), 3.70 (s, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 186.8, 166.3, 162.8, 160.0, 151.6, 139.8, 138.7, 138.3, 135.8, 133.3, 132.1, 129.7, 128.1, 127.9, 116.7, 109.9, 102.0, 72.4, 66.1, 62.8, 60.2, 53.1. ESI-HRMS [M – H]<sup>+</sup> calculated: 610.1454. Found: 610.1456.</div></div><div id="sec5-12-46" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Methyl 3-((4-Fluoro-2-methyl-5-(thiophene-3-carboxamido)phenyl)amino)-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxylate (<b>7a</b>)</h3><div class="NLM_p last">Compound <b>7a</b> was prepared according to general procedure Va to afford 0.16 mmol (0.31 mmol, 38.4%) of the title compound <b>7a</b>. Melting point, 154.4 °C. HPLC, 7.95 min. IR (ATR) [cm<sup>–1</sup>] 3296, 2953, 1716, 1607, 1568, 1558, 1520, 1247, 1118, 1002. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ (s, 1H), 8.56 (s, 1H), 8.36 (d, <i>J</i> = 6.0 Hz, 2H), 8.08 (dd, <i>J</i> = 45.2, 7.9 Hz, 2H), 7.74–7.53 (m, 3H), 7.47 (d, <i>J</i> = 6.5 Hz, 1H), 7.33–7.21 (m, 1H), 6.62 (d, <i>J</i> = 8.1 Hz, 1H), 6.20 (s, 1H), 5.26 (s, 2H), 3.89 (s, 3H), 2.19 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 183.6, 163.3, 160.9, 158.7, 151.1, 149.4, 138.5, 138.0, 134.8, 131.94, 131.5, 130.3, 130.1, 130.1, 128.0, 128.0, 127.7, 126.6, 125.0, 124.8, 121.5, 121.4, 121.1, 115.6, 115.4, 113.7, 107.6, 98.8, 70.3, 62.7, 50.2. ESI-HRMS [M + H]<sup>+</sup> calculated: 517.1228. Found: 517.1218.</div></div><div id="sec5-12-47" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> 3-((2,4-Difluoro-5-(thiophene-3-carboxamido)phenyl)amino)-<i>N-</i>(1,3-dihydroxypropan-2-yl)-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxamide (<b>7b</b>)</h3><div class="NLM_p last">Compound <b>7b</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.04 g (0.07 mmol, 33.0%) of the title compound <b>7b</b>. Melting point, 171.3 °C. HPLC, 5.14 min. IR (ATR) [cm<sup>–1</sup>] 3271, 2921, 2852, 1606, 1531, 1471, 1416, 1254, 1121, 1033. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.01 (s, 1H), 8.85 (s, 1H), 8.35 (d, <i>J</i> = 15.0 Hz, 1H), 8.30 (s, 1H), 8.22 (d, <i>J</i> = 7.9 Hz, 1H), 8.05 (dd, <i>J</i> = 12.0, 8.8 Hz, 2H), 7.71–7.44 (m, 5H), 6.71 (d, <i>J</i> = 8.8 Hz, 1H), 6.36 (s, 1H), 5.29 (d, <i>J</i> = 23.4 Hz, 2H), 4.67 (s, 1H), 3.98 (d, <i>J</i> = 6.1 Hz, 1H), 3.52 (d, <i>J</i> = 5.1 Hz, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 186.9, 165.3, 162.7, 160.9, 151.7, 139.9, 138.2, 136.7, 135.3, 133.3, 131.1, 130.3, 128.1, 127.9, 127.1 123.9, 122.7, 116.7, 109.9, 105.23, 102.0, 72.4, 60.4, 54.0. ESI-HRMS [M – H]<sup>+</sup> calculated: 580.1348. Found: 580.1304.</div></div><div id="sec5-12-48" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> <i>N-</i>(2,3-Dihydroxypropyl)-3-((4-fluoro-2-methyl-5-(thiophene-3-carboxamido)phenyl)amino)-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxamide (<b>7c</b>)</h3><div class="NLM_p last">Compound <b>7c</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.01 g (0.02 mmol, 78.6%) of the title compound <b>7c</b>. HPLC, 5.45 min. <sup>1</sup>H NMR (400 MHz, MeOD) δ 8.32 (d, <i>J</i> = 17.6 Hz, 1H), 8.21 (d, <i>J</i> = 12.0 Hz, 1H), 8.08 (dd, <i>J</i> = 9.0, 2.4 Hz, 1H), 8.02 (d, <i>J</i> = 7.8 Hz, 1H), 7.60 (d, <i>J</i> = 6.8 Hz, 2H), 7.51 (dd, <i>J</i> = 9.6, 4.8 Hz, 2H), 7.15 (d, <i>J</i> = 11.0 Hz, 1H), 6.59 (d, <i>J</i> = 9.0 Hz, 1H), 6.22 (d, <i>J</i> = 2.1 Hz, 1H), 5.17 (s, 2H), 4.59 (s, 3H), 3.90–3.79 (m, 1H), 3.57–3.53 (m, 2H), 3.43 (td, <i>J</i> = 13.5, 5.6 Hz, 2H). <sup>13</sup>C NMR (100 MHz, MeOD) δ 187.8, 172.1, 168.2, 164.0, 156.4, 154.1, 139.4, 135.0, 133.6, 130.7, 129.5, 128.0, 126.5, 126.3, 123.4, 117.2, 109.6, 101.2, 72.8, 70.7, 63.8, 42.8, 29.3, 16.3. ESI-HRMS [M – H]<sup>+</sup> calculated: 517.1228. Found: 517.1218.</div></div><div id="sec5-12-49" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> Methyl 8-((3-benzamido-4-fluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxylate (<b>8a</b>)</h3><div class="NLM_p last">Compound <b>8a</b> was prepared according to general procedure Va to afford 0.18 g (0.36 mmol, 56.0%) of the title compound <b>8a</b>. Melting point, 216.9 °C. HPLC, 8.32 min. IR (ATR) [cm<sup>–1</sup>] 3324, 1718, 1600, 1555, 1405, 1353, 1256, 1111, 954, 832, 801, 706, 520. <sup>1</sup>H NMR (400 MHz, DMSO) δ 1H NMR (400 MHz, DMSO) δ 10.12 (s, 1H), 8.92 (s, 1H), 8.46 (s, 1H), 8.09–7.94 (m, 4H), 7.62–7.44 (m, 5H), 7.35–7.16 (m, 1H), 7.15–7.04 (m, 1H), 6.98 (d, <i>J</i> = 8.6 Hz, 1H), 6.87 (s, 1H), 3.87 (s, 3H), 3.23–3.07 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO) δ 189.7, 165.8, 165.6, 148.9, 147.1, 145.6, 145.6, 139.1, 137.1, 134.0, 133.8, 132.1, 132.0, 131.4, 129.7, 128.5, 128.1, 127.9, 127.0, 126.5, 118.3, 118.3, 116.6, 116.2, 114.0, 113.9, 112.7, 52.3, 35.3, 34.1. ESI-HRMS [M + H]<sup>+</sup> calculated: 495.1715. Found: 495.1712.</div></div><div id="sec5-12-50" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> 8-((3-Benzamido-4-fluorophenyl)amino)-<i>N-</i>(2-morpholinoethyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>8b</b>)</h3><div class="NLM_p last">Compound <b>8b</b> was prepared according to general procedure Va. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.01 g (0.02 mmol, 87.0%) of the title compound <b>8b</b>. Melting point, 185.3 °C. HPLC, 5.12 min. IR (ATR) [cm<sup>–1</sup>] 3306, 2919, 1582, 1639, 1486, 1400, 1317, 1217, 1106, 1001, 834, 870, 834, 790, 677, 601, 473. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10. One (s, 1H), 8.89 (s, 1H), 8.45–8.61 (m, 1H), 8.32 (d, 1H), 7.86–8.06 (m, 4H), 7.47–7.62 (m, 4H), 6.93–7.44 (m, 4H), 6.86 (s, 1H), 3.49–3.62 (m, 4H), 3.24–3.48 (m, 2H), 2.99–3.21 (m, 4H), 2.27–2.62 (m, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.3, 165.5, 150.9 (d, <i>J</i> = 241.4 Hz), 148.7, 144.5, 138.9, 137.1, 137.0, 134.0, 133.5, 131.8, 130.4, 129.1, 128.9, 128.4, 127.8, 127.2, 126.2 (d, <i>J</i> = 13.8 Hz), 118.2, 118.1 (d, <i>J</i> = 6.5 Hz). ESI-HRMS [M – H]<sup>+</sup> calculated: 593.2559. Found: 593.2555.</div></div><div id="sec5-12-51" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> 8-((3-Benzamido-4-fluorophenyl)amino)-<i>N-</i>methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>8c</b>)</h3><div class="NLM_p last">Compound <b>8c</b> was prepared according to general procedure Va. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.02 g (0.42 mmol, 65.0%) of the title compound <b>8c</b>. Melting point, 166.4 °C. HPLC, 6.28 min. IR (ATR) [cm<sup>–1</sup>] 3303, 1654, 1577, 1447, 1354, 1214, 973, 706. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.13 (s, 1H), 8.91 (s, 1H), 8.62–8.48 (m, 1H), 8.33 (s, 1H), 8.04–7.88 (m, 4H), 7.63–7.51 (m, 4H), 7.43–7.37 (m, 1H), 7.30–7.23 (m, 1H), 7.09–7.04 (m, 1H), 6.99 (d, <i>J</i> = 8.4 Hz, 1H), 6.87 (s, 1H), 3.18–3.03 (m, 4H), 2.83–2.74 (m, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.3, 172.3, 165.9, 165.5, 154.3, 150.9 (d, <i>J</i> = 242.2 Hz), 148.7, 148.7, 145.4, 144.5, 138.9, 137.1, 134.0, 133.5, 132.8, 131.8, 130.2, 129.0 (d, <i>J</i> = 15.5 Hz), 128.4, 127.8, 127.2, 126.2 (d, <i>J</i> = 13.2 Hz), 118.1 (d, <i>J</i> = 10.2 Hz), 116.3 (d, <i>J</i> = 21.4 Hz), 113.9, 112.6, 35.44, 33.8, 26.2. ESI-HRMS [M – H]<sup>+</sup> calculated: 480.1718. Found: 480.1682.</div></div><div id="sec5-12-52" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> 8-((3-Benzamido-4-fluorophenyl)amino)-<i>N-</i>methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>8d</b>)</h3><div class="NLM_p last">Compound <b>8d</b> was prepared according to general procedure Va. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.09 g (0.18 mmol, 78.0%) of the title compound <b>8d</b>. Melting point, 135.5 °C. HPLC, 6.49 min. IR (ATR) [cm<sup>–1</sup>] 3291, 1601, 1575, 1525, 1505, 1398, 1354, 1261, 1213, 1114, 1207, 964, 785, 761, 704, 610, 452. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.13 (s, 1H), 8.91 (s, 1H), 8.62–8.48 (m, 1H), 8.33 (s, 1H), 8.04–7.88 (m, 4H), 7.63–7.51 (m, 4H), 7.43–7.37 (m, 1H), 7.30–7.23 (m, 1H), 7.09–7.04 (m, 1H), 6.99 (d, <i>J</i> = 8.4 Hz, 1H), 6.87 (s, 1H), 3.18–3.03 (m, 4H), 2.83–2.74 (m, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.3, 172.3, 165.9, 165.5, 154.3, 150.9 (d, <i>J</i> = 242.2 Hz), 148.8, 148.7, 145.4, 144.5, 138.9, 137.1, 134.0, 133.5, 132.8, 131.8, 130.2, 129.0 (d, <i>J</i> = 15.5 Hz), 128.4, 127.8, 127.2, 126.3 (d, <i>J</i> = 13.2 Hz), 118.1 (d, <i>J</i> = 10.2 Hz), 116.3 (d, <i>J</i> = 21.4 Hz), 114.0, 112.6, 35.4, 33.8, 26.2. ESI-HRMS [M – H]<sup>+</sup> calculated: 494.1874. Found: 494.1871.</div></div><div id="sec5-12-53" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> 8-((3-Benzamido-4-fluorophenyl)amino)-<i>N</i>-(2,3-dihydroxypropyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>8e</b>)</h3><div class="NLM_p last">Compound <b>8e</b> was prepared according to general procedure Va. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.02 g (0.54 mmol, 43.7%) of the title compound <b>8e</b>. Melting point, 107.4 °C. HPLC, 6.01 min. IR (ATR) [cm<sup>–1</sup>] 3296, 2921, 1600, 1520, 1445, 1353, 1112, 785, 572. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1H NMR (400 MHz, DMSO) δ 10.14 (s, 1H), 8.90 (s, 1H), 8.58–8.46 (m, 1H), 8.33 (s, 1H), 8.07–7.85 (m, 6H), 7.66–7.58 (m, 1H), 7.56–7.49 (m, 4H), 7.43–7.39 (m, 1H), 7.01–6.96 (m, 1H), 6.87 (s, 1H), 4.90–4.81 (m, 1H), 4.69–4.59 (m, 1H), 3.20–3.17 (m, 1H), 3.12–3.05 (m, 4H), 2.88 (s, 2H), 2.72 (s, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.5, 166.1, 165.7, 162.5, 151.1 (d, <i>J</i> = 242.5 Hz), 148.8, 145.5, 144.7, 139.0, 137.1 (d, <i>J</i> = 2.4 Hz), 134.0, 133.6, 132.9, 132.0, 130.5, 129.3, 129.0, 128.5, 127.9, 127.3, 126.3 (d, <i>J</i> = 13.4 Hz), 118.3, 116.4 (d, <i>J</i> = 21.3 Hz), 114.1, 112.7, 70.5, 64.0, 43.1, 39.5, 35.9, 35.5. ESI-HRMS [M – H]<sup>+</sup> calculated: 554.2086. Found: 554.2074.</div></div><div id="sec5-12-54" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> 8-((3-Benzamido-4-fluorophenyl)amino)-<i>N-</i>methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>8f</b>)</h3><div class="NLM_p last">Compound <b>8f</b> was prepared according to general procedure Va. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.04 g (0.08 mmol, 64.0%) of the title compound <b>8f</b>. Melting point, 108.0 °C. HPLC, 6.24 min. IR (ATR) [cm<sup>–1</sup>] 3292, 2917, 1675, 1560, 1517, 1448, 1354, 1213, 785, 609. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 1H NMR (400 MHz, DMSO) δ 10.12 (s, 1H), 8.89 (s, 1H), 8.57–8.52 (m, 1H), 8.35 (s, 1H), 8.04–7.90 (m, 4H), 7.65–7.58 (m, 1H), 7.57–7.49 (m, 3H), 7.41 (d, <i>J</i> = 7.8 Hz, 1H), 7.32–7.22 (m, 1H), 7.13–7.05 (m, 1H), 6.99 (d, <i>J</i> = 8.7 Hz, 1H), 6.87 (s, 1H), 4.77–4.68 (m, 1H), 3.50–3.46 (m, 2H), 3.44–3.38 (m, 2H), 3.16–3.05 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.4, 165.7, 165.5, 150.1 (d, <i>J</i> = 252.4 Hz), 148.7, 145.4, 144.5, 138.9, 137.0, 134.0, 133.5, 132.9, 131.8, 130.4, 129.2, 128.8, 128.4, 127.8, 127.2, 126.2 (d, <i>J</i> = 13.0 Hz), 121.2, 118.1 (d, <i>J</i> = 10.1 Hz), 116.3 (d, <i>J</i> = 21.3 Hz), 114.0, 112.6, 59.7, 42.2, 35.5, 33.8. ESI-HRMS [M – H]<sup>+</sup> calculated: 524.1980. Found: 524.1986.</div></div><div id="sec5-12-55" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> 8-((5-Benzamido-2,4-difluorophenyl)amino)-<i>N</i>-(2-morpholinoethyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>8g</b>)</h3><div class="NLM_p last">Compound <b>8g</b> was prepared according to general procedure Va. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.1 g (0.08 mmol, 65.4%) of the title compound <b>8g</b>. Melting point, 121.5 °C. HPLC, 5.26 min. IR (ATR) [cm<sup>–1</sup>] 1643, 1602, 1531, 1437, 1354, 1264, 1114, 860, 709, 626, 531, 455. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.17 (s, 1H), 8.69 (s, 1H), 8.53 (t, <i>J</i> = 5.6 Hz, 1H), 8.37–8.28 (m, 1H), 8.01 (d, <i>J</i> = 8.8 Hz, 1H), 7.99–7.93 (m, 2H), 7.94–7.87 (m, 1H), 7.67–7.58 (m, 2H), 7.57–7.47 (m, 3H), 7.41 (d, <i>J</i> = 8.0 Hz, 1H), 6.85–6.81 (m, 1H), 6.71 (s, 1H), 3.59–3.54 (m, 4H), 3.44–3.38 (m, 2H), 3.16–3.04 (m, 4H), 2.48–2.43 (m, 2H), 2.43–2.37 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13C NMR (101 MHz, DMSO) δ 190.5, 190.5, 165.5, 165.4, 165.4, 149.0, 145.2, 144.5, 138.9, 133.7, 133.7, 133.3, 132.8, 131.9, 131.9, 130.4, 129.0, 129.0, 128.9, 128.4, 128.4, 127.7, 127.7, 127.3, 122.2, 113.9, 112.4, 66.2, 57.3, 53.2, 36.5, 35.4, 33.7. ESI-HRMS [M – H]<sup>+</sup> calculated 611.1650 found 611.1653 [M + H]<sup>+</sup>.</div></div><div id="sec5-12-56" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> 8-((5-Benzamido-2,4-difluorophenyl)amino)-<i>N</i>-(2,3-dihydroxypropyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>8h</b>)</h3><div class="NLM_p last">Compound <b>8h</b> was prepared according to general procedure <b>Va.</b> The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.03 g (0.05 mmol, 88.0%) of the title compound <b>8h</b>. Melting point, 204.5 °C. HPLC, 6.91 min. IR (ATR) [cm<sup>–1</sup>] 3322, 1685, 1641, 1544, 1517, 1363, 1283, 1217, 1116, 923, 863, 784, 686, 515. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ <sup>1</sup>H NMR (400 MHz, DMSO) δ 10.17 (s, 1H), 8.69 (s, 1H), 8.51 (s, 1H), 8.34 (s, 1H), 8.06–7.93 (m, 3H), 7.67–7.45 (m, 5H), 7.45–7.37 (m, 1H), 6.88–6.78 (m, 1H), 6.71 (s, 1H), 4.92–4.72 (m, 1H), 4.76–4.46 (m, 1H), 3.69–3.58 (m, 2H), 3.30–3.17 (m, 2H), 3.16–2.98 (m, 4H). ESI-HRMS [M + H]<sup>+</sup> calculated: 572.1992. Found: 572.1957.</div></div><div id="sec5-12-57" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> 8-((5-Benzamido-2,4-difluorophenyl)amino)-<i>N</i>-(2-hydroxyethyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>8i</b>)</h3><div class="NLM_p last">Compound <b>8i</b> was prepared according to general procedure Va. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.04 g (0.74 mmol, 93.0%) of the title compound <b>8i</b>. Melting point, 188,8 °C. HPLC, 6.82 min. IR (ATR) [cm<sup>–1</sup>] 3288, 1635, 1577, 1521, 1400, 1355, 1266, 1116, 857, 708. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.16 (s, 1H), 8.68 (s, 2H), 8.54 (t, <i>J</i> = 5.5 Hz, 2H), 8.40–8.24 (m, 2H), 8.03–7.99 (m, 2H), 7.99–7.95 (m, 4H), 7.94–7.91 (m, 2H), 7.64–7.58 (m, 4H), 7.56–7.45 (m, 7H), 7.43–7.39 (m, 2H), 6.83 (d, <i>J</i> = 8.8 Hz, 2H), 6.70 (s, 2H), 4.73 (t, <i>J</i> = 5.6 Hz, 3H), 3.50 (s, 4H), 3.14–3.06 (m, 8H). ESI-HRMS [M + H]<sup>+</sup> calculated: 542,1885. Found: 542,1885.</div></div><div id="sec5-12-58" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> 8-((5-Benzamido-2,4-difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>8j</b>)</h3><div class="NLM_p last">Compound <b>8j</b> was prepared according to general procedure V. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.02 g (0.04 mmol, 50.1%) of the title compound <b>8j</b>. Melting point, 106.0. HPLC, 6.91 min. IR (ATR) [cm<sup>–1</sup>] 3288, 2940, 1772, 1696, 1602, 1560, 1508, 1436, 1263, 1263, 1113, 1028, 955, 858, 761, 689. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.67–8.57 (m, 11H), 8.38 (s, 7H), 8.25–8.15 (m, 12H), 8.06–7.99 (m, 25H), 7.92–7.83 (m, 26H), 7.67–7.59 (m, 16H), 7.58–7.50 (m, 33H), 7.42–7.34 (m, 22H), 7.13–6.95 (m, 24H), 6.49 (s, 6H), 3.25 (dd, <i>J</i> = 23.0, 7.4 Hz, 40H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.5, 167.2, 165.5, 148.9, 145.1, 144.6, 138.8, 133.7, 133.2, 132.6, 131.8, 130.6, 129.5, 128.8, 128.4, 128.1, 127.7, 127.3, 124.2 (dd, <i>J</i> = 12.8, 3.7 Hz), 122.2, 113.8, 112.4, 105.1 (t, <i>J</i> = 25.7 Hz), 35.3, 33.7. ESI-HRMS [M + H]<sup>+</sup> calculated: 498.1624. Found: 498.1583.</div></div><div id="sec5-12-59" class="NLM_sec NLM_sec_level_2"><div id="ac_i95" class="anchor-spacer"></div><h3 class="article-section__title" id="_i95"> 8-((5-Benzamido-2,4-difluorophenyl)amino)-<i>N</i>-(2,3-dihydroxypropyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>8k</b>)</h3><div class="NLM_p last">Compound <b>8k</b> was prepared according to general procedure V. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.04 g (0.08 mmol, 41.2%) of the title compound <b>8k</b>. Melting point, 230.0 °C. HPLC, 7.29 min. IR (ATR) [cm<sup>–1</sup>] 3294, 3048, 1737, 1629, 1532, 1434, 1267, 1117, 1029, 900, 827, 709, 650, 631. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.21 (s, 1H), 8.66 (s, 1H), 8.62–8.50 (m, 1H), 8.30–8.23 (m, 1H), 7.97 (d, <i>J</i> = 8.8 Hz, 1H), 7.92 (d, <i>J</i> = 7.3 Hz, 2H), 7.90–7.82 (m, 1H), 7.59–7.47 (m, 4H), 7.47–7.37 (m, 2H), 6.83–6.75 (m, 1H), 6.69 (s, 1H), 3.12–2.99 (m, 4H), 2.77 (d, <i>J</i> = 4.5 Hz, 3H). ESI-HRMS [M + H]<sup>+</sup> calculated: 512.1780. Found: 512.1788.</div></div><div id="sec5-12-60" class="NLM_sec NLM_sec_level_2"><div id="ac_i96" class="anchor-spacer"></div><h3 class="article-section__title" id="_i96"> Methyl 3-((3-Benzamido-4-fluorophenyl)amino)-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxylate (<b>8l</b>)</h3><div class="NLM_p last">Compound <b>8l</b> was prepared according to general procedure Va to afford 0.23 g (0.46 mmol, 72.9%) of the title compound <b>8l</b>. HPLC, 7.51 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.16 (s, 1H), 9.87 (s, 1H), 9.10 (s, 1H), 8.36 (s, 1H), 8.13 (d, <i>J</i> = 7.7 Hz, 1H), 8.04 (t, <i>J</i> = 12.8 Hz, 1H), 7.65 (t, <i>J</i> = 7.6 Hz, 1H), 7.57–7.46 (m, 5H), 7.29 (t, <i>J</i> = 9.2 Hz, 1H), 7.13–7.00 (m, 1H), 6.94 (dd, <i>J</i> = 22.1, 12.9 Hz, 1H), 6.81 (d, <i>J</i> = 7.0 Hz, 2H), 6.57 (s, 1H), 6.40 (dd, <i>J</i> = 17.7, 13.7 Hz, 1H), 5.26 (s, 2H), 3.84 (d, <i>J</i> = 30.0 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 185.89, 165.6, 165.5, 165.3, 163.0, 152.5, 151.5, 150.1, 149.04, 146.7, 144.9, 140.5, 140.0, 136.4, 134.1, 133.8, 133.6, 132.5, 131.9, 131.6, 130.2, 129.8, 128.7, 128.4, 128.4, 127.7, 127.6, 126.3, 126.2, 125.5, 125.4, 118.9, 118.8, 118.7, 116.4, 116.3, 115.5, 115.3, 111.8, 111.5, 111.5, 110.4, 101.7, 72.4, 66.3. ESI-HRMS [M + H]<sup>+</sup> calculated: 497.1507. Found: 497.1510.</div></div><div id="sec5-12-61" class="NLM_sec NLM_sec_level_2"><div id="ac_i97" class="anchor-spacer"></div><h3 class="article-section__title" id="_i97"> 3-((3-Benzamido-4-fluorophenyl)amino)-<i>N-</i>(2-morpholinoethyl)-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxamide (<b>8m</b>)</h3><div class="NLM_p last">Compound <b>8m</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.04 g (0.07 mmol, 40.6%) of the title compound <b>8m</b>. HPLC, 5.27 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.15 (s, 1H), 9.07 (s, 1H), 8.63 (t, <i>J</i> = 5.3 Hz, 1H), 8.27 (s, 1H), 8.04 (t, <i>J</i> = 7.8 Hz, 2H), 7.97 (d, <i>J</i> = 7.7 Hz, 2H), 7.61 (t, <i>J</i> = 7.2 Hz, 2H), 7.53 (t, <i>J</i> = 7.3 Hz, 3H), 7.29 (t, <i>J</i> = 9.5 Hz, 1H), 7.12–7.00 (m, 1H), 6.80 (d, <i>J</i> = 9.0 Hz, 1H), 6.56 (s, 1H), 5.25 (s, 2H), 3.64–3.50 (m, 6H), 2.46 (d, <i>J</i> = 6.7 Hz, 2H), 2.41 (s, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 186.6, 186.6, 165.5, 165.5, 165.2, 162.9, 162.9, 151.3, 150.1, 140.0, 138.9, 135.1, 133.9, 133.4, 131.9, 130.8, 128.4, 128.2, 127.8, 127.7, 126.4, 118.6, 116.5, 110.2, 101.7, 72.4, 66.2, 57.2, 53.2, 36.6. ESI-HRMS [M – H]<sup>+</sup> calculated: 595.2351. Found: 595.2352.</div></div><div id="sec5-12-62" class="NLM_sec NLM_sec_level_2"><div id="ac_i98" class="anchor-spacer"></div><h3 class="article-section__title" id="_i98"> 3-((3-Benzamido-4-fluorophenyl)amino)-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxamide (<b>8n</b>)</h3><div class="NLM_p last">Compound <b>8n</b> was prepared according to general procedure VI. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.02 g (0.04 mmol, 40.6%) of the title compound <b>8n</b>. HPLC, 6.02 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.15 (s, 1H), 9.07 (s, 1H), 8.63 (t, <i>J</i> = 5.3 Hz, 1H), 8.27 (s, 1H), 8.04 (t, <i>J</i> = 7.8 Hz, 2H), 7.97 (d, <i>J</i> = 7.7 Hz, 2H), 7.61 (t, <i>J</i> = 7.2 Hz, 2H), 7.53 (t, <i>J</i> = 7.3 Hz, 3H), 7.29 (t, <i>J</i> = 9.5 Hz, 1H), 7.12–7.00 (m, 1H), 6.80 (d, <i>J</i> = 9.0 Hz, 1H), 6.56 (s, 1H), 5.25 (s, 2H), 3.64–3.50 (m, 6H), 2.46 (d, <i>J</i> = 6.7 Hz, 2H), 2.41 (s, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 186.6, 186.6, 165.5, 165.5, 165.2, 162.9, 162.9, 151.3, 150.1, 140.0, 138.4, 135.1, 133.9, 133.4, 131.9, 130.8, 128.4, 128.2, 127.8, 127.7, 126.4, 118.6, 116.5, 110.2, 101.7, 72.4, 66.2, 57.2, 53.2, 36.6. ESI-HRMS [M – H]<sup>+</sup> calculated: 482.1511. Found: 482.1510.</div></div><div id="sec5-12-63" class="NLM_sec NLM_sec_level_2"><div id="ac_i99" class="anchor-spacer"></div><h3 class="article-section__title" id="_i99"> 8-((5-(4-Chlorobenzamido)-2,4-difluorophenyl)amino)-<i>N</i>-methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>9a</b>)</h3><div class="NLM_p last">Compound <b>9a</b> was prepared according to general procedure Vb. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.06 g (0.11 mmol, 62.9%) of the title compound <b>9a</b>. Melting point, 257.0 °C. HPLC, 7.32 min. IR (ATR) [cm<sup>–1</sup>] 3406, 3288, 3043, 1650, 1557, 1486, 1358, 1262, 1178, 1116, 1030, 900, 826, 784, 648, 566, 450. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.15 (s, 1H), 8.67 (s, 1H), 8.53 (s, 1H), 8.33 (s, 1H), 8.05–7.88 (m, 5H), 7.67–7.58 (m, 2H), 7.57–7.47 (m, 4H), 7.43–7.38 (m, 1H), 6.87–6.80 (m, 1H), 6.71 (s, 1H), 3.17–2.97 (m, 5H), 2.79 (d, <i>J</i> = 4.3 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 201.0, 190.5, 165.9, 165.5, 152.5 (dd, <i>J</i> = 246.9, 11.1 Hz), 151.7 (dd, <i>J</i> = 246.7, 11.1 Hz), 149.0, 145.1, 144.4, 138.8, 133.7, 133.3, 132.8, 131.8, 130.2, 128.9 (d, <i>J</i> = 11.1 Hz), 128.4, 127.7, 127.4, 124.3 (dd, <i>J</i> = 12.8, 3.5 Hz), 122.3 (dd, <i>J</i> = 13.8, 2.7 Hz), 122.2, 113.8, 112.4, 105.1 (t, <i>J</i> = 25.6 Hz), 35.4, 33.7, 26.2. ESI-HRMS [M-Cl]<sup>−</sup> calculated: 510.1635. Found: 510.1642</div></div><div id="sec5-12-64" class="NLM_sec NLM_sec_level_2"><div id="ac_i100" class="anchor-spacer"></div><h3 class="article-section__title" id="_i100"> 8-((5-(3-Chlorobenzamido)-2,4-difluorophenyl)amino)-<i>N-</i>methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>9b</b>)</h3><div class="NLM_p last">Compound <b>9b</b> was prepared according to general procedure Vb. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.08 g (0.14 mmol, 85.0%) of the title compound <b>9b</b>. Melting point, 234,0 °C. HPLC, 7.34 min. IR (ATR) [cm<sup>–1</sup>] 3408, 3311, 3051, 1669, 1563, 1435, 1360, 1218, 1106, 1030, 931, 826, 719, 679, 625, 503, 462. <sup>1</sup>H NMR (400 MHz, acetone-<i>d</i><sub>6</sub>) δ 8.35 (s, 1H), 8.15–8.02 (m, 2H), 8.02–7.89 (m, 3H), 7.82 (s, 1H), 7.62–7.42 (m, 3H), 7.37–7.32 (m, 1H), 7.27–7.17 (m, 1H), 6.98–6.89 (m, 1H), 6.87 (s, 1H), 4.05–3.92 (m, 1H), 3.21–3.04 (m, 4H), 2.87 (d, <i>J</i> = 9.9 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.5, 179.3, 165.9, 165.5, 164.2, 149.0, 145.2, 144.4, 138.8, 135.7, 133.7, 133.3, 133.2, 132.8, 131.9, 131.7, 130.4, 130.2, 129.0, 128.9, 128.4, 127.7, 127.5, 127.4, 126.5, 122.2, 113.8, 112.4, 105.2, 35.3, 33.7, 26.2. ESI-HRMS [M + Na]<sup>+</sup> calculated: 568.1210. Found: 568.1215</div></div><div id="sec5-12-65" class="NLM_sec NLM_sec_level_2"><div id="ac_i101" class="anchor-spacer"></div><h3 class="article-section__title" id="_i101"> 8-((2,4-Difluoro-5-(4-fluorobenzamido)phenyl)amino)-<i>N</i>-methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>10a</b>)</h3><div class="NLM_p last">Compound <b>10a</b> was prepared according to general procedure Vb. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.04 g (0.08 mmol, 39.8%) of the title compound <b>10a</b>. Melting point, 100.3 °C. HPLC, 7.53 min. IR (ATR) [cm<sup>–1</sup>] 3040, 1732, 1626, 1601, 1525, 1434, 1360, 1266, 1163, 1086, 904, 851, 784, 627, 470. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.23 (s, 1H), 8.71 (s, 1H), 8.65–8.45 (m, 1H), 8.13–7.89 (m, 4H), 7.73–7.00 (m, 9H), 6.96–6.82 (m, 1H), 6.74 (s, 1H), 3.38 (s, 4H), 3.26–3.00 (m, 5H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 191.0, 166.4, 165.0, 150.0, 145.7, 145.0, 139.3, 133.8, 133.3, 131.1, 131.0, 130.7, 130.4, 129.5, 129.4, 127.9, 122.7, 116.0, 115.8, 114.4, 112.9, 105.7, 35.8, 34.3, 26.7. ESI-HRMS [M + Na]<sup>+</sup> calculated: 552.1506. Found: 552.1513</div></div><div id="sec5-12-66" class="NLM_sec NLM_sec_level_2"><div id="ac_i102" class="anchor-spacer"></div><h3 class="article-section__title" id="_i102"> 8-((2,4-Difluoro-5-(3-fluorobenzamido)phenyl)amino)-<i>N</i>-methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>10b</b>)</h3><div class="NLM_p last">Compound <b>10b</b> was prepared according to general procedure Vb. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.04 g (0.08 mmol, 45.3%) of the title compound <b>10b</b>. Melting point, 244,1 °C. HPLC, 7.62 min. IR (ATR) [cm<sup>–1</sup>] 3405, 3313, 3044, 1625, 1557, 1519, 1485, 1406, 1358, 1217, 1178, 968, 804, 719, 679, 568, 456. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.26 (s, 1H), 8.68 (s, 1H), 8.63–8.50 (m, 1H), 8.32 (s, 1H), 8.01 (d, <i>J</i> = 8.8 Hz, 1H), 7.90 (d, <i>J</i> = 6.1 Hz, 1H), 7.85–7.72 (m, 2H), 7.65–7.55 (m, 2H), 7.55–7.45 (m, 2H), 7.41 (d, <i>J</i> = 7.9 Hz, 1H), 6.83 (d, <i>J</i> = 8.8 Hz, 1H), 6.71 (s, 1H), 3.16–3.00 (m, 4H), 2.78 (d, <i>J</i> = 4.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.5, 166.0, 164.3, 163.1, 160.7, 148.9, 145.2, 144.5, 138.9, 136.1 (d, <i>J</i> = 7.1 Hz), 133.3, 132.8, 130.7 (d, <i>J</i> = 8.0 Hz), 130.7, 129.0 (d, <i>J</i> = 8.9 Hz), 127.4, 124.4 (dd, <i>J</i> = 14.4, 4.1 Hz), 124.0 (d, <i>J</i> = 2.7 Hz), 122.3, 122.0 (dd, <i>J</i> = 12.8, 3.4 Hz), 118.9, 118.7, 114.6 (d, <i>J</i> = 23.0 Hz), 113.9, 112.5, 105.2, 35.3, 33.8, 26.3. ESI-HRMS [M + Na]<sup>+</sup> calculated: 552.1506. Found: 552.1506</div></div><div id="sec5-12-67" class="NLM_sec NLM_sec_level_2"><div id="ac_i103" class="anchor-spacer"></div><h3 class="article-section__title" id="_i103"> 8-((2,4-Difluoro-5-(4-methoxybenzamido)phenyl)amino)-<i>N</i>-methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>11a</b>)</h3><div class="NLM_p last">Compound <b>11a</b> was prepared according to general procedure Vb. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.06 g (0.11 mmol, 62.9%) of the title compound <b>11a</b>. Melting point, 269,2 °C. HPLC, 7.40 min. IR (ATR) [cm<sup>–1</sup>] 3242, 3041, 1626, 1526, 1431, 1359, 1255, 1118, 1029, 903, 826, 768, 607, 502. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.00 (s, 1H), 8.67 (s, 1H), 8.59–8.51 (m, 1H), 8.39–8.28 (m, 1H), 8.01 (d, <i>J</i> = 8.8 Hz, 1H), 7.96 (d, <i>J</i> = 8.8 Hz, 2H), 7.93–7.86 (m, 1H), 7.60 (t, <i>J</i> = 8.3 Hz, 1H), 7.48 (t, <i>J</i> = 10.4 Hz, 1H), 7.40 (d, <i>J</i> = 7.9 Hz, 1H), 7.06 (d, <i>J</i> = 8.8 Hz, 2H), 6.82 (d, <i>J</i> = 8.6 Hz, 1H), 6.70 (s, 1H), 3.83 (s, 3H), 3.13–3.04 (m, 4H), 2.78 (d, <i>J</i> = 4.4 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 206.9, 190.5, 165.9, 164.9, 162.1, 152.5 (dd, <i>J</i> = 246.5, 2.6 Hz), 151.8 (dd, <i>J</i> = 247.3, 2.2 Hz), 149.0, 145.2, 144.4, 138.8, 133.3, 132.8, 130.2, 129.7, 129.0, 128.9, 127.3, 125.8, 124.2 (dd, <i>J</i> = 12.5, 2.8 Hz), 122.5 (dd, <i>J</i> = 12.8, 3.2 Hz), 122.3, 113.7 (d, <i>J</i> = 19.4 Hz), 112.4, 105.1 (t, <i>J</i> = 25.0 Hz), 55.4, 35.3, 33.8, 26.2. ESI-HRMS [M + Na]<sup>+</sup> calculated: 564.1705. Found: 564.1709</div></div><div id="sec5-12-68" class="NLM_sec NLM_sec_level_2"><div id="ac_i104" class="anchor-spacer"></div><h3 class="article-section__title" id="_i104"> 8-((2,4-Difluoro-5-(3-methoxybenzamido)phenyl)amino)-<i>N</i>-methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>11b</b>)</h3><div class="NLM_p last">Compound <b>11b</b> was prepared according to general procedure Vb. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.06 g (0.12 mmol, 68.9%) of the title compound <b>11b</b>. Melting point, 120.4 °C. HPLC, 7.40 min. IR (ATR) [cm<sup>–1</sup>] 3405, 3313, 3044, 1625, 1557, 1519, 1485, 1406, 1358, 1217, 1178, 968, 804, 719, 679, 568, 456. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.71 (s, 1H), 8.64–8.50 (m, 1H), 8.36 (s, 1H), 8.13–7.89 (m, 2H), 7.71–7.38 (m, 6H), 7.29–7.16 (m, 1H), 6.93–6.81 (m, 1H), 6.74 (s, 1H), 3.86 (s, 3H), 3.19 (s, 1H), 3.19–3.01 (m, 4H), 2.01 (s, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.90, 172.38, 170.71, 166.30, 165.62, 159.60, 149.38, 145.63, 144.88, 139.26, 135.50, 133.73, 133.14, 130.67, 130.02, 129.45, 129.33, 127.73, 122.79, 122.71, 122.51, 122.44, 120.40, 118.16, 114.27, 113.28, 112.81, 55.73, 35.77, 34.15, 21.12. ESI-HRMS [M + Na]<sup>+</sup> calculated: 564.1705. Found: 564.1707</div></div><div id="sec5-12-69" class="NLM_sec NLM_sec_level_2"><div id="ac_i105" class="anchor-spacer"></div><h3 class="article-section__title" id="_i105"> 8-((2,4-Difluoro-5-(4-(trifluoromethyl)benzamido)phenyl)amino)-<i>N</i>-methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>12</b>)</h3><div class="NLM_p last">Compound <b>12</b> was prepared according to general procedure Vb. The compound was purified by flash chromatography (silica gel, gradient DCM/methanol 95:05) to afford 0.03 g (0.05 mmol, 86.2%) of the title compound <b>12</b>. Melting point, 257,1 °C. HPLC, 8.43 min. IR (ATR) [cm<sup>–1</sup>] 3043, 1656, 1576, 1531, 1360, 1265, 1165, 1123, 902, 878, 813, 759, 655, 492, 453. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.45 (s, 1H), 8.70 (s, 1H), 8.57–8.53 (m, 1H), 8.32 (d, <i>J</i> = 9.5 Hz, 2H), 8.27 (d, <i>J</i> = 7.8 Hz, 1H), 8.04–7.95 (m, 2H), 7.91 (d, <i>J</i> = 8.7 Hz, 1H), 7.79 (t, <i>J</i> = 7.8 Hz, 1H), 7.66 (t, <i>J</i> = 8.3 Hz, 1H), 7.53 (t, <i>J</i> = 10.4 Hz, 1H), 7.40 (d, <i>J</i> = 7.8 Hz, 1H), 6.85 (d, <i>J</i> = 9.5 Hz, 1H), 6.72 (s, 1H), 3.18–3.03 (m, 4H), 2.78 (d, <i>J</i> = 4.3 Hz, 3H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 190.5, 165.9, 164.2, 152.7 (dd, <i>J</i> = 246.9, 11.2 Hz), 151.6 (dd, <i>J</i> = 245.6, 9.9 Hz), 148.9, 145.1, 144.4, 138.8, 134.7, 133.3, 132.8, 131.9, 130.2, 129.6 (d, <i>J</i> = 38.9 Hz), 128.95 (d, <i>J</i> = 12.1 Hz), 128.4 (d, <i>J</i> = 3.2 Hz), 127.4, 124.5, 124.5, 124.4 (dd, <i>J</i> = 8.7, 3.5 Hz), 122.2, 121.9 (dd, <i>J</i> = 13.1, 3.5 Hz), 113.9, 112.5, 105.2 (t, <i>J</i> = 25.0 Hz), 35.3, 33.8, 26.2. ESI-HRMS [M + Na]<sup>+</sup> calculated: 602.1474. Found: 602.1476</div></div><div id="sec5-12-70" class="NLM_sec NLM_sec_level_2"><div id="ac_i106" class="anchor-spacer"></div><h3 class="article-section__title" id="_i106"> 4-Methylisophthalic Acid<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> (<b>15</b>)</h3><div class="NLM_p last">3-Bromo-4-methylbenzoic acid <b>14</b> (10.0 g, 46.50 mmol) was suspended in 50 mL of THF<sub>dry</sub> in a three-neck flask under argon atmosphere. At 0 °C, a 3.0 M solution of methylmagnesium bromide (17.70 mL, 51.15 mmol) in diethyl ether was added dropwise and was stirred for 2 h. The resulting solution was cooled to −65 °C and then <i>n</i>-butyllithium in a 1.6 M hexane solution (35.05 mL, 93.00 mmol) was added carefully, followed by stirring. The temperature of the reaction solution was elevated to −40 °C, and an amount of approximately 25.0 g of dry ice was added. The flask was sealed and stirred overnight. When the reaction was completed, 20% sodium hydroxide solution was added and the reaction mixture was transferred to a separating funnel. The aqueous phase was washed three times with ethyl acetate. Afterward the solution was ice cooled and acidified with concentrated hydrochloric acid whereupon the product precipitated. The precipitate was filtered and collected, and 4-methylisophthalic acid <b>15</b> was obtained as a white solid in 87.4% yield (7.32 g, 40.66 mmol). <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.36 (s, 1H), 7.96 (d, <i>J</i> = 7.7 Hz, 1H), 7.43 (d, <i>J</i> = 7.7 Hz, 1H), 2.11–2.03 (m, 3H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.9, 166.6, 144.3, 132.2, 132.1, 131.2, 130.6, 128.5, 21.2. ESI-MS <i>m</i>/<i>z</i> = 179.0 [M – H]<sup>−</sup>.</div></div><div id="sec5-12-71" class="NLM_sec NLM_sec_level_2"><div id="ac_i107" class="anchor-spacer"></div><h3 class="article-section__title" id="_i107"> Dimethyl 4-Methylisophthalate (<b>16</b>)</h3><div class="NLM_p last">3-Bromo-4-methylbenzoic acid <b>15</b> and catalytic amounts of H<sub>2</sub>SO<sub>4conc</sub> were dissolved in methanol and stirred under reflux. The implementation was controlled with TLC. When the reaction was completed, the mixture was allowed to cool to room temperature, diluted with water, and extracted with ethyl acetate. The organic phase was evaporated under reduced pressure and the residue was purified by column chromatography (silica gel, gradient petroleum ether/ethyl acetate, 95:5 in 60 min to 90:10) affording the desired compound (1.63 g, 7.83 mmol, 94%). HPLC, 6.41 min. IR (ATR) [cm<sup>–1</sup>] 3051, 2984, 2934, 2843, 1715, 1444, 1315, 1065, 995, 845, 757. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.35 (d, <i>J</i> = 1.9 Hz, 1H), 8.00 (dd, <i>J</i> = 8.0, 1.9 Hz, 1H), 7.47 (d, <i>J</i> = 8.0 Hz, 1H), 3.86 (d, <i>J</i> = 1.1 Hz, 6H), 2.57 (s, 3H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i>6) δ 166.3, 165.4, 144.8, 132.3 (s, <i>J</i> = 7.0 Hz), 132.3, 130.7, 129.7, 127.5, 52.2 (d, <i>J</i> = 8.1 Hz), 21.1. ESI-MS <i>m</i>/<i>z</i> = 209.1 [M + H]<sup>+</sup>.</div></div><div id="sec5-12-72" class="NLM_sec NLM_sec_level_2"><div id="ac_i108" class="anchor-spacer"></div><h3 class="article-section__title" id="_i108"> 3-Chlorobenzyliodide (<b>17</b>)</h3><div class="NLM_p last">3-Chlorobenzyl chloride (4.1 g, 25 mmol) was dissolved in 18 mL of acetone, and 6.50 g of sodium iodide was added. The reaction mixture was refluxed for 2 h under argon atmosphere. When the reaction was completed, the mixture was allowed to cool to room temperature, diluted with water, and extracted with ethyl acetate. The extracts were combined and the solvent was removed under reduced pressure to give a brown viscous liquid. This compound was further used directly without any purification in the next step, and the purity was below 95% (6.15 g of crude product, 96%). GC–MS 7.11 min; 254/252 [M + H]<sup>+</sup>.</div></div><div id="sec5-12-73" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> Dimethyl 4-(Bromomethyl)isophthalate (<b>18</b>)</h3><div class="NLM_p last">Dimethyl 4-methylisophthalate <b>16</b> (2.5 g, 12.01 mmol) was dissolved in a single-neck flask in a few milliliters of CCl<sub>4</sub> and <i>N-</i>bromosuccinimide (2.35 g, 13.21 mmol), and catalytic amounts of azodiisobutyrodinitrile (AIBN) were added and heated to 70 °C. The reaction mixture was refluxed for 6 h, and the accruing succinimide precipitates on the surface. Afterward the succinimide was separated by filtration and the organic layer was evaporated in vacuo to afford the reaction mixture as a yellow oil. The reaction mixture was further purified by flash chromatography (SiO<sub>2</sub>, petroleum ether/ethyl acetate 5:1) to obtain dimethyl 4-(bromomethyl)isophthalate as a yellow oil, which crystallizes by cooling (3.11 g, 90.2%). Melting point, 74.1 °C. HPLC, 6.86 min. IR (ATR) [cm<sup>–1</sup>] 3080, 3007, 2945, 2847, 1439, 1403, 1287, 1128, 1070, 799, 603. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.40 (s, 1H), 8.13 (d, <i>J</i> = 8.0 Hz, 1H), 7.76 (d, <i>J</i> = 8.0 Hz, 1H), 5.06 (s, 2H), 3.90 (d, <i>J</i> = 8.1 Hz, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.6, 165.0, 143.6, 132.9, 132.5, 131.2, 129.8, 129.4, 52.5 (d, <i>J</i> = 10.1 Hz), 30.8. GC–MS 10.43 min; <i>m</i>/<i>z</i> 287.1. FAB <i>m</i>/<i>z</i> = 289.0 [M + H]<sup>+</sup>.</div></div><div id="sec5-12-74" class="NLM_sec NLM_sec_level_2"><div id="ac_i110" class="anchor-spacer"></div><h3 class="article-section__title" id="_i110"> Dimethyl 4-(3-Chlorophenethyl)isophthalate (<b>20</b>)</h3><div class="NLM_p last"><i>n</i>-BuLi (18.0 mL, 45.0 mmol) in a 2.5 M hexane solution was added dropwise in 15 min to diisopropylamine (6.35 mL, 45.2 mmol), dissolved in THF, at a temperature of 0 °C. The reaction mixture was stirred for 15 min. The solution was cooled to −78 °C, and dimethyl 4-methylisophthalate <b>16</b> (5.0 g, 24.0 mmol), dissolved in THF, was added dropwise. The solution was stirred for another 1 h. Subsequently the 3-chlorobenzyliodide <b>17</b> was added dropwise within 30 min. The reaction mixture was allowed to warm to room temperature, diluted with saturated ammonium chloride solution, and extracted with ethyl acetate. The extracts were combined and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was evaporated under reduced pressure and the crude product was purified by column chromatography (silica gel, gradient petroleum ether/ethyl acetate, 95:5 to 90:10 in 1 h) to afford the desired compound <b>20</b> (3.92 g, 11.78 mmol, 50%). HPLC, 9.23 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.36 (s, 1H), 8.03 (d, <i>J</i> = 8.0 Hz, 1H), 7.51 (d, <i>J</i> = 8.0 Hz, 1H), 7.32–7.22 (m, 3H), 7.15 (d, <i>J</i> = 7.2 Hz, 1H), 3.86 (s, 6H), 3.25–3.17 (m, 2H), 2.87–2.77 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.3, 165.3, 147.8, 143.64, 132.9, 132.2, 131.8, 130.9, 130.0, 129.5, 128.1, 127.7, 127.0, 125.9, 52.3, 52.2, 36.4, 35.3. ESI-MS <i>m</i>/<i>z</i> = 331.1 [M – H]<sup>−</sup>.</div></div><div id="sec5-12-75" class="NLM_sec NLM_sec_level_2"><div id="ac_i111" class="anchor-spacer"></div><h3 class="article-section__title" id="_i111"> Dimethyl 4-((3-Chlorophenoxy)methyl)isophthalate (<b>21</b>)</h3><div class="NLM_p last">A suspension of potassium carbonate (1.64 g, 11.88 mmol) and 3-chlorophenol (1.53 g, 11.88 mmol) in 50 mL of acetone in a single-neck flask was heated to 50 °C. A solution of dimethyl 4-(bromomethyl)isophthalate <b>18</b> (3.1 g, 10.80 mmol) in acetone was added, and the reaction mixture was refluxed for 6 h. When the reaction was finished, the solvent was removed in vacuo and the residue was redissolved in ethyl acetate. The organic layer was washed with a 20% sodium hydroxide solution, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated in vacuo. The remaining oil was purified with flash chromatography (SiO<sub>2</sub>, petroleum ether/ethyl acetate 4:1) to obtain dimethyl 4-((3-chlorophenoxy)methyl)isophthalate <b>21</b> as a white solid (2.87 g, 79.4%). Melting point, 111.6 °C. HPLC, 9.44 min. IR (ATR) [cm<sup>–1</sup>] 3072, 2994, 2949, 2839, 1715, 1590, 1433, 1300, 1231, 1085, 879, 751, 677. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.46 (s, 1H), 8.18 (d, <i>J</i> = 8.1 Hz, 1H), 7.82 (d, <i>J</i> = 7.7 Hz, 1H), 7.32 (d, <i>J</i> = 8.0 Hz, 1H), 7.14–6.91 (m, 3H), 5.52 (s, 2H), 3.88 (d, <i>J</i> = 4.4 Hz, 6H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 166.2, 165.5, 159.3, 143.5, 134.1, 133.2, 131.3 (d, <i>J</i> = 10.4 Hz), 129.4, 128.9 (d, <i>J</i> = 17.0 Hz), 121.4, 115.2, 114.1, 67.9, 52.8. FAB <i>m</i>/<i>z</i> = 337.1 [M + H]<sup>+</sup>.</div></div><div id="sec5-12-76" class="NLM_sec NLM_sec_level_2"><div id="ac_i112" class="anchor-spacer"></div><h3 class="article-section__title" id="_i112"> 4-(3-Chlorophenethyl)isophthalic Acid (<b>22</b>)</h3><div class="NLM_p last">Dimethyl 4-(3-chlorophenethyl)isophthalate <b>20</b> (0.7 g, 2.1 mmol) was dissolved in 20 mL of methanol and a little portion of H<sub>2</sub>O. KOH (0.24 g, 4.2 mmol) was added and refluxed for 6 h while stirring. When the reaction was completed, the mixture was allowed to cool to room temperature, diluted with 1 N HCl solution (pH value 1), and extracted with ethyl acetate. The extracts were combined, washed with Na<sub>2</sub>CO<sub>3</sub> solution, and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed under reduced pressure to give a white solid (0.59 g, 1.94 mmol, 92%). HPLC, 7.52 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.17 (s, 2H), 8.41 (s, 1H), 7.99 (d, <i>J</i> = 8.0 Hz, 1H), 7.44 (d, <i>J</i> = 8.0 Hz, 1H), 7.34–7.15 (m, 4H), 3.30–3.22 (m, 2H), 2.90–2.81 (m, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.9, 166.5, 147.4, 144.0, 132.9, 132.1, 131.4, 131.4, 130.5, 130.0, 128.9, 128.2, 127.0, 125.9, 36.5, 35.6. EI-MS <i>m</i>/<i>z</i> = 303.4 [M – H]<sup>−</sup>.</div></div><div id="sec5-12-77" class="NLM_sec NLM_sec_level_2"><div id="ac_i113" class="anchor-spacer"></div><h3 class="article-section__title" id="_i113"> 4-((3-Chlorophenoxy)methyl)isophthalic Acid (<b>23</b>)</h3><div class="NLM_p last">For saponification, dimethyl 4-((3-chlorophenoxy)methyl)isophthalate <b>21</b> (2.0 g, 5.97 mmol) was dissolved in sufficient methanol and heated to 50 °C. After complete solvation, potassium hydroxide (0.84 g, 14.94 mmol) was added and refluxed for 4 h. When the reaction was completed, the solvent was evaporated in vacuo, and the residue was suspended in water. The aqueous layer got ice cooled and acidified with a 10% solution of hydrochloric acid whereupon the product precipitated. The white powder of 4-((3-chlorophenoxy)methyl)isophthalic acid <b>23</b> was obtained by filtration (1.81 g, 98.8%). Melting point, 243.4 °C. HPLC, 7.95 min. IR (ATR) [cm<sup>–1</sup>] 2908, 2851, 2639, 2524, 1681, 1596, 1431, 1249, 869, 752, 676, 493. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.25 (s, 2H), 8.47 (s, 1H), 8.13 (d, <i>J</i> = 8.0 Hz, 1H), 7.77 (d, <i>J</i> = 7.9 Hz, 1H), 7.38–7.24 (m, 1H), 7.06 (d, <i>J</i> = 12.5 Hz, 1H), 7.01 (t, <i>J</i> = 7.4 Hz, 1H), 6.96 (d, <i>J</i> = 8.3 Hz, 1H), 5.53 (s, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.3, 166.3, 159.1, 142.6, 133.7, 132.6, 131.23, 130.9, 130.2, 129.5, 128.0, 120.9, 114.9, 113.7, 67.8. FAB <i>m</i>/<i>z</i> = 306.9 [M – H]<sup>−</sup>.</div></div><div id="sec5-12-78" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> 8-Chloro-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxylic Acid (<b>24</b>)</h3><div class="NLM_p last">4-(3-Chlorophenethyl)isophthalic acid <b>22</b> (3.25 g, 10.67 mmol) was suspended in 150 mL of DCM and refluxed while stirring. Then SOCl<sub>2</sub> (6.98 g, 58.67 mmol) was added dropwise. The reaction mixture was refluxed until a clear solution is obtained. Otherwise, 1–2 drops of DMF were added after 3 h. The solution was cooled to 0 °C, and AlCl<sub>3</sub> (7.83 g, 58.72 mmol) was added and stirred for further 20 min. The solution was then poured onto ice and extracted with DCM. The combined organic layers were washed with water. The solvent was dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated under reduced pressure to yield the product <b>24</b> (3.0 g, 10.46 mmol, 98%). HPLC, 8.31 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.66 (s, 1H), 8.44 (s, 2H), 8.06–7.99 (m, 2H), 7.93–7.86 (m, 2H), 7.50–7.38 (m, 6H), 3.27–3.12 (m, 8H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 192.4, 166.5, 146.8, 144.3, 137.56, 137.4, 136.3, 132.9, 132.33, 131.34, 130.3, 129.3, 129.2, 126.8, 33.9, 33.4. EI-MS <i>m</i>/<i>z</i> = 285.0 [M – H]<sup>−</sup>.</div></div><div id="sec5-12-79" class="NLM_sec NLM_sec_level_2"><div id="ac_i115" class="anchor-spacer"></div><h3 class="article-section__title" id="_i115"> 3-Chloro-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxylic Acid (<b>25</b>)</h3><div class="NLM_p last">4-((3-Chlorophenoxy)methyl)isophthalic acid <b>23</b> (0.4 g, 1.3 mmol) was dissolved in 25 mL of dry DCM and 2.5 mL of dry DMF and was heated to reflux. Thionyl chloride (0.24 mL, 7.17 mmol) was added dropwise and stirred for 1 h. The reaction mixture was allowed to cool to approximately 40 °C, and aluminum chloride (0.97 g, 7.17 mmol) was added in small portions and was stirred for 1 h. After the reaction showed completeness, the mixture was poured on ice and was stirred for another hour. The reaction mixture was transferred to a separation funnel, and the organic layer was washed sequentially with a 10% solution of hydrochloric acid, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated to dryness. The resulting solid of <b>25</b> could be suspended in cold DCM and be filtered to achieve higher purity (0.21 g, 55.8%). Melting point, 245.6 °C. HPLC, 8.66 min. IR (ATR) [cm<sup>–1</sup>] 2984, 2814, 2533, 2361, 1681, 1596, 1486, 1414, 1251, 1040, 869, 829, 753, 599, 678. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.71–12.82 (s, 1H), 8.31 (s, 1H), 8.13 (d, <i>J</i> = 9.1 Hz, 2H), 7.72 (d, <i>J</i> = 7.8 Hz, 1H), 7.36–7.15 (m, 2H), 5.42 (s, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 167.23, 166.3, 159.1, 142.6, 133.78, 132.6, 131.28, 131.0, 130.2, 129.6, 128.1, 121.0, 114.9, 113.7, 67.8. FAB <i>m</i>/<i>z</i> = 288.8 [M – H]<sup>−</sup>.</div></div><div id="sec5-12-80" class="NLM_sec NLM_sec_level_2"><div id="ac_i116" class="anchor-spacer"></div><h3 class="article-section__title" id="_i116"> Methyl 8-Chlor-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxylate (<b>26</b>)</h3><div class="NLM_p last">8-Chloro-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxylic acid <b>24</b> (0.6 g, 2.09 mmol) was dissolved in 20 mL of methanol. Catalytic amounts of concentrated HCl were added and refluxed while stirring. When the reaction was completed, the mixture was allowed to cool to room temperature, diluted with 20% NaOH solution, and extracted with ethyl acetate. The extracts were combined and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed under reduced pressure to give the desired compound <b>26</b> (0.62 g, 2.06 mmol) in 99% yield. HPLC, 8.61. <sup>1</sup>H NMR (200 MHz, <i>d6</i>-DMSO) δ 8.44 (s, 1H), 8.08–7.98 (m, 1H), 7.94–7.82 (m, 1H), 7.53–7.37 (m, 3H), 3.86 (s, 3H), 3.29–3.11 (m, 4H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 192.2, 165.5, 147.3, 144.3, 137.6, 137.5, 136.1, 132.7, 132.3, 131.2, 130.5, 129.2, 128.1, 126.8, 52.3, 33.8, 33.2. ESI-MS <i>m</i>/<i>z</i> = 301.3 [M + H]<sup>+</sup>.</div></div><div id="sec5-12-81" class="NLM_sec NLM_sec_level_2"><div id="ac_i117" class="anchor-spacer"></div><h3 class="article-section__title" id="_i117"> Methyl 3-Chloro-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxylate (<b>27</b>)</h3><div class="NLM_p last">3-Chloro-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxylic acid <b>25</b> (2.0 g, 6.93 mmol) was dissolved in a single-neck flask in 75 mL of methanol while 1 mL of conc sulfuric acid was added. The solution was refluxed for 6 h until the reaction showed completeness. After cooling to room temperature, the excess methanol was evaporated in vacuo. The residue was redissolved in ethyl acetate and washed three times with a 20% sodium hydroxide solution. The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was then removed in vacuo to obtain methyl 3-chloro-11-oxo-6,11-dihydrodibenzo[<i>b</i>,<i>e</i>]oxepine-9-carboxylate (<b>27</b>) as a white powder. (2.01 g, 6.64 mmol, 95.8%). Melting point, 271.4 °C. HPLC, 8.62 min. IR (ATR) [cm<sup>–1</sup>] 2982, 2962, 2925, 1639, 1594, 1567, 1376, 1263, 1196, 1017, 761, 644. <sup>1</sup>H N<b>MR</b> (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.33 (s, 1H), 8.22 (d, <i>J</i> = 7.8 Hz, 1H), 8.18–8.08 (m, 1H), 7.77 (d, <i>J</i> = 7.8 Hz, 1H), 7.29 (d, <i>J</i> = 7.1 Hz, 2H), 5.44 (s, 3H), 3.89 (s, 3H). FAB <i>m</i>/<i>z</i> = 303.1 [M + H]<sup>+</sup>.</div></div><div id="sec5-12-82" class="NLM_sec NLM_sec_level_2"><div id="ac_i118" class="anchor-spacer"></div><h3 class="article-section__title" id="_i118"> 8-Chloro-<i>N</i>-methyl-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>28</b>)</h3><div class="NLM_p last">8-Chloro-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxylic acid <b>24</b> (1.0 g, 3.49 mmol) was dissolved in DCM and catalytic amounts of DMF. Oxalyl chloride (0.66 g, 5.19 mmol) was added and stirred at ambient temperature for 1 h under argon atmosphere. Afterward, a solution of methylamine and trietylamine in DCM is prepared. The activated carboxylic acid was added dropwise, and the reaction mixture was stirred at ambient temperature under argon atmosphere overnight. Then the solution was poured into water, extracted several times with DCM, dried over Na<sub>2</sub>SO<sub>4</sub>, and evaporated under reduced pressure. The extract was further purified by column chromatography (silica gel, gradient ethyl acetate/petroleum ether, 50:70 in 40 min to 50:50) to afford the desired compound (0.92 g, 3.22 mmol, 92.1%). HPLC, 6.78 min. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.63–8.54 (m, 1H), 8.38–8.34 (m, 1H), 8.00–7.87 (m, 2H), 7.52–7.42 (m, 3H), 3.20 (s, 4H), 2.83–2.76 (m, 3H). FAB <i>m</i>/<i>z</i> = 300.0 [M + H]<sup>+</sup>.</div></div><div id="sec5-12-83" class="NLM_sec NLM_sec_level_2"><div id="ac_i119" class="anchor-spacer"></div><h3 class="article-section__title" id="_i119"> 8-Chloro-<i>N</i>-(2-morpholinethyl)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxamide (<b>29</b>)</h3><div class="NLM_p last">8-Chloro-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxylic acid <b>24</b> (0.20 g, 0.70 mmol) was dissolved in 2 mL of THF<sub>dry</sub>. TBTU (0.29 g, 0.91 mmol) and DIPEA (0.27 g, 2.09 mmol) were added to the solution. After activation, 2-morpholinoethan-1-amine (0.09 g, 0.70 mmol) was added. When the reaction was completed, the reaction mixture was diluted with water and extracted with ethyl acetate. The organic layers were combined and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed under reduced pressure and the crude product was purified by column chromatography (silica gel, gradient petroleum ether/ethyl acetate, 95:5 to 90:10 in 1 h) to give the desired compound (0,75 g, 1.88 mmol, 89.3%). HPLC, 5.19 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.58 (s, 1H), 8.35 (s, 1H), 7.94 (dd, <i>J</i> = 20.5, 8.0 Hz, 2H), 7.51 (s, 1H), 7.46 (d, <i>J</i> = 8.0 Hz, 2H), 3.61–3.53 (m, 4H), 3.42–3.34 (m, 4H), 3.25–3.16 (m, 4H), 2.45–2.36 (m, 4H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 192.9, 165.2, 144.8, 144.3, 137.5, 137.3, 136.4, 133.0, 132.2, 131.1, 129.8, 129.3, 129.0, 126.7, 66.2, 57.3, 53.2, 36.6.</div></div><div id="sec5-12-84" class="NLM_sec NLM_sec_level_2"><div id="ac_i120" class="anchor-spacer"></div><h3 class="article-section__title" id="_i120"> <i>N</i>-Isopropyl-<i>N</i>,4-dimethyl-3-nitrobenzamide (<b>30a</b>)</h3><div class="NLM_p last">Compound <b>30a</b> was prepared according to general procedure Ia. The residue was purified by flash chromatographie (silica gel, gradient petroleum ether/ethyl acetate 70:30) to afford 1.10 g (4.6 mmol, 84.62%) of the title compound <b>30a</b>. HPLC, 5.53 min. <sup>1</sup>H NMR (200 MHz, DMSO) δ 6.94 (d, <i>J</i> = 7.4 Hz, 1H), 6.56 (s, 1H), 6.40 (d, <i>J</i> = 7.4 Hz, 1H), 4.97 (s, 2H), 2.74 (s, 3H), 2.50 (s, 1H), 2.06 (s, 3H), 1.08 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.2, 148.7, 135.8, 133.3, 132.9, 131.6, 123.0, 61.9, 23.1, 19.5, 5.7. EI-MS <i>m</i>/<i>z</i> = 235.0 [M – H]<sup>−</sup>.</div></div><div id="sec5-12-85" class="NLM_sec NLM_sec_level_2"><div id="ac_i121" class="anchor-spacer"></div><h3 class="article-section__title" id="_i121"> <i>N</i>-Cyclopropyl-4-methyl-3-nitrobenzamide (<b>31a</b>)</h3><div class="NLM_p last">Compound <b>31a</b> was prepared according to general procedure Ia. The residue was purified by flash chromatography (silica gel, gradient petroleum ether/ethyl acetate 60:40) to afford 1.17g (5.32 mmol, 91.05%) of the title compound <b>31a</b>. HPLC, 4.49 min. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.78–8.60 (m, 1H), 8.41 (d, <i>J</i> = 1.8 Hz, 1H), 8.05 (dd, <i>J</i> = 8.1, 1.8 Hz, 1H), 7.60 (d, <i>J</i> = 8.1 Hz, 1H), 2.95–2.79 (m, 1H), 2.55 (s, 3H), 0.77–0.65 (m, 2H), 0.63–0.53 (m, 2H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 165.1, 148.7, 135.7, 133.3, 132.9, 131.6, 123.0, 23.1, 19.45, 5.7. EI-MS <i>m</i>/<i>z</i> = 219.3 [M – H]<sup>−</sup>.</div></div><div id="sec5-12-86" class="NLM_sec NLM_sec_level_2"><div id="ac_i122" class="anchor-spacer"></div><h3 class="article-section__title" id="_i122"> <i>N</i>-(2-Fluoro-5-nitrophenyl)cyclopropanecarboxamide (<b>32a</b>)</h3><div class="NLM_p last">Compound <b>32a</b> was prepared according to general procedure Ib. The residue was purified by flash chromatography (silica gel, gradient petroleum ether/ethyl acetate 60:40) to afford 0.62 g (2.77 mmol, 88.11%) of the title compound <b>32a</b>. HPLC, 4.41 min. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.42 (s, 1H), 9.11–8.89 (m, 1H), 8.07–7.87 (m, 1H), 7.68–7.42 (m, 1H), 2.19–1.95 (m, 1H), 0.98–0.72 (m, 4H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 173.3, 156.3 (d, <i>J</i> = 255.5 Hz), 144.0 (d, <i>J</i> = 2.7 Hz), 127.9 (d, <i>J</i> = 13.2 Hz), 120.2 (d, <i>J</i> = 9.5 Hz), 118.2 (d, <i>J</i> = 4.3 Hz), 116.9 (d, <i>J</i> = 22.5 Hz), 14.5, 8.3. EI-MS <i>m</i>/<i>z</i> = 222.6 [M – H]<sup>−</sup>.</div></div><div id="sec5-12-87" class="NLM_sec NLM_sec_level_2"><div id="ac_i123" class="anchor-spacer"></div><h3 class="article-section__title" id="_i123"> <i>N</i>-(2-Fluoro-5-nitrophenyl)thiophene-2-carboxamide (<b>33a</b>)</h3><div class="NLM_p last">Compound <b>33a</b> was synthesized according to general procedure Ic. The residue was purified by flash chromatography (silica gel, gradient petroleum ether/ethyl acetate 80:20) to afford 1.51 g (5.72 mmol, 41.6%) of the title compound <b>33a</b>. Melting point, 86.1 °C. HPLC, 6.34 min. IR (ATR) [cm<sup>–1</sup>] 3080, 1673, 1528, 1492, 1406, 1345, 1237, 797, 718, 656. <sup>1</sup>H NMR 400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.58 (s, 1H), 9.74 (dd, <i>J</i> = 13.3, 4.1 Hz, 2H), 9.08–8.92 (m, 2H), 8.92–8.74 (m, 2H). FAB <i>m</i>/<i>z</i> = 265 [M + H]<sup>−</sup>.</div></div><div id="sec5-12-88" class="NLM_sec NLM_sec_level_2"><div id="ac_i124" class="anchor-spacer"></div><h3 class="article-section__title" id="_i124"> <i>N</i>-(2-Fluoro-5-nitrophenyl)benzamide (<b>33b</b>)</h3><div class="NLM_p last">Compound <b>36</b> was synthesized according to general procedure Id. The crude product was purified by recrystallization in hexan/ethyl acetate to afford 1.96 g (7.7 mmol, 53.4%) of the desired compound <b>36</b>. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.76–8.68 (m, 1H), 8.38–8.23 (m, 1H), 7.70–7.35 (m, 7H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.9, 144.4, 144.3, 133.7, 132.8, 129.0, 128.6, 128.4, 126.6, 126.1, 117.9, 112.4. ESI-MS <i>m</i>/<i>z</i> = 283.3 [M + Na]<sup>+</sup>.</div></div><div id="sec5-12-89" class="NLM_sec NLM_sec_level_2"><div id="ac_i125" class="anchor-spacer"></div><h3 class="article-section__title" id="_i125"> 2,4-Difluoro-5-nitroaniline (<b>34a</b>)</h3><div class="NLM_p last">Compound <b>34a</b> was synthesized according to general procedure II. The residue was not further purified (2.41g, 89.4%). HPLC, 5.85 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.57–7.32 (m, 2H), 5.65 (s, 2H). <sup>13</sup>C NMR (100 MHz, DMSO-<i>d</i><sub>6</sub>) δ 155.9, 149.2, 144.2, 135.0, 111.5, 107.0. FAB (<i>m</i>/<i>z</i>) <i>m</i>/<i>z</i> = 175.2 [M + H]<sup>+</sup>.</div></div><div id="sec5-12-90" class="NLM_sec NLM_sec_level_2"><div id="ac_i126" class="anchor-spacer"></div><h3 class="article-section__title" id="_i126"> 3-Amino-<i>N</i>-cyclopropyl-<i>N</i>,4-dimethylbenzamide (<b>37a</b>)</h3><div class="NLM_p last">Compound <b>37a</b> was prepared according to general procedure IIIa to afford 0.9 g (4.36 mmol, 96.9%) of the title compound <b>37a</b>. HPLC, 4.03 min. <sup>1</sup>H NMR (200 MHz, DMSO-<i>d</i><sub>6</sub>) δ 6.94 (d, <i>J</i> = 7.4 Hz, 1H), 6.56 (s, 1H), 6.40 (d, <i>J</i> = 7.4 Hz, 1H), 4.97 (s, 2H), 2.74 (s, 3H), 2.06 (s, 3H), 1.08 (d, <i>J</i> = 6.7 Hz, 6H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.6, 146.5, 135.6, 129.6, 121.9, 113.7, 111.6, 42.1, 19.7, 17.2. EI-MS <i>m</i>/<i>z</i> = 205.3 [M – H]<sup>−</sup>.</div></div><div id="sec5-12-91" class="NLM_sec NLM_sec_level_2"><div id="ac_i127" class="anchor-spacer"></div><h3 class="article-section__title" id="_i127"> <i>N</i>-(5-Amino-2-fluorophenyl)cyclopropanecarboxamide (<b>42a</b>)</h3><div class="NLM_p last">Compound <b>42a</b> was prepared according to general procedure IIIb to afford 0.43 g (2.21 mmol, 82.73%) of the title compound <b>42a</b>. HPLC, 1.91 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.66 (s, 1H), 7.21–7.07 (m, 1H), 6.94–6.78 (m, 1H), 6.32–6.20 (m, 1H), 4.92 (s, 2H), 2.05–1.85 (m, 1H), 0.76 (d, <i>J</i> = 6.8 Hz, 4H). <sup>13</sup>C NMR (50 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.7, 147.0–144.4 (m), 144.9 (d, <i>J</i> = 1.2 Hz), 126.1 (d, <i>J</i> = 12.5 Hz), 115.0 (d, <i>J</i> = 20.2 Hz), 109.4 (d, <i>J</i> = 5.4 Hz), 19.9, 7.1. EI-MS <i>m</i>/<i>z</i> = 192.8 [M – H]<sup>−</sup>.</div></div><div id="sec5-12-92" class="NLM_sec NLM_sec_level_2"><div id="ac_i128" class="anchor-spacer"></div><h3 class="article-section__title" id="_i128"> Methyl 8-((5-(Cyclopropanecarboxamido)-2,4-difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxylate (<b>46</b>)</h3><div class="NLM_p last">Compound <b>46</b> was prepared according to general procedure Va to afford 0.28 g (0.59 mmol, 96%) of the title compound <b>46</b>. HPLC, 8.21 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.06 (s, 1H), 8.65 (s, 1H), 8.44 (d, <i>J</i> = 1.8 Hz, 1H), 8.03–7.97 (m, 2H), 7.94–7.86 (m, 1H), 7.50–7.40 (m, 2H), 6.81–6.74 (m, 1H), 6.65 (s, 1H), 3.87 (s, 3H), 3.17–3.01 (m, 4H), 2.00–1.93 (m, 1H), 0.80 (s, 2H), 0.78 (s, 2H). ESI-MS = 475.1 [M – H]<sup>−</sup>.</div></div><div id="sec5-12-93" class="NLM_sec NLM_sec_level_2"><div id="ac_i129" class="anchor-spacer"></div><h3 class="article-section__title" id="_i129"> Methyl 8-((3-(Cyclopropylcarboxamido)-4-fluorphenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulen-3-carboxylate (<b>47</b>)</h3><div class="NLM_p last">Compound <b>47</b> was prepared according to general procedure Va to afford 0.33 g (0.72 mmol, 72.2%) of the title compound <b>47</b>. HPLC, 7.59 min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.00 (s, 1H), 8.85 (s, 1H), 8.45 (d, <i>J</i> = 2.0 Hz, 1H), 8.07–7.95 (m, 2H), 7.92–7.80 (m, 1H), 7.48 (d, <i>J</i> = 8.3 Hz, 1H), 7.32–7.15 (m, 1H), 7.04–6.90 (m, 2H), 6.87–6.76 (m, 1H), 5.75 (s, 1H), 3.87 (s, 3H), 3.24–3.00 (m, 4H), 2.15–2.01 (m, 1H), 0.92–0.72 (m, 4H). ESI-MS = 457.3 [M – H]<sup>−</sup>.</div></div><div id="sec5-12-94" class="NLM_sec NLM_sec_level_2"><div id="ac_i130" class="anchor-spacer"></div><h3 class="article-section__title" id="_i130"> Methyl 8-((5-Benzamido-2,4-difluorophenyl)amino)-5-oxo-10,11-dihydro-5<i>H</i>-dibenzo[<i>a</i>,<i>d</i>][7]annulene-3-carboxylate (<b>48</b>)</h3><div class="NLM_p last">Compound <b>48</b> was prepared according to general procedure Va to afford 0.13 g (0.25 mmol, 42.0%) of the title compound <b>48</b>. HPLC, min. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.62–8.54 (m, 1H), 8.45 (t, <i>J</i> = 8.4 Hz, 1H), 8.10 (d, <i>J</i> = 8.7 Hz, 1H), 8.02–7.93 (m, 2H), 7.84–7.77 (m, 2H), 7.56–7.39 (m, 3H), 7.30–7.08 (m, 2H), 6.96–6.88 (m, 1H), 6.87–6.79 (m, 1H), 6.80–6.72 (m, 1H), 6.00 (s, 1H), 3.84 (s, 3H), 3.15–3.03 (m, 4H). ESI-MS = 510.8 [M – H]<sup>−</sup>.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i131"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00745">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54633" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54633" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.7b00745" class="ext-link">10.1021/acs.jmedchem.7b00745</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">SMILES and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00745/suppl_file/jm7b00745_si_001.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Experimental and analytical data, including HPLC purity, (HR)MS, and NMR data of compounds <b>2</b>–<b>60</b>; additional characterization of binding kinetics; all general methods; experimental section for materials and intermediates; X-ray crystallography; metabolic stability determination in vitro (<a href="/doi/suppl/10.1021/acs.jmedchem.7b00745/suppl_file/jm7b00745_si_002.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00745/suppl_file/jm7b00745_si_001.csv">jm7b00745_si_001.csv (6.93 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00745/suppl_file/jm7b00745_si_002.pdf">jm7b00745_si_002.pdf (626.26 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Cocrystal structures of the human p38α MAP kinase in complex with <b>6j</b> and <b>8m</b>, respectively, are deposited under the accession codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MTY">5MTY</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MTX">5MTX</a> in the Protein Data Bank. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.7b00745" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54153" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54153" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Stefan A. Laufer</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical
and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard-Karls-Universitaet Tuebingen, Auf der Morgenstelle 8, 72076 Tuebingen, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6952-1486" title="Orcid link">http://orcid.org/0000-0001-6952-1486</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#eb989f8e8d8a85c5878a9e8d8e99ab9e8582c69f9e8e8982858c8e85c58f8e"><span class="__cf_email__" data-cfemail="4e3d3a2b282f2060222f3b282b3c0e3b2027633a3b2b2c2720292b20602a2b">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Niklas M. Walter</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical
and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard-Karls-Universitaet Tuebingen, Auf der Morgenstelle 8, 72076 Tuebingen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Heike K. Wentsch</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical
and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard-Karls-Universitaet Tuebingen, Auf der Morgenstelle 8, 72076 Tuebingen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mike Bührmann</span> - <span class="hlFld-Affiliation affiliation">Faculty of Chemistry and Chemical Biology, Technische Universitaet Dortmund, Otto-Hahn-Strasse 4a, 44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Silke M. Bauer</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical
and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard-Karls-Universitaet Tuebingen, Auf der Morgenstelle 8, 72076 Tuebingen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eva Döring</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical
and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard-Karls-Universitaet Tuebingen, Auf der Morgenstelle 8, 72076 Tuebingen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Svenja Mayer-Wrangowski</span> - <span class="hlFld-Affiliation affiliation">Faculty of Chemistry and Chemical Biology, Technische Universitaet Dortmund, Otto-Hahn-Strasse 4a, 44227 Dortmund, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Adrian Sievers-Engler</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical
and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard-Karls-Universitaet Tuebingen, Auf der Morgenstelle 8, 72076 Tuebingen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicole Willemsen-Seegers</span> - <span class="hlFld-Affiliation affiliation">Netherlands Translational Research Center B.V. (NTRC), Pivot Park, RE1210, Molenstraat
110, 5342 CC Oss, The Netherlands</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Guido Zaman</span> - <span class="hlFld-Affiliation affiliation">Netherlands Translational Research Center B.V. (NTRC), Pivot Park, RE1210, Molenstraat
110, 5342 CC Oss, The Netherlands</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rogier Buijsman</span> - <span class="hlFld-Affiliation affiliation">Netherlands Translational Research Center B.V. (NTRC), Pivot Park, RE1210, Molenstraat
110, 5342 CC Oss, The Netherlands</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Lämmerhofer</span> - <span class="hlFld-Affiliation affiliation">Department of Pharmaceutical
and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard-Karls-Universitaet Tuebingen, Auf der Morgenstelle 8, 72076 Tuebingen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Rauh</span> - <span class="hlFld-Affiliation affiliation">Faculty of Chemistry and Chemical Biology, Technische Universitaet Dortmund, Otto-Hahn-Strasse 4a, 44227 Dortmund, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1970-7642" title="Orcid link">http://orcid.org/0000-0002-1970-7642</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>N.M.W., H.K.W., and M.B. contributed equally to this publication.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i134">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77472" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77472" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Katharina Bauer, Silke Bauer, and Daniela Müller for the skillful technical assistance in compound testing and Michael Forster for synthesis of the precatalysts.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i135" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i135"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i136" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i136"> Abbreviations Used</h2><tr><td class="NLM_term">MAP</td><td class="NLM_def"><p class="first last">mitogen activated protein</p></td></tr><tr><td class="NLM_term">R-Spine</td><td class="NLM_def"><p class="first last">regulatory spine</p></td></tr><tr><td class="NLM_term">TRT</td><td class="NLM_def"><p class="first last">target residence time</p></td></tr><tr><td class="NLM_term">ATF</td><td class="NLM_def"><p class="first last">activating transcription factor</p></td></tr><tr><td class="NLM_term">HR</td><td class="NLM_def"><p class="first last">hydrophobic region</p></td></tr><tr><td class="NLM_term">C-Spine</td><td class="NLM_def"><p class="first last">catalytic spine</p></td></tr><tr><td class="NLM_term">BTK</td><td class="NLM_def"><p class="first last">Bruton’s tyrosine kinase</p></td></tr><tr><td class="NLM_term">IUPAC</td><td class="NLM_def"><p class="first last">International Union of Pure and Applied Chemistry</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">1,1′-carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">TBTU</td><td class="NLM_def"><p class="first last"><i>O</i>-(benzotriazol-1-yl)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium tetrafluoroborate</p></td></tr><tr><td class="NLM_term">SEM</td><td class="NLM_def"><p class="first last">standard error of the mean</p></td></tr><tr><td class="NLM_term">SPR</td><td class="NLM_def"><p class="first last">surface plasmon resonance</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsome</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i137">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35711" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35711" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 56 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matter, A.</span><span> </span><span class="NLM_article-title">Glivec (sti571, imatinib), a rationally developed, targeted anticancer drug</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span><span class="refDoi"> DOI: 10.1038/nrd839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28sti571%2C+imatinib%29%2C+a+rationally+developed%2C+targeted+anticancer+drug&doi=10.1038%2Fnrd839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0ljli6ua9tKP2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528sti571%252C%2520imatinib%2529%252C%2520a%2520rationally%2520developed%252C%2520targeted%2520anticancer%2520drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D493%26epage%3D502%26doi%3D10.1038%2Fnrd839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Manning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whyte, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudarsanam, S.</span><span> </span><span class="NLM_article-title">The protein kinase complement of the human genome</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">298</span><span class="NLM_x">, </span> <span class="NLM_fpage">1912</span><span class="NLM_x">–</span> <span class="NLM_lpage">1934</span><span class="refDoi"> DOI: 10.1126/science.1075762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1126%2Fscience.1075762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=12471243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1912-1934&author=G.+Manningauthor=D.+B.+Whyteauthor=R.+Martinezauthor=T.+Hunterauthor=S.+Sudarsanam&title=The+protein+kinase+complement+of+the+human+genome&doi=10.1126%2Fscience.1075762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Kinase Complement of the Human Genome</span></div><div class="casAuthors">Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5600</span>),
    <span class="NLM_cas:pages">1912-1916, 1933-1934</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">We have catalogued the protein kinase complement of the human genome (the "kinome") using public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences.  This provides a starting point for comprehensive anal. of protein phosphorylation in normal and disease states, as well as a detailed view of the current state of human genome anal. through a focus on one large gene family.  We identify 518 putative protein kinase genes, of which 71 have not previously been reported or described as kinases, and we extend or correct the protein sequences of 56 more kinases.  New genes include members of well-studied families as well as previously unidentified families, some of which are conserved in model organisms.  Classification and comparison with model organism kinomes identified orthologous groups and highlighted expansions specific to human and other lineages.  We also identified 106 protein kinase pseudogenes.  Chromosomal mapping revealed several small clusters of kinase genes and revealed that 244 kinases map to disease loci or cancer amplicons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTj1hf_0cQcrVg90H21EOLACvtfcHk0ljli6ua9tKP2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D&md5=b3def83bace52257a3252a3347b8bb92</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.1075762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1075762%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DG.%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DSudarsanam%26aufirst%3DS.%26atitle%3DThe%2520protein%2520kinase%2520complement%2520of%2520the%2520human%2520genome%26jtitle%3DScience%26date%3D2002%26volume%3D298%26spage%3D1912%26epage%3D1934%26doi%3D10.1126%2Fscience.1075762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span>Cell Signaling Technology Inc. Kinase-disease associations. <a href="https://www.cellsignal.com/common/content/content.jsp?id=science-tables-kinase-disease" class="extLink">https://www.cellsignal.com/common/content/content.jsp?id=science-tables-kinase-disease</a> (accessed June 19,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cell+Signaling+Technology+Inc.+Kinase-disease+associations.+https%3A%2F%2Fwww.cellsignal.com%2Fcommon%2Fcontent%2Fcontent.jsp%3Fid%3Dscience-tables-kinase-disease+%28accessed+June+19%2C+2017%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, A.</span><span> </span><span class="NLM_article-title">Novel strategies for inhibition of the p38 mapk pathway</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">286</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span><span class="refDoi"> DOI: 10.1016/j.tips.2007.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1016%2Fj.tips.2007.04.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=286-295&author=J.+Zhangauthor=B.+Shenauthor=A.+Lin&title=Novel+strategies+for+inhibition+of+the+p38+mapk+pathway&doi=10.1016%2Fj.tips.2007.04.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DB.%26aulast%3DLin%26aufirst%3DA.%26atitle%3DNovel%2520strategies%2520for%2520inhibition%2520of%2520the%2520p38%2520mapk%2520pathway%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D28%26spage%3D286%26epage%3D295%26doi%3D10.1016%2Fj.tips.2007.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Schett, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwerina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Firestein, G.</span><span> </span><span class="NLM_article-title">The p38 mitogen-activated protein kinase (mapk) pathway in rheumatoid arthritis</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">909</span><span class="NLM_x">–</span> <span class="NLM_lpage">916</span><span class="refDoi"> DOI: 10.1136/ard.2007.074278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1136%2Fard.2007.074278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=17827184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslChsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2008&pages=909-916&author=G.+Schettauthor=J.+Zwerinaauthor=G.+Firestein&title=The+p38+mitogen-activated+protein+kinase+%28mapk%29+pathway+in+rheumatoid+arthritis&doi=10.1136%2Fard.2007.074278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis</span></div><div class="casAuthors">Schett, G.; Zwerina, J.; Firestein, G.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">909-916</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chronic inflammatory processes are based on a sustained and tightly regulated communication network among different cells types.  This network comprises extracellular mediators such as cytokines, chemokines and matrix-degrading proteases, which orchestrate the participation of cells in the chronic inflammatory process.  The mirrors of this outside communication world are intracellular transcription factor pathways, which shuttle information about inflammatory stimuli to the cell nucleus.  This review examines the function of one key signal transduction pathway of inflammation-the p38 mitogen-activated protein kinases (p38MAPK).  The signalling pathway is considered as crucial for the induction and maintenance of chronic inflammation, and its components thus emerge as interesting mol. targets of small mol. inhibitors for controlling inflammation.  This review not only summarizes the current knowledge of activation, regulation and function of the p38MAPK pathway but also examines the role of this pathway in clin. disease.  It gives an overview of current evidence of p38MAPK activation in inflammatory arthritis and elaborates the key mol. determinants which contribute to p38MAPK activation in joint disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVrSODN-vBCrVg90H21EOLACvtfcHk0lgPzMVz1RyhSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslChsL4%253D&md5=eafcfc4d371a539ef290edc39792ce33</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1136%2Fard.2007.074278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.2007.074278%26sid%3Dliteratum%253Aachs%26aulast%3DSchett%26aufirst%3DG.%26aulast%3DZwerina%26aufirst%3DJ.%26aulast%3DFirestein%26aufirst%3DG.%26atitle%3DThe%2520p38%2520mitogen-activated%2520protein%2520kinase%2520%2528mapk%2529%2520pathway%2520in%2520rheumatoid%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2008%26volume%3D67%26spage%3D909%26epage%3D916%26doi%3D10.1136%2Fard.2007.074278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Tsai, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nussinov, R.</span><span> </span><span class="NLM_article-title">The molecular basis of targeting protein kinases in cancer therapeutics</span> <span class="citation_source-journal">Semin. Cancer Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span><span class="refDoi"> DOI: 10.1016/j.semcancer.2013.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1016%2Fj.semcancer.2013.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=23651790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVCks74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=235-242&author=C.+J.+Tsaiauthor=R.+Nussinov&title=The+molecular+basis+of+targeting+protein+kinases+in+cancer+therapeutics&doi=10.1016%2Fj.semcancer.2013.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular basis of targeting protein kinases in cancer therapeutics</span></div><div class="casAuthors">Tsai, Chung-Jung; Nussinov, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In this paper, we provide an overview of targeted anticancer therapies with small mol. kinase inhibitors.  First, we discuss why a single constitutively active kinase emanating from a variety of aberrant genetic alterations is capable of transforming a normal cell, leading it to acquire the hallmarks of a cancer cell.  To draw attention to the fact that kinase inhibition in targeted cancer therapeutics differs from conventional cytotoxic chemotherapy, we exploit a conceptual framework explaining why suppressed kinase activity will selectively kill only the so-called oncogene 'addicted' cancer cell, while sparing the healthy cell.  Second, we introduce the protein kinase superfamily in light of its common active conformation with precisely positioned structural elements, and the diversified auto-inhibitory conformations among the kinase families.  Understanding the detailed activation mechanism of individual kinases is essential to relate the obsd. oncogenic alterations to the elevated constitutively active state, to identify the mechanism of consequent drug resistance, and to guide the development of the next-generation inhibitors.  To clarify the vital importance of structural guidelines in studies of oncogenesis, we explain how somatic mutations in EGFR result in kinase constitutive activation.  Third, in addn. to the common theme of secondary (acquired) mutations that prevent drug binding from blocking a signaling pathway which is hijacked by the aberrant activated kinase, we discuss scenarios of drug resistance and relapse by compensating lesions that bypass the inactivated pathway in a vertical or horizontal fashion.  Collectively, these suggest that the future challenge of cancer therapy with small mol. kinase inhibitors will rely on the discovery of distinct combinations of optimized drugs to target individual subtypes of different cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon6j95mBzDh7Vg90H21EOLACvtfcHk0lgPzMVz1RyhSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVCks74%253D&md5=0359b4bc5b0aae4740c1eacbb1eba083</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2013.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2013.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DC.%2BJ.%26aulast%3DNussinov%26aufirst%3DR.%26atitle%3DThe%2520molecular%2520basis%2520of%2520targeting%2520protein%2520kinases%2520in%2520cancer%2520therapeutics%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2013%26volume%3D23%26spage%3D235%26epage%3D242%26doi%3D10.1016%2Fj.semcancer.2013.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Wagey, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krieger, C.</span><span> </span><span class="NLM_article-title">Abnormalities of protein kinases in neurodegenerative diseases</span> <span class="citation_source-journal">Prog. Drug Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span><span class="refDoi"> DOI: 10.1007/978-3-0348-8845-5_4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1007%2F978-3-0348-8845-5_4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=9949861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADyaK1MXitlKmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1998&pages=133-183&author=R.+T.+Wageyauthor=C.+Krieger&title=Abnormalities+of+protein+kinases+in+neurodegenerative+diseases&doi=10.1007%2F978-3-0348-8845-5_4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Abnormalities of protein kinases in neurodegenerative diseases</span></div><div class="casAuthors">Wagey, Ravenska T. E.; Krieger, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Drug Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">133-183</span>CODEN:
                <span class="NLM_cas:coden">FAZMAE</span>;
        ISSN:<span class="NLM_cas:issn">0071-786X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review with 248 refs. is given on neurodegenerative diseases, esp. amyotrophic lateral sclerosis and Alzheimer's disease, in relation to evidence of altered protein phosphorylation.  Pathogenesis and treatment, mechanisms of cell death, signal transduction, the role of excitatory amino acid and protein phosphorylation, and current model systems in research are discussed.  Evidence of impairment in protein kinase signalling may be a primary cause, a secondary event, or a compensatory mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh5IjTF6sWo7Vg90H21EOLACvtfcHk0lg_WC_DCJWOVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitlKmsw%253D%253D&md5=643f2900faff6fb537d57bb2d9886a22</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2F978-3-0348-8845-5_4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-0348-8845-5_4%26sid%3Dliteratum%253Aachs%26aulast%3DWagey%26aufirst%3DR.%2BT.%26aulast%3DKrieger%26aufirst%3DC.%26atitle%3DAbnormalities%2520of%2520protein%2520kinases%2520in%2520neurodegenerative%2520diseases%26jtitle%3DProg.%2520Drug%2520Res.%26date%3D1998%26volume%3D51%26spage%3D133%26epage%3D183%26doi%3D10.1007%2F978-3-0348-8845-5_4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Vlahopoulos, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logotheti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giarika, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorgoulis, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoumpourlis, V.</span><span> </span><span class="NLM_article-title">The role of atf-2 in oncogenesis</span> <span class="citation_source-journal">BioEssays</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span><span class="refDoi"> DOI: 10.1002/bies.20734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1002%2Fbies.20734" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2008&pages=314-327&author=S.+A.+Vlahopoulosauthor=S.+Logothetiauthor=D.+Mikasauthor=A.+Giarikaauthor=V.+Gorgoulisauthor=V.+Zoumpourlis&title=The+role+of+atf-2+in+oncogenesis&doi=10.1002%2Fbies.20734"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fbies.20734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbies.20734%26sid%3Dliteratum%253Aachs%26aulast%3DVlahopoulos%26aufirst%3DS.%2BA.%26aulast%3DLogotheti%26aufirst%3DS.%26aulast%3DMikas%26aufirst%3DD.%26aulast%3DGiarika%26aufirst%3DA.%26aulast%3DGorgoulis%26aufirst%3DV.%26aulast%3DZoumpourlis%26aufirst%3DV.%26atitle%3DThe%2520role%2520of%2520atf-2%2520in%2520oncogenesis%26jtitle%3DBioEssays%26date%3D2008%26volume%3D30%26spage%3D314%26epage%3D327%26doi%3D10.1002%2Fbies.20734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Cuenda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousseau, S.</span><span> </span><span class="NLM_article-title">P38 map-kinases pathway regulation, function and role in human diseases</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1773</span><span class="NLM_x">, </span> <span class="NLM_fpage">1358</span><span class="NLM_x">–</span> <span class="NLM_lpage">1375</span><span class="refDoi"> DOI: 10.1016/j.bbamcr.2007.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1016%2Fj.bbamcr.2007.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=17481747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosFyktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1773&publication_year=2007&pages=1358-1375&author=A.+Cuendaauthor=S.+Rousseau&title=P38+map-kinases+pathway+regulation%2C+function+and+role+in+human+diseases&doi=10.1016%2Fj.bbamcr.2007.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">p38 MAP-Kinases pathway regulation, function and role in human diseases</span></div><div class="casAuthors">Cuenda, Ana; Rousseau, Simon</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1773</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1358-1375</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Mammalian p38 mitogen-activated protein kinases (MAPKs) are activated by a wide range of cellular stresses as well as in response to inflammatory cytokines.  There are four members of the p38MAPK family (p38α, p38β, p38γ and p38δ) which are about 60% identical in their amino acid sequence but differ in their expression patterns, substrate specificities and sensitivities to chem. inhibitors such as SB203580.  A large body of evidences indicates that p38MAPK activity is crit. for normal immune and inflammatory response.  The p38MAPK pathway is a key regulator of pro-inflammatory cytokines biosynthesis at the transcriptional and translational levels, which makes different components of this pathway potential targets for the treatment of autoimmune and inflammatory diseases.  However, recent studies have shed light on the broad effect of p38MAPK activation in the control of many other aspects of the physiol. of the cell, such as control of cell cycle or cytoskeleton remodelling.  Here we focus on these emergent roles of p38MAPKs and their implication in different pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNYx9ozz5qArVg90H21EOLACvtfcHk0lg_WC_DCJWOVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosFyktr0%253D&md5=ca9b5a57fd95eee52cca68f3f0da1f15</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2007.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2007.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DCuenda%26aufirst%3DA.%26aulast%3DRousseau%26aufirst%3DS.%26atitle%3DP38%2520map-kinases%2520pathway%2520regulation%252C%2520function%2520and%2520role%2520in%2520human%2520diseases%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2007%26volume%3D1773%26spage%3D1358%26epage%3D1375%26doi%3D10.1016%2Fj.bbamcr.2007.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mobitz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martiny-Baron, G.</span><span> </span><span class="NLM_article-title">Targeting cancer with small-molecular-weight kinase inhibitors</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">795</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span><span class="refDoi"> DOI: 10.1007/978-1-61779-337-0_1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1007%2F978-1-61779-337-0_1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=21960212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlersLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=795&publication_year=2012&pages=1-34&author=D.+Fabbroauthor=S.+W.+Cowan-Jacobauthor=H.+Mobitzauthor=G.+Martiny-Baron&title=Targeting+cancer+with+small-molecular-weight+kinase+inhibitors&doi=10.1007%2F978-1-61779-337-0_1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small-molecular-weight kinase inhibitors</span></div><div class="casAuthors">Fabbro, Doriano; Cowan-Jacob, Sandra W.; Mobitz, Henrik; Martiny-Baron, Georg</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">795</span>
        (<span class="NLM_cas:issue">Kinase Inhibitors</span>),
    <span class="NLM_cas:pages">1-34</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Protein and lipid kinases fulfill essential roles in many signaling pathways that regulate normal cell functions.  Deregulation of these kinase activities lead to a variety of pathologies ranging from cancer to inflammatory diseases, diabetes, infectious diseases, cardiovascular disorders, cell growth and survival.  518 Protein kinases and about 20 lipid-modifying kinases are encoded by the human genome, and a much larger proportion of addnl. kinases are present in parasite, bacterial, fungal, and viral genomes that are susceptible to exploitation as drug targets.  Since many human diseases result from overactivation of protein and lipid kinases due to mutations and/or overexpression, this enzyme class represents an important target for the pharmaceutical industry.  Approx. one third of all protein targets under investigation in the pharmaceutical industry are protein or lipid kinases.  The kinase inhibitors that have been launched, thus far, are mainly in oncol. indications and are directed against a handful of protein and lipid kinases.  With one exception, all of these registered kinase inhibitors are directed toward the ATP-site and display different selectivities, potencies, and pharmacokinetic properties.  At present, about 150 kinase-targeted drugs are in clin. development and many more in various stages of preclin. development.  Kinase inhibitor drugs that are in clin. trials target all stages of signal transduction from the receptor protein tyrosine kinases that initiate intracellular signaling, through second-messenger-dependent lipid and protein kinases, and protein kinases that regulate the cell cycle.  This review provides an insight into protein and lipid kinase drug discovery with respect to achievements, binding modes of inhibitors, and novel avenues for the generation of second-generation kinase inhibitors to treat cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR2s-rg3sGDbVg90H21EOLACvtfcHk0lg_WC_DCJWOVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlersLrI&md5=f5b030e41ace1007efacda9f34d898db</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2F978-1-61779-337-0_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-61779-337-0_1%26sid%3Dliteratum%253Aachs%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DMobitz%26aufirst%3DH.%26aulast%3DMartiny-Baron%26aufirst%3DG.%26atitle%3DTargeting%2520cancer%2520with%2520small-molecular-weight%2520kinase%2520inhibitors%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2012%26volume%3D795%26spage%3D1%26epage%3D34%26doi%3D10.1007%2F978-1-61779-337-0_1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span>Blue Ridge Institute for Medical Research. USFDA approved protein kinase inhibitors. <a href="http://www.brimr.org/PKI/PKIs.htm" class="extLink">http://www.brimr.org/PKI/PKIs.htm</a> (accessed June 19,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Blue+Ridge+Institute+for+Medical+Research.+USFDA+approved+protein+kinase+inhibitors.+http%3A%2F%2Fwww.brimr.org%2FPKI%2FPKIs.htm+%28accessed+June+19%2C+2017%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span> </span><span class="NLM_article-title">P38 map kinases: Key signalling molecules as therapeutic targets for inflammatory diseases</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">717</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span><span class="refDoi"> DOI: 10.1038/nrd1177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1038%2Fnrd1177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=12951578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVWlsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=717-726&author=S.+Kumarauthor=J.+Boehmauthor=J.+C.+Lee&title=P38+map+kinases%3A+Key+signalling+molecules+as+therapeutic+targets+for+inflammatory+diseases&doi=10.1038%2Fnrd1177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases</span></div><div class="casAuthors">Kumar, Sanjay; Boehm, Jeffrey; Lee, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">717-726</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The p38 MAP kinases are a family of serine/threonine protein kinases that play important roles in cellular responses to external stress signals.  Since their identification about 10 yr ago, much has been learned of the activation and regulation of the p38 MAP kinase pathways.  Inhibitors of two members of the p38 family have been shown to have anti-inflammatory effects in preclin. disease models, primarily through the inhibition of the expression of inflammatory mediators.  Several promising compds. have also progressed to clin. trials.  In this review, we provide an overview of the role of p38 MAP kinases in stress-activated pathways and the progress towards clin. development of p38 MAP kinase inhibitors in the treatment of inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHXx_X3Trc8bVg90H21EOLACvtfcHk0lj-NEAL4q7Gpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVWlsbw%253D&md5=282ccf8914c252db2228c6590f8e5a13</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd1177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1177%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DBoehm%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DP38%2520map%2520kinases%253A%2520Key%2520signalling%2520molecules%2520as%2520therapeutic%2520targets%2520for%2520inflammatory%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D717%26epage%3D726%26doi%3D10.1038%2Fnrd1177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Dambach, D. M.</span><span> </span><span class="NLM_article-title">Potential adverse effects associated with inhibition of p38alpha/beta map kinases</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">929</span><span class="NLM_x">–</span> <span class="NLM_lpage">939</span><span class="refDoi"> DOI: 10.2174/1568026054985911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.2174%2F1568026054985911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=16178738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFeitrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=929-939&author=D.+M.+Dambach&title=Potential+adverse+effects+associated+with+inhibition+of+p38alpha%2Fbeta+map+kinases&doi=10.2174%2F1568026054985911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Potential adverse effects associated with inhibition of p38α/β MAP kinases</span></div><div class="casAuthors">Dambach, Donna M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">929-939</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Inhibitors of p38 MAP kinases show promise for the treatment of inflammatory and immunol. disorders and some cancers.  There is a substantial body of exptl. evidence across several organ systems suggesting that p38 also mediates developmental, differentiation and proliferation processes.  As a consequence of the wide-ranging regulatory role of p38 kinase in diverse cellular processes, the possibility of adverse events resulting from undesired pharmacol. activity is a major concern for the p38 inhibitor drug class.  Taking into consideration the limitations of exptl. modeling systems, together the data may indicate that profound inhibition of p38 has the potential to impact these processes during fetal or neonatal development.  The difficulty comes in extrapolating these findings to predict potential adverse effects under conditions of partial inhibition of p38 activity, and in an adult population in which these processes are typically only recapitulated during repair or adaptive responses.  As such, the goal of this review of the targets of p38 activity is to bring an awareness of the those organ systems that should be monitored for potential toxicity, as well as to present a potential mechanistic basis for such monitoring or for investigation of adverse effects that may develop with administration of a p38 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9YoS9QjJnfrVg90H21EOLACvtfcHk0lj-NEAL4q7Gpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFeitrbM&md5=ece8a45395222f3039bc51485453ac15</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F1568026054985911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026054985911%26sid%3Dliteratum%253Aachs%26aulast%3DDambach%26aufirst%3DD.%2BM.%26atitle%3DPotential%2520adverse%2520effects%2520associated%2520with%2520inhibition%2520of%2520p38alpha%252Fbeta%2520map%2520kinases%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D929%26epage%3D939%26doi%3D10.2174%2F1568026054985911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Cohen, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chindalore, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damjanov, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgos-Vargas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delora, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimany, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caulfield, J. P.</span><span> </span><span class="NLM_article-title">Evaluation of the efficacy and safety of pamapimod, a p38 map kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">344</span><span class="refDoi"> DOI: 10.1002/art.24266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1002%2Fart.24266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=19180516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjt1CgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=335-344&author=S.+B.+Cohenauthor=T.+T.+Chengauthor=V.+Chindaloreauthor=N.+Damjanovauthor=R.+Burgos-Vargasauthor=P.+Deloraauthor=K.+Zimanyauthor=H.+Traversauthor=J.+P.+Caulfield&title=Evaluation+of+the+efficacy+and+safety+of+pamapimod%2C+a+p38+map+kinase+inhibitor%2C+in+a+double-blind%2C+methotrexate-controlled+study+of+patients+with+active+rheumatoid+arthritis&doi=10.1002%2Fart.24266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active Rheumatoid arthritis</span></div><div class="casAuthors">Cohen, Stanley B.; Cheng, Tien-Tsai; Chindalore, Vishala; Damjanov, Nemanja; Burgos-Vargas, Ruben; DeLora, Patricia; Zimany, Kathleen; Travers, Helen; Caulfield, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">335-344</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: To det. the efficacy and safety of pamapimod (a selective inhibitor of the α-isoform of p38 MAP kinase) as monotherapy in comparison with methotrexate (MTX) treatment in adult patients with active rheumatoid arthritis (RA).  Methods: Patients were randomly assigned to 1 of 4 treatment groups and received 12 wk of double-blind treatment.  One group received MTX (7.5 mg/wk with planned escalation to 20 mg/wk), and 3 groups received pamapimod (50, 150, or 300 mg) once daily.  The primary efficacy end point was the proportion of patients meeting the American College of Rheumatol. 20% improvement criteria (achieving an ACR20 response) at 12 wk.  Secondary end points included ACR50 and ACR70 responses, change from baseline in the Disease Activity Score in 28 joints (DAS28), categorical analyses of DAS28/European League Against Rheumatism response, and change from baseline in each parameter of the ACR core set of measures.  Safety monitoring included recording of adverse events (AEs), lab. testing, immunol. assessments, administration of electrocardiograms, and assessment of vital signs.  Results: Patients assigned to receive MTX and pamapimod had similar demographics and baseline characteristics.  At week 12, fewer patients taking pamapimod had an ACR20 response (23%, 18%, and 31% in the 50-, 150-, and 300-mg groups, resp.) compared with patients taking MTX (45%).  Secondary efficacy end points showed a similar pattern.  AEs were typically characterized as mild and included infections, skin disorders, and dizziness.  Pamapimod was generally well tolerated, but the 300-mg dose appeared to be more toxic than either the 2 lower doses or MTX.  Conclusion: The present results showed that pamapimod was not as effective as MTX in the treatment of active RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp98GB6seTS2rVg90H21EOLACvtfcHk0lj-NEAL4q7Gpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjt1CgtL4%253D&md5=d76a0ea256ab02b1c16d388be13c2f3e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fart.24266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24266%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DS.%2BB.%26aulast%3DCheng%26aufirst%3DT.%2BT.%26aulast%3DChindalore%26aufirst%3DV.%26aulast%3DDamjanov%26aufirst%3DN.%26aulast%3DBurgos-Vargas%26aufirst%3DR.%26aulast%3DDelora%26aufirst%3DP.%26aulast%3DZimany%26aufirst%3DK.%26aulast%3DTravers%26aufirst%3DH.%26aulast%3DCaulfield%26aufirst%3DJ.%2BP.%26atitle%3DEvaluation%2520of%2520the%2520efficacy%2520and%2520safety%2520of%2520pamapimod%252C%2520a%2520p38%2520map%2520kinase%2520inhibitor%252C%2520in%2520a%2520double-blind%252C%2520methotrexate-controlled%2520study%2520of%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D335%26epage%3D344%26doi%3D10.1002%2Fart.24266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Schreiber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feagan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Haens, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombel, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geboes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yurcov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isakov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golovenko, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffgen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">BIRB 796 Study Group.</span><span> </span><span class="NLM_article-title">Oral p38 mitogen-activated protein kinase inhibition with birb 796 for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial</span> <span class="citation_source-journal">Clin. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">334</span><span class="refDoi"> DOI: 10.1016/j.cgh.2005.11.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1016%2Fj.cgh.2005.11.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=16527696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD28XjsFOqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=325-334&author=S.+Schreiberauthor=B.+Feaganauthor=G.+D%E2%80%99Haensauthor=J.+F.+Colombelauthor=K.+Geboesauthor=M.+Yurcovauthor=V.+Isakovauthor=O.+Golovenkoauthor=C.+N.+Bernsteinauthor=D.+Ludwigauthor=T.+Winterauthor=U.+Meierauthor=C.+Yongauthor=J.+Steffgenauthor=BIRB+796+Study+Group.&title=Oral+p38+mitogen-activated+protein+kinase+inhibition+with+birb+796+for+active+Crohn%E2%80%99s+disease%3A+a+randomized%2C+double-blind%2C+placebo-controlled+trial&doi=10.1016%2Fj.cgh.2005.11.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double- blind, placebo- controlled trial</span></div><div class="casAuthors">Schreiber, Stefan; Feagan, Brian; D'Haens, Geert; Colombel, Jean-Frederic; Geboes, Karel; Yurcov, Mikhail; Isakov, Vasily; Golovenko, Oleg; Bernstein, Charles N.; Ludwig, Diether; Winter, Trevor; Meier, Ulrich; Yong, Chan; Steffgen, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Gastroenterology and Hepatology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">325-334</span>CODEN:
                <span class="NLM_cas:coden">CGHLAW</span>;
        ISSN:<span class="NLM_cas:issn">1542-3565</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The p38 mitogen-activated protein kinase (MAPK) regulates the expression of proinflammatory cytokines, which play a crit. role in the pathophysiol. of Crohn's disease (CD).  This study investigated the efficacy and safety of BIRB 796, a highly potent inhibitor of p38 MAPK, in chronic active CD.  In a multicenter, multinational trial, 284 patients with moderate to severe CD were randomized to receive placebo, or 10, 20, 30, or 60 mg of BIRB 796 twice daily for 8 wk.  Clin. endpoints were based on std. safety assessments, CD Activity Index, C-reactive protein levels, and quality of life (Inflammatory Bowel Disease Questionnaire).  In a substudy, the Crohn's Disease Endoscopic Index of Severity and histol. results of biopsy specimens were assessed.  No clin. efficacy (primary end point, clin. remission; secondary end point, clin. response; Inflammatory Bowel Disease Questionnaire; Crohn's Disease Endoscopic Index of Severity) was seen for BIRB 796 in comparison with placebo.  A significant, dose-dependent decrease of C-reactive protein level was obsd. transiently after BIRB 796 after 1 wk with a return to baseline level over time.  The incidence of adverse events was comparable between all treatment groups, with the exception of a mild increase of transaminase levels that was seen more frequently in the BIRB 796 groups.  Geog. center effects were obsd. with Russian centers producing distinctly higher remission and response rates and lower adverse event rates than in other countries in both placebo and active treatment groups.  There was no evidence for clin. efficacy of BIRB 796 in CD.  A remarkable difference in the course of CD exists between Russia and non-Russian centers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPlk4HFJbHhrVg90H21EOLACvtfcHk0lgq_JS4pbMaMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjsFOqsrs%253D&md5=f99fbaeea2b16c7e5fa11069b99518f1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.cgh.2005.11.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cgh.2005.11.013%26sid%3Dliteratum%253Aachs%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DFeagan%26aufirst%3DB.%26aulast%3DD%25E2%2580%2599Haens%26aufirst%3DG.%26aulast%3DColombel%26aufirst%3DJ.%2BF.%26aulast%3DGeboes%26aufirst%3DK.%26aulast%3DYurcov%26aufirst%3DM.%26aulast%3DIsakov%26aufirst%3DV.%26aulast%3DGolovenko%26aufirst%3DO.%26aulast%3DBernstein%26aufirst%3DC.%2BN.%26aulast%3DLudwig%26aufirst%3DD.%26aulast%3DWinter%26aufirst%3DT.%26aulast%3DMeier%26aufirst%3DU.%26aulast%3DYong%26aufirst%3DC.%26aulast%3DSteffgen%26aufirst%3DJ.%26aulast%3D%26atitle%3DOral%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibition%2520with%2520birb%2520796%2520for%2520active%2520Crohn%25E2%2580%2599s%2520disease%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DClin.%2520Gastroenterol.%2520Hepatol.%26date%3D2006%26volume%3D4%26spage%3D325%26epage%3D334%26doi%3D10.1016%2Fj.cgh.2005.11.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wofsy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinblatt, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Firestein, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brahn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strand, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, S. E.</span><span> </span><span class="NLM_article-title">A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral scio-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">846</span><span class="NLM_x">–</span> <span class="NLM_lpage">854</span><span class="refDoi"> DOI: 10.3899/jrheum.100602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.3899%2Fjrheum.100602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=21285160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvVeitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2011&pages=846-854&author=M.+C.+Genoveseauthor=S.+B.+Cohenauthor=D.+Wofsyauthor=M.+E.+Weinblattauthor=G.+S.+Firesteinauthor=E.+Brahnauthor=V.+Strandauthor=D.+G.+Bakerauthor=S.+E.+Tong&title=A+24-week%2C+randomized%2C+double-blind%2C+placebo-controlled%2C+parallel+group+study+of+the+efficacy+of+oral+scio-469%2C+a+p38+mitogen-activated+protein+kinase+inhibitor%2C+in+patients+with+active+rheumatoid+arthritis&doi=10.3899%2Fjrheum.100602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arhritis</span></div><div class="casAuthors">Genovese, Mark C.; Cohen, Stanley B.; Wofsy, David; Weinblatt, Michael E.; Firestein, Gary S.; Brahn, Ernest; Strand, Vibeke; Baker, Daniel G.; Tong, Sandra E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">846-854</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective: To evaluate the efficacy, safety, and tolerability of oral SCIO-469, a p38 MAPK inhibitor that blocks tumor necrosis factor-α, interleukin-1β, and cyclooxygenase-2 synthesis in patients with active rheumatoid arthritis (RA).  Methods: Patients were randomized to receive SCIO-469 at either 30 or 60 mg three times daily in an immediate-release (IR) formulation or at 100 mg once daily in an extended-release (ER) formulation, or placebo for 24 wk.  The primary endpoint was American College of Rheumatol. (ACR)20 response at week 12.  Safety was monitored through Week 26.  Results: Overall, 302 patients were randomized: 76 to placebo, 75 to 30 mg IR, 73 to 60 mg IR, and 78 to 100 mg ER.  There were no significant differences in ACR20 responses at week 12 between SCIO-469 and placebo.  Declines in C-reactive protein and erythrocyte sedimentation rate during early treatment did not persist to week 12 and were not a consequence of decreased SCIO-469 plasma levels.  The 60 mg IR regimen showed a dose-limiting toxicity manifested by elevations in alanine aminotransferase.  Adverse events were common in all groups (79.7% and 86.7% through 13 and 26 wk, resp.).  Twenty-one patients reported 28 serious adverse events (SAE).  SAE were more common with IR SCIO-469 than with placebo (7% vs 4%) but were not reported with ER SCIO-469.  Conclusion: In all regimens tested, SCIO-469 showed no greater efficacy compared to placebo in patients with RA.  The transient effect of SCIO-469 on acute-phase reactants suggests a complex role of p38 MAPK in inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbaWHdpEn1jLVg90H21EOLACvtfcHk0lgq_JS4pbMaMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvVeitrw%253D&md5=2249e455ce2936a8aa881aab6af3db92</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.100602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.100602%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DCohen%26aufirst%3DS.%2BB.%26aulast%3DWofsy%26aufirst%3DD.%26aulast%3DWeinblatt%26aufirst%3DM.%2BE.%26aulast%3DFirestein%26aufirst%3DG.%2BS.%26aulast%3DBrahn%26aufirst%3DE.%26aulast%3DStrand%26aufirst%3DV.%26aulast%3DBaker%26aufirst%3DD.%2BG.%26aulast%3DTong%26aufirst%3DS.%2BE.%26atitle%3DA%252024-week%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520parallel%2520group%2520study%2520of%2520the%2520efficacy%2520of%2520oral%2520scio-469%252C%2520a%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Rheumatol.%26date%3D2011%26volume%3D38%26spage%3D846%26epage%3D854%26doi%3D10.3899%2Fjrheum.100602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Zuccotto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angiolini, M.</span><span> </span><span class="NLM_article-title">Through the “gatekeeper door”: Exploiting the active kinase conformation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2681</span><span class="NLM_x">–</span> <span class="NLM_lpage">2694</span><span class="refDoi"> DOI: 10.1021/jm901443h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901443h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGhtb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2681-2694&author=F.+Zuccottoauthor=E.+Ardiniauthor=E.+Casaleauthor=M.+Angiolini&title=Through+the+%E2%80%9Cgatekeeper+door%E2%80%9D%3A+Exploiting+the+active+kinase+conformation&doi=10.1021%2Fjm901443h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Through the "Gatekeeper Door": Exploiting the Active Kinase Conformation</span></div><div class="casAuthors">Zuccotto, Fabio; Ardini, Elena; Casale, Elena; Angiolini, Mauro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2681-2694</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The development of new kinase inhibitors is still a slow and problematic process.  Generally, type I compds. suffer from widespread cross-reactivity among other members of the kinase target family, and intense medicinal chem. optimization programs are required to modulate their activity.  Also, fierce competition in the development of scaffolds that could mimic ATP has led to a crowded intellectual property space.  The new opportunities opened by the type II compds. created great expectations, as targeting the allosteric site of the ATP pocket offered addnl. opportunities to control selectivity and introduce intellectual property novelty.  However, clin. evaluation of these compds. has highlighted how the acquisition of resistance-causing mutations of the kinase target limits their efficacy in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd_iA7sWS-g7Vg90H21EOLACvtfcHk0lgijHUU-OMR1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGhtb3K&md5=5c6acd058bacfec89b1eff2090f0fe67</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm901443h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901443h%26sid%3Dliteratum%253Aachs%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DAngiolini%26aufirst%3DM.%26atitle%3DThrough%2520the%2520%25E2%2580%259Cgatekeeper%2520door%25E2%2580%259D%253A%2520Exploiting%2520the%2520active%2520kinase%2520conformation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2681%26epage%3D2694%26doi%3D10.1021%2Fjm901443h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Traxler, P.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors in cancer treatment (part ii)</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1599</span><span class="NLM_x">–</span> <span class="NLM_lpage">1625</span><span class="refDoi"> DOI: 10.1517/13543776.8.12.1599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1517%2F13543776.8.12.1599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADyaK1cXnvFymsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=1599-1625&author=P.+Traxler&title=Tyrosine+kinase+inhibitors+in+cancer+treatment+%28part+ii%29&doi=10.1517%2F13543776.8.12.1599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors in cancer treatment (part II)</span></div><div class="casAuthors">Traxler, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1599-1625</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications</span>)
        </div><div class="casAbstract">A review with 169 refs.  In the last few years, enormous progress in the field of signal transduction inhibition has been made.  Many companies have entered the field.  Along with the epidermal growth factor receptor (EGFR) tyrosine kinase, many other tyrosine kinases have been identified as interesting targets for drug discovery projects.  X-ray data of more than 40 crystal structures of protein kinases, in most cases complexed with an inhibitor, have been published.  Pharmacophore models for the binding of inhibitors in the ATP-binding site of protein kinases have been developed that are generally applicable, enabling the rational design of tyrosine as well as serine/threonine kinase inhibitors.  It has been proven by numerous examples that the ATP-binding of protein kinases is an exciting target for the design of anticancer drugs.  In many cases, it has also been demonstrated that through rational design it is possible to modify a lead structure in such a way that inhibitors with an altered selectivity profile are obtained.  Chem. optimization of several lead structures led to development candidates with potent in vitro and in vivo activity fulfilling the pharmacodynamic, pharmacokinetic, toxicol. and tech. (synthesis, formulation) requirements for a clin. candidate.  Currently, there are seven tyrosine kinase inhibitors in early phases of clin. trials.  In addn., several candidates are close to entering Phase I trials this year or at the beginning of next year.  It is expected that pos. results from clin. trials will greatly contribute to the clin. proof of concept of the value of signal transduction inhibition and will greatly stimulate further research in this area.  This review is a continuation of a review with the same title of last year and summarizes published patent literature and related publications between 1997 and Sept. 1998.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr804idCxibYrVg90H21EOLACvtfcHk0lgijHUU-OMR1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvFymsLs%253D&md5=43097dfbadeb732c98371ac30ab40cb6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1517%2F13543776.8.12.1599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.8.12.1599%26sid%3Dliteratum%253Aachs%26aulast%3DTraxler%26aufirst%3DP.%26atitle%3DTyrosine%2520kinase%2520inhibitors%2520in%2520cancer%2520treatment%2520%2528part%2520ii%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D1998%26volume%3D8%26spage%3D1599%26epage%3D1625%26doi%3D10.1517%2F13543776.8.12.1599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Young, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNulty, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huddleston, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seibel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livi, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span> </span><span class="NLM_article-title">Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the atp site</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">12116</span><span class="NLM_x">–</span> <span class="NLM_lpage">12121</span><span class="refDoi"> DOI: 10.1074/jbc.272.18.12116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1074%2Fjbc.272.18.12116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=9115281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADyaK2sXivF2kt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=12116-12121&author=P.+R.+Youngauthor=M.+M.+McLaughlinauthor=S.+Kumarauthor=S.+Kassisauthor=M.+L.+Doyleauthor=D.+McNultyauthor=T.+F.+Gallagherauthor=S.+Fisherauthor=P.+C.+McDonnellauthor=S.+A.+Carrauthor=M.+J.+Huddlestonauthor=G.+Seibelauthor=T.+G.+Porterauthor=G.+P.+Liviauthor=J.+L.+Adamsauthor=J.+C.+Lee&title=Pyridinyl+imidazole+inhibitors+of+p38+mitogen-activated+protein+kinase+bind+in+the+atp+site&doi=10.1074%2Fjbc.272.18.12116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site</span></div><div class="casAuthors">Young, Peter R.; McLaughlin, Megan M.; Kumar, Sanjay; Kassis, Shouki; Doyle, Michael L.; McNulty, Dean; Gallagher, Timothy F.; Fisher, Seth; McDonnell, Peter C.; Carr, Steven A.; Huddleston, Michael J.; Seibel, George; Porter, Terence G.; Livi, George P.; Adams, Jerry L.; Lee, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">12116-12121</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The site of action of a series of pyridinyl imidazole compds. that are selective inhibitors of p38 mitogen-activated protein kinase in vitro and block proinflammatory cytokine prodn. in vivo has been detd.  Using Edman sequencing, 125I-SB206718 was shown to cross-link to the nonphosphorylated Escherichia coli-expressed p38 kinase at Thr175, which is proximal to the ATP binding site.  Titrn. calorimetric studies with E. coli-expressed p38 kinase showed that SB203580 bound with a stoichiometry of 1:1 and that binding was blocked by preincubation of p38 kinase with the ATP analog, FSBA (5'-[p-(fluorosulfonyl)benzoyl]adenosine), which covalently modifies the ATP binding site.  The intrinsic ATPase activity of the nonphosphorylated enzyme was inhibited by SB203580 with a Km of 9.6 mM.  Kinetic studies of active, phosphorylated yeast-expressed p38 kinase using a peptide substrate showed that SB203580 was competitive with ATP with a Ki of 21 nM and that kinase inhibition correlated with binding and biol. activity.  Mutagenesis indicated that binding of 125I-SB206718 was dependent on the catalytic residues K53 and D168 in the ATP pocket.  These findings indicate that the pyridinyl imidazoles act in vivo by inhibiting p38 kinase activity through competition with ATP and that their selectivity is probably detd. by differences in nonconserved regions within or near the ATP binding pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX_W0as-RlKrVg90H21EOLACvtfcHk0lgijHUU-OMR1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivF2kt7w%253D&md5=fafa90d4fb8d2d7eca53f17e19af74e4</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.18.12116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.18.12116%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BM.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DKassis%26aufirst%3DS.%26aulast%3DDoyle%26aufirst%3DM.%2BL.%26aulast%3DMcNulty%26aufirst%3DD.%26aulast%3DGallagher%26aufirst%3DT.%2BF.%26aulast%3DFisher%26aufirst%3DS.%26aulast%3DMcDonnell%26aufirst%3DP.%2BC.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DHuddleston%26aufirst%3DM.%2BJ.%26aulast%3DSeibel%26aufirst%3DG.%26aulast%3DPorter%26aufirst%3DT.%2BG.%26aulast%3DLivi%26aufirst%3DG.%2BP.%26aulast%3DAdams%26aufirst%3DJ.%2BL.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DPyridinyl%2520imidazole%2520inhibitors%2520of%2520p38%2520mitogen-activated%2520protein%2520kinase%2520bind%2520in%2520the%2520atp%2520site%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D12116%26epage%3D12121%26doi%3D10.1074%2Fjbc.272.18.12116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Pargellis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Churchill, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pav, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regan, J.</span><span> </span><span class="NLM_article-title">Inhibition of p38 map kinase by utilizing a novel allosteric binding site</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span><span class="refDoi"> DOI: 10.1038/nsb770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1038%2Fnsb770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=11896401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=268-272&author=C.+Pargellisauthor=L.+Tongauthor=L.+Churchillauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=P.+M.+Grobauthor=E.+R.+Hickeyauthor=N.+Mossauthor=S.+Pavauthor=J.+Regan&title=Inhibition+of+p38+map+kinase+by+utilizing+a+novel+allosteric+binding+site&doi=10.1038%2Fnsb770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span></div><div class="casAuthors">Pargellis, Christopher; Tong, Liang; Churchill, Laurie; Cirillo, Pier F.; Gilmore, Thomas; Graham, Anne G.; Grob, Peter M.; Hickey, Eugene R.; Moss, Neil; Pav, Susan; Regan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-272</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The p38 MAP kinase plays a crucial role in regulating the prodn. of proinflammatory cytokines, such as tumor necrosis factor and interleukin-1.  Blocking this kinase may offer an effective therapy for treating many inflammatory diseases.  Here we report a new allosteric binding site for a diaryl urea class of highly potent and selective inhibitors against human p38 MAP kinase.  The formation of this binding site requires a large conformational change not obsd. previously for any of the protein Ser/Thr kinases.  This change is in the highly conserved Asp-Phe-Gly motif within the active site of the kinase.  Soln. studies demonstrate that this class of compds. has slow binding kinetics, consistent with the requirement for conformational change.  Improving interactions in this allosteric pocket, as well as establishing binding interactions in the ATP pocket, enhanced the affinity of the inhibitors by 12,000-fold.  One of the most potent compds. in this series, BIRB 796, has picomolar affinity for the kinase and low nanomolar inhibitory activity in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT8_QT7_pbYrVg90H21EOLACvtfcHk0lg4EXrV7iqe6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D&md5=68850ecdbe08df4285ba38cfa2c93ea4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnsb770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb770%26sid%3Dliteratum%253Aachs%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DRegan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520p38%2520map%2520kinase%2520by%2520utilizing%2520a%2520novel%2520allosteric%2520binding%2520site%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D268%26epage%3D272%26doi%3D10.1038%2Fnsb770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Cusack, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoemann, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marjanovic, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heym, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasudevan, A.</span><span> </span><span class="NLM_article-title">Design strategies to address kinetics of drug binding and residence time</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">2019</span><span class="NLM_x">–</span> <span class="NLM_lpage">2027</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.02.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1016%2Fj.bmcl.2015.02.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=25782745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktVCjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2019-2027&author=K.+P.+Cusackauthor=Y.+Wangauthor=M.+Z.+Hoemannauthor=J.+Marjanovicauthor=R.+G.+Heymauthor=A.+Vasudevan&title=Design+strategies+to+address+kinetics+of+drug+binding+and+residence+time&doi=10.1016%2Fj.bmcl.2015.02.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Design strategies to address kinetics of drug binding and residence time</span></div><div class="casAuthors">Cusack, Kevin P.; Wang, Ying; Hoemann, Michael Z.; Marjanovic, Jasmina; Heym, Roland G.; Vasudevan, Anil</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2019-2027</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The kinetics of drug binding and drug residence time are recognized to be important in the clin. effectiveness of drug candidates.  In most cases a long residence time of the drug-target complex results in an extended duration of pharmacodynamic activity, even when systemic concns. of drug have been notably reduced through elimination routes.  Hence, if selective for target, long residence times can increase the duration of drug efficacy in vivo and can significantly diminish the potential for off-target-mediated toxicities.  Furthermore, a compd. with a slower dissocn. rate may allow a reduced dosing schedule relative to a compd. with a rapid dissocn. rate.  Factors contributing to long residence time that could be useful to medicinal chemists in the prospective design of compds. with long residence times will be discussed in this perspective.  Particular emphasis will be on case studies highlighting how kinetics can be measured, modulated based on supporting structure kinetic relationships and whether these effects are translatable into man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru6nmUGLHP_rVg90H21EOLACvtfcHk0lg4EXrV7iqe6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktVCjsLg%253D&md5=c3735de36094915768dbecc7472917d4</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.02.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.02.027%26sid%3Dliteratum%253Aachs%26aulast%3DCusack%26aufirst%3DK.%2BP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHoemann%26aufirst%3DM.%2BZ.%26aulast%3DMarjanovic%26aufirst%3DJ.%26aulast%3DHeym%26aufirst%3DR.%2BG.%26aulast%3DVasudevan%26aufirst%3DA.%26atitle%3DDesign%2520strategies%2520to%2520address%2520kinetics%2520of%2520drug%2520binding%2520and%2520residence%2520time%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2019%26epage%3D2027%26doi%3D10.1016%2Fj.bmcl.2015.02.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelias, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lg4EXrV7iqe6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lhQic6x9cMCaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Eswaran, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">Insights into protein kinase regulation and inhibition by large scale structural comparison</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Proteins Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1804</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">432</span><span class="refDoi"> DOI: 10.1016/j.bbapap.2009.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1016%2Fj.bbapap.2009.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=19854302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1ynurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1804&publication_year=2010&pages=429-432&author=J.+Eswaranauthor=S.+Knapp&title=Insights+into+protein+kinase+regulation+and+inhibition+by+large+scale+structural+comparison&doi=10.1016%2Fj.bbapap.2009.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into protein kinase regulation and inhibition by large scale structural comparison</span></div><div class="casAuthors">Eswaran, Jeyanthy; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1804</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">429-432</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Protein structure detn. of sol. globular protein domains has developed into an efficient routine technol. which can now be applied to generate and analyze structures of entire human protein families.  In the kinase area, several kinase families still lack comprehensive structural anal.  Nevertheless, structural genomics efforts contributed >40 kinase catalytic domain structures during the past 4 years providing a rich resource of information for large scale comparisons of kinase active sites.  Moreover, many of the released structures are inhibitor complexes that offer chem. starting points for development of selective and potent inhibitors.  Here, the authors discuss currently available structural data and strategies that can be utilized for the development of highly selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0BkEEFUKP67Vg90H21EOLACvtfcHk0lhQic6x9cMCaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1ynurY%253D&md5=5f0566316bae37a7fd8d1039792398f1</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2009.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2009.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DEswaran%26aufirst%3DJ.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DInsights%2520into%2520protein%2520kinase%2520regulation%2520and%2520inhibition%2520by%2520large%2520scale%2520structural%2520comparison%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2010%26volume%3D1804%26spage%3D429%26epage%3D432%26doi%3D10.1016%2Fj.bbapap.2009.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Kluter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grutter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naqvi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Displacement assay for the detection of stabilizers of inactive kinase conformations</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">357</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span><span class="refDoi"> DOI: 10.1021/jm901297e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901297e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=357-367&author=S.+Kluterauthor=C.+Grutterauthor=T.+Naqviauthor=M.+Rabillerauthor=J.+R.+Simardauthor=V.+Pawarauthor=M.+Getlikauthor=D.+Rauh&title=Displacement+assay+for+the+detection+of+stabilizers+of+inactive+kinase+conformations&doi=10.1021%2Fjm901297e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm901297e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901297e%26sid%3Dliteratum%253Aachs%26aulast%3DKluter%26aufirst%3DS.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DNaqvi%26aufirst%3DT.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DPawar%26aufirst%3DV.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DDisplacement%2520assay%2520for%2520the%2520detection%2520of%2520stabilizers%2520of%2520inactive%2520kinase%2520conformations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D357%26epage%3D367%26doi%3D10.1021%2Fjm901297e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Laufer, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margutti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritz, M. D.</span><span> </span><span class="NLM_article-title">Substituted isoxazoles as potent inhibitors of p38 map kinase</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span><span class="refDoi"> DOI: 10.1002/cmdc.200500025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1002%2Fcmdc.200500025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=197-207&author=S.+A.+Lauferauthor=S.+Marguttiauthor=M.+D.+Fritz&title=Substituted+isoxazoles+as+potent+inhibitors+of+p38+map+kinase&doi=10.1002%2Fcmdc.200500025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200500025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200500025%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26aulast%3DMargutti%26aufirst%3DS.%26aulast%3DFritz%26aufirst%3DM.%2BD.%26atitle%3DSubstituted%2520isoxazoles%2520as%2520potent%2520inhibitors%2520of%2520p38%2520map%2520kinase%26jtitle%3DChemMedChem%26date%3D2006%26volume%3D1%26spage%3D197%26epage%3D207%26doi%3D10.1002%2Fcmdc.200500025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Hauser, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scior, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domeyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kammerer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S. A.</span><span> </span><span class="NLM_article-title">Synthesis, biological testing, and binding mode prediction of 6,9-diarylpurin-8-ones as p38 map kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2060</span><span class="NLM_x">–</span> <span class="NLM_lpage">2066</span><span class="refDoi"> DOI: 10.1021/jm061061w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061061w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2060-2066&author=D.+R.+Hauserauthor=T.+Sciorauthor=D.+M.+Domeyerauthor=B.+Kammererauthor=S.+A.+Laufer&title=Synthesis%2C+biological+testing%2C+and+binding+mode+prediction+of+6%2C9-diarylpurin-8-ones+as+p38+map+kinase+inhibitors&doi=10.1021%2Fjm061061w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm061061w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061061w%26sid%3Dliteratum%253Aachs%26aulast%3DHauser%26aufirst%3DD.%2BR.%26aulast%3DScior%26aufirst%3DT.%26aulast%3DDomeyer%26aufirst%3DD.%2BM.%26aulast%3DKammerer%26aufirst%3DB.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DSynthesis%252C%2520biological%2520testing%252C%2520and%2520binding%2520mode%2520prediction%2520of%25206%252C9-diarylpurin-8-ones%2520as%2520p38%2520map%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2060%26epage%3D2066%26doi%3D10.1021%2Fjm061061w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Laufer, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahrens, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karcher, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hering, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niess, R.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of phenylamino-substituted 6,11-dihydro-dibenzo[b,e]oxepin-11-ones and dibenzo[a,d]cycloheptan-5-ones: Novel p38 map kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">7912</span><span class="NLM_x">–</span> <span class="NLM_lpage">7915</span><span class="refDoi"> DOI: 10.1021/jm061072p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061072p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCqsLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7912-7915&author=S.+A.+Lauferauthor=G.+M.+Ahrensauthor=S.+C.+Karcherauthor=J.+S.+Heringauthor=R.+Niess&title=Design%2C+synthesis%2C+and+biological+evaluation+of+phenylamino-substituted+6%2C11-dihydro-dibenzo%5Bb%2Ce%5Doxepin-11-ones+and+dibenzo%5Ba%2Cd%5Dcycloheptan-5-ones%3A+Novel+p38+map+kinase+inhibitors&doi=10.1021%2Fjm061072p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Phenylamino-Substituted 6,11-Dihydro-dibenzo[b,e]oxepin-11-ones and Dibenzo[a,d]cycloheptan-5-ones: Novel p38 MAP Kinase Inhibitors</span></div><div class="casAuthors">Laufer, Stefan A.; Ahrens, Gabriele M.; Karcher, Solveigh C.; Hering, Joerg S.; Niess, Raimund</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7912-7915</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pathogenesis of chronic inflammatory diseases is promoted by various pro-inflammatory cytokines.  P38 MAP kinase seems to be a valid target as it controls proinflammatory cytokine levels on both transcriptional and translational levels.  Starting from benzophenone-type inhibitors, a rigidization strategy led to 3-amino-6,11-dihydro-dibenzo[b,e]thiepin-11-one, phenylamino-substituted 6,11-dihydro-dibenzo[b,e]oxepin-11-ones, and dibenzo[a,d]cyclohepten-5-ones.  Synthesis, p38 inhibition, and CYP-inhibition of selected compds. are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2Jvib81kr5rVg90H21EOLACvtfcHk0liKiO6yQGcWfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCqsLvF&md5=efeb93681a203a07502c3ff1e964001f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm061072p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061072p%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26aulast%3DAhrens%26aufirst%3DG.%2BM.%26aulast%3DKarcher%26aufirst%3DS.%2BC.%26aulast%3DHering%26aufirst%3DJ.%2BS.%26aulast%3DNiess%26aufirst%3DR.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520phenylamino-substituted%25206%252C11-dihydro-dibenzo%255Bb%252Ce%255Doxepin-11-ones%2520and%2520dibenzo%255Ba%252Cd%255Dcycloheptan-5-ones%253A%2520Novel%2520p38%2520map%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D7912%26epage%3D7915%26doi%3D10.1021%2Fjm061072p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Koeberle, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romir, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeberle, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schattel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grutter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stehle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S. A.</span><span> </span><span class="NLM_article-title">Skepinone-l is a selective p38 mitogen-activated protein kinase inhibitor</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span><span class="refDoi"> DOI: 10.1038/nchembio.761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1038%2Fnchembio.761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Olur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=141-143&author=S.+C.+Koeberleauthor=J.+Romirauthor=S.+Fischerauthor=A.+Koeberleauthor=V.+Schattelauthor=W.+Albrechtauthor=C.+Grutterauthor=O.+Werzauthor=D.+Rauhauthor=T.+Stehleauthor=S.+A.+Laufer&title=Skepinone-l+is+a+selective+p38+mitogen-activated+protein+kinase+inhibitor&doi=10.1038%2Fnchembio.761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor</span></div><div class="casAuthors">Koeberle, Solveigh C.; Romir, Johannes; Fischer, Stefan; Koeberle, Andreas; Schattel, Verena; Albrecht, Wolfgang; Gruetter, Christian; Werz, Oliver; Rauh, Daniel; Stehle, Thilo; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-143</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Until now, a lack of inhibitors with high potency and selectivity in vivo has hampered investigation of the p38 mitogen-activated protein kinase (MAPK) signaling pathway.  We describe the design of skepinone-L, which is, to our knowledge, the first ATP-competitive p38 MAPK inhibitor with excellent in vivo efficacy and selectivity.  Therefore, skepinone-L is a valuable probe for chem. biol. research, and it may foster the development of a unique class of kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkdYtKPp4C1rVg90H21EOLACvtfcHk0liKiO6yQGcWfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Olur%252FK&md5=17ca91bebd48a1804e31ebccc192aa93</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.761%26sid%3Dliteratum%253Aachs%26aulast%3DKoeberle%26aufirst%3DS.%2BC.%26aulast%3DRomir%26aufirst%3DJ.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DKoeberle%26aufirst%3DA.%26aulast%3DSchattel%26aufirst%3DV.%26aulast%3DAlbrecht%26aufirst%3DW.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DWerz%26aufirst%3DO.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DStehle%26aufirst%3DT.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DSkepinone-l%2520is%2520a%2520selective%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibitor%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D141%26epage%3D143%26doi%3D10.1038%2Fnchembio.761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Martz, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baur, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schattel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goettert, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer-Wrangowski, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S. A.</span><span> </span><span class="NLM_article-title">Targeting the hinge glycine flip and the activation loop: Novel approach to potent p38α inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7862</span><span class="NLM_x">–</span> <span class="NLM_lpage">7874</span><span class="refDoi"> DOI: 10.1021/jm300951u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300951u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1SlsrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7862-7874&author=K.+E.+Martzauthor=A.+Dornauthor=B.+Baurauthor=V.+Schattelauthor=M.+I.+Goettertauthor=S.+C.+Mayer-Wrangowskiauthor=D.+Rauhauthor=S.+A.+Laufer&title=Targeting+the+hinge+glycine+flip+and+the+activation+loop%3A+Novel+approach+to+potent+p38%CE%B1+inhibitors&doi=10.1021%2Fjm300951u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Hinge Glycine Flip and the Activation Loop: Novel Approach to Potent p38α Inhibitors</span></div><div class="casAuthors">Martz, Kathrin E.; Dorn, Angelika; Baur, Benjamin; Schattel, Verena; Goettert, Marcia I.; Mayer-Wrangowski, Svenja C.; Rauh, Daniel; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7862-7874</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The p38 MAP kinase is a key player in signaling pathways regulating the biosynthesis of inflammatory cytokines.  Small mol. p38 inhibitors suppress the prodn. of these cytokines.  Therefore p38 is a promising drug target for novel anti-inflammatory drugs.  In this study, we report novel dibenzepinones, dibenzoxepines, and benzosuberones as p38α MAP kinase inhibitors.  Previously reported dibenzepinones and dibenzoxepines were chem. modified by introduction of functional groups or removal of a Ph ring.  This should result in targeting of the hydrophobic region I, the "deep pocket", and the hinge glycine flip of the kinase.  Potent inhibitors with IC50 values in the single digit nanomolar range (up to 3 nM) were identified.  Instead of targeting the "deep pocket" in the DFG-out conformation, interactions with the DFG-motif in the in-conformation could be obsd. by protein x-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9ZkVG97Ru-bVg90H21EOLACvtfcHk0lh-eYPYi9xpAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1SlsrbP&md5=c1e76ed9bac1b5c1c4c5b4c630c845b8</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm300951u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300951u%26sid%3Dliteratum%253Aachs%26aulast%3DMartz%26aufirst%3DK.%2BE.%26aulast%3DDorn%26aufirst%3DA.%26aulast%3DBaur%26aufirst%3DB.%26aulast%3DSchattel%26aufirst%3DV.%26aulast%3DGoettert%26aufirst%3DM.%2BI.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%2BC.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DTargeting%2520the%2520hinge%2520glycine%2520flip%2520and%2520the%2520activation%2520loop%253A%2520Novel%2520approach%2520to%2520potent%2520p38%25CE%25B1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7862%26epage%3D7874%26doi%3D10.1021%2Fjm300951u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Fischer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wentsch, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer-Wrangowski, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niess, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeberle, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grutter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boeckler, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S. A.</span><span> </span><span class="NLM_article-title">Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low atp competitiveness and outstanding whole blood activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">241</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span><span class="refDoi"> DOI: 10.1021/jm301539x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301539x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFWiurzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=241-253&author=S.+Fischerauthor=H.+K.+Wentschauthor=S.+C.+Mayer-Wrangowskiauthor=M.+Zimmermannauthor=S.+M.+Bauerauthor=K.+Storchauthor=R.+Niessauthor=S.+C.+Koeberleauthor=C.+Grutterauthor=F.+M.+Boecklerauthor=D.+Rauhauthor=S.+A.+Laufer&title=Dibenzosuberones+as+p38+mitogen-activated+protein+kinase+inhibitors+with+low+atp+competitiveness+and+outstanding+whole+blood+activity&doi=10.1021%2Fjm301539x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Dibenzosuberones as p38 Mitogen-Activated Protein Kinase Inhibitors with Low ATP Competitiveness and Outstanding Whole Blood Activity</span></div><div class="casAuthors">Fischer, Stefan; Wentsch, Heike K.; Mayer-Wrangowski, Svenja C.; Zimmermann, Markus; Bauer, Silke M.; Storch, Kirsten; Niess, Raimund; Koeberle, Solveigh C.; Gruetter, Christian; Boeckler, Frank M.; Rauh, Daniel; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">241-253</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P38α mitogen-activated protein (MAP) kinase is a main target in drug research concerning inflammatory diseases.  Nevertheless, no inhibitor of p38α MAP kinase has been introduced to the market.  This might be attributed to the fact that there is no inhibitor which combines outstanding activity in biol. systems and selectivity.  Herein an approach to the development of such inhibitors on the basis of the highly selective mol. probe Skepinone-L (I) is described.  Introduction of a "deep pocket" moiety addressing the DFG motif led to an increased activity of the compds.  Hydrophilic moieties, addressing the solvent-exposed area adjacent to hydrophilic region II, conserved a high activity of the compds. in a whole blood assay.  Combined with their outstanding selectivity and low ATP competitiveness, these inhibitors are very interesting candidates for use in biol. systems and in therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbi31syvBEYrVg90H21EOLACvtfcHk0lh-eYPYi9xpAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFWiurzP&md5=bfce0ba26af365a1d218095e54ba169f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm301539x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301539x%26sid%3Dliteratum%253Aachs%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DWentsch%26aufirst%3DH.%2BK.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%2BC.%26aulast%3DZimmermann%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DS.%2BM.%26aulast%3DStorch%26aufirst%3DK.%26aulast%3DNiess%26aufirst%3DR.%26aulast%3DKoeberle%26aufirst%3DS.%2BC.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DBoeckler%26aufirst%3DF.%2BM.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DDibenzosuberones%2520as%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibitors%2520with%2520low%2520atp%2520competitiveness%2520and%2520outstanding%2520whole%2520blood%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D241%26epage%3D253%26doi%3D10.1021%2Fjm301539x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Baur, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martz, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goettert, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S. A.</span><span> </span><span class="NLM_article-title">Metabolically stable dibenzo[b,e]oxepin-11(6h)-ones as highly selective p38 map kinase inhibitors: Optimizing anti-cytokine activity in human whole blood</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">8561</span><span class="NLM_x">–</span> <span class="NLM_lpage">8578</span><span class="refDoi"> DOI: 10.1021/jm401276h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401276h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8561-8578&author=B.+Baurauthor=K.+Storchauthor=K.+E.+Martzauthor=M.+I.+Goettertauthor=A.+Richtersauthor=D.+Rauhauthor=S.+A.+Laufer&title=Metabolically+stable+dibenzo%5Bb%2Ce%5Doxepin-11%286h%29-ones+as+highly+selective+p38+map+kinase+inhibitors%3A+Optimizing+anti-cytokine+activity+in+human+whole+blood&doi=10.1021%2Fjm401276h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm401276h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401276h%26sid%3Dliteratum%253Aachs%26aulast%3DBaur%26aufirst%3DB.%26aulast%3DStorch%26aufirst%3DK.%26aulast%3DMartz%26aufirst%3DK.%2BE.%26aulast%3DGoettert%26aufirst%3DM.%2BI.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DMetabolically%2520stable%2520dibenzo%255Bb%252Ce%255Doxepin-11%25286h%2529-ones%2520as%2520highly%2520selective%2520p38%2520map%2520kinase%2520inhibitors%253A%2520Optimizing%2520anti-cytokine%2520activity%2520in%2520human%2520whole%2520blood%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8561%26epage%3D8578%26doi%3D10.1021%2Fjm401276h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Thurmond, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadsworth, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schafer, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zivin, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siekierka, J. J.</span><span> </span><span class="NLM_article-title">Kinetics of small molecule inhibitor binding to p38 kinase</span> <span class="citation_source-journal">Eur. J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">268</span><span class="NLM_x">, </span> <span class="NLM_fpage">5747</span><span class="NLM_x">–</span> <span class="NLM_lpage">5754</span><span class="refDoi"> DOI: 10.1046/j.0014-2956.2001.02512.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1046%2Fj.0014-2956.2001.02512.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=11722559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD3MXosFyms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=2001&pages=5747-5754&author=R.+L.+Thurmondauthor=S.+A.+Wadsworthauthor=P.+H.+Schaferauthor=R.+A.+Zivinauthor=J.+J.+Siekierka&title=Kinetics+of+small+molecule+inhibitor+binding+to+p38+kinase&doi=10.1046%2Fj.0014-2956.2001.02512.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetics of small molecule inhibitor binding to p38 kinase</span></div><div class="casAuthors">Thurmond, Robin L.; Wadsworth, Scott A.; Schafer, Peter H.; Zivin, Robert A.; Siekierka, John J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5747-5754</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">P38 mitogen-activated protein kinase (MAPK) (p38/p38-α/CSBP2/RK) has been implicated in the regulation of many pro-inflammatory pathways.  Because of this, it has received much attention as a potential drug target for controlling diseases such as rheumatoid arthritis, endotoxic shock, inflammatory bowel disease, osteoporosis, and many others.  A no. of small mol. inhibitors of this kinase have been described, and in this paper we have used surface plasmon resonance to directly measure and quantitate their binding to p38.  Despite the relatively low mol. mass (≈ 400 Da) of these inhibitors, specific binding can be obsd.  For the two most potent inhibitors studied, SB 203580 and RWJ 67657, dissocn. consts., Kd's, of 22 and 10 nM, resp., were obtained.  These values closely match the IC50 values obsd. in a cell-based TNFα release assay implying that p38 plays a major role in TNFα release.  The assocn. and dissocn. rates for the binding of these inhibitors to p38 have also been quantitated.  SB 203580 and RWJ 67657 have very similar assocn. rates of around 8 × 105 M-1 ·s-1, and the differences in affinity are detd. by different dissocn. rates.  The weaker binding compds. have dissocn. rates similar to SB 203580, but the assocn. rates vary by an order of magnitude or more.  The direct measurement of compds. binding to p38 may help in understanding the difference between potency and efficacy for these inhibitors.  This in turn may yield clues on how to develop better inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiWyahpK3jILVg90H21EOLACvtfcHk0lh-eYPYi9xpAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXosFyms78%253D&md5=08df8a6f30299cccc59fe911ea2fb82b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1046%2Fj.0014-2956.2001.02512.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.0014-2956.2001.02512.x%26sid%3Dliteratum%253Aachs%26aulast%3DThurmond%26aufirst%3DR.%2BL.%26aulast%3DWadsworth%26aufirst%3DS.%2BA.%26aulast%3DSchafer%26aufirst%3DP.%2BH.%26aulast%3DZivin%26aufirst%3DR.%2BA.%26aulast%3DSiekierka%26aufirst%3DJ.%2BJ.%26atitle%3DKinetics%2520of%2520small%2520molecule%2520inhibitor%2520binding%2520to%2520p38%2520kinase%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D2001%26volume%3D268%26spage%3D5747%26epage%3D5754%26doi%3D10.1046%2Fj.0014-2956.2001.02512.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Unzue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafleur, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frugier, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caflisch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nevado, C.</span><span> </span><span class="NLM_article-title">Pyrrolo[3,2-b]quinoxaline derivatives as types i1/2 and ii eph tyrosine kinase inhibitors: Structure-based design, synthesis, and in vivo validation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">6834</span><span class="NLM_x">–</span> <span class="NLM_lpage">6844</span><span class="refDoi"> DOI: 10.1021/jm5009242</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5009242" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6834-6844&author=A.+Unzueauthor=J.+Dongauthor=K.+Lafleurauthor=H.+Zhaoauthor=E.+Frugierauthor=A.+Caflischauthor=C.+Nevado&title=Pyrrolo%5B3%2C2-b%5Dquinoxaline+derivatives+as+types+i1%2F2+and+ii+eph+tyrosine+kinase+inhibitors%3A+Structure-based+design%2C+synthesis%2C+and+in+vivo+validation&doi=10.1021%2Fjm5009242"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm5009242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5009242%26sid%3Dliteratum%253Aachs%26aulast%3DUnzue%26aufirst%3DA.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DLafleur%26aufirst%3DK.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DFrugier%26aufirst%3DE.%26aulast%3DCaflisch%26aufirst%3DA.%26aulast%3DNevado%26aufirst%3DC.%26atitle%3DPyrrolo%255B3%252C2-b%255Dquinoxaline%2520derivatives%2520as%2520types%2520i1%252F2%2520and%2520ii%2520eph%2520tyrosine%2520kinase%2520inhibitors%253A%2520Structure-based%2520design%252C%2520synthesis%252C%2520and%2520in%2520vivo%2520validation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6834%26epage%3D6844%26doi%3D10.1021%2Fjm5009242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pompliano, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meek, T. D.</span><span> </span><span class="NLM_article-title">Drug-target residence time and its implications for lead optimization</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span><span class="refDoi"> DOI: 10.1038/nrd2082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-target+residence+time+and+its+implications+for+lead+optimization&doi=10.1038%2Fnrd2082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0lgdjGu646Yr_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739%26doi%3D10.1038%2Fnrd2082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Hothersall, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dale, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawlins, P.</span><span> </span><span class="NLM_article-title">Can residence time offer a useful strategy to target agonist drugs for sustained gpcr responses?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span><span class="refDoi"> DOI: 10.1016/j.drudis.2015.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1016%2Fj.drudis.2015.07.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=26226643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Ohu7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=90-96&author=J.+D.+Hothersallauthor=A.+J.+Brownauthor=I.+Daleauthor=P.+Rawlins&title=Can+residence+time+offer+a+useful+strategy+to+target+agonist+drugs+for+sustained+gpcr+responses%3F&doi=10.1016%2Fj.drudis.2015.07.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Can residence time offer a useful strategy to target agonist drugs for sustained GPCR responses?</span></div><div class="casAuthors">Hothersall, J. Daniel; Brown, Alastair J.; Dale, Ian; Rawlins, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-96</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Residence time describes the how long a ligand is bound to its target, and is attracting interest in drug discovery as a potential means of improving clin. efficacy by increasing target coverage.  This concept, as originally applied to antagonists, is more complicated for G-protein-coupled receptor (GPCR) agonists because of the transiency of receptor responses (via desensitization and internalization).  However, in some cases sustained GPCR agonist responses have been obsd., with evidence consistent with a role for slow binding kinetics.  We propose a model to explain our understanding of how residence time and rebinding might influence sustained signaling by internalized receptors.  We also highlight the anticipated benefit for drug discovery of fully understanding and exploiting these phenomena to target desirable receptor response profiles selectively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNbH-40pZCqbVg90H21EOLACvtfcHk0lgdjGu646Yr_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Ohu7bO&md5=314ffbd12a8cc2a3068d86b91d7a13fb</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DHothersall%26aufirst%3DJ.%2BD.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DDale%26aufirst%3DI.%26aulast%3DRawlins%26aufirst%3DP.%26atitle%3DCan%2520residence%2520time%2520offer%2520a%2520useful%2520strategy%2520to%2520target%2520agonist%2520drugs%2520for%2520sustained%2520gpcr%2520responses%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D90%26epage%3D96%26doi%3D10.1016%2Fj.drudis.2015.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Dahl, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akerud, T.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and the drug-target residence time concept</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">697</span><span class="NLM_x">–</span> <span class="NLM_lpage">707</span><span class="refDoi"> DOI: 10.1016/j.drudis.2013.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1016%2Fj.drudis.2013.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=23500610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVyqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=697-707&author=G.+Dahlauthor=T.+Akerud&title=Pharmacokinetics+and+the+drug-target+residence+time+concept&doi=10.1016%2Fj.drudis.2013.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and the drug-target residence time concept</span></div><div class="casAuthors">Dahl, Goeran; Akerud, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15-16</span>),
    <span class="NLM_cas:pages">697-707</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The concept of drug-target residence time has been in focus in recent drug discovery literature.  However, few studies consider the combined effect of pharmacokinetics (PK) and binding kinetics (BK) on the duration of effect of a drug.  Using a simple model that takes both PK and BK into account, we found that prolongation of binding owing to a long drug-target residence time can only occur when the binding dissocn. is slower than the PK elimination.  Data for several drugs and/or drug candidates in the literature indicate that the opposite is obsd., i.e., they have a slower elimination compared with dissocn.  These observations greatly reduce the usability of drug-target residence times for estg. the duration of effect of a drug in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon2xZ9fJkTybVg90H21EOLACvtfcHk0lgdjGu646Yr_g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVyqtL0%253D&md5=73b190a44d359f55ee19af9099846505</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DDahl%26aufirst%3DG.%26aulast%3DAkerud%26aufirst%3DT.%26atitle%3DPharmacokinetics%2520and%2520the%2520drug-target%2520residence%2520time%2520concept%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D697%26epage%3D707%26doi%3D10.1016%2Fj.drudis.2013.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Tummino, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, R. A.</span><span> </span><span class="NLM_article-title">Residence time of receptor-ligand complexes and its effect on biological function</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">5481</span><span class="NLM_x">–</span> <span class="NLM_lpage">5492</span><span class="refDoi"> DOI: 10.1021/bi8002023</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi8002023" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1Ont7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=5481-5492&author=P.+J.+Tumminoauthor=R.+A.+Copeland&title=Residence+time+of+receptor-ligand+complexes+and+its+effect+on+biological+function&doi=10.1021%2Fbi8002023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Residence Time of Receptor-Ligand Complexes and Its Effect on Biological Function</span></div><div class="casAuthors">Tummino, Peter J.; Copeland, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5481-5492</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The formation and duration of binary receptor-ligand complexes are fundamental to many physiol. processes.  Most often, the effectiveness of interaction between a receptor and its ligand is quantified in terms of closed system, equil. affinity measurements, such as IC50 and Kd.  In the context of in vivo biol., however, the extent and duration of responses to receptor-ligand interactions depend greatly on the time period over which the ligand is in residence on its receptor.  Here we define receptor-ligand complex residence time in quant. terms and describe its significance to biol. function.  Examples of the importance of residence time are presented for natural ligands of different receptor types.  The impact of residence time on the optimization of potential ligands as drugs for human medicine is also described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHshN2Bt_r9LVg90H21EOLACvtfcHk0lglSNz86l0YnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1Ont7s%253D&md5=57f79f69f12c6ed14e3347638381d943</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fbi8002023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi8002023%26sid%3Dliteratum%253Aachs%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DResidence%2520time%2520of%2520receptor-ligand%2520complexes%2520and%2520its%2520effect%2520on%2520biological%2520function%26jtitle%3DBiochemistry%26date%3D2008%26volume%3D47%26spage%3D5481%26epage%3D5492%26doi%3D10.1021%2Fbi8002023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Basavapathruni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daigle, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majer, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therkelsen, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigle, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuntz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chesworth, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richon, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olhava, E. J.</span><span> </span><span class="NLM_article-title">Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase dot1l</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">971</span><span class="NLM_x">–</span> <span class="NLM_lpage">980</span><span class="refDoi"> DOI: 10.1111/cbdd.12050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1111%2Fcbdd.12050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=22978415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslClsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2012&pages=971-980&author=A.+Basavapathruniauthor=L.+Jinauthor=S.+R.+Daigleauthor=C.+R.+Majerauthor=C.+A.+Therkelsenauthor=T.+J.+Wigleauthor=K.+W.+Kuntzauthor=R.+Chesworthauthor=R.+M.+Pollockauthor=M.+P.+Scottauthor=M.+P.+Moyerauthor=V.+M.+Richonauthor=R.+A.+Copelandauthor=E.+J.+Olhava&title=Conformational+adaptation+drives+potent%2C+selective+and+durable+inhibition+of+the+human+protein+methyltransferase+dot1l&doi=10.1111%2Fcbdd.12050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L</span></div><div class="casAuthors">Basavapathruni, Aravind; Jin, Lei; Daigle, Scott R.; Majer, Christina R. A.; Therkelsen, Carly A.; Wigle, Tim J.; Kuntz, Kevin W.; Chesworth, Richard; Pollock, Roy M.; Scott, Margaret P.; Moyer, Mikel P.; Richon, Victoria M.; Copeland, Robert A.; Olhava, Edward J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">971-980</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">DOT1L is the human protein methyltransferase responsible for catalyzing the methylation of histone H3 on lysine 79 (H3K79).  The ectopic activity of DOT1L, assocd. with the chromosomal translocation that is a universal hallmark of MLL-rearranged leukemia, is a required driver of leukemogenesis in this malignancy.  Here, we present studies on the structure-activity relation of aminonucleoside-based DOT1L inhibitors.  Within this series, we find that improvements in target enzyme affinity and selectivity are driven entirely by diminution of the dissocn. rate const. for the enzyme-inhibitor complex, leading to long residence times for the binary complex.  The biochem. Ki and residence times measured for these inhibitors correlate well with their effects on intracellular H3K79 methylation and MLL-rearranged leukemic cell killing.  Crystallog. studies reveal a conformational adaptation mechanism assocd. with high-affinity inhibitor binding and prolonged residence time; these studies also suggest that conformational adaptation likewise plays a crit. role in natural ligand interactions with the enzyme, hence, facilitating enzyme turnover.  These results provide crit. insights into the role of conformational adaptation in the enzymic mechanism of catalysis and in pharmacol. intervention for DOT1L and other members of this enzyme class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJm_d3iX3p77Vg90H21EOLACvtfcHk0lglSNz86l0YnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslClsr7O&md5=de628fcd2c37b5f6496cc3b483125309</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12050%26sid%3Dliteratum%253Aachs%26aulast%3DBasavapathruni%26aufirst%3DA.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DDaigle%26aufirst%3DS.%2BR.%26aulast%3DMajer%26aufirst%3DC.%2BR.%26aulast%3DTherkelsen%26aufirst%3DC.%2BA.%26aulast%3DWigle%26aufirst%3DT.%2BJ.%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26aulast%3DChesworth%26aufirst%3DR.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DScott%26aufirst%3DM.%2BP.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DOlhava%26aufirst%3DE.%2BJ.%26atitle%3DConformational%2520adaptation%2520drives%2520potent%252C%2520selective%2520and%2520durable%2520inhibition%2520of%2520the%2520human%2520protein%2520methyltransferase%2520dot1l%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2012%26volume%3D80%26spage%3D971%26epage%3D980%26doi%3D10.1111%2Fcbdd.12050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Chang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiebel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bommineni, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khanna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sotriffer, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonge, P. J.</span><span> </span><span class="NLM_article-title">Rational optimization of drug-target residence time: Insights from inhibitor binding to the staphylococcus aureus fabi enzyme-product complex</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4217</span><span class="NLM_x">–</span> <span class="NLM_lpage">4228</span><span class="refDoi"> DOI: 10.1021/bi400413c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi400413c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotVSlsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=4217-4228&author=A.+Changauthor=J.+Schiebelauthor=W.+Yuauthor=G.+R.+Bommineniauthor=P.+Panauthor=M.+V.+Baxterauthor=A.+Khannaauthor=C.+A.+Sotrifferauthor=C.+Kiskerauthor=P.+J.+Tonge&title=Rational+optimization+of+drug-target+residence+time%3A+Insights+from+inhibitor+binding+to+the+staphylococcus+aureus+fabi+enzyme-product+complex&doi=10.1021%2Fbi400413c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Optimization of Drug-Target Residence Time: Insights from Inhibitor Binding to the Staphylococcus aureus FabI Enzyme-Product Complex</span></div><div class="casAuthors">Chang, Andrew; Schiebel, Johannes; Yu, Weixuan; Bommineni, Gopal R.; Pan, Pan; Baxter, Michael V.; Khanna, Avinash; Sotriffer, Christoph A.; Kisker, Caroline; Tonge, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4217-4228</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug-target kinetics has recently emerged as an esp. important facet of the drug discovery process.  In particular, prolonged drug-target residence times may confer enhanced efficacy and selectivity in the open in vivo system.  However, the lack of accurate kinetic and structural data for a series of congeneric compds. hinders the rational design of inhibitors with decreased off-rates.  Therefore, we chose the Staphylococcus aureus enoyl-ACP reductase (saFabI) - an important target for the development of new anti-staphylococcal drugs - as a model system to rationalize and optimize the drug-target residence time on a structural basis.  Using our new, efficient, and widely applicable mechanistically informed kinetic approach, we obtained a full characterization of saFabI inhibition by a series of 20 di-Ph ethers complemented by a collection of 9 saFabI-inhibitor crystal structures.  We identified a strong correlation between the affinities of the investigated saFabI di-Ph ether inhibitors and their corresponding residence times, which can be rationalized on a structural basis.  Because of its favorable interactions with the enzyme, the residence time of our most potent compd. exceeds 10 h.  In addn., we found that affinity and residence time in this system can be significantly enhanced by modifications predictable by a careful consideration of catalysis.  Our study provides a blueprint for investigating and prolonging drug-target kinetics and may aid in the rational design of long-residence-time inhibitors targeting the essential saFabI enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVCwUUpjx2QrVg90H21EOLACvtfcHk0lglSNz86l0YnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotVSlsLo%253D&md5=bc06231375d06e4e58772f4afc7f8829</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fbi400413c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi400413c%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DA.%26aulast%3DSchiebel%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DBommineni%26aufirst%3DG.%2BR.%26aulast%3DPan%26aufirst%3DP.%26aulast%3DBaxter%26aufirst%3DM.%2BV.%26aulast%3DKhanna%26aufirst%3DA.%26aulast%3DSotriffer%26aufirst%3DC.%2BA.%26aulast%3DKisker%26aufirst%3DC.%26aulast%3DTonge%26aufirst%3DP.%2BJ.%26atitle%3DRational%2520optimization%2520of%2520drug-target%2520residence%2520time%253A%2520Insights%2520from%2520inhibitor%2520binding%2520to%2520the%2520staphylococcus%2520aureus%2520fabi%2520enzyme-product%2520complex%26jtitle%3DBiochemistry%26date%3D2013%26volume%3D52%26spage%3D4217%26epage%3D4228%26doi%3D10.1021%2Fbi400413c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Meharena, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keshwani, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oruganty, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nene, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kannan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornev, A. P.</span><span> </span><span class="NLM_article-title">Deciphering the structural basis of eukaryotic protein kinase regulation</span> <span class="citation_source-journal">PLoS Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1001680</span><span class="refDoi"> DOI: 10.1371/journal.pbio.1001680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1371%2Fjournal.pbio.1001680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=24143133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslags7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=e1001680&author=H.+S.+Meharenaauthor=P.+Changauthor=M.+M.+Keshwaniauthor=K.+Orugantyauthor=A.+K.+Neneauthor=N.+Kannanauthor=S.+S.+Taylorauthor=A.+P.+Kornev&title=Deciphering+the+structural+basis+of+eukaryotic+protein+kinase+regulation&doi=10.1371%2Fjournal.pbio.1001680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Deciphering the structural basis of Eukaryotic protein kinase regulation</span></div><div class="casAuthors">Meharena, Hiruy S.; Chang, Philip; Keshwani, Malik M.; Oruganty, Krishnadev; Nene, Aishwarya K.; Kannan, Natarajan; Taylor, Susan S.; Kornev, Alexandr P.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e1001680</span>CODEN:
                <span class="NLM_cas:coden">PBLIBG</span>;
        ISSN:<span class="NLM_cas:issn">1545-7885</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Eukaryotic protein kinases (EPKs) regulate numerous signaling processes by phosphorylating targeted substrates through the highly conserved catalytic domain.  Our previous computational studies proposed a model stating that a properly assembled nonlinear motif termed the Regulatory (R) spine is essential for catalytic activity of EPKs.  Here we define the required intramol. interactions and biochem. properties of the R-spine and the newly identified "Shell" that surrounds the R-spine using site-directed mutagenesis and various in vitro phosphoryl transfer assays using cAMP-dependent protein kinase (PKA) as a representative of the entire kinome.  Anal. of the 172 available Apo EPK structures in the protein data bank (PDB) revealed four unique structural conformations of the R-spine that correspond with catalytic inactivation of various EPKs.  Elucidating the mol. entities required for the catalytic activation of EPKs and the identification of these inactive conformations opens new avenues for the design of efficient therapeutic EPK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwdeD18CvhBLVg90H21EOLACvtfcHk0ljtOgRBo0qFIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslags7bM&md5=fa8a4d5a9383bca04d15f017b4cc9194</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.1001680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.1001680%26sid%3Dliteratum%253Aachs%26aulast%3DMeharena%26aufirst%3DH.%2BS.%26aulast%3DChang%26aufirst%3DP.%26aulast%3DKeshwani%26aufirst%3DM.%2BM.%26aulast%3DOruganty%26aufirst%3DK.%26aulast%3DNene%26aufirst%3DA.%2BK.%26aulast%3DKannan%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DKornev%26aufirst%3DA.%2BP.%26atitle%3DDeciphering%2520the%2520structural%2520basis%2520of%2520eukaryotic%2520protein%2520kinase%2520regulation%26jtitle%3DPLoS%2520Biol.%26date%3D2013%26volume%3D11%26spage%3De1001680%26doi%3D10.1371%2Fjournal.pbio.1001680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Hu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahuja, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meharena, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kannan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornev, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. S.</span><span> </span><span class="NLM_article-title">Kinase regulation by hydrophobic spine assembly in cancer</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">264</span><span class="NLM_x">–</span> <span class="NLM_lpage">276</span><span class="refDoi"> DOI: 10.1128/MCB.00943-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1128%2FMCB.00943-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=25348715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFerurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=264-276&author=J.+Huauthor=L.+G.+Ahujaauthor=H.+S.+Meharenaauthor=N.+Kannanauthor=A.+P.+Kornevauthor=S.+S.+Taylorauthor=A.+S.+Shaw&title=Kinase+regulation+by+hydrophobic+spine+assembly+in+cancer&doi=10.1128%2FMCB.00943-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase regulation by hydrophobic spine assembly in cancer</span></div><div class="casAuthors">Hu, Jiancheng; Ahuja, Lalima G.; Meharena, Hiruy S.; Kannan, Natarajan; Kornev, Alexandr P.; Taylor, Susan S.; Shaw, Andrey S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">264-276/1-264-276/13, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A new model of kinase regulation based on the assembly of hydrophobic spines has been proposed.  Changes in their positions can explain the mechanism of kinase activation.  Here, we examd. mutations in human cancer for clues about the regulation of the hydrophobic spines by focusing initially on mutations to Phe.  We identified a selected no. of Phe mutations in a small group of kinases that included BRAF, ABL1, and the epidermal growth factor receptor.  Testing some of these mutations in BRAF, we found that one of the mutations impaired ATP binding and catalytic activity but promoted noncatalytic allosteric functions.  Other Phe mutations functioned to promote constitutive catalytic activity.  One of these mutations revealed a previously underappreciated hydrophobic surface that functions to position the dynamic regulatory αC-helix.  This supports the key role of the C-helix as a signal integration motif for coordinating multiple elements of the kinase to create an active conformation.  The importance of the hydrophobic space around the αC-helix was further tested by studying a V600F mutant, which was constitutively active in the absence of the neg. charge that is assocd. with the common V600E mutation.  Many hydrophobic mutations strategically localized along the C-helix can thus drive kinase activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRC2fQzzavjrVg90H21EOLACvtfcHk0ljtOgRBo0qFIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFerurY%253D&md5=94b744e5233f1afd640d67fb2355a569</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1128%2FMCB.00943-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00943-14%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DAhuja%26aufirst%3DL.%2BG.%26aulast%3DMeharena%26aufirst%3DH.%2BS.%26aulast%3DKannan%26aufirst%3DN.%26aulast%3DKornev%26aufirst%3DA.%2BP.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DShaw%26aufirst%3DA.%2BS.%26atitle%3DKinase%2520regulation%2520by%2520hydrophobic%2520spine%2520assembly%2520in%2520cancer%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2015%26volume%3D35%26spage%3D264%26epage%3D276%26doi%3D10.1128%2FMCB.00943-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Yurtsever, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheaffer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holtzman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brett, T. J.</span><span> </span><span class="NLM_article-title">The crystal structure of phosphorylated mapk13 reveals common structural features and differences in p38 mapk family activation</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">790</span><span class="NLM_x">–</span> <span class="NLM_lpage">799</span><span class="refDoi"> DOI: 10.1107/S1399004715001212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1107%2FS1399004715001212" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=790-799&author=Z.+Yurtseverauthor=S.+M.+Scheafferauthor=A.+G.+Romeroauthor=M.+J.+Holtzmanauthor=T.+J.+Brett&title=The+crystal+structure+of+phosphorylated+mapk13+reveals+common+structural+features+and+differences+in+p38+mapk+family+activation&doi=10.1107%2FS1399004715001212"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1107%2FS1399004715001212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS1399004715001212%26sid%3Dliteratum%253Aachs%26aulast%3DYurtsever%26aufirst%3DZ.%26aulast%3DScheaffer%26aufirst%3DS.%2BM.%26aulast%3DRomero%26aufirst%3DA.%2BG.%26aulast%3DHoltzman%26aufirst%3DM.%2BJ.%26aulast%3DBrett%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520crystal%2520structure%2520of%2520phosphorylated%2520mapk13%2520reveals%2520common%2520structural%2520features%2520and%2520differences%2520in%2520p38%2520mapk%2520family%2520activation%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2015%26volume%3D71%26spage%3D790%26epage%3D799%26doi%3D10.1107%2FS1399004715001212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Kornev, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ten Eyck, L. F.</span><span> </span><span class="NLM_article-title">A helix scaffold for the assembly of active protein kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">14377</span><span class="NLM_x">–</span> <span class="NLM_lpage">14382</span><span class="refDoi"> DOI: 10.1073/pnas.0807988105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1073%2Fpnas.0807988105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=14377-14382&author=A.+P.+Kornevauthor=S.+S.+Taylorauthor=L.+F.+Ten+Eyck&title=A+helix+scaffold+for+the+assembly+of+active+protein+kinases&doi=10.1073%2Fpnas.0807988105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0807988105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0807988105%26sid%3Dliteratum%253Aachs%26aulast%3DKornev%26aufirst%3DA.%2BP.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DTen%2BEyck%26aufirst%3DL.%2BF.%26atitle%3DA%2520helix%2520scaffold%2520for%2520the%2520assembly%2520of%2520active%2520protein%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D14377%26epage%3D14382%26doi%3D10.1073%2Fpnas.0807988105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Francis, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rozycki, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koveal, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hummer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peti, W.</span><span> </span><span class="NLM_article-title">Structural basis of p38 alpha regulation by hematopoietic tyrosine phosphatase</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">916</span><span class="NLM_x">–</span> <span class="NLM_lpage">924</span><span class="refDoi"> DOI: 10.1038/nchembio.707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1038%2Fnchembio.707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=22057126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVagtL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=916-924&author=D.+M.+Francisauthor=B.+Rozyckiauthor=D.+Kovealauthor=G.+Hummerauthor=R.+Pageauthor=W.+Peti&title=Structural+basis+of+p38+alpha+regulation+by+hematopoietic+tyrosine+phosphatase&doi=10.1038%2Fnchembio.707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of p38α regulation by hematopoietic tyrosine phosphatase</span></div><div class="casAuthors">Francis, Dana M.; Rozycki, Bartosz; Koveal, Dorothy; Hummer, Gerhard; Page, Rebecca; Peti, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">916-924</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">MAP kinases regulate essential cellular events, including cell growth, differentiation and inflammation.  The soln. structure of a complete MAPK-MAPK-regulatory protein complex, p38α-HePTP, was detd., enabling a comprehensive investigation of the mol. basis of specificity and fidelity in MAPK regulation.  Structure detn. was achieved by combining NMR spectroscopy and small-angle X-ray scattering data with a new ensemble calcn.-refinement procedure.  We identified 25 residues outside of the HePTP kinase interaction motif necessary for p38α recognition.  The complex adopts an extended conformation in soln. and rarely samples the conformation necessary for kinase deactivation.  Complex formation also does not affect the N-terminal lobe, the activation loop of p38α or the catalytic domain of HePTP.  Together, these results show how the downstream tyrosine phosphatase HePTP regulates p38α and provide for fundamentally new insights into MAPK regulation and specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh8OtxlNaLJrVg90H21EOLACvtfcHk0lhxMGe8Jh9rhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVagtL3L&md5=bde10f5d0142704475ba8fd390598c99</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.707%26sid%3Dliteratum%253Aachs%26aulast%3DFrancis%26aufirst%3DD.%2BM.%26aulast%3DRozycki%26aufirst%3DB.%26aulast%3DKoveal%26aufirst%3DD.%26aulast%3DHummer%26aufirst%3DG.%26aulast%3DPage%26aufirst%3DR.%26aulast%3DPeti%26aufirst%3DW.%26atitle%3DStructural%2520basis%2520of%2520p38%2520alpha%2520regulation%2520by%2520hematopoietic%2520tyrosine%2520phosphatase%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D916%26epage%3D924%26doi%3D10.1038%2Fnchembio.707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Bukhtiyarova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karpusas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Northrop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namboodiri, H. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springman, E. B.</span><span> </span><span class="NLM_article-title">Mutagenesis of p38alpha map kinase establishes key roles of phe169 in function and structural dynamics and reveals a novel dfg-out state</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">5687</span><span class="NLM_x">–</span> <span class="NLM_lpage">5696</span><span class="refDoi"> DOI: 10.1021/bi0622221</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi0622221" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=5687-5696&author=M.+Bukhtiyarovaauthor=M.+Karpusasauthor=K.+Northropauthor=H.+V.+Namboodiriauthor=E.+B.+Springman&title=Mutagenesis+of+p38alpha+map+kinase+establishes+key+roles+of+phe169+in+function+and+structural+dynamics+and+reveals+a+novel+dfg-out+state&doi=10.1021%2Fbi0622221"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fbi0622221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0622221%26sid%3Dliteratum%253Aachs%26aulast%3DBukhtiyarova%26aufirst%3DM.%26aulast%3DKarpusas%26aufirst%3DM.%26aulast%3DNorthrop%26aufirst%3DK.%26aulast%3DNamboodiri%26aufirst%3DH.%2BV.%26aulast%3DSpringman%26aufirst%3DE.%2BB.%26atitle%3DMutagenesis%2520of%2520p38alpha%2520map%2520kinase%2520establishes%2520key%2520roles%2520of%2520phe169%2520in%2520function%2520and%2520structural%2520dynamics%2520and%2520reveals%2520a%2520novel%2520dfg-out%2520state%26jtitle%3DBiochemistry%26date%3D2007%26volume%3D46%26spage%3D5687%26epage%3D5696%26doi%3D10.1021%2Fbi0622221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Wentsch, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhrmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer-Wrangowski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaman, G. J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willemsen-Seegers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buijsman, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henning, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zender, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">Optimized target residence time: Type i1/2 inhibitors for p38alpha map kinase with improved binding kinetics through direct interaction with the r-spine</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5363</span><span class="NLM_x">–</span> <span class="NLM_lpage">5367</span><span class="refDoi"> DOI: 10.1002/anie.201701185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1002%2Fanie.201701185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVCmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=5363-5367&author=H.+K.+Wentschauthor=N.+M.+Walterauthor=M.+Buhrmannauthor=S.+Mayer-Wrangowskiauthor=D.+Rauhauthor=G.+J.+R.+Zamanauthor=N.+Willemsen-Seegersauthor=R.+C.+Buijsmanauthor=M.+Henningauthor=D.+Dauchauthor=L.+Zenderauthor=S.+Laufer&title=Optimized+target+residence+time%3A+Type+i1%2F2+inhibitors+for+p38alpha+map+kinase+with+improved+binding+kinetics+through+direct+interaction+with+the+r-spine&doi=10.1002%2Fanie.201701185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine</span></div><div class="casAuthors">Wentsch, Heike K.; Walter, Niklas M.; Buehrmann, Mike; Mayer-Wrangowski, Svenja; Rauh, Daniel; Zaman, Guido J. R.; Willemsen-Seegers, Nicole; Buijsman, Rogier C.; Henning, Melanie; Dauch, Daniel; Zender, Lars; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5363-5367</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Skepinone-L was recently reported to be a p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo.  However, this class of compds. still act as fully ATP-competitive Type I binders which, furthermore, suffer from short residence times at the enzyme.  We herein describe a further development with the first Type I1/2 binders for p38α MAP kinase.  Type I1/2 inhibitors interfere with the R-spine, inducing a glycine flip and occupying both hydrophobic regions I and II.  This design approach leads to prolonged target residence time, binding to both the active and inactive states of the kinase, excellent selectivity, excellent potency on the enzyme level, and low nanomolar activity in a human whole blood assay.  This promising binding mode is proven by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO3M43Sl8vibVg90H21EOLACvtfcHk0lhxMGe8Jh9rhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVCmu70%253D&md5=c4a1f981eaf8a2146f758fe4e71ac8b5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fanie.201701185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201701185%26sid%3Dliteratum%253Aachs%26aulast%3DWentsch%26aufirst%3DH.%2BK.%26aulast%3DWalter%26aufirst%3DN.%2BM.%26aulast%3DBuhrmann%26aufirst%3DM.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%2BR.%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3DBuijsman%26aufirst%3DR.%2BC.%26aulast%3DHenning%26aufirst%3DM.%26aulast%3DDauch%26aufirst%3DD.%26aulast%3DZender%26aufirst%3DL.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DOptimized%2520target%2520residence%2520time%253A%2520Type%2520i1%252F2%2520inhibitors%2520for%2520p38alpha%2520map%2520kinase%2520with%2520improved%2520binding%2520kinetics%2520through%2520direct%2520interaction%2520with%2520the%2520r-spine%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D5363%26epage%3D5367%26doi%3D10.1002%2Fanie.201701185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Seo, Y.</span><span> </span><span class="NLM_article-title">Novel isoindolinone derivatives having inhibitory activity against t-type calcium channel and method for preparation</span>. U.S. Patent US 2010/0004286 A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=Y.+Seo&title=Novel+isoindolinone+derivatives+having+inhibitory+activity+against+t-type+calcium+channel+and+method+for+preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSeo%26aufirst%3DY.%26atitle%3DNovel%2520isoindolinone%2520derivatives%2520having%2520inhibitory%2520activity%2520against%2520t-type%2520calcium%2520channel%2520and%2520method%2520for%2520preparation%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Surry, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Dialkylbiaryl phosphines in pd-catalyzed amination: A user’s guide</span> <span class="citation_source-journal">Chem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span><span class="refDoi"> DOI: 10.1039/C0SC00331J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1039%2FC0SC00331J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=22432049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWqsbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=27-50&author=D.+S.+Surryauthor=S.+L.+Buchwald&title=Dialkylbiaryl+phosphines+in+pd-catalyzed+amination%3A+A+user%E2%80%99s+guide&doi=10.1039%2FC0SC00331J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Dialkylbiaryl phosphines in Pd-catalyzed amination: a user's guide</span></div><div class="casAuthors">Surry, David S.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-50</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Dialkylbiaryl phosphines are a valuable class of ligand for Pd-catalyzed amination reactions and have been applied in a range of contexts.  This perspective attempts to aid the reader in the selection of the best choice of reaction conditions and ligand of this class for the most commonly encountered and practically important substrate combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY0vbHHdx-_rVg90H21EOLACvtfcHk0lhxMGe8Jh9rhQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWqsbnM&md5=8743358f11af138189d106c51b5942b9</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1039%2FC0SC00331J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC0SC00331J%26sid%3Dliteratum%253Aachs%26aulast%3DSurry%26aufirst%3DD.%2BS.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DDialkylbiaryl%2520phosphines%2520in%2520pd-catalyzed%2520amination%253A%2520A%2520user%25E2%2580%2599s%2520guide%26jtitle%3DChem.%2520Sci.%26date%3D2011%26volume%3D2%26spage%3D27%26epage%3D50%26doi%3D10.1039%2FC0SC00331J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dabbagh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phippard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suttmann, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papp, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leaffer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aud, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dal Porto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B. R.</span><span> </span><span class="NLM_article-title">Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: Preclinical analysis of efficacy and selectivity</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">327</span><span class="NLM_x">, </span> <span class="NLM_fpage">610</span><span class="NLM_x">–</span> <span class="NLM_lpage">619</span><span class="refDoi"> DOI: 10.1124/jpet.108.139006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1124%2Fjpet.108.139006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=18776065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVCjtL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2008&pages=610-619&author=R.+J.+Hillauthor=K.+Dabbaghauthor=D.+Phippardauthor=C.+Liauthor=R.+T.+Suttmannauthor=M.+Welchauthor=E.+Pappauthor=K.+W.+Songauthor=K.+C.+Changauthor=D.+Leafferauthor=Y.+N.+Kimauthor=R.+T.+Robertsauthor=T.+S.+Zabkaauthor=D.+Audauthor=J.+Dal+Portoauthor=A.+M.+Manningauthor=S.+L.+Pengauthor=D.+M.+Goldsteinauthor=B.+R.+Wong&title=Pamapimod%2C+a+novel+p38+mitogen-activated+protein+kinase+inhibitor%3A+Preclinical+analysis+of+efficacy+and+selectivity&doi=10.1124%2Fjpet.108.139006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity</span></div><div class="casAuthors">Hill, Ronald J.; Dabbagh, Karim; Phippard, Deborah; Li, Ching; Suttmann, Rebecca T.; Welch, Mary; Papp, Eva; Song, Kyung W.; Chang, Kung-ching; Leaffer, David; Kim, Yong-Nam; Roberts, Richard T.; Zabka, Tanja S.; Aud, Dee; Dal Porto, Joseph; Manning, Anthony M.; Peng, Stanford L.; Goldstein, David M.; Wong, Brian R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">610-619</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">P38α is a protein kinase that regulates the expression of inflammatory cytokines, suggesting a role in the pathogenesis of diseases such as rheumatoid arthritis (RA) or systemic lupus erythematosus.  Here, we describe the preclin. pharmacol. of pamapimod, a novel p38 mitogen-activated protein kinase inhibitor.  Pamapimod inhibited p38α and p38β enzymic activity, with IC50 values of 0.014±0.002 and 0.48±0.04 μM, resp.  There was no activity against p38δ or p38γ isoforms.  When profiled across 350 kinases, pamapimod bound only to four kinases in addn. to p38.  Cellular potency was assessed using phosphorylation of heat shock protein-27 and c-Jun as selective readouts for p38 and c-Jun NH2-terminal kinase (JNK), resp.  Pamapimod inhibited p38 (IC50, 0.06 μM), but inhibition of JNK was not detected.  Pamapimod also inhibited lipopolysaccharide (LPS)-stimulated tumor necrosis factor (TNF) α prodn. by monocytes, interleukin (IL)-1β prodn. in human whole blood, and spontaneous TNFα prodn. by synovial explants from RA patients.  LPS- and TNFα-stimulated prodn. of TNFα and IL-6 in rodents also was inhibited by pamapimod.  In murine collagen-induced arthritis, pamapimod reduced clin. signs of inflammation and bone loss at 50 mg/kg or greater.  In a rat model of hyperalgesia, pamapimod increased tolerance to pressure in a dose-dependent manner, suggesting an important role of p38 in pain assocd. with inflammation.  Finally, an analog of pamapimod that has equiv. potency and selectivity inhibited renal disease in lupus-prone MRL/lpr mice.  Our study demonstrates that pamapimod is a potent, selective inhibitor of p38α with the ability to inhibit the signs and symptoms of RA and other autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoImm011NnzW7Vg90H21EOLACvtfcHk0liIng1imnqFXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVCjtL3F&md5=9311aa6b1a51544ac755d1cc77cdd92f</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.139006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.139006%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DDabbagh%26aufirst%3DK.%26aulast%3DPhippard%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DSuttmann%26aufirst%3DR.%2BT.%26aulast%3DWelch%26aufirst%3DM.%26aulast%3DPapp%26aufirst%3DE.%26aulast%3DSong%26aufirst%3DK.%2BW.%26aulast%3DChang%26aufirst%3DK.%2BC.%26aulast%3DLeaffer%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.%2BN.%26aulast%3DRoberts%26aufirst%3DR.%2BT.%26aulast%3DZabka%26aufirst%3DT.%2BS.%26aulast%3DAud%26aufirst%3DD.%26aulast%3DDal%2BPorto%26aufirst%3DJ.%26aulast%3DManning%26aufirst%3DA.%2BM.%26aulast%3DPeng%26aufirst%3DS.%2BL.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DWong%26aufirst%3DB.%2BR.%26atitle%3DPamapimod%252C%2520a%2520novel%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibitor%253A%2520Preclinical%2520analysis%2520of%2520efficacy%2520and%2520selectivity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D327%26spage%3D610%26epage%3D619%26doi%3D10.1124%2Fjpet.108.139006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Goettert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graeser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S. A.</span><span> </span><span class="NLM_article-title">Optimization of a nonradioactive immunosorbent assay for p38alpha mitogen-activated protein kinase activity</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">406</span><span class="NLM_x">, </span> <span class="NLM_fpage">233</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span><span class="refDoi"> DOI: 10.1016/j.ab.2010.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1016%2Fj.ab.2010.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=20638357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFamu7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2010&pages=233-234&author=M.+Goettertauthor=R.+Graeserauthor=S.+A.+Laufer&title=Optimization+of+a+nonradioactive+immunosorbent+assay+for+p38alpha+mitogen-activated+protein+kinase+activity&doi=10.1016%2Fj.ab.2010.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a nonradioactive immunosorbent assay for p38α mitogen-activated protein kinase activity</span></div><div class="casAuthors">Goettert, Marcia; Graeser, Ralph; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">406</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">233-234</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here, the authors describe the optimization of a nonradioactive immunosorbent p38α-MAP kinase (MAPK) activity assay to det. the inhibitory potency of small mol. inhibitors.  The assay omitted the secondary antibody and, therefore, was shorter, more accurate, and easier to handle (total assay time of 3 h).  This direct assay used a new monoclonal anti-phospho-ATF-2 (Thr69/71) peroxidase-conjugated antibody, increasing the specificity and eliminating problems with cross-reactivities of secondary antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXu4ELn6_1brVg90H21EOLACvtfcHk0liIng1imnqFXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFamu7zP&md5=23b6434a50195acd27895d7d2205556c</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2010.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2010.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DGoettert%26aufirst%3DM.%26aulast%3DGraeser%26aufirst%3DR.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DOptimization%2520of%2520a%2520nonradioactive%2520immunosorbent%2520assay%2520for%2520p38alpha%2520mitogen-activated%2520protein%2520kinase%2520activity%26jtitle%3DAnal.%2520Biochem.%26date%3D2010%26volume%3D406%26spage%3D233%26epage%3D234%26doi%3D10.1016%2Fj.ab.2010.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Bauer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubiak, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothbauer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">From enzyme to whole blood: Sequential screening procedure for identification and evaluation of p38 mapk inhibitors</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">1360</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span><span class="refDoi"> DOI: 10.1007/978-1-4939-3073-9_10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1007%2F978-1-4939-3073-9_10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=26501907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntVenu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1360&publication_year=2016&pages=123-148&author=S.+M.+Bauerauthor=J.+M.+Kubiakauthor=U.+Rothbauerauthor=S.+Laufer&title=From+enzyme+to+whole+blood%3A+Sequential+screening+procedure+for+identification+and+evaluation+of+p38+mapk+inhibitors&doi=10.1007%2F978-1-4939-3073-9_10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">From Enzyme to Whole Blood: Sequential Screening Procedure for Identification and Evaluation of p38 MAPK Inhibitors</span></div><div class="casAuthors">Bauer, Silke M.; Kubiak, Jakub M.; Rothbauer, Ulrich; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1360</span>
        (<span class="NLM_cas:issue">Kinase Screening and Profiling</span>),
    <span class="NLM_cas:pages">123-148</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">P38 mitogen-activated protein kinase (MAPK) is a pivotal enzyme in the biosynthesis of pro-inflammatory cytokines like IL-1 and TNF.  Therefore, the success of anti-cytokine therapy for treatment of inflammatory processes qualified p38-MAPK as a solid target in drug research concerning chronic inflammatory diseases including infectious vascular, neurobiol., and autoimmune disorders.  However, the discovery of new kinase inhibitors is limited by the need for a high biol. activity combined with restricted activity to the target enzyme or pathway interaction.  As a consequence, no p38 MAPK inhibitor has been introduced to the market so far, although several p38 inhibitors have proceeded into clin. trials.  The development of novel inhibitor types and optimization of already known structural classes of MAPK inhibitors require appropriate testing systems reaching across these crucial parameters.  As a new approach, we describe the sequential arrangement of three testing systems custom-tailored to the requirements of drug discovery programs with focus on p38 inhibition.  Integrated anal. of the obtained results enables a concerted step-by-step selection of tested mols. in order to screen a compd. library for the most suitable inhibitor.  First, evaluation of the inhibitor's activity on the isolated p38 MAPK enzyme via an ELISA assay gives a first idea about the inhibitory potency of the mol.  Moreover, structure-activity relationships can be elucidated when comparing mols. within inhibitor series.  Second, screening in living cells via a p38 substrate-specific MK2-EGFP translocation assay supplies further information about efficacy, but provides also a first notion concerning selectivity and toxicity.  Third, efficacy is evaluated more specifically in vivo in LPS-stimulated human whole blood with regard to in vivo parameters, e.g., pharmacokinetic characteristics like plasma protein binding and cellular permeability.  These three testing systems complement one another synergistically by providing a high overlap and predictability.  Clear advantages of all presented systems are their realizability in an academic environment as well as their applicability for high-throughput screenings on a larger scale.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzgA7iA4wN77Vg90H21EOLACvtfcHk0liIng1imnqFXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntVenu7Y%253D&md5=3b170d3e07e05e52d383d2acf1525b02</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-3073-9_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-3073-9_10%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DS.%2BM.%26aulast%3DKubiak%26aufirst%3DJ.%2BM.%26aulast%3DRothbauer%26aufirst%3DU.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DFrom%2520enzyme%2520to%2520whole%2520blood%253A%2520Sequential%2520screening%2520procedure%2520for%2520identification%2520and%2520evaluation%2520of%2520p38%2520mapk%2520inhibitors%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2016%26volume%3D1360%26spage%3D123%26epage%3D148%26doi%3D10.1007%2F978-1-4939-3073-9_10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrobleski, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyckman, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillooly, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salter-Cid, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuster, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newitt, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKinnon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leftheris, K.</span><span> </span><span class="NLM_article-title">Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-n-propylpyrrolo[1,2-f][ 1,2,4]triazine-6-carboxamide (bms-582949), a clinical p38alpha map kinase inhibitor for the treatment of inflammatory diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6629</span><span class="NLM_x">–</span> <span class="NLM_lpage">6639</span><span class="refDoi"> DOI: 10.1021/jm100540x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100540x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6629-6639&author=C.+Liuauthor=J.+Linauthor=S.+T.+Wrobleskiauthor=S.+Linauthor=J.+Hynesauthor=H.+Wuauthor=A.+J.+Dyckmanauthor=T.+Liauthor=J.+Wityakauthor=K.+M.+Gilloolyauthor=S.+Pittauthor=D.+R.+Shenauthor=R.+F.+Zhangauthor=K.+W.+McIntyreauthor=L.+Salter-Cidauthor=D.+J.+Shusterauthor=H.+Zhangauthor=P.+H.+Maratheauthor=A.+M.+Doweykoauthor=J.+S.+Sackauthor=S.+E.+Kieferauthor=K.+F.+Kishauthor=J.+A.+Newittauthor=M.+McKinnonauthor=J.+H.+Doddauthor=J.+C.+Barrishauthor=G.+L.+Schievenauthor=K.+Leftheris&title=Discovery+of+4-%285-%28cyclopropylcarbamoyl%29-2-methylphenylamino%29-5-methyl-n-propylpyrrolo%5B1%2C2-f%5D%5B+1%2C2%2C4%5Dtriazine-6-carboxamide+%28bms-582949%29%2C+a+clinical+p38alpha+map+kinase+inhibitor+for+the+treatment+of+inflammatory+diseases&doi=10.1021%2Fjm100540x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm100540x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100540x%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DZhang%26aufirst%3DR.%2BF.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%2BH.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DKiefer%26aufirst%3DS.%2BE.%26aulast%3DKish%26aufirst%3DK.%2BF.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DMcKinnon%26aufirst%3DM.%26aulast%3DDodd%26aufirst%3DJ.%2BH.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DLeftheris%26aufirst%3DK.%26atitle%3DDiscovery%2520of%25204-%25285-%2528cyclopropylcarbamoyl%2529-2-methylphenylamino%2529-5-methyl-n-propylpyrrolo%255B1%252C2-f%255D%255B%25201%252C2%252C4%255Dtriazine-6-carboxamide%2520%2528bms-582949%2529%252C%2520a%2520clinical%2520p38alpha%2520map%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6629%26epage%3D6639%26doi%3D10.1021%2Fjm100540x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Chin, N. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neu, H. C.</span><span> </span><span class="NLM_article-title">Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1128/AAC.25.3.319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1128%2FAAC.25.3.319" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1984&pages=319-326&author=N.+X.+Chinauthor=H.+C.+Neu&title=Ciprofloxacin%2C+a+quinolone+carboxylic+acid+compound+active+against+aerobic+and+anaerobic+bacteria&doi=10.1128%2FAAC.25.3.319"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1128%2FAAC.25.3.319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.25.3.319%26sid%3Dliteratum%253Aachs%26aulast%3DChin%26aufirst%3DN.%2BX.%26aulast%3DNeu%26aufirst%3DH.%2BC.%26atitle%3DCiprofloxacin%252C%2520a%2520quinolone%2520carboxylic%2520acid%2520compound%2520active%2520against%2520aerobic%2520and%2520anaerobic%2520bacteria%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1984%26volume%3D25%26spage%3D319%26epage%3D326%26doi%3D10.1128%2FAAC.25.3.319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Willemsen-Seegers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uitdehaag, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prinsen, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vetter, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Man, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawase, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buijsman, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaman, G. J.</span><span> </span><span class="NLM_article-title">Compound selectivity and target residence time of kinase inhibitors studied with surface plasmon resonance</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">429</span><span class="NLM_x">, </span> <span class="NLM_fpage">574</span><span class="NLM_x">–</span> <span class="NLM_lpage">586</span><span class="refDoi"> DOI: 10.1016/j.jmb.2016.12.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1016%2Fj.jmb.2016.12.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=28043854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlt12ltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=429&publication_year=2017&pages=574-586&author=N.+Willemsen-Seegersauthor=J.+C.+Uitdehaagauthor=M.+B.+Prinsenauthor=J.+R.+de+Vetterauthor=J.+de+Manauthor=M.+Sawaauthor=Y.+Kawaseauthor=R.+C.+Buijsmanauthor=G.+J.+Zaman&title=Compound+selectivity+and+target+residence+time+of+kinase+inhibitors+studied+with+surface+plasmon+resonance&doi=10.1016%2Fj.jmb.2016.12.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance</span></div><div class="casAuthors">Willemsen-Seegers, Nicole; Uitdehaag, Joost C. M.; Prinsen, Martine B. W.; de Vetter, Judith R. F.; de Man, Jos; Sawa, Masaaki; Kawase, Yusuke; Buijsman, Rogier C.; Zaman, Guido J. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">429</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">574-586</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Target residence time (τ) has been suggested to be a better predictor of the biol. activity of kinase inhibitors than inhibitory potency (IC50) in enzyme assays.  Surface plasmon resonance binding assays for 46 human protein and lipid kinases were developed.  The assocn. and dissocn. consts. of 80 kinase inhibitor interactions were detd. τ and equil. affinity consts. (KD) were calcd. to det. kinetic selectivity.  Comparison of τ and KD or IC50 values revealed a strikingly different view on the selectivity of several kinase inhibitors, including the multi-kinase inhibitor ponatinib, which was tested on 10 different kinases.  In addn., known pan-Aurora inhibitors resided much longer on Aurora B than on Aurora A, despite having comparable affinity for Aurora A and B.  Furthermore, the γ/δ-selective PI3K inhibitor duvelisib and the δ-selective drug idelalisib had similar 20-fold selectivity for δ- over γ-isoform but duvelisib resided much longer on both targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8CehT0ysswLVg90H21EOLACvtfcHk0lgCbop8DUStfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlt12ltw%253D%253D&md5=3970beac9a1fcdcfe013f6750b6537b5</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2016.12.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2016.12.019%26sid%3Dliteratum%253Aachs%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3DUitdehaag%26aufirst%3DJ.%2BC.%26aulast%3DPrinsen%26aufirst%3DM.%2BB.%26aulast%3Dde%2BVetter%26aufirst%3DJ.%2BR.%26aulast%3Dde%2BMan%26aufirst%3DJ.%26aulast%3DSawa%26aufirst%3DM.%26aulast%3DKawase%26aufirst%3DY.%26aulast%3DBuijsman%26aufirst%3DR.%2BC.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%26atitle%3DCompound%2520selectivity%2520and%2520target%2520residence%2520time%2520of%2520kinase%2520inhibitors%2520studied%2520with%2520surface%2520plasmon%2520resonance%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2017%26volume%3D429%26spage%3D574%26epage%3D586%26doi%3D10.1016%2Fj.jmb.2016.12.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Xing, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devadas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devraj, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selness, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shieh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messing, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monahan, J. B.</span><span> </span><span class="NLM_article-title">Discovery and characterization of atropisomer ph-797804, a p38 map kinase inhibitor, as a clinical drug candidate</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span><span class="refDoi"> DOI: 10.1002/cmdc.201100439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1002%2Fcmdc.201100439" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=273-280&author=L.+Xingauthor=B.+Devadasauthor=R.+V.+Devrajauthor=S.+R.+Selnessauthor=H.+Shiehauthor=J.+K.+Walkerauthor=M.+Maoauthor=D.+Messingauthor=B.+Samasauthor=J.+Z.+Yangauthor=G.+D.+Andersonauthor=E.+G.+Webbauthor=J.+B.+Monahan&title=Discovery+and+characterization+of+atropisomer+ph-797804%2C+a+p38+map+kinase+inhibitor%2C+as+a+clinical+drug+candidate&doi=10.1002%2Fcmdc.201100439"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100439%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DL.%26aulast%3DDevadas%26aufirst%3DB.%26aulast%3DDevraj%26aufirst%3DR.%2BV.%26aulast%3DSelness%26aufirst%3DS.%2BR.%26aulast%3DShieh%26aufirst%3DH.%26aulast%3DWalker%26aufirst%3DJ.%2BK.%26aulast%3DMao%26aufirst%3DM.%26aulast%3DMessing%26aufirst%3DD.%26aulast%3DSamas%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DJ.%2BZ.%26aulast%3DAnderson%26aufirst%3DG.%2BD.%26aulast%3DWebb%26aufirst%3DE.%2BG.%26aulast%3DMonahan%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520atropisomer%2520ph-797804%252C%2520a%2520p38%2520map%2520kinase%2520inhibitor%252C%2520as%2520a%2520clinical%2520drug%2520candidate%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D273%26epage%3D280%26doi%3D10.1002%2Fcmdc.201100439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 15 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Niklas M. Tormählen, Mariella Martorelli, Annette Kuhn, Florian Maier, Jamil Guezguez, Michael Burnet, Wolfgang Albrecht, Stefan A. Laufer, <span class="NLM_string-name hlFld-ContribAuthor">Pierre Koch</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of Highly Selective Brain Penetrant p38α Mitogen-Activated Protein Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021</strong>, Article ASAP.</span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01773%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252BHighly%252BSelective%252BBrain%252BPenetrant%252Bp38%2525CE%2525B1%252BMitogen-Activated%252BProtein%252BKinase%252BInhibitors%26aulast%3DTorm%25C3%25A4hlen%26aufirst%3DNiklas%2BM.%26date%3D2021%26date%3D2020%26date%3D09102020%26volume%3D0%26issue%3D0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Júlia G. B. Pedreira, Philipp Nahidino, Mark Kudolo, Tatu Pantsar, Benedict-Tilman Berger, Michael Forster, Stefan Knapp, Stefan Laufer, <span class="NLM_string-name hlFld-ContribAuthor">Eliezer J. Barreiro</span>. </span><span class="cited-content_cbyCitation_article-title">Bioisosteric Replacement of Arylamide-Linked Spine Residues with N-Acylhydrazones and Selenophenes as a Design Strategy to Novel Dibenzosuberone Derivatives as Type I 1/2 p38α MAP Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (13)
                                     , 7347-7354. <a href="https://doi.org/10.1021/acs.jmedchem.0c00508" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00508</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00508&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00508%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DBioisosteric%252BReplacement%252Bof%252BArylamide-Linked%252BSpine%252BResidues%252Bwith%252BN-Acylhydrazones%252Band%252BSelenophenes%252Bas%252Ba%252BDesign%252BStrategy%252Bto%252BNovel%252BDibenzosuberone%252BDerivatives%252Bas%252BType%252BI%252B1%25252F2%252Bp38%2525CE%2525B1%252BMAP%252BKinase%252BInhibitors%26aulast%3DPedreira%26aufirst%3DJ%25C3%25BAlia%2BG.%2BB.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D27032020%26date%3D11062020%26date%3D28052020%26volume%3D63%26issue%3D13%26spage%3D7347%26epage%3D7354" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiaotian Kong, Peichen Pan, Huiyong Sun, Hongguang Xia, Xuwen Wang, Youyong Li, <span class="NLM_string-name hlFld-ContribAuthor">Tingjun Hou</span>. </span><span class="cited-content_cbyCitation_article-title">Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK). </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (24)
                                     , 10927-10954. <a href="https://doi.org/10.1021/acs.jmedchem.9b00446" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00446</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00446&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00446%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDrug%252BDiscovery%252BTargeting%252BAnaplastic%252BLymphoma%252BKinase%252B%252528ALK%252529%26aulast%3DKong%26aufirst%3DXiaotian%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D14032019%26date%3D26082019%26date%3D16082019%26volume%3D62%26issue%3D24%26spage%3D10927%26epage%3D10954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Wanli You, Zhiye Tang, <span class="NLM_string-name hlFld-ContribAuthor">Chia-en A. Chang</span>. </span><span class="cited-content_cbyCitation_article-title">Potential Mean Force from Umbrella Sampling Simulations: What Can We Learn and What Is Missed?. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Theory and Computation</span><span> <strong>2019,</strong> <em>15 </em>
                                    (4)
                                     , 2433-2443. <a href="https://doi.org/10.1021/acs.jctc.8b01142" title="DOI URL">https://doi.org/10.1021/acs.jctc.8b01142</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jctc.8b01142&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jctc.8b01142%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Theory%2520and%2520Computation%26atitle%3DPotential%252BMean%252BForce%252Bfrom%252BUmbrella%252BSampling%252BSimulations%25253A%252BWhat%252BCan%252BWe%252BLearn%252Band%252BWhat%252BIs%252BMissed%25253F%26aulast%3DYou%26aufirst%3DWanli%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D08112018%26date%3D14032019%26date%3D27022019%26volume%3D15%26issue%3D4%26spage%3D2433%26epage%3D2443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Marian C. Bryan, <span class="NLM_string-name hlFld-ContribAuthor">Naomi S. Rajapaksa</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (20)
                                     , 9030-9058. <a href="https://doi.org/10.1021/acs.jmedchem.8b00667" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00667</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00667&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00667%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKinase%252BInhibitors%252Bfor%252Bthe%252BTreatment%252Bof%252BImmunological%252BDisorders%25253A%252BRecent%252BAdvances%26aulast%3DBryan%26aufirst%3DMarian%2BC.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D26042018%26date%3D15062018%26date%3D05062018%26volume%3D61%26issue%3D20%26spage%3D9030%26epage%3D9058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haoyue  Xiang</span>, <span class="hlFld-ContribAuthor ">Qing-Lan  Zhao</span>, <span class="hlFld-ContribAuthor ">Peng-Ju  Xia</span>, <span class="hlFld-ContribAuthor ">Jun-An  Xiao</span>, <span class="hlFld-ContribAuthor ">Zhi-Peng  Ye</span>, <span class="hlFld-ContribAuthor ">Xiong  Xie</span>, <span class="hlFld-ContribAuthor ">Huan  Sheng</span>, <span class="hlFld-ContribAuthor ">Xiao-Qing  Chen</span>, and <span class="hlFld-ContribAuthor ">Hua  Yang</span>  . </span><span class="cited-content_cbyCitation_article-title">Visible-Light-Induced External Radical-Triggered Annulation To Access CF2-Containing Benzoxepine Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2018,</strong> <em>20 </em>
                                    (5)
                                     , 1363-1366. <a href="https://doi.org/10.1021/acs.orglett.8b00131" title="DOI URL">https://doi.org/10.1021/acs.orglett.8b00131</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.8b00131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.8b00131%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DVisible-Light-Induced%252BExternal%252BRadical-Triggered%252BAnnulation%252BTo%252BAccess%252BCF2-Containing%252BBenzoxepine%252BDerivatives%26aulast%3DXiang%26aufirst%3DHaoyue%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D12012018%26date%3D15022018%26date%3D02032018%26volume%3D20%26issue%3D5%26spage%3D1363%26epage%3D1366" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thamires R.  Machado</span>, <span class="hlFld-ContribAuthor ">Thayná R.  Machado</span>, <span class="hlFld-ContribAuthor ">Pedro G.  Pascutti</span>. </span><span class="cited-content_cbyCitation_article-title">The p38 MAPK Inhibitors and Their Role in Inflammatory Diseases. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2021,</strong> <em>6 </em>
                                    (23)
                                     , 5729-5742. <a href="https://doi.org/10.1002/slct.202100406" title="DOI URL">https://doi.org/10.1002/slct.202100406</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202100406&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202100406%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DThe%252Bp38%252BMAPK%252BInhibitors%252Band%252BTheir%252BRole%252Bin%252BInflammatory%252BDiseases%26aulast%3DMachado%26aufirst%3DThamires%2BR.%26date%3D2021%26date%3D2021%26volume%3D6%26issue%3D23%26spage%3D5729%26epage%3D5742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Débora Bublitz  Anton</span>, <span class="hlFld-ContribAuthor ">Rodrigo Gay  Ducati</span>, <span class="hlFld-ContribAuthor ">Luís Fernando Saraiva Macedo  Timmers</span>, <span class="hlFld-ContribAuthor ">Stefan  Laufer</span>, <span class="hlFld-ContribAuthor ">Márcia Inês  Goettert</span>. </span><span class="cited-content_cbyCitation_article-title">A Special View of What Was Almost Forgotten: p38δ MAPK. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (9)
                                     , 2077. <a href="https://doi.org/10.3390/cancers13092077" title="DOI URL">https://doi.org/10.3390/cancers13092077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13092077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13092077%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DA%252BSpecial%252BView%252Bof%252BWhat%252BWas%252BAlmost%252BForgotten%25253A%252Bp38%2525CE%2525B4%252BMAPK%26aulast%3DAnton%26aufirst%3DD%25C3%25A9bora%2BBublitz%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D9%26spage%3D2077" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Moustafa M.  Madkour</span>, <span class="hlFld-ContribAuthor ">Hanan S.  Anbar</span>, <span class="hlFld-ContribAuthor ">Mohammed I.  El-Gamal</span>. </span><span class="cited-content_cbyCitation_article-title">Current status and future prospects of p38α/MAPK14 kinase and its inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>213 </em>, 113216. <a href="https://doi.org/10.1016/j.ejmech.2021.113216" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113216</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113216%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCurrent%252Bstatus%252Band%252Bfuture%252Bprospects%252Bof%252Bp38%2525CE%2525B1%25252FMAPK14%252Bkinase%252Band%252Bits%252Binhibitors%26aulast%3DMadkour%26aufirst%3DMoustafa%2BM.%26date%3D2021%26volume%3D213%26spage%3D113216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vanessa  Haller</span>, <span class="hlFld-ContribAuthor ">Philipp  Nahidino</span>, <span class="hlFld-ContribAuthor ">Michael  Forster</span>, <span class="hlFld-ContribAuthor ">Stefan A.  Laufer</span>. </span><span class="cited-content_cbyCitation_article-title">An updated patent review of p38 MAP kinase inhibitors (2014-2019). </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Patents</span><span> <strong>2020,</strong> <em>30 </em>
                                    (6)
                                     , 453-466. <a href="https://doi.org/10.1080/13543776.2020.1749263" title="DOI URL">https://doi.org/10.1080/13543776.2020.1749263</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/13543776.2020.1749263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F13543776.2020.1749263%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Patents%26atitle%3DAn%252Bupdated%252Bpatent%252Breview%252Bof%252Bp38%252BMAP%252Bkinase%252Binhibitors%252B%2525282014-2019%252529%26aulast%3DHaller%26aufirst%3DVanessa%26date%3D2020%26date%3D2020%26volume%3D30%26issue%3D6%26spage%3D453%26epage%3D466" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Antti  Poso</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Modeling of Protein Kinases: Current Status and Challenges. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 25-41. <a href="https://doi.org/10.1007/7355_2020_106" title="DOI URL">https://doi.org/10.1007/7355_2020_106</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2020_106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2020_106%26sid%3Dliteratum%253Aachs%26atitle%3DMolecular%252BModeling%252Bof%252BProtein%252BKinases%25253A%252BCurrent%252BStatus%252Band%252BChallenges%26aulast%3DPoso%26aufirst%3DAntti%26date%3D2020%26date%3D2020%26spage%3D25%26epage%3D41%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DProteinkinase%252BInhibitors%26aulast%3DLaufer%26aufirst%3DStefan%26date%3D2021%26volume%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ireoluwa Yinka  Joel</span>, <span class="hlFld-ContribAuthor ">Temidayo Olamide  Adigun</span>, <span class="hlFld-ContribAuthor ">Olukayode Olusola  Bankole</span>, <span class="hlFld-ContribAuthor ">Mohammed Aminu  Iduze</span>, <span class="hlFld-ContribAuthor ">Tamonokorite  AbelJack-Soala</span>, <span class="hlFld-ContribAuthor ">Onyedika Gabriel  ANI</span>, <span class="hlFld-ContribAuthor ">Elijah Oluwafunto  Olapade</span>, <span class="hlFld-ContribAuthor ">Friday Micheal  Dada</span>, <span class="hlFld-ContribAuthor ">Olusola Mercy  Adetiwa</span>, <span class="hlFld-ContribAuthor ">Bankole Emmanuel  Ofeniforo</span>, <span class="hlFld-ContribAuthor ">Funmilola Olamide  Akanni</span>. </span><span class="cited-content_cbyCitation_article-title">Insights into features and lead optimization of novel type 1½ inhibitors of p38α mitogen-activated protein kinase using QSAR, quantum mechanics, bioisostere replacement and ADMET studies. </span><span class="cited-content_cbyCitation_journal-name">Results in Chemistry</span><span> <strong>2020,</strong> <em>2 </em>, 100044. <a href="https://doi.org/10.1016/j.rechem.2020.100044" title="DOI URL">https://doi.org/10.1016/j.rechem.2020.100044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.rechem.2020.100044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.rechem.2020.100044%26sid%3Dliteratum%253Aachs%26jtitle%3DResults%2520in%2520Chemistry%26atitle%3DInsights%252Binto%252Bfeatures%252Band%252Blead%252Boptimization%252Bof%252Bnovel%252Btype%252B1%2525C2%2525BD%252Binhibitors%252Bof%252Bp38%2525CE%2525B1%252Bmitogen-activated%252Bprotein%252Bkinase%252Busing%252BQSAR%25252C%252Bquantum%252Bmechanics%25252C%252Bbioisostere%252Breplacement%252Band%252BADMET%252Bstudies%26aulast%3DJoel%26aufirst%3DIreoluwa%2BYinka%26date%3D2020%26volume%3D2%26spage%3D100044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Takayoshi  Kinoshita</span>. </span><span class="cited-content_cbyCitation_article-title">Protein Allostery in Rational Drug Design. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 45-64. <a href="https://doi.org/10.1007/978-981-13-8719-7_3" title="DOI URL">https://doi.org/10.1007/978-981-13-8719-7_3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-981-13-8719-7_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-981-13-8719-7_3%26sid%3Dliteratum%253Aachs%26atitle%3DProtein%252BAllostery%252Bin%252BRational%252BDrug%252BDesign%26aulast%3DKinoshita%26aufirst%3DTakayoshi%26date%3D2019%26date%3D2019%26spage%3D45%26epage%3D64%26pub%3DSpringer%2520Singapore%26atitle%3DProtein%252BAllostery%252Bin%252BDrug%252BDiscovery%26aulast%3DZhang%26aufirst%3DJian%26date%3D2019%26volume%3D1163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Lu</span>, <span class="hlFld-ContribAuthor ">James N  Iuliano</span>, <span class="hlFld-ContribAuthor ">Peter J  Tonge</span>. </span><span class="cited-content_cbyCitation_article-title">Structure–kinetic relationships that control the residence time of drug–target complexes: insights from molecular structure and dynamics. </span><span class="cited-content_cbyCitation_journal-name">Current Opinion in Chemical Biology</span><span> <strong>2018,</strong> <em>44 </em>, 101-109. <a href="https://doi.org/10.1016/j.cbpa.2018.06.002" title="DOI URL">https://doi.org/10.1016/j.cbpa.2018.06.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cbpa.2018.06.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cbpa.2018.06.002%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Opinion%2520in%2520Chemical%2520Biology%26atitle%3DStructure%2525E2%252580%252593kinetic%252Brelationships%252Bthat%252Bcontrol%252Bthe%252Bresidence%252Btime%252Bof%252Bdrug%2525E2%252580%252593target%252Bcomplexes%25253A%252Binsights%252Bfrom%252Bmolecular%252Bstructure%252Band%252Bdynamics%26aulast%3DLu%26aufirst%3DHao%26date%3D2018%26volume%3D44%26spage%3D101%26epage%3D109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adam G.  Meyer</span>, <span class="hlFld-ContribAuthor ">Alex C.  Bissember</span>, <span class="hlFld-ContribAuthor ">Christopher J.T.  Hyland</span>, <span class="hlFld-ContribAuthor ">Charlotte C.  Williams</span>, <span class="hlFld-ContribAuthor ">Monika  Szabo</span>, <span class="hlFld-ContribAuthor ">Steven-Alan G.  Abel</span>, <span class="hlFld-ContribAuthor ">Melissa J.  Bird</span>, <span class="hlFld-ContribAuthor ">Isabel K.  Hyland</span>, <span class="hlFld-ContribAuthor ">Hoang  Pham</span>. </span><span class="cited-content_cbyCitation_article-title">Seven-Membered Rings. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 493-550. <a href="https://doi.org/10.1016/B978-0-08-102788-2.00016-7" title="DOI URL">https://doi.org/10.1016/B978-0-08-102788-2.00016-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102788-2.00016-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102788-2.00016-7%26sid%3Dliteratum%253Aachs%26atitle%3DSeven-Membered%252BRings%26aulast%3DMeyer%26aufirst%3DAdam%2BG.%26date%3D2018%26spage%3D493%26epage%3D550%26pub%3DElsevier%26date%3D2018%26volume%3D30" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0024.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00745&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Comparison of type I, type II, and type III kinase inhibitors based on representative cocrystal structures in complex with corresponding p38α MAP kinase inhibitors. (A) <b>1a</b> (white, type I) addressing the kinase’s active DFG-“in between” conformation, occupying the adenine binding site (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QUE">3QUE</a>). (B) <b>13b</b> (yellow, type II) bound to the kinase’s inactive DFG-out conformation, occupying both the adenine binding site and the deep pocket (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV2">1KV2</a>). (C) <b>13c</b> (green, type III) addressing the kinase’s inactive DFG-out conformation, occupying the deep pocket (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HV7">3HV7</a>). Hydrogen bonds are shown as yellow dots.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00745&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Assembly of the R-Spine. Crystal structures of p38α MAP kinase in complex with (A) compound <b>1b</b> targeting the active DFG-in conformation with assembled R-Spine (green) and (B) <b>13b</b> addressing the inactive DFG-out conformation with nonassembled R-Spine (white and red surfaces) (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV2">1KV2</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UVQ">3UVQ</a>). Hydrogen bonds are shown as yellow dots; regions relevant for inhibitor binding are highlighted in the background: HRII (beige), HRI (brown), deep pocket (red).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00745&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Planned design of type I<sup>1</sup>/<sub>2</sub> dibenzepinone inhibitors interfering with the R-Spine. The core template of <b>1a</b> is equipped with an additional hydrophobic moiety (HM), reaching into the R-Spine.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00745&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0028.jpeg" id="rightTab-GRAPHIC-d237e818-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Numbering Pattern of the Two Scaffolds:<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00745&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Scaffold <b>A</b>: dibenzooxepinone. Scaffold <b>B</b>: dibenzosuberone.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Preparation of the Dibenzepinones<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00745&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and reaction conditions: (i) (1) MeMgBr, THF<sub>dry</sub>, 0 °C, (2) <i>n</i>-BuLi,-78 °C, (3) dry ice, −40 °C; (ii) H<sub>2</sub>SO<sub>4</sub>, MeOH, reflux; (iii) LDA, THF<sub>dry</sub>, −78 °C; (iv) NBS, AIBN, CCl<sub>4</sub>, reflux; (v) K<sub>2</sub>CO<sub>3</sub>, Me<sub>2</sub>CO, reflux; (vi) KOH, MeOH/H<sub>2</sub>O, reflux; (vii) (1) SOCl<sub>2</sub>, DCM, reflux, (2) AlCl<sub>3</sub>, room temperature; (viii) H<sub>2</sub>SO<sub>4</sub>, MeOH, reflux; (ix) (1) CDI/TBTU, DMF, 50 °C, (2) methylamine/2-morpholin-4-ethan-1-amine, 50 °C; (x) substituted aniline derivative, Cs<sub>2</sub>CO<sub>3</sub>, X-Phos, Pd(OAc)<sub>2</sub>, 1,4-dioxane, <i>t</i>-BuOH, reflux; (xi) KOH, MeOH/H<sub>2</sub>O, reflux; (xii) CDI/TBTU, corresponding amine, DMF/DCM, 50 °C. For the nature of R<sup>1</sup>–R<sup>6</sup>, see <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of the Inverse Amides <b>37a</b>–<b>d</b> and <b>38a</b>–<b>d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00745&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and reaction conditions: (i) C<sub>2</sub>O<sub>2</sub>Cl<sub>2</sub>/SOCl<sub>2</sub>, triethylamine, DCM, room temperature; (ii) H<sub>2</sub>, Pd/C, EtOAc, room temperature. For the nature of R<sup>1</sup>–R<sup>3</sup>, see <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>.</p></p></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of the Regular Amides <b>39</b>, <b>40a</b>,<b>b</b>, <b>41a</b>–<b>g</b>, <b>42a</b>–<b>d</b>, <b>43</b>, <b>44</b>, <b>45a</b>,<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00745&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and reaction conditions: (i) (1) NaH, THF<sub>dry</sub>, room temperature, (2) acid chloride, 0 °C; (ii) (1) acid, SOCl<sub>2</sub>, reflux, (2) amine, NaH, THF<sub>dry</sub>/DMF, room temperature, (3) 1 + 2, 0 °C; (iii) H<sub>2</sub>, Pd/C, EtOAc, room temperature; (iv) SnCl<sub>2</sub>, EtOH, reflux. For the nature of R<sup>1</sup>–R<sup>3</sup> see <a class="ref internalNav" href="#tbl1" aria-label="Tables 1">Tables 1</a>–<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>.</p></p></figure><figure data-id="fig4" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cocrystal structure of type I<sup>1</sup>/<sub>2</sub> inhibitors in complex with p38α MAP kinase. (A) Detailed binding mode of <b>6j</b> (cyan) and (B) <b>8m</b> (yellow) in the kinases active site. Hydrogen bonds shown as yellow dots. (C) Overlay of the inhibitors occupying HRI (brown) and HRII (beige) (PDB codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MTY">5MTY</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MTX">5MTX</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00745&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/medium/jm-2017-00745w_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Substrate degradation and metabolite formation of compounds <b>6b</b>, <b>8b</b>, and <b>8m</b>. (A) Overview of the analyte decrease during 180 min incubation with RLM. (B) Percentage of all formed metabolites during 180 min incubation. Incubations were carried out in triplicates, and average mean values with standard deviation are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-19/acs.jmedchem.7b00745/20171006/images/large/jm-2017-00745w_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.7b00745&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i137">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77341" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77341" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 56 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Capdeville, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchdunger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matter, A.</span><span> </span><span class="NLM_article-title">Glivec (sti571, imatinib), a rationally developed, targeted anticancer drug</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">502</span><span class="refDoi"> DOI: 10.1038/nrd839</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1038%2Fnrd839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=12120256" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2002&pages=493-502&author=R.+Capdevilleauthor=E.+Buchdungerauthor=J.+Zimmermannauthor=A.+Matter&title=Glivec+%28sti571%2C+imatinib%29%2C+a+rationally+developed%2C+targeted+anticancer+drug&doi=10.1038%2Fnrd839"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug</span></div><div class="casAuthors">Capdeville, Renaud; Buchdunger, Elisabeth; Zimmermann, Juerg; Matter, Alex</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">493-502</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  In the early 1980s, it became apparent that the work of pioneers such as Robert Weinberg, Mariano Barbacid and many others in identifying cancer-causing genes in humans was opening the door to a new era in anticancer research.  Motivated by this, and by dissatisfaction with the limited efficacy and tolerability of available anticancer modalities, a drug discovery program was initiated with the aim of rationally developing targeted anticancer therapies.  Here, we describe how this program led to the discovery and continuing development of Glivec (Gleevec in the United States), the first selective tyrosine-kinase inhibitor to be approved for the treatment of a cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoeI0HV4de6ObVg90H21EOLACvtfcHk0lhCN8UhZs2bVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKlurY%253D&md5=c8f6b7a66f74b64f0dedb5e641097acc</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnrd839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd839%26sid%3Dliteratum%253Aachs%26aulast%3DCapdeville%26aufirst%3DR.%26aulast%3DBuchdunger%26aufirst%3DE.%26aulast%3DZimmermann%26aufirst%3DJ.%26aulast%3DMatter%26aufirst%3DA.%26atitle%3DGlivec%2520%2528sti571%252C%2520imatinib%2529%252C%2520a%2520rationally%2520developed%252C%2520targeted%2520anticancer%2520drug%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2002%26volume%3D1%26spage%3D493%26epage%3D502%26doi%3D10.1038%2Fnrd839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Manning, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whyte, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martinez, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sudarsanam, S.</span><span> </span><span class="NLM_article-title">The protein kinase complement of the human genome</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">298</span><span class="NLM_x">, </span> <span class="NLM_fpage">1912</span><span class="NLM_x">–</span> <span class="NLM_lpage">1934</span><span class="refDoi"> DOI: 10.1126/science.1075762</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1126%2Fscience.1075762" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=12471243" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=298&publication_year=2002&pages=1912-1934&author=G.+Manningauthor=D.+B.+Whyteauthor=R.+Martinezauthor=T.+Hunterauthor=S.+Sudarsanam&title=The+protein+kinase+complement+of+the+human+genome&doi=10.1126%2Fscience.1075762"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The Protein Kinase Complement of the Human Genome</span></div><div class="casAuthors">Manning, G.; Whyte, D. B.; Martinez, R.; Hunter, T.; Sudarsanam, S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">298</span>
        (<span class="NLM_cas:issue">5600</span>),
    <span class="NLM_cas:pages">1912-1916, 1933-1934</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">We have catalogued the protein kinase complement of the human genome (the "kinome") using public and proprietary genomic, complementary DNA, and expressed sequence tag (EST) sequences.  This provides a starting point for comprehensive anal. of protein phosphorylation in normal and disease states, as well as a detailed view of the current state of human genome anal. through a focus on one large gene family.  We identify 518 putative protein kinase genes, of which 71 have not previously been reported or described as kinases, and we extend or correct the protein sequences of 56 more kinases.  New genes include members of well-studied families as well as previously unidentified families, some of which are conserved in model organisms.  Classification and comparison with model organism kinomes identified orthologous groups and highlighted expansions specific to human and other lineages.  We also identified 106 protein kinase pseudogenes.  Chromosomal mapping revealed several small clusters of kinase genes and revealed that 244 kinases map to disease loci or cancer amplicons.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpTj1hf_0cQcrVg90H21EOLACvtfcHk0lhCN8UhZs2bVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xpt1Wisb0%253D&md5=b3def83bace52257a3252a3347b8bb92</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1126%2Fscience.1075762&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1075762%26sid%3Dliteratum%253Aachs%26aulast%3DManning%26aufirst%3DG.%26aulast%3DWhyte%26aufirst%3DD.%2BB.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DHunter%26aufirst%3DT.%26aulast%3DSudarsanam%26aufirst%3DS.%26atitle%3DThe%2520protein%2520kinase%2520complement%2520of%2520the%2520human%2520genome%26jtitle%3DScience%26date%3D2002%26volume%3D298%26spage%3D1912%26epage%3D1934%26doi%3D10.1126%2Fscience.1075762" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span>Cell Signaling Technology Inc. Kinase-disease associations. <a href="https://www.cellsignal.com/common/content/content.jsp?id=science-tables-kinase-disease" class="extLink">https://www.cellsignal.com/common/content/content.jsp?id=science-tables-kinase-disease</a> (accessed June 19,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Cell+Signaling+Technology+Inc.+Kinase-disease+associations.+https%3A%2F%2Fwww.cellsignal.com%2Fcommon%2Fcontent%2Fcontent.jsp%3Fid%3Dscience-tables-kinase-disease+%28accessed+June+19%2C+2017%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, A.</span><span> </span><span class="NLM_article-title">Novel strategies for inhibition of the p38 mapk pathway</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">286</span><span class="NLM_x">–</span> <span class="NLM_lpage">295</span><span class="refDoi"> DOI: 10.1016/j.tips.2007.04.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1016%2Fj.tips.2007.04.008" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2007&pages=286-295&author=J.+Zhangauthor=B.+Shenauthor=A.+Lin&title=Novel+strategies+for+inhibition+of+the+p38+mapk+pathway&doi=10.1016%2Fj.tips.2007.04.008"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2007.04.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2007.04.008%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DB.%26aulast%3DLin%26aufirst%3DA.%26atitle%3DNovel%2520strategies%2520for%2520inhibition%2520of%2520the%2520p38%2520mapk%2520pathway%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2007%26volume%3D28%26spage%3D286%26epage%3D295%26doi%3D10.1016%2Fj.tips.2007.04.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Schett, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zwerina, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Firestein, G.</span><span> </span><span class="NLM_article-title">The p38 mitogen-activated protein kinase (mapk) pathway in rheumatoid arthritis</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">909</span><span class="NLM_x">–</span> <span class="NLM_lpage">916</span><span class="refDoi"> DOI: 10.1136/ard.2007.074278</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1136%2Fard.2007.074278" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=17827184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslChsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2008&pages=909-916&author=G.+Schettauthor=J.+Zwerinaauthor=G.+Firestein&title=The+p38+mitogen-activated+protein+kinase+%28mapk%29+pathway+in+rheumatoid+arthritis&doi=10.1136%2Fard.2007.074278"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis</span></div><div class="casAuthors">Schett, G.; Zwerina, J.; Firestein, G.</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the Rheumatic Diseases</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">909-916</span>CODEN:
                <span class="NLM_cas:coden">ARDIAO</span>;
        ISSN:<span class="NLM_cas:issn">0003-4967</span>.
    
            (<span class="NLM_cas:orgname">BMJ Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chronic inflammatory processes are based on a sustained and tightly regulated communication network among different cells types.  This network comprises extracellular mediators such as cytokines, chemokines and matrix-degrading proteases, which orchestrate the participation of cells in the chronic inflammatory process.  The mirrors of this outside communication world are intracellular transcription factor pathways, which shuttle information about inflammatory stimuli to the cell nucleus.  This review examines the function of one key signal transduction pathway of inflammation-the p38 mitogen-activated protein kinases (p38MAPK).  The signalling pathway is considered as crucial for the induction and maintenance of chronic inflammation, and its components thus emerge as interesting mol. targets of small mol. inhibitors for controlling inflammation.  This review not only summarizes the current knowledge of activation, regulation and function of the p38MAPK pathway but also examines the role of this pathway in clin. disease.  It gives an overview of current evidence of p38MAPK activation in inflammatory arthritis and elaborates the key mol. determinants which contribute to p38MAPK activation in joint disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVrSODN-vBCrVg90H21EOLACvtfcHk0ljhl8qNa2-ZgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslChsL4%253D&md5=eafcfc4d371a539ef290edc39792ce33</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1136%2Fard.2007.074278&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fard.2007.074278%26sid%3Dliteratum%253Aachs%26aulast%3DSchett%26aufirst%3DG.%26aulast%3DZwerina%26aufirst%3DJ.%26aulast%3DFirestein%26aufirst%3DG.%26atitle%3DThe%2520p38%2520mitogen-activated%2520protein%2520kinase%2520%2528mapk%2529%2520pathway%2520in%2520rheumatoid%2520arthritis%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2008%26volume%3D67%26spage%3D909%26epage%3D916%26doi%3D10.1136%2Fard.2007.074278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Tsai, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nussinov, R.</span><span> </span><span class="NLM_article-title">The molecular basis of targeting protein kinases in cancer therapeutics</span> <span class="citation_source-journal">Semin. Cancer Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">235</span><span class="NLM_x">–</span> <span class="NLM_lpage">242</span><span class="refDoi"> DOI: 10.1016/j.semcancer.2013.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1016%2Fj.semcancer.2013.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=23651790" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC3sXovVCks74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=235-242&author=C.+J.+Tsaiauthor=R.+Nussinov&title=The+molecular+basis+of+targeting+protein+kinases+in+cancer+therapeutics&doi=10.1016%2Fj.semcancer.2013.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The molecular basis of targeting protein kinases in cancer therapeutics</span></div><div class="casAuthors">Tsai, Chung-Jung; Nussinov, Ruth</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Cancer Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-242</span>CODEN:
                <span class="NLM_cas:coden">SECBE7</span>;
        ISSN:<span class="NLM_cas:issn">1044-579X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  In this paper, we provide an overview of targeted anticancer therapies with small mol. kinase inhibitors.  First, we discuss why a single constitutively active kinase emanating from a variety of aberrant genetic alterations is capable of transforming a normal cell, leading it to acquire the hallmarks of a cancer cell.  To draw attention to the fact that kinase inhibition in targeted cancer therapeutics differs from conventional cytotoxic chemotherapy, we exploit a conceptual framework explaining why suppressed kinase activity will selectively kill only the so-called oncogene 'addicted' cancer cell, while sparing the healthy cell.  Second, we introduce the protein kinase superfamily in light of its common active conformation with precisely positioned structural elements, and the diversified auto-inhibitory conformations among the kinase families.  Understanding the detailed activation mechanism of individual kinases is essential to relate the obsd. oncogenic alterations to the elevated constitutively active state, to identify the mechanism of consequent drug resistance, and to guide the development of the next-generation inhibitors.  To clarify the vital importance of structural guidelines in studies of oncogenesis, we explain how somatic mutations in EGFR result in kinase constitutive activation.  Third, in addn. to the common theme of secondary (acquired) mutations that prevent drug binding from blocking a signaling pathway which is hijacked by the aberrant activated kinase, we discuss scenarios of drug resistance and relapse by compensating lesions that bypass the inactivated pathway in a vertical or horizontal fashion.  Collectively, these suggest that the future challenge of cancer therapy with small mol. kinase inhibitors will rely on the discovery of distinct combinations of optimized drugs to target individual subtypes of different cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon6j95mBzDh7Vg90H21EOLACvtfcHk0ljhl8qNa2-ZgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXovVCks74%253D&md5=0359b4bc5b0aae4740c1eacbb1eba083</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.semcancer.2013.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.semcancer.2013.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DC.%2BJ.%26aulast%3DNussinov%26aufirst%3DR.%26atitle%3DThe%2520molecular%2520basis%2520of%2520targeting%2520protein%2520kinases%2520in%2520cancer%2520therapeutics%26jtitle%3DSemin.%2520Cancer%2520Biol.%26date%3D2013%26volume%3D23%26spage%3D235%26epage%3D242%26doi%3D10.1016%2Fj.semcancer.2013.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Wagey, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krieger, C.</span><span> </span><span class="NLM_article-title">Abnormalities of protein kinases in neurodegenerative diseases</span> <span class="citation_source-journal">Prog. Drug Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">133</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span><span class="refDoi"> DOI: 10.1007/978-3-0348-8845-5_4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1007%2F978-3-0348-8845-5_4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=9949861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADyaK1MXitlKmsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1998&pages=133-183&author=R.+T.+Wageyauthor=C.+Krieger&title=Abnormalities+of+protein+kinases+in+neurodegenerative+diseases&doi=10.1007%2F978-3-0348-8845-5_4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Abnormalities of protein kinases in neurodegenerative diseases</span></div><div class="casAuthors">Wagey, Ravenska T. E.; Krieger, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Drug Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">133-183</span>CODEN:
                <span class="NLM_cas:coden">FAZMAE</span>;
        ISSN:<span class="NLM_cas:issn">0071-786X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review with 248 refs. is given on neurodegenerative diseases, esp. amyotrophic lateral sclerosis and Alzheimer's disease, in relation to evidence of altered protein phosphorylation.  Pathogenesis and treatment, mechanisms of cell death, signal transduction, the role of excitatory amino acid and protein phosphorylation, and current model systems in research are discussed.  Evidence of impairment in protein kinase signalling may be a primary cause, a secondary event, or a compensatory mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrh5IjTF6sWo7Vg90H21EOLACvtfcHk0ljhl8qNa2-ZgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXitlKmsw%253D%253D&md5=643f2900faff6fb537d57bb2d9886a22</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1007%2F978-3-0348-8845-5_4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-3-0348-8845-5_4%26sid%3Dliteratum%253Aachs%26aulast%3DWagey%26aufirst%3DR.%2BT.%26aulast%3DKrieger%26aufirst%3DC.%26atitle%3DAbnormalities%2520of%2520protein%2520kinases%2520in%2520neurodegenerative%2520diseases%26jtitle%3DProg.%2520Drug%2520Res.%26date%3D1998%26volume%3D51%26spage%3D133%26epage%3D183%26doi%3D10.1007%2F978-3-0348-8845-5_4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Vlahopoulos, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Logotheti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikas, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giarika, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorgoulis, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zoumpourlis, V.</span><span> </span><span class="NLM_article-title">The role of atf-2 in oncogenesis</span> <span class="citation_source-journal">BioEssays</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">–</span> <span class="NLM_lpage">327</span><span class="refDoi"> DOI: 10.1002/bies.20734</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1002%2Fbies.20734" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2008&pages=314-327&author=S.+A.+Vlahopoulosauthor=S.+Logothetiauthor=D.+Mikasauthor=A.+Giarikaauthor=V.+Gorgoulisauthor=V.+Zoumpourlis&title=The+role+of+atf-2+in+oncogenesis&doi=10.1002%2Fbies.20734"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fbies.20734&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fbies.20734%26sid%3Dliteratum%253Aachs%26aulast%3DVlahopoulos%26aufirst%3DS.%2BA.%26aulast%3DLogotheti%26aufirst%3DS.%26aulast%3DMikas%26aufirst%3DD.%26aulast%3DGiarika%26aufirst%3DA.%26aulast%3DGorgoulis%26aufirst%3DV.%26aulast%3DZoumpourlis%26aufirst%3DV.%26atitle%3DThe%2520role%2520of%2520atf-2%2520in%2520oncogenesis%26jtitle%3DBioEssays%26date%3D2008%26volume%3D30%26spage%3D314%26epage%3D327%26doi%3D10.1002%2Fbies.20734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Cuenda, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rousseau, S.</span><span> </span><span class="NLM_article-title">P38 map-kinases pathway regulation, function and role in human diseases</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Mol. Cell Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">1773</span><span class="NLM_x">, </span> <span class="NLM_fpage">1358</span><span class="NLM_x">–</span> <span class="NLM_lpage">1375</span><span class="refDoi"> DOI: 10.1016/j.bbamcr.2007.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1016%2Fj.bbamcr.2007.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=17481747" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD2sXosFyktr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1773&publication_year=2007&pages=1358-1375&author=A.+Cuendaauthor=S.+Rousseau&title=P38+map-kinases+pathway+regulation%2C+function+and+role+in+human+diseases&doi=10.1016%2Fj.bbamcr.2007.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">p38 MAP-Kinases pathway regulation, function and role in human diseases</span></div><div class="casAuthors">Cuenda, Ana; Rousseau, Simon</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Molecular Cell Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">1773</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1358-1375</span>CODEN:
                <span class="NLM_cas:coden">BBAMCO</span>;
        ISSN:<span class="NLM_cas:issn">0167-4889</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Mammalian p38 mitogen-activated protein kinases (MAPKs) are activated by a wide range of cellular stresses as well as in response to inflammatory cytokines.  There are four members of the p38MAPK family (p38α, p38β, p38γ and p38δ) which are about 60% identical in their amino acid sequence but differ in their expression patterns, substrate specificities and sensitivities to chem. inhibitors such as SB203580.  A large body of evidences indicates that p38MAPK activity is crit. for normal immune and inflammatory response.  The p38MAPK pathway is a key regulator of pro-inflammatory cytokines biosynthesis at the transcriptional and translational levels, which makes different components of this pathway potential targets for the treatment of autoimmune and inflammatory diseases.  However, recent studies have shed light on the broad effect of p38MAPK activation in the control of many other aspects of the physiol. of the cell, such as control of cell cycle or cytoskeleton remodelling.  Here we focus on these emergent roles of p38MAPKs and their implication in different pathologies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNYx9ozz5qArVg90H21EOLACvtfcHk0lgi7oFJpR8Jdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXosFyktr0%253D&md5=ca9b5a57fd95eee52cca68f3f0da1f15</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bbamcr.2007.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbamcr.2007.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DCuenda%26aufirst%3DA.%26aulast%3DRousseau%26aufirst%3DS.%26atitle%3DP38%2520map-kinases%2520pathway%2520regulation%252C%2520function%2520and%2520role%2520in%2520human%2520diseases%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Mol.%2520Cell%2520Res.%26date%3D2007%26volume%3D1773%26spage%3D1358%26epage%3D1375%26doi%3D10.1016%2Fj.bbamcr.2007.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Fabbro, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowan-Jacob, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mobitz, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martiny-Baron, G.</span><span> </span><span class="NLM_article-title">Targeting cancer with small-molecular-weight kinase inhibitors</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">795</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">34</span><span class="refDoi"> DOI: 10.1007/978-1-61779-337-0_1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1007%2F978-1-61779-337-0_1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=21960212" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlersLrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=795&publication_year=2012&pages=1-34&author=D.+Fabbroauthor=S.+W.+Cowan-Jacobauthor=H.+Mobitzauthor=G.+Martiny-Baron&title=Targeting+cancer+with+small-molecular-weight+kinase+inhibitors&doi=10.1007%2F978-1-61779-337-0_1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting cancer with small-molecular-weight kinase inhibitors</span></div><div class="casAuthors">Fabbro, Doriano; Cowan-Jacob, Sandra W.; Mobitz, Henrik; Martiny-Baron, Georg</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">795</span>
        (<span class="NLM_cas:issue">Kinase Inhibitors</span>),
    <span class="NLM_cas:pages">1-34</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1064-3745</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">A review.  Protein and lipid kinases fulfill essential roles in many signaling pathways that regulate normal cell functions.  Deregulation of these kinase activities lead to a variety of pathologies ranging from cancer to inflammatory diseases, diabetes, infectious diseases, cardiovascular disorders, cell growth and survival.  518 Protein kinases and about 20 lipid-modifying kinases are encoded by the human genome, and a much larger proportion of addnl. kinases are present in parasite, bacterial, fungal, and viral genomes that are susceptible to exploitation as drug targets.  Since many human diseases result from overactivation of protein and lipid kinases due to mutations and/or overexpression, this enzyme class represents an important target for the pharmaceutical industry.  Approx. one third of all protein targets under investigation in the pharmaceutical industry are protein or lipid kinases.  The kinase inhibitors that have been launched, thus far, are mainly in oncol. indications and are directed against a handful of protein and lipid kinases.  With one exception, all of these registered kinase inhibitors are directed toward the ATP-site and display different selectivities, potencies, and pharmacokinetic properties.  At present, about 150 kinase-targeted drugs are in clin. development and many more in various stages of preclin. development.  Kinase inhibitor drugs that are in clin. trials target all stages of signal transduction from the receptor protein tyrosine kinases that initiate intracellular signaling, through second-messenger-dependent lipid and protein kinases, and protein kinases that regulate the cell cycle.  This review provides an insight into protein and lipid kinase drug discovery with respect to achievements, binding modes of inhibitors, and novel avenues for the generation of second-generation kinase inhibitors to treat cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR2s-rg3sGDbVg90H21EOLACvtfcHk0lgi7oFJpR8Jdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlersLrI&md5=f5b030e41ace1007efacda9f34d898db</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1007%2F978-1-61779-337-0_1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-61779-337-0_1%26sid%3Dliteratum%253Aachs%26aulast%3DFabbro%26aufirst%3DD.%26aulast%3DCowan-Jacob%26aufirst%3DS.%2BW.%26aulast%3DMobitz%26aufirst%3DH.%26aulast%3DMartiny-Baron%26aufirst%3DG.%26atitle%3DTargeting%2520cancer%2520with%2520small-molecular-weight%2520kinase%2520inhibitors%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2012%26volume%3D795%26spage%3D1%26epage%3D34%26doi%3D10.1007%2F978-1-61779-337-0_1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span>Blue Ridge Institute for Medical Research. USFDA approved protein kinase inhibitors. <a href="http://www.brimr.org/PKI/PKIs.htm" class="extLink">http://www.brimr.org/PKI/PKIs.htm</a> (accessed June 19,<span class="NLM_x"> </span><span class="NLM_year">2017</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Blue+Ridge+Institute+for+Medical+Research.+USFDA+approved+protein+kinase+inhibitors.+http%3A%2F%2Fwww.brimr.org%2FPKI%2FPKIs.htm+%28accessed+June+19%2C+2017%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boehm, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span> </span><span class="NLM_article-title">P38 map kinases: Key signalling molecules as therapeutic targets for inflammatory diseases</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">717</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span><span class="refDoi"> DOI: 10.1038/nrd1177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1038%2Fnrd1177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=12951578" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmvVWlsbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2003&pages=717-726&author=S.+Kumarauthor=J.+Boehmauthor=J.+C.+Lee&title=P38+map+kinases%3A+Key+signalling+molecules+as+therapeutic+targets+for+inflammatory+diseases&doi=10.1038%2Fnrd1177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases</span></div><div class="casAuthors">Kumar, Sanjay; Boehm, Jeffrey; Lee, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">717-726</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The p38 MAP kinases are a family of serine/threonine protein kinases that play important roles in cellular responses to external stress signals.  Since their identification about 10 yr ago, much has been learned of the activation and regulation of the p38 MAP kinase pathways.  Inhibitors of two members of the p38 family have been shown to have anti-inflammatory effects in preclin. disease models, primarily through the inhibition of the expression of inflammatory mediators.  Several promising compds. have also progressed to clin. trials.  In this review, we provide an overview of the role of p38 MAP kinases in stress-activated pathways and the progress towards clin. development of p38 MAP kinase inhibitors in the treatment of inflammatory diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHXx_X3Trc8bVg90H21EOLACvtfcHk0lgi7oFJpR8Jdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmvVWlsbw%253D&md5=282ccf8914c252db2228c6590f8e5a13</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrd1177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1177%26sid%3Dliteratum%253Aachs%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DBoehm%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DP38%2520map%2520kinases%253A%2520Key%2520signalling%2520molecules%2520as%2520therapeutic%2520targets%2520for%2520inflammatory%2520diseases%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2003%26volume%3D2%26spage%3D717%26epage%3D726%26doi%3D10.1038%2Fnrd1177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Dambach, D. M.</span><span> </span><span class="NLM_article-title">Potential adverse effects associated with inhibition of p38alpha/beta map kinases</span> <span class="citation_source-journal">Curr. Top. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">929</span><span class="NLM_x">–</span> <span class="NLM_lpage">939</span><span class="refDoi"> DOI: 10.2174/1568026054985911</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.2174%2F1568026054985911" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=16178738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFeitrbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2005&pages=929-939&author=D.+M.+Dambach&title=Potential+adverse+effects+associated+with+inhibition+of+p38alpha%2Fbeta+map+kinases&doi=10.2174%2F1568026054985911"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Potential adverse effects associated with inhibition of p38α/β MAP kinases</span></div><div class="casAuthors">Dambach, Donna M.</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">929-939</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Inhibitors of p38 MAP kinases show promise for the treatment of inflammatory and immunol. disorders and some cancers.  There is a substantial body of exptl. evidence across several organ systems suggesting that p38 also mediates developmental, differentiation and proliferation processes.  As a consequence of the wide-ranging regulatory role of p38 kinase in diverse cellular processes, the possibility of adverse events resulting from undesired pharmacol. activity is a major concern for the p38 inhibitor drug class.  Taking into consideration the limitations of exptl. modeling systems, together the data may indicate that profound inhibition of p38 has the potential to impact these processes during fetal or neonatal development.  The difficulty comes in extrapolating these findings to predict potential adverse effects under conditions of partial inhibition of p38 activity, and in an adult population in which these processes are typically only recapitulated during repair or adaptive responses.  As such, the goal of this review of the targets of p38 activity is to bring an awareness of the those organ systems that should be monitored for potential toxicity, as well as to present a potential mechanistic basis for such monitoring or for investigation of adverse effects that may develop with administration of a p38 inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9YoS9QjJnfrVg90H21EOLACvtfcHk0lhbzq4EqUfSiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFeitrbM&md5=ece8a45395222f3039bc51485453ac15</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.2174%2F1568026054985911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026054985911%26sid%3Dliteratum%253Aachs%26aulast%3DDambach%26aufirst%3DD.%2BM.%26atitle%3DPotential%2520adverse%2520effects%2520associated%2520with%2520inhibition%2520of%2520p38alpha%252Fbeta%2520map%2520kinases%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2005%26volume%3D5%26spage%3D929%26epage%3D939%26doi%3D10.2174%2F1568026054985911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Cohen, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chindalore, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damjanov, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burgos-Vargas, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delora, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimany, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caulfield, J. P.</span><span> </span><span class="NLM_article-title">Evaluation of the efficacy and safety of pamapimod, a p38 map kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">335</span><span class="NLM_x">–</span> <span class="NLM_lpage">344</span><span class="refDoi"> DOI: 10.1002/art.24266</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1002%2Fart.24266" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=19180516" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjt1CgtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=335-344&author=S.+B.+Cohenauthor=T.+T.+Chengauthor=V.+Chindaloreauthor=N.+Damjanovauthor=R.+Burgos-Vargasauthor=P.+Deloraauthor=K.+Zimanyauthor=H.+Traversauthor=J.+P.+Caulfield&title=Evaluation+of+the+efficacy+and+safety+of+pamapimod%2C+a+p38+map+kinase+inhibitor%2C+in+a+double-blind%2C+methotrexate-controlled+study+of+patients+with+active+rheumatoid+arthritis&doi=10.1002%2Fart.24266"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active Rheumatoid arthritis</span></div><div class="casAuthors">Cohen, Stanley B.; Cheng, Tien-Tsai; Chindalore, Vishala; Damjanov, Nemanja; Burgos-Vargas, Ruben; DeLora, Patricia; Zimany, Kathleen; Travers, Helen; Caulfield, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">335-344</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: To det. the efficacy and safety of pamapimod (a selective inhibitor of the α-isoform of p38 MAP kinase) as monotherapy in comparison with methotrexate (MTX) treatment in adult patients with active rheumatoid arthritis (RA).  Methods: Patients were randomly assigned to 1 of 4 treatment groups and received 12 wk of double-blind treatment.  One group received MTX (7.5 mg/wk with planned escalation to 20 mg/wk), and 3 groups received pamapimod (50, 150, or 300 mg) once daily.  The primary efficacy end point was the proportion of patients meeting the American College of Rheumatol. 20% improvement criteria (achieving an ACR20 response) at 12 wk.  Secondary end points included ACR50 and ACR70 responses, change from baseline in the Disease Activity Score in 28 joints (DAS28), categorical analyses of DAS28/European League Against Rheumatism response, and change from baseline in each parameter of the ACR core set of measures.  Safety monitoring included recording of adverse events (AEs), lab. testing, immunol. assessments, administration of electrocardiograms, and assessment of vital signs.  Results: Patients assigned to receive MTX and pamapimod had similar demographics and baseline characteristics.  At week 12, fewer patients taking pamapimod had an ACR20 response (23%, 18%, and 31% in the 50-, 150-, and 300-mg groups, resp.) compared with patients taking MTX (45%).  Secondary efficacy end points showed a similar pattern.  AEs were typically characterized as mild and included infections, skin disorders, and dizziness.  Pamapimod was generally well tolerated, but the 300-mg dose appeared to be more toxic than either the 2 lower doses or MTX.  Conclusion: The present results showed that pamapimod was not as effective as MTX in the treatment of active RA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp98GB6seTS2rVg90H21EOLACvtfcHk0lhbzq4EqUfSiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjt1CgtL4%253D&md5=d76a0ea256ab02b1c16d388be13c2f3e</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1002%2Fart.24266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24266%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DS.%2BB.%26aulast%3DCheng%26aufirst%3DT.%2BT.%26aulast%3DChindalore%26aufirst%3DV.%26aulast%3DDamjanov%26aufirst%3DN.%26aulast%3DBurgos-Vargas%26aufirst%3DR.%26aulast%3DDelora%26aufirst%3DP.%26aulast%3DZimany%26aufirst%3DK.%26aulast%3DTravers%26aufirst%3DH.%26aulast%3DCaulfield%26aufirst%3DJ.%2BP.%26atitle%3DEvaluation%2520of%2520the%2520efficacy%2520and%2520safety%2520of%2520pamapimod%252C%2520a%2520p38%2520map%2520kinase%2520inhibitor%252C%2520in%2520a%2520double-blind%252C%2520methotrexate-controlled%2520study%2520of%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D335%26epage%3D344%26doi%3D10.1002%2Fart.24266" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Schreiber, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feagan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Haens, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colombel, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geboes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yurcov, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isakov, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golovenko, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernstein, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludwig, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winter, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steffgen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">BIRB 796 Study Group.</span><span> </span><span class="NLM_article-title">Oral p38 mitogen-activated protein kinase inhibition with birb 796 for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial</span> <span class="citation_source-journal">Clin. Gastroenterol. Hepatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">325</span><span class="NLM_x">–</span> <span class="NLM_lpage">334</span><span class="refDoi"> DOI: 10.1016/j.cgh.2005.11.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1016%2Fj.cgh.2005.11.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=16527696" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD28XjsFOqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2006&pages=325-334&author=S.+Schreiberauthor=B.+Feaganauthor=G.+D%E2%80%99Haensauthor=J.+F.+Colombelauthor=K.+Geboesauthor=M.+Yurcovauthor=V.+Isakovauthor=O.+Golovenkoauthor=C.+N.+Bernsteinauthor=D.+Ludwigauthor=T.+Winterauthor=U.+Meierauthor=C.+Yongauthor=J.+Steffgenauthor=BIRB+796+Study+Group.&title=Oral+p38+mitogen-activated+protein+kinase+inhibition+with+birb+796+for+active+Crohn%E2%80%99s+disease%3A+a+randomized%2C+double-blind%2C+placebo-controlled+trial&doi=10.1016%2Fj.cgh.2005.11.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double- blind, placebo- controlled trial</span></div><div class="casAuthors">Schreiber, Stefan; Feagan, Brian; D'Haens, Geert; Colombel, Jean-Frederic; Geboes, Karel; Yurcov, Mikhail; Isakov, Vasily; Golovenko, Oleg; Bernstein, Charles N.; Ludwig, Diether; Winter, Trevor; Meier, Ulrich; Yong, Chan; Steffgen, Juergen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Gastroenterology and Hepatology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">325-334</span>CODEN:
                <span class="NLM_cas:coden">CGHLAW</span>;
        ISSN:<span class="NLM_cas:issn">1542-3565</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The p38 mitogen-activated protein kinase (MAPK) regulates the expression of proinflammatory cytokines, which play a crit. role in the pathophysiol. of Crohn's disease (CD).  This study investigated the efficacy and safety of BIRB 796, a highly potent inhibitor of p38 MAPK, in chronic active CD.  In a multicenter, multinational trial, 284 patients with moderate to severe CD were randomized to receive placebo, or 10, 20, 30, or 60 mg of BIRB 796 twice daily for 8 wk.  Clin. endpoints were based on std. safety assessments, CD Activity Index, C-reactive protein levels, and quality of life (Inflammatory Bowel Disease Questionnaire).  In a substudy, the Crohn's Disease Endoscopic Index of Severity and histol. results of biopsy specimens were assessed.  No clin. efficacy (primary end point, clin. remission; secondary end point, clin. response; Inflammatory Bowel Disease Questionnaire; Crohn's Disease Endoscopic Index of Severity) was seen for BIRB 796 in comparison with placebo.  A significant, dose-dependent decrease of C-reactive protein level was obsd. transiently after BIRB 796 after 1 wk with a return to baseline level over time.  The incidence of adverse events was comparable between all treatment groups, with the exception of a mild increase of transaminase levels that was seen more frequently in the BIRB 796 groups.  Geog. center effects were obsd. with Russian centers producing distinctly higher remission and response rates and lower adverse event rates than in other countries in both placebo and active treatment groups.  There was no evidence for clin. efficacy of BIRB 796 in CD.  A remarkable difference in the course of CD exists between Russia and non-Russian centers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPlk4HFJbHhrVg90H21EOLACvtfcHk0lhbzq4EqUfSiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XjsFOqsrs%253D&md5=f99fbaeea2b16c7e5fa11069b99518f1</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.cgh.2005.11.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cgh.2005.11.013%26sid%3Dliteratum%253Aachs%26aulast%3DSchreiber%26aufirst%3DS.%26aulast%3DFeagan%26aufirst%3DB.%26aulast%3DD%25E2%2580%2599Haens%26aufirst%3DG.%26aulast%3DColombel%26aufirst%3DJ.%2BF.%26aulast%3DGeboes%26aufirst%3DK.%26aulast%3DYurcov%26aufirst%3DM.%26aulast%3DIsakov%26aufirst%3DV.%26aulast%3DGolovenko%26aufirst%3DO.%26aulast%3DBernstein%26aufirst%3DC.%2BN.%26aulast%3DLudwig%26aufirst%3DD.%26aulast%3DWinter%26aufirst%3DT.%26aulast%3DMeier%26aufirst%3DU.%26aulast%3DYong%26aufirst%3DC.%26aulast%3DSteffgen%26aufirst%3DJ.%26aulast%3D%26atitle%3DOral%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibition%2520with%2520birb%2520796%2520for%2520active%2520Crohn%25E2%2580%2599s%2520disease%253A%2520a%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%2520trial%26jtitle%3DClin.%2520Gastroenterol.%2520Hepatol.%26date%3D2006%26volume%3D4%26spage%3D325%26epage%3D334%26doi%3D10.1016%2Fj.cgh.2005.11.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Genovese, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wofsy, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinblatt, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Firestein, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brahn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strand, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baker, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, S. E.</span><span> </span><span class="NLM_article-title">A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral scio-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arthritis</span> <span class="citation_source-journal">J. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">38</span><span class="NLM_x">, </span> <span class="NLM_fpage">846</span><span class="NLM_x">–</span> <span class="NLM_lpage">854</span><span class="refDoi"> DOI: 10.3899/jrheum.100602</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.3899%2Fjrheum.100602" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=21285160" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC3MXnvVeitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2011&pages=846-854&author=M.+C.+Genoveseauthor=S.+B.+Cohenauthor=D.+Wofsyauthor=M.+E.+Weinblattauthor=G.+S.+Firesteinauthor=E.+Brahnauthor=V.+Strandauthor=D.+G.+Bakerauthor=S.+E.+Tong&title=A+24-week%2C+randomized%2C+double-blind%2C+placebo-controlled%2C+parallel+group+study+of+the+efficacy+of+oral+scio-469%2C+a+p38+mitogen-activated+protein+kinase+inhibitor%2C+in+patients+with+active+rheumatoid+arthritis&doi=10.3899%2Fjrheum.100602"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in patients with active rheumatoid arhritis</span></div><div class="casAuthors">Genovese, Mark C.; Cohen, Stanley B.; Wofsy, David; Weinblatt, Michael E.; Firestein, Gary S.; Brahn, Ernest; Strand, Vibeke; Baker, Daniel G.; Tong, Sandra E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Rheumatology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">846-854</span>CODEN:
                <span class="NLM_cas:coden">JRHUA9</span>;
        ISSN:<span class="NLM_cas:issn">0315-162X</span>.
    
            (<span class="NLM_cas:orgname">Journal of Rheumatology Publishing Co. Ltd.</span>)
        </div><div class="casAbstract">Objective: To evaluate the efficacy, safety, and tolerability of oral SCIO-469, a p38 MAPK inhibitor that blocks tumor necrosis factor-α, interleukin-1β, and cyclooxygenase-2 synthesis in patients with active rheumatoid arthritis (RA).  Methods: Patients were randomized to receive SCIO-469 at either 30 or 60 mg three times daily in an immediate-release (IR) formulation or at 100 mg once daily in an extended-release (ER) formulation, or placebo for 24 wk.  The primary endpoint was American College of Rheumatol. (ACR)20 response at week 12.  Safety was monitored through Week 26.  Results: Overall, 302 patients were randomized: 76 to placebo, 75 to 30 mg IR, 73 to 60 mg IR, and 78 to 100 mg ER.  There were no significant differences in ACR20 responses at week 12 between SCIO-469 and placebo.  Declines in C-reactive protein and erythrocyte sedimentation rate during early treatment did not persist to week 12 and were not a consequence of decreased SCIO-469 plasma levels.  The 60 mg IR regimen showed a dose-limiting toxicity manifested by elevations in alanine aminotransferase.  Adverse events were common in all groups (79.7% and 86.7% through 13 and 26 wk, resp.).  Twenty-one patients reported 28 serious adverse events (SAE).  SAE were more common with IR SCIO-469 than with placebo (7% vs 4%) but were not reported with ER SCIO-469.  Conclusion: In all regimens tested, SCIO-469 showed no greater efficacy compared to placebo in patients with RA.  The transient effect of SCIO-469 on acute-phase reactants suggests a complex role of p38 MAPK in inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbaWHdpEn1jLVg90H21EOLACvtfcHk0litAF-8u5fgMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXnvVeitrw%253D&md5=2249e455ce2936a8aa881aab6af3db92</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.3899%2Fjrheum.100602&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3899%252Fjrheum.100602%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DCohen%26aufirst%3DS.%2BB.%26aulast%3DWofsy%26aufirst%3DD.%26aulast%3DWeinblatt%26aufirst%3DM.%2BE.%26aulast%3DFirestein%26aufirst%3DG.%2BS.%26aulast%3DBrahn%26aufirst%3DE.%26aulast%3DStrand%26aufirst%3DV.%26aulast%3DBaker%26aufirst%3DD.%2BG.%26aulast%3DTong%26aufirst%3DS.%2BE.%26atitle%3DA%252024-week%252C%2520randomized%252C%2520double-blind%252C%2520placebo-controlled%252C%2520parallel%2520group%2520study%2520of%2520the%2520efficacy%2520of%2520oral%2520scio-469%252C%2520a%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520active%2520rheumatoid%2520arthritis%26jtitle%3DJ.%2520Rheumatol.%26date%3D2011%26volume%3D38%26spage%3D846%26epage%3D854%26doi%3D10.3899%2Fjrheum.100602" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Zuccotto, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ardini, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casale, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angiolini, M.</span><span> </span><span class="NLM_article-title">Through the “gatekeeper door”: Exploiting the active kinase conformation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">2681</span><span class="NLM_x">–</span> <span class="NLM_lpage">2694</span><span class="refDoi"> DOI: 10.1021/jm901443h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901443h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGhtb3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=2681-2694&author=F.+Zuccottoauthor=E.+Ardiniauthor=E.+Casaleauthor=M.+Angiolini&title=Through+the+%E2%80%9Cgatekeeper+door%E2%80%9D%3A+Exploiting+the+active+kinase+conformation&doi=10.1021%2Fjm901443h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Through the "Gatekeeper Door": Exploiting the Active Kinase Conformation</span></div><div class="casAuthors">Zuccotto, Fabio; Ardini, Elena; Casale, Elena; Angiolini, Mauro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2681-2694</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The development of new kinase inhibitors is still a slow and problematic process.  Generally, type I compds. suffer from widespread cross-reactivity among other members of the kinase target family, and intense medicinal chem. optimization programs are required to modulate their activity.  Also, fierce competition in the development of scaffolds that could mimic ATP has led to a crowded intellectual property space.  The new opportunities opened by the type II compds. created great expectations, as targeting the allosteric site of the ATP pocket offered addnl. opportunities to control selectivity and introduce intellectual property novelty.  However, clin. evaluation of these compds. has highlighted how the acquisition of resistance-causing mutations of the kinase target limits their efficacy in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd_iA7sWS-g7Vg90H21EOLACvtfcHk0litAF-8u5fgMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGhtb3K&md5=5c6acd058bacfec89b1eff2090f0fe67</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm901443h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901443h%26sid%3Dliteratum%253Aachs%26aulast%3DZuccotto%26aufirst%3DF.%26aulast%3DArdini%26aufirst%3DE.%26aulast%3DCasale%26aufirst%3DE.%26aulast%3DAngiolini%26aufirst%3DM.%26atitle%3DThrough%2520the%2520%25E2%2580%259Cgatekeeper%2520door%25E2%2580%259D%253A%2520Exploiting%2520the%2520active%2520kinase%2520conformation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D2681%26epage%3D2694%26doi%3D10.1021%2Fjm901443h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Traxler, P.</span><span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors in cancer treatment (part ii)</span> <span class="citation_source-journal">Expert Opin. Ther. Pat.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">1599</span><span class="NLM_x">–</span> <span class="NLM_lpage">1625</span><span class="refDoi"> DOI: 10.1517/13543776.8.12.1599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1517%2F13543776.8.12.1599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADyaK1cXnvFymsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=1998&pages=1599-1625&author=P.+Traxler&title=Tyrosine+kinase+inhibitors+in+cancer+treatment+%28part+ii%29&doi=10.1517%2F13543776.8.12.1599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine kinase inhibitors in cancer treatment (part II)</span></div><div class="casAuthors">Traxler, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1599-1625</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Ashley Publications</span>)
        </div><div class="casAbstract">A review with 169 refs.  In the last few years, enormous progress in the field of signal transduction inhibition has been made.  Many companies have entered the field.  Along with the epidermal growth factor receptor (EGFR) tyrosine kinase, many other tyrosine kinases have been identified as interesting targets for drug discovery projects.  X-ray data of more than 40 crystal structures of protein kinases, in most cases complexed with an inhibitor, have been published.  Pharmacophore models for the binding of inhibitors in the ATP-binding site of protein kinases have been developed that are generally applicable, enabling the rational design of tyrosine as well as serine/threonine kinase inhibitors.  It has been proven by numerous examples that the ATP-binding of protein kinases is an exciting target for the design of anticancer drugs.  In many cases, it has also been demonstrated that through rational design it is possible to modify a lead structure in such a way that inhibitors with an altered selectivity profile are obtained.  Chem. optimization of several lead structures led to development candidates with potent in vitro and in vivo activity fulfilling the pharmacodynamic, pharmacokinetic, toxicol. and tech. (synthesis, formulation) requirements for a clin. candidate.  Currently, there are seven tyrosine kinase inhibitors in early phases of clin. trials.  In addn., several candidates are close to entering Phase I trials this year or at the beginning of next year.  It is expected that pos. results from clin. trials will greatly contribute to the clin. proof of concept of the value of signal transduction inhibition and will greatly stimulate further research in this area.  This review is a continuation of a review with the same title of last year and summarizes published patent literature and related publications between 1997 and Sept. 1998.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr804idCxibYrVg90H21EOLACvtfcHk0litAF-8u5fgMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnvFymsLs%253D&md5=43097dfbadeb732c98371ac30ab40cb6</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1517%2F13543776.8.12.1599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F13543776.8.12.1599%26sid%3Dliteratum%253Aachs%26aulast%3DTraxler%26aufirst%3DP.%26atitle%3DTyrosine%2520kinase%2520inhibitors%2520in%2520cancer%2520treatment%2520%2528part%2520ii%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D1998%26volume%3D8%26spage%3D1599%26epage%3D1625%26doi%3D10.1517%2F13543776.8.12.1599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Young, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassis, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doyle, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNulty, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, T. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fisher, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carr, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huddleston, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seibel, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Porter, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Livi, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span> </span><span class="NLM_article-title">Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the atp site</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">272</span><span class="NLM_x">, </span> <span class="NLM_fpage">12116</span><span class="NLM_x">–</span> <span class="NLM_lpage">12121</span><span class="refDoi"> DOI: 10.1074/jbc.272.18.12116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1074%2Fjbc.272.18.12116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=9115281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADyaK2sXivF2kt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=12116-12121&author=P.+R.+Youngauthor=M.+M.+McLaughlinauthor=S.+Kumarauthor=S.+Kassisauthor=M.+L.+Doyleauthor=D.+McNultyauthor=T.+F.+Gallagherauthor=S.+Fisherauthor=P.+C.+McDonnellauthor=S.+A.+Carrauthor=M.+J.+Huddlestonauthor=G.+Seibelauthor=T.+G.+Porterauthor=G.+P.+Liviauthor=J.+L.+Adamsauthor=J.+C.+Lee&title=Pyridinyl+imidazole+inhibitors+of+p38+mitogen-activated+protein+kinase+bind+in+the+atp+site&doi=10.1074%2Fjbc.272.18.12116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site</span></div><div class="casAuthors">Young, Peter R.; McLaughlin, Megan M.; Kumar, Sanjay; Kassis, Shouki; Doyle, Michael L.; McNulty, Dean; Gallagher, Timothy F.; Fisher, Seth; McDonnell, Peter C.; Carr, Steven A.; Huddleston, Michael J.; Seibel, George; Porter, Terence G.; Livi, George P.; Adams, Jerry L.; Lee, John C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">12116-12121</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The site of action of a series of pyridinyl imidazole compds. that are selective inhibitors of p38 mitogen-activated protein kinase in vitro and block proinflammatory cytokine prodn. in vivo has been detd.  Using Edman sequencing, 125I-SB206718 was shown to cross-link to the nonphosphorylated Escherichia coli-expressed p38 kinase at Thr175, which is proximal to the ATP binding site.  Titrn. calorimetric studies with E. coli-expressed p38 kinase showed that SB203580 bound with a stoichiometry of 1:1 and that binding was blocked by preincubation of p38 kinase with the ATP analog, FSBA (5'-[p-(fluorosulfonyl)benzoyl]adenosine), which covalently modifies the ATP binding site.  The intrinsic ATPase activity of the nonphosphorylated enzyme was inhibited by SB203580 with a Km of 9.6 mM.  Kinetic studies of active, phosphorylated yeast-expressed p38 kinase using a peptide substrate showed that SB203580 was competitive with ATP with a Ki of 21 nM and that kinase inhibition correlated with binding and biol. activity.  Mutagenesis indicated that binding of 125I-SB206718 was dependent on the catalytic residues K53 and D168 in the ATP pocket.  These findings indicate that the pyridinyl imidazoles act in vivo by inhibiting p38 kinase activity through competition with ATP and that their selectivity is probably detd. by differences in nonconserved regions within or near the ATP binding pocket.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX_W0as-RlKrVg90H21EOLACvtfcHk0ljId4rsHxh4Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXivF2kt7w%253D&md5=fafa90d4fb8d2d7eca53f17e19af74e4</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.18.12116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.18.12116%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DP.%2BR.%26aulast%3DMcLaughlin%26aufirst%3DM.%2BM.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DKassis%26aufirst%3DS.%26aulast%3DDoyle%26aufirst%3DM.%2BL.%26aulast%3DMcNulty%26aufirst%3DD.%26aulast%3DGallagher%26aufirst%3DT.%2BF.%26aulast%3DFisher%26aufirst%3DS.%26aulast%3DMcDonnell%26aufirst%3DP.%2BC.%26aulast%3DCarr%26aufirst%3DS.%2BA.%26aulast%3DHuddleston%26aufirst%3DM.%2BJ.%26aulast%3DSeibel%26aufirst%3DG.%26aulast%3DPorter%26aufirst%3DT.%2BG.%26aulast%3DLivi%26aufirst%3DG.%2BP.%26aulast%3DAdams%26aufirst%3DJ.%2BL.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DPyridinyl%2520imidazole%2520inhibitors%2520of%2520p38%2520mitogen-activated%2520protein%2520kinase%2520bind%2520in%2520the%2520atp%2520site%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D12116%26epage%3D12121%26doi%3D10.1074%2Fjbc.272.18.12116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Pargellis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Churchill, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cirillo, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmore, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grob, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickey, E. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moss, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pav, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Regan, J.</span><span> </span><span class="NLM_article-title">Inhibition of p38 map kinase by utilizing a novel allosteric binding site</span> <span class="citation_source-journal">Nat. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">268</span><span class="NLM_x">–</span> <span class="NLM_lpage">272</span><span class="refDoi"> DOI: 10.1038/nsb770</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1038%2Fnsb770" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=11896401" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2002&pages=268-272&author=C.+Pargellisauthor=L.+Tongauthor=L.+Churchillauthor=P.+F.+Cirilloauthor=T.+Gilmoreauthor=A.+G.+Grahamauthor=P.+M.+Grobauthor=E.+R.+Hickeyauthor=N.+Mossauthor=S.+Pavauthor=J.+Regan&title=Inhibition+of+p38+map+kinase+by+utilizing+a+novel+allosteric+binding+site&doi=10.1038%2Fnsb770"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site</span></div><div class="casAuthors">Pargellis, Christopher; Tong, Liang; Churchill, Laurie; Cirillo, Pier F.; Gilmore, Thomas; Graham, Anne G.; Grob, Peter M.; Hickey, Eugene R.; Moss, Neil; Pav, Susan; Regan, John</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">268-272</span>CODEN:
                <span class="NLM_cas:coden">NSBIEW</span>;
        ISSN:<span class="NLM_cas:issn">1072-8368</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">The p38 MAP kinase plays a crucial role in regulating the prodn. of proinflammatory cytokines, such as tumor necrosis factor and interleukin-1.  Blocking this kinase may offer an effective therapy for treating many inflammatory diseases.  Here we report a new allosteric binding site for a diaryl urea class of highly potent and selective inhibitors against human p38 MAP kinase.  The formation of this binding site requires a large conformational change not obsd. previously for any of the protein Ser/Thr kinases.  This change is in the highly conserved Asp-Phe-Gly motif within the active site of the kinase.  Soln. studies demonstrate that this class of compds. has slow binding kinetics, consistent with the requirement for conformational change.  Improving interactions in this allosteric pocket, as well as establishing binding interactions in the ATP pocket, enhanced the affinity of the inhibitors by 12,000-fold.  One of the most potent compds. in this series, BIRB 796, has picomolar affinity for the kinase and low nanomolar inhibitory activity in cell culture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqT8_QT7_pbYrVg90H21EOLACvtfcHk0ljId4rsHxh4Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xis1Kisbk%253D&md5=68850ecdbe08df4285ba38cfa2c93ea4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fnsb770&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsb770%26sid%3Dliteratum%253Aachs%26aulast%3DPargellis%26aufirst%3DC.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DChurchill%26aufirst%3DL.%26aulast%3DCirillo%26aufirst%3DP.%2BF.%26aulast%3DGilmore%26aufirst%3DT.%26aulast%3DGraham%26aufirst%3DA.%2BG.%26aulast%3DGrob%26aufirst%3DP.%2BM.%26aulast%3DHickey%26aufirst%3DE.%2BR.%26aulast%3DMoss%26aufirst%3DN.%26aulast%3DPav%26aufirst%3DS.%26aulast%3DRegan%26aufirst%3DJ.%26atitle%3DInhibition%2520of%2520p38%2520map%2520kinase%2520by%2520utilizing%2520a%2520novel%2520allosteric%2520binding%2520site%26jtitle%3DNat.%2520Struct.%2520Biol.%26date%3D2002%26volume%3D9%26spage%3D268%26epage%3D272%26doi%3D10.1038%2Fnsb770" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Cusack, K. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoemann, M. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marjanovic, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heym, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasudevan, A.</span><span> </span><span class="NLM_article-title">Design strategies to address kinetics of drug binding and residence time</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">2019</span><span class="NLM_x">–</span> <span class="NLM_lpage">2027</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2015.02.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1016%2Fj.bmcl.2015.02.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=25782745" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC2MXktVCjsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2015&pages=2019-2027&author=K.+P.+Cusackauthor=Y.+Wangauthor=M.+Z.+Hoemannauthor=J.+Marjanovicauthor=R.+G.+Heymauthor=A.+Vasudevan&title=Design+strategies+to+address+kinetics+of+drug+binding+and+residence+time&doi=10.1016%2Fj.bmcl.2015.02.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Design strategies to address kinetics of drug binding and residence time</span></div><div class="casAuthors">Cusack, Kevin P.; Wang, Ying; Hoemann, Michael Z.; Marjanovic, Jasmina; Heym, Roland G.; Vasudevan, Anil</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2019-2027</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The kinetics of drug binding and drug residence time are recognized to be important in the clin. effectiveness of drug candidates.  In most cases a long residence time of the drug-target complex results in an extended duration of pharmacodynamic activity, even when systemic concns. of drug have been notably reduced through elimination routes.  Hence, if selective for target, long residence times can increase the duration of drug efficacy in vivo and can significantly diminish the potential for off-target-mediated toxicities.  Furthermore, a compd. with a slower dissocn. rate may allow a reduced dosing schedule relative to a compd. with a rapid dissocn. rate.  Factors contributing to long residence time that could be useful to medicinal chemists in the prospective design of compds. with long residence times will be discussed in this perspective.  Particular emphasis will be on case studies highlighting how kinetics can be measured, modulated based on supporting structure kinetic relationships and whether these effects are translatable into man.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGru6nmUGLHP_rVg90H21EOLACvtfcHk0lhc0hmuHhKYLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXktVCjsLg%253D&md5=c3735de36094915768dbecc7472917d4</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2015.02.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2015.02.027%26sid%3Dliteratum%253Aachs%26aulast%3DCusack%26aufirst%3DK.%2BP.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHoemann%26aufirst%3DM.%2BZ.%26aulast%3DMarjanovic%26aufirst%3DJ.%26aulast%3DHeym%26aufirst%3DR.%2BG.%26aulast%3DVasudevan%26aufirst%3DA.%26atitle%3DDesign%2520strategies%2520to%2520address%2520kinetics%2520of%2520drug%2520binding%2520and%2520residence%2520time%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2015%26volume%3D25%26spage%3D2019%26epage%3D2027%26doi%3D10.1016%2Fj.bmcl.2015.02.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Fabian, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biggs, W. H.,  3rd</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azimioara, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benedetti, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ford, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galvin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grotzfeld, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Insko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lelias, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mehta, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Velasco, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span> </span><span class="NLM_article-title">A small molecule-kinase interaction map for clinical kinase inhibitors</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">329</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nbt1068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1038%2Fnbt1068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=15711537" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=329-336&author=M.+A.+Fabianauthor=W.+H.+Biggsauthor=D.+K.+Treiberauthor=C.+E.+Atteridgeauthor=M.+D.+Azimioaraauthor=M.+G.+Benedettiauthor=T.+A.+Carterauthor=P.+Ciceriauthor=P.+T.+Edeenauthor=M.+Floydauthor=J.+M.+Fordauthor=M.+Galvinauthor=J.+L.+Gerlachauthor=R.+M.+Grotzfeldauthor=S.+Herrgardauthor=D.+E.+Inskoauthor=M.+A.+Inskoauthor=A.+G.+Laiauthor=J.+M.+Leliasauthor=S.+A.+Mehtaauthor=Z.+V.+Milanovauthor=A.+M.+Velascoauthor=L.+M.+Wodickaauthor=H.+K.+Patelauthor=P.+P.+Zarrinkarauthor=D.+J.+Lockhart&title=A+small+molecule-kinase+interaction+map+for+clinical+kinase+inhibitors&doi=10.1038%2Fnbt1068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A small molecule-kinase interaction map for clinical kinase inhibitors</span></div><div class="casAuthors">Fabian, Miles A.; Biggs, William H.; Treiber, Daniel K.; Atteridge, Corey E.; Azimioara, Mihai D.; Benedetti, Michael G.; Carter, Todd A.; Ciceri, Pietro; Edeen, Philip T.; Floyd, Mark; Ford, Julia M.; Galvin, Margaret; Gerlach, Jay L.; Grotzfeld, Robert M.; Herrgard, Sanna; Insko, Darren E.; Insko, Michael A.; Lai, Andiliy G.; Lelias, Jean-Michel; Mehta, Shamal A.; Milanov, Zdravko V.; Velasco, Anne Marie; Wodicka, Lisa M.; Patel, Hitesh K.; Zarrinkar, Patrick P.; Lockhart, David J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">329-336</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors show great promise as a new class of therapeutics.  Here the authors describe an efficient way to det. kinase inhibitor specificity by measuring binding of small mols. to the ATP site of kinases.  The authors have profiled 20 kinase inhibitors, including 16 that are approved drugs or in clin. development, against a panel of 119 protein kinases.  The authors find that specificity varies widely and is not strongly correlated with chem. structure or the identity of the intended target.  Many novel interactions were identified, including tight binding of the p38 inhibitor BIRB-796 to an imatinib-resistant variant of the ABL kinase, and binding of imatinib to the SRC-family kinase LCK.  The authors also show that mutations in the epidermal growth factor receptor (EGFR) found in gefitinib-responsive patients do not affect the binding affinity of gefitinib or erlotinib.  Our results represent a systematic small mol.-protein interaction map for clin. compds. across a large no. of related proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqA0vNmMOXrnrVg90H21EOLACvtfcHk0lhc0hmuHhKYLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXitF2nt7w%253D&md5=6aedd5ceb8f77cd26ee50425dcec7bdf</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnbt1068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1068%26sid%3Dliteratum%253Aachs%26aulast%3DFabian%26aufirst%3DM.%2BA.%26aulast%3DBiggs%26aufirst%3DW.%2BH.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DAzimioara%26aufirst%3DM.%2BD.%26aulast%3DBenedetti%26aufirst%3DM.%2BG.%26aulast%3DCarter%26aufirst%3DT.%2BA.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DFord%26aufirst%3DJ.%2BM.%26aulast%3DGalvin%26aufirst%3DM.%26aulast%3DGerlach%26aufirst%3DJ.%2BL.%26aulast%3DGrotzfeld%26aufirst%3DR.%2BM.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DInsko%26aufirst%3DD.%2BE.%26aulast%3DInsko%26aufirst%3DM.%2BA.%26aulast%3DLai%26aufirst%3DA.%2BG.%26aulast%3DLelias%26aufirst%3DJ.%2BM.%26aulast%3DMehta%26aufirst%3DS.%2BA.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DVelasco%26aufirst%3DA.%2BM.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26atitle%3DA%2520small%2520molecule-kinase%2520interaction%2520map%2520for%2520clinical%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Biotechnol.%26date%3D2005%26volume%3D23%26spage%3D329%26epage%3D336%26doi%3D10.1038%2Fnbt1068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lgMvre-fQJHtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Eswaran, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span> </span><span class="NLM_article-title">Insights into protein kinase regulation and inhibition by large scale structural comparison</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Proteins Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1804</span><span class="NLM_x">, </span> <span class="NLM_fpage">429</span><span class="NLM_x">–</span> <span class="NLM_lpage">432</span><span class="refDoi"> DOI: 10.1016/j.bbapap.2009.10.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1016%2Fj.bbapap.2009.10.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=19854302" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1ynurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1804&publication_year=2010&pages=429-432&author=J.+Eswaranauthor=S.+Knapp&title=Insights+into+protein+kinase+regulation+and+inhibition+by+large+scale+structural+comparison&doi=10.1016%2Fj.bbapap.2009.10.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into protein kinase regulation and inhibition by large scale structural comparison</span></div><div class="casAuthors">Eswaran, Jeyanthy; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1804</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">429-432</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Protein structure detn. of sol. globular protein domains has developed into an efficient routine technol. which can now be applied to generate and analyze structures of entire human protein families.  In the kinase area, several kinase families still lack comprehensive structural anal.  Nevertheless, structural genomics efforts contributed >40 kinase catalytic domain structures during the past 4 years providing a rich resource of information for large scale comparisons of kinase active sites.  Moreover, many of the released structures are inhibitor complexes that offer chem. starting points for development of selective and potent inhibitors.  Here, the authors discuss currently available structural data and strategies that can be utilized for the development of highly selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0BkEEFUKP67Vg90H21EOLACvtfcHk0lgMvre-fQJHtQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1ynurY%253D&md5=5f0566316bae37a7fd8d1039792398f1</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2009.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2009.10.013%26sid%3Dliteratum%253Aachs%26aulast%3DEswaran%26aufirst%3DJ.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DInsights%2520into%2520protein%2520kinase%2520regulation%2520and%2520inhibition%2520by%2520large%2520scale%2520structural%2520comparison%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2010%26volume%3D1804%26spage%3D429%26epage%3D432%26doi%3D10.1016%2Fj.bbapap.2009.10.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Kluter, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grutter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naqvi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rabiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simard, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pawar, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Displacement assay for the detection of stabilizers of inactive kinase conformations</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">357</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span><span class="refDoi"> DOI: 10.1021/jm901297e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm901297e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=357-367&author=S.+Kluterauthor=C.+Grutterauthor=T.+Naqviauthor=M.+Rabillerauthor=J.+R.+Simardauthor=V.+Pawarauthor=M.+Getlikauthor=D.+Rauh&title=Displacement+assay+for+the+detection+of+stabilizers+of+inactive+kinase+conformations&doi=10.1021%2Fjm901297e"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm901297e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm901297e%26sid%3Dliteratum%253Aachs%26aulast%3DKluter%26aufirst%3DS.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DNaqvi%26aufirst%3DT.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DPawar%26aufirst%3DV.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DDisplacement%2520assay%2520for%2520the%2520detection%2520of%2520stabilizers%2520of%2520inactive%2520kinase%2520conformations%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D357%26epage%3D367%26doi%3D10.1021%2Fjm901297e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Laufer, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Margutti, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritz, M. D.</span><span> </span><span class="NLM_article-title">Substituted isoxazoles as potent inhibitors of p38 map kinase</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">197</span><span class="NLM_x">–</span> <span class="NLM_lpage">207</span><span class="refDoi"> DOI: 10.1002/cmdc.200500025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1002%2Fcmdc.200500025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2006&pages=197-207&author=S.+A.+Lauferauthor=S.+Marguttiauthor=M.+D.+Fritz&title=Substituted+isoxazoles+as+potent+inhibitors+of+p38+map+kinase&doi=10.1002%2Fcmdc.200500025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.200500025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.200500025%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26aulast%3DMargutti%26aufirst%3DS.%26aulast%3DFritz%26aufirst%3DM.%2BD.%26atitle%3DSubstituted%2520isoxazoles%2520as%2520potent%2520inhibitors%2520of%2520p38%2520map%2520kinase%26jtitle%3DChemMedChem%26date%3D2006%26volume%3D1%26spage%3D197%26epage%3D207%26doi%3D10.1002%2Fcmdc.200500025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Hauser, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scior, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Domeyer, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kammerer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S. A.</span><span> </span><span class="NLM_article-title">Synthesis, biological testing, and binding mode prediction of 6,9-diarylpurin-8-ones as p38 map kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">2060</span><span class="NLM_x">–</span> <span class="NLM_lpage">2066</span><span class="refDoi"> DOI: 10.1021/jm061061w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061061w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=2060-2066&author=D.+R.+Hauserauthor=T.+Sciorauthor=D.+M.+Domeyerauthor=B.+Kammererauthor=S.+A.+Laufer&title=Synthesis%2C+biological+testing%2C+and+binding+mode+prediction+of+6%2C9-diarylpurin-8-ones+as+p38+map+kinase+inhibitors&doi=10.1021%2Fjm061061w"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fjm061061w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061061w%26sid%3Dliteratum%253Aachs%26aulast%3DHauser%26aufirst%3DD.%2BR.%26aulast%3DScior%26aufirst%3DT.%26aulast%3DDomeyer%26aufirst%3DD.%2BM.%26aulast%3DKammerer%26aufirst%3DB.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DSynthesis%252C%2520biological%2520testing%252C%2520and%2520binding%2520mode%2520prediction%2520of%25206%252C9-diarylpurin-8-ones%2520as%2520p38%2520map%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D2060%26epage%3D2066%26doi%3D10.1021%2Fjm061061w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Laufer, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahrens, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karcher, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hering, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niess, R.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of phenylamino-substituted 6,11-dihydro-dibenzo[b,e]oxepin-11-ones and dibenzo[a,d]cycloheptan-5-ones: Novel p38 map kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">7912</span><span class="NLM_x">–</span> <span class="NLM_lpage">7915</span><span class="refDoi"> DOI: 10.1021/jm061072p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm061072p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtlCqsLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7912-7915&author=S.+A.+Lauferauthor=G.+M.+Ahrensauthor=S.+C.+Karcherauthor=J.+S.+Heringauthor=R.+Niess&title=Design%2C+synthesis%2C+and+biological+evaluation+of+phenylamino-substituted+6%2C11-dihydro-dibenzo%5Bb%2Ce%5Doxepin-11-ones+and+dibenzo%5Ba%2Cd%5Dcycloheptan-5-ones%3A+Novel+p38+map+kinase+inhibitors&doi=10.1021%2Fjm061072p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Design, Synthesis, and Biological Evaluation of Phenylamino-Substituted 6,11-Dihydro-dibenzo[b,e]oxepin-11-ones and Dibenzo[a,d]cycloheptan-5-ones: Novel p38 MAP Kinase Inhibitors</span></div><div class="casAuthors">Laufer, Stefan A.; Ahrens, Gabriele M.; Karcher, Solveigh C.; Hering, Joerg S.; Niess, Raimund</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7912-7915</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The pathogenesis of chronic inflammatory diseases is promoted by various pro-inflammatory cytokines.  P38 MAP kinase seems to be a valid target as it controls proinflammatory cytokine levels on both transcriptional and translational levels.  Starting from benzophenone-type inhibitors, a rigidization strategy led to 3-amino-6,11-dihydro-dibenzo[b,e]thiepin-11-one, phenylamino-substituted 6,11-dihydro-dibenzo[b,e]oxepin-11-ones, and dibenzo[a,d]cyclohepten-5-ones.  Synthesis, p38 inhibition, and CYP-inhibition of selected compds. are described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2Jvib81kr5rVg90H21EOLACvtfcHk0lh9TmW8RBIW2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtlCqsLvF&md5=efeb93681a203a07502c3ff1e964001f</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjm061072p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm061072p%26sid%3Dliteratum%253Aachs%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26aulast%3DAhrens%26aufirst%3DG.%2BM.%26aulast%3DKarcher%26aufirst%3DS.%2BC.%26aulast%3DHering%26aufirst%3DJ.%2BS.%26aulast%3DNiess%26aufirst%3DR.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520phenylamino-substituted%25206%252C11-dihydro-dibenzo%255Bb%252Ce%255Doxepin-11-ones%2520and%2520dibenzo%255Ba%252Cd%255Dcycloheptan-5-ones%253A%2520Novel%2520p38%2520map%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D7912%26epage%3D7915%26doi%3D10.1021%2Fjm061072p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Koeberle, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romir, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeberle, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schattel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albrecht, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grutter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werz, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stehle, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S. A.</span><span> </span><span class="NLM_article-title">Skepinone-l is a selective p38 mitogen-activated protein kinase inhibitor</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">141</span><span class="NLM_x">–</span> <span class="NLM_lpage">143</span><span class="refDoi"> DOI: 10.1038/nchembio.761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1038%2Fnchembio.761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1Olur%252FK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=141-143&author=S.+C.+Koeberleauthor=J.+Romirauthor=S.+Fischerauthor=A.+Koeberleauthor=V.+Schattelauthor=W.+Albrechtauthor=C.+Grutterauthor=O.+Werzauthor=D.+Rauhauthor=T.+Stehleauthor=S.+A.+Laufer&title=Skepinone-l+is+a+selective+p38+mitogen-activated+protein+kinase+inhibitor&doi=10.1038%2Fnchembio.761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor</span></div><div class="casAuthors">Koeberle, Solveigh C.; Romir, Johannes; Fischer, Stefan; Koeberle, Andreas; Schattel, Verena; Albrecht, Wolfgang; Gruetter, Christian; Werz, Oliver; Rauh, Daniel; Stehle, Thilo; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">141-143</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Until now, a lack of inhibitors with high potency and selectivity in vivo has hampered investigation of the p38 mitogen-activated protein kinase (MAPK) signaling pathway.  We describe the design of skepinone-L, which is, to our knowledge, the first ATP-competitive p38 MAPK inhibitor with excellent in vivo efficacy and selectivity.  Therefore, skepinone-L is a valuable probe for chem. biol. research, and it may foster the development of a unique class of kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkdYtKPp4C1rVg90H21EOLACvtfcHk0lh9TmW8RBIW2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1Olur%252FK&md5=17ca91bebd48a1804e31ebccc192aa93</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.761%26sid%3Dliteratum%253Aachs%26aulast%3DKoeberle%26aufirst%3DS.%2BC.%26aulast%3DRomir%26aufirst%3DJ.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DKoeberle%26aufirst%3DA.%26aulast%3DSchattel%26aufirst%3DV.%26aulast%3DAlbrecht%26aufirst%3DW.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DWerz%26aufirst%3DO.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DStehle%26aufirst%3DT.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DSkepinone-l%2520is%2520a%2520selective%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibitor%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D141%26epage%3D143%26doi%3D10.1038%2Fnchembio.761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Martz, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baur, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schattel, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goettert, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer-Wrangowski, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S. A.</span><span> </span><span class="NLM_article-title">Targeting the hinge glycine flip and the activation loop: Novel approach to potent p38α inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">7862</span><span class="NLM_x">–</span> <span class="NLM_lpage">7874</span><span class="refDoi"> DOI: 10.1021/jm300951u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300951u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1SlsrbP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=7862-7874&author=K.+E.+Martzauthor=A.+Dornauthor=B.+Baurauthor=V.+Schattelauthor=M.+I.+Goettertauthor=S.+C.+Mayer-Wrangowskiauthor=D.+Rauhauthor=S.+A.+Laufer&title=Targeting+the+hinge+glycine+flip+and+the+activation+loop%3A+Novel+approach+to+potent+p38%CE%B1+inhibitors&doi=10.1021%2Fjm300951u"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Hinge Glycine Flip and the Activation Loop: Novel Approach to Potent p38α Inhibitors</span></div><div class="casAuthors">Martz, Kathrin E.; Dorn, Angelika; Baur, Benjamin; Schattel, Verena; Goettert, Marcia I.; Mayer-Wrangowski, Svenja C.; Rauh, Daniel; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7862-7874</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The p38 MAP kinase is a key player in signaling pathways regulating the biosynthesis of inflammatory cytokines.  Small mol. p38 inhibitors suppress the prodn. of these cytokines.  Therefore p38 is a promising drug target for novel anti-inflammatory drugs.  In this study, we report novel dibenzepinones, dibenzoxepines, and benzosuberones as p38α MAP kinase inhibitors.  Previously reported dibenzepinones and dibenzoxepines were chem. modified by introduction of functional groups or removal of a Ph ring.  This should result in targeting of the hydrophobic region I, the "deep pocket", and the hinge glycine flip of the kinase.  Potent inhibitors with IC50 values in the single digit nanomolar range (up to 3 nM) were identified.  Instead of targeting the "deep pocket" in the DFG-out conformation, interactions with the DFG-motif in the in-conformation could be obsd. by protein x-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9ZkVG97Ru-bVg90H21EOLACvtfcHk0lh9TmW8RBIW2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1SlsrbP&md5=c1e76ed9bac1b5c1c4c5b4c630c845b8</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm300951u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300951u%26sid%3Dliteratum%253Aachs%26aulast%3DMartz%26aufirst%3DK.%2BE.%26aulast%3DDorn%26aufirst%3DA.%26aulast%3DBaur%26aufirst%3DB.%26aulast%3DSchattel%26aufirst%3DV.%26aulast%3DGoettert%26aufirst%3DM.%2BI.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%2BC.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DTargeting%2520the%2520hinge%2520glycine%2520flip%2520and%2520the%2520activation%2520loop%253A%2520Novel%2520approach%2520to%2520potent%2520p38%25CE%25B1%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D7862%26epage%3D7874%26doi%3D10.1021%2Fjm300951u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Fischer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wentsch, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer-Wrangowski, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zimmermann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bauer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niess, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeberle, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grutter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boeckler, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S. A.</span><span> </span><span class="NLM_article-title">Dibenzosuberones as p38 mitogen-activated protein kinase inhibitors with low atp competitiveness and outstanding whole blood activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">241</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span><span class="refDoi"> DOI: 10.1021/jm301539x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301539x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvFWiurzP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=241-253&author=S.+Fischerauthor=H.+K.+Wentschauthor=S.+C.+Mayer-Wrangowskiauthor=M.+Zimmermannauthor=S.+M.+Bauerauthor=K.+Storchauthor=R.+Niessauthor=S.+C.+Koeberleauthor=C.+Grutterauthor=F.+M.+Boecklerauthor=D.+Rauhauthor=S.+A.+Laufer&title=Dibenzosuberones+as+p38+mitogen-activated+protein+kinase+inhibitors+with+low+atp+competitiveness+and+outstanding+whole+blood+activity&doi=10.1021%2Fjm301539x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Dibenzosuberones as p38 Mitogen-Activated Protein Kinase Inhibitors with Low ATP Competitiveness and Outstanding Whole Blood Activity</span></div><div class="casAuthors">Fischer, Stefan; Wentsch, Heike K.; Mayer-Wrangowski, Svenja C.; Zimmermann, Markus; Bauer, Silke M.; Storch, Kirsten; Niess, Raimund; Koeberle, Solveigh C.; Gruetter, Christian; Boeckler, Frank M.; Rauh, Daniel; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">241-253</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">P38α mitogen-activated protein (MAP) kinase is a main target in drug research concerning inflammatory diseases.  Nevertheless, no inhibitor of p38α MAP kinase has been introduced to the market.  This might be attributed to the fact that there is no inhibitor which combines outstanding activity in biol. systems and selectivity.  Herein an approach to the development of such inhibitors on the basis of the highly selective mol. probe Skepinone-L (I) is described.  Introduction of a "deep pocket" moiety addressing the DFG motif led to an increased activity of the compds.  Hydrophilic moieties, addressing the solvent-exposed area adjacent to hydrophilic region II, conserved a high activity of the compds. in a whole blood assay.  Combined with their outstanding selectivity and low ATP competitiveness, these inhibitors are very interesting candidates for use in biol. systems and in therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbi31syvBEYrVg90H21EOLACvtfcHk0li7TbIbBp2Ekg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvFWiurzP&md5=bfce0ba26af365a1d218095e54ba169f</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1021%2Fjm301539x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301539x%26sid%3Dliteratum%253Aachs%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DWentsch%26aufirst%3DH.%2BK.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%2BC.%26aulast%3DZimmermann%26aufirst%3DM.%26aulast%3DBauer%26aufirst%3DS.%2BM.%26aulast%3DStorch%26aufirst%3DK.%26aulast%3DNiess%26aufirst%3DR.%26aulast%3DKoeberle%26aufirst%3DS.%2BC.%26aulast%3DGrutter%26aufirst%3DC.%26aulast%3DBoeckler%26aufirst%3DF.%2BM.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DDibenzosuberones%2520as%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibitors%2520with%2520low%2520atp%2520competitiveness%2520and%2520outstanding%2520whole%2520blood%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D241%26epage%3D253%26doi%3D10.1021%2Fjm301539x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Baur, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Storch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martz, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goettert, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S. A.</span><span> </span><span class="NLM_article-title">Metabolically stable dibenzo[b,e]oxepin-11(6h)-ones as highly selective p38 map kinase inhibitors: Optimizing anti-cytokine activity in human whole blood</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">8561</span><span class="NLM_x">–</span> <span class="NLM_lpage">8578</span><span class="refDoi"> DOI: 10.1021/jm401276h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401276h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8561-8578&author=B.+Baurauthor=K.+Storchauthor=K.+E.+Martzauthor=M.+I.+Goettertauthor=A.+Richtersauthor=D.+Rauhauthor=S.+A.+Laufer&title=Metabolically+stable+dibenzo%5Bb%2Ce%5Doxepin-11%286h%29-ones+as+highly+selective+p38+map+kinase+inhibitors%3A+Optimizing+anti-cytokine+activity+in+human+whole+blood&doi=10.1021%2Fjm401276h"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fjm401276h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401276h%26sid%3Dliteratum%253Aachs%26aulast%3DBaur%26aufirst%3DB.%26aulast%3DStorch%26aufirst%3DK.%26aulast%3DMartz%26aufirst%3DK.%2BE.%26aulast%3DGoettert%26aufirst%3DM.%2BI.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DMetabolically%2520stable%2520dibenzo%255Bb%252Ce%255Doxepin-11%25286h%2529-ones%2520as%2520highly%2520selective%2520p38%2520map%2520kinase%2520inhibitors%253A%2520Optimizing%2520anti-cytokine%2520activity%2520in%2520human%2520whole%2520blood%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D8561%26epage%3D8578%26doi%3D10.1021%2Fjm401276h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Thurmond, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wadsworth, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schafer, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zivin, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siekierka, J. J.</span><span> </span><span class="NLM_article-title">Kinetics of small molecule inhibitor binding to p38 kinase</span> <span class="citation_source-journal">Eur. J. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">268</span><span class="NLM_x">, </span> <span class="NLM_fpage">5747</span><span class="NLM_x">–</span> <span class="NLM_lpage">5754</span><span class="refDoi"> DOI: 10.1046/j.0014-2956.2001.02512.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1046%2Fj.0014-2956.2001.02512.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=11722559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD3MXosFyms78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=2001&pages=5747-5754&author=R.+L.+Thurmondauthor=S.+A.+Wadsworthauthor=P.+H.+Schaferauthor=R.+A.+Zivinauthor=J.+J.+Siekierka&title=Kinetics+of+small+molecule+inhibitor+binding+to+p38+kinase&doi=10.1046%2Fj.0014-2956.2001.02512.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetics of small molecule inhibitor binding to p38 kinase</span></div><div class="casAuthors">Thurmond, Robin L.; Wadsworth, Scott A.; Schafer, Peter H.; Zivin, Robert A.; Siekierka, John J.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Biochemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">5747-5754</span>CODEN:
                <span class="NLM_cas:coden">EJBCAI</span>;
        ISSN:<span class="NLM_cas:issn">0014-2956</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Science Ltd.</span>)
        </div><div class="casAbstract">P38 mitogen-activated protein kinase (MAPK) (p38/p38-α/CSBP2/RK) has been implicated in the regulation of many pro-inflammatory pathways.  Because of this, it has received much attention as a potential drug target for controlling diseases such as rheumatoid arthritis, endotoxic shock, inflammatory bowel disease, osteoporosis, and many others.  A no. of small mol. inhibitors of this kinase have been described, and in this paper we have used surface plasmon resonance to directly measure and quantitate their binding to p38.  Despite the relatively low mol. mass (≈ 400 Da) of these inhibitors, specific binding can be obsd.  For the two most potent inhibitors studied, SB 203580 and RWJ 67657, dissocn. consts., Kd's, of 22 and 10 nM, resp., were obtained.  These values closely match the IC50 values obsd. in a cell-based TNFα release assay implying that p38 plays a major role in TNFα release.  The assocn. and dissocn. rates for the binding of these inhibitors to p38 have also been quantitated.  SB 203580 and RWJ 67657 have very similar assocn. rates of around 8 × 105 M-1 ·s-1, and the differences in affinity are detd. by different dissocn. rates.  The weaker binding compds. have dissocn. rates similar to SB 203580, but the assocn. rates vary by an order of magnitude or more.  The direct measurement of compds. binding to p38 may help in understanding the difference between potency and efficacy for these inhibitors.  This in turn may yield clues on how to develop better inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiWyahpK3jILVg90H21EOLACvtfcHk0li7TbIbBp2Ekg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXosFyms78%253D&md5=08df8a6f30299cccc59fe911ea2fb82b</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1046%2Fj.0014-2956.2001.02512.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.0014-2956.2001.02512.x%26sid%3Dliteratum%253Aachs%26aulast%3DThurmond%26aufirst%3DR.%2BL.%26aulast%3DWadsworth%26aufirst%3DS.%2BA.%26aulast%3DSchafer%26aufirst%3DP.%2BH.%26aulast%3DZivin%26aufirst%3DR.%2BA.%26aulast%3DSiekierka%26aufirst%3DJ.%2BJ.%26atitle%3DKinetics%2520of%2520small%2520molecule%2520inhibitor%2520binding%2520to%2520p38%2520kinase%26jtitle%3DEur.%2520J.%2520Biochem.%26date%3D2001%26volume%3D268%26spage%3D5747%26epage%3D5754%26doi%3D10.1046%2Fj.0014-2956.2001.02512.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Unzue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lafleur, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frugier, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caflisch, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nevado, C.</span><span> </span><span class="NLM_article-title">Pyrrolo[3,2-b]quinoxaline derivatives as types i1/2 and ii eph tyrosine kinase inhibitors: Structure-based design, synthesis, and in vivo validation</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">6834</span><span class="NLM_x">–</span> <span class="NLM_lpage">6844</span><span class="refDoi"> DOI: 10.1021/jm5009242</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5009242" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=6834-6844&author=A.+Unzueauthor=J.+Dongauthor=K.+Lafleurauthor=H.+Zhaoauthor=E.+Frugierauthor=A.+Caflischauthor=C.+Nevado&title=Pyrrolo%5B3%2C2-b%5Dquinoxaline+derivatives+as+types+i1%2F2+and+ii+eph+tyrosine+kinase+inhibitors%3A+Structure-based+design%2C+synthesis%2C+and+in+vivo+validation&doi=10.1021%2Fjm5009242"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fjm5009242&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5009242%26sid%3Dliteratum%253Aachs%26aulast%3DUnzue%26aufirst%3DA.%26aulast%3DDong%26aufirst%3DJ.%26aulast%3DLafleur%26aufirst%3DK.%26aulast%3DZhao%26aufirst%3DH.%26aulast%3DFrugier%26aufirst%3DE.%26aulast%3DCaflisch%26aufirst%3DA.%26aulast%3DNevado%26aufirst%3DC.%26atitle%3DPyrrolo%255B3%252C2-b%255Dquinoxaline%2520derivatives%2520as%2520types%2520i1%252F2%2520and%2520ii%2520eph%2520tyrosine%2520kinase%2520inhibitors%253A%2520Structure-based%2520design%252C%2520synthesis%252C%2520and%2520in%2520vivo%2520validation%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D6834%26epage%3D6844%26doi%3D10.1021%2Fjm5009242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pompliano, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meek, T. D.</span><span> </span><span class="NLM_article-title">Drug-target residence time and its implications for lead optimization</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">730</span><span class="NLM_x">–</span> <span class="NLM_lpage">739</span><span class="refDoi"> DOI: 10.1038/nrd2082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1038%2Fnrd2082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=16888652" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=730-739&author=R.+A.+Copelandauthor=D.+L.+Pomplianoauthor=T.+D.+Meek&title=Drug-target+residence+time+and+its+implications+for+lead+optimization&doi=10.1038%2Fnrd2082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Drug-target residence time and its implications for lead optimization</span></div><div class="casAuthors">Copeland, Robert A.; Pompliano, David L.; Meek, Thomas D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">730-739</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromols. by low-mol.-mass drugs.  The binding of drugs to their macromol. targets is therefore seen as paramount for pharmacol. activity.  In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC50 or Kd.  This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex.  We describe the potential advantages of long residence time in terms of duration of pharmacol. effect and target selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGry6SJrMlrrTbVg90H21EOLACvtfcHk0lhuijb4_r7Tpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XptVCltro%253D&md5=60ede2301584b10ac4e8fa18e1e6d107</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fnrd2082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2082%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DPompliano%26aufirst%3DD.%2BL.%26aulast%3DMeek%26aufirst%3DT.%2BD.%26atitle%3DDrug-target%2520residence%2520time%2520and%2520its%2520implications%2520for%2520lead%2520optimization%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D730%26epage%3D739%26doi%3D10.1038%2Fnrd2082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Hothersall, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dale, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rawlins, P.</span><span> </span><span class="NLM_article-title">Can residence time offer a useful strategy to target agonist drugs for sustained gpcr responses?</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">90</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span><span class="refDoi"> DOI: 10.1016/j.drudis.2015.07.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1016%2Fj.drudis.2015.07.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=26226643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1Ohu7bO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2016&pages=90-96&author=J.+D.+Hothersallauthor=A.+J.+Brownauthor=I.+Daleauthor=P.+Rawlins&title=Can+residence+time+offer+a+useful+strategy+to+target+agonist+drugs+for+sustained+gpcr+responses%3F&doi=10.1016%2Fj.drudis.2015.07.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Can residence time offer a useful strategy to target agonist drugs for sustained GPCR responses?</span></div><div class="casAuthors">Hothersall, J. Daniel; Brown, Alastair J.; Dale, Ian; Rawlins, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">90-96</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Residence time describes the how long a ligand is bound to its target, and is attracting interest in drug discovery as a potential means of improving clin. efficacy by increasing target coverage.  This concept, as originally applied to antagonists, is more complicated for G-protein-coupled receptor (GPCR) agonists because of the transiency of receptor responses (via desensitization and internalization).  However, in some cases sustained GPCR agonist responses have been obsd., with evidence consistent with a role for slow binding kinetics.  We propose a model to explain our understanding of how residence time and rebinding might influence sustained signaling by internalized receptors.  We also highlight the anticipated benefit for drug discovery of fully understanding and exploiting these phenomena to target desirable receptor response profiles selectively.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNbH-40pZCqbVg90H21EOLACvtfcHk0lhuijb4_r7Tpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1Ohu7bO&md5=314ffbd12a8cc2a3068d86b91d7a13fb</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2015.07.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2015.07.015%26sid%3Dliteratum%253Aachs%26aulast%3DHothersall%26aufirst%3DJ.%2BD.%26aulast%3DBrown%26aufirst%3DA.%2BJ.%26aulast%3DDale%26aufirst%3DI.%26aulast%3DRawlins%26aufirst%3DP.%26atitle%3DCan%2520residence%2520time%2520offer%2520a%2520useful%2520strategy%2520to%2520target%2520agonist%2520drugs%2520for%2520sustained%2520gpcr%2520responses%253F%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2016%26volume%3D21%26spage%3D90%26epage%3D96%26doi%3D10.1016%2Fj.drudis.2015.07.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Dahl, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akerud, T.</span><span> </span><span class="NLM_article-title">Pharmacokinetics and the drug-target residence time concept</span> <span class="citation_source-journal">Drug Discovery Today</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">697</span><span class="NLM_x">–</span> <span class="NLM_lpage">707</span><span class="refDoi"> DOI: 10.1016/j.drudis.2013.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1016%2Fj.drudis.2013.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=23500610" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC3sXksVyqtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=697-707&author=G.+Dahlauthor=T.+Akerud&title=Pharmacokinetics+and+the+drug-target+residence+time+concept&doi=10.1016%2Fj.drudis.2013.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacokinetics and the drug-target residence time concept</span></div><div class="casAuthors">Dahl, Goeran; Akerud, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Drug Discovery Today</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">15-16</span>),
    <span class="NLM_cas:pages">697-707</span>CODEN:
                <span class="NLM_cas:coden">DDTOFS</span>;
        ISSN:<span class="NLM_cas:issn">1359-6446</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The concept of drug-target residence time has been in focus in recent drug discovery literature.  However, few studies consider the combined effect of pharmacokinetics (PK) and binding kinetics (BK) on the duration of effect of a drug.  Using a simple model that takes both PK and BK into account, we found that prolongation of binding owing to a long drug-target residence time can only occur when the binding dissocn. is slower than the PK elimination.  Data for several drugs and/or drug candidates in the literature indicate that the opposite is obsd., i.e., they have a slower elimination compared with dissocn.  These observations greatly reduce the usability of drug-target residence times for estg. the duration of effect of a drug in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon2xZ9fJkTybVg90H21EOLACvtfcHk0lhuijb4_r7Tpg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXksVyqtL0%253D&md5=73b190a44d359f55ee19af9099846505</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2Fj.drudis.2013.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.drudis.2013.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DDahl%26aufirst%3DG.%26aulast%3DAkerud%26aufirst%3DT.%26atitle%3DPharmacokinetics%2520and%2520the%2520drug-target%2520residence%2520time%2520concept%26jtitle%3DDrug%2520Discovery%2520Today%26date%3D2013%26volume%3D18%26spage%3D697%26epage%3D707%26doi%3D10.1016%2Fj.drudis.2013.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Tummino, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, R. A.</span><span> </span><span class="NLM_article-title">Residence time of receptor-ligand complexes and its effect on biological function</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">5481</span><span class="NLM_x">–</span> <span class="NLM_lpage">5492</span><span class="refDoi"> DOI: 10.1021/bi8002023</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi8002023" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1Ont7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2008&pages=5481-5492&author=P.+J.+Tumminoauthor=R.+A.+Copeland&title=Residence+time+of+receptor-ligand+complexes+and+its+effect+on+biological+function&doi=10.1021%2Fbi8002023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Residence Time of Receptor-Ligand Complexes and Its Effect on Biological Function</span></div><div class="casAuthors">Tummino, Peter J.; Copeland, Robert A.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5481-5492</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The formation and duration of binary receptor-ligand complexes are fundamental to many physiol. processes.  Most often, the effectiveness of interaction between a receptor and its ligand is quantified in terms of closed system, equil. affinity measurements, such as IC50 and Kd.  In the context of in vivo biol., however, the extent and duration of responses to receptor-ligand interactions depend greatly on the time period over which the ligand is in residence on its receptor.  Here we define receptor-ligand complex residence time in quant. terms and describe its significance to biol. function.  Examples of the importance of residence time are presented for natural ligands of different receptor types.  The impact of residence time on the optimization of potential ligands as drugs for human medicine is also described.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHshN2Bt_r9LVg90H21EOLACvtfcHk0lj7ZoUIe1HzDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1Ont7s%253D&md5=57f79f69f12c6ed14e3347638381d943</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fbi8002023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi8002023%26sid%3Dliteratum%253Aachs%26aulast%3DTummino%26aufirst%3DP.%2BJ.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26atitle%3DResidence%2520time%2520of%2520receptor-ligand%2520complexes%2520and%2520its%2520effect%2520on%2520biological%2520function%26jtitle%3DBiochemistry%26date%3D2008%26volume%3D47%26spage%3D5481%26epage%3D5492%26doi%3D10.1021%2Fbi8002023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Basavapathruni, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daigle, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majer, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Therkelsen, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wigle, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuntz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chesworth, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollock, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scott, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moyer, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richon, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Copeland, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olhava, E. J.</span><span> </span><span class="NLM_article-title">Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase dot1l</span> <span class="citation_source-journal">Chem. Biol. Drug Des.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">80</span><span class="NLM_x">, </span> <span class="NLM_fpage">971</span><span class="NLM_x">–</span> <span class="NLM_lpage">980</span><span class="refDoi"> DOI: 10.1111/cbdd.12050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1111%2Fcbdd.12050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=22978415" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC38XhslClsr7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=80&publication_year=2012&pages=971-980&author=A.+Basavapathruniauthor=L.+Jinauthor=S.+R.+Daigleauthor=C.+R.+Majerauthor=C.+A.+Therkelsenauthor=T.+J.+Wigleauthor=K.+W.+Kuntzauthor=R.+Chesworthauthor=R.+M.+Pollockauthor=M.+P.+Scottauthor=M.+P.+Moyerauthor=V.+M.+Richonauthor=R.+A.+Copelandauthor=E.+J.+Olhava&title=Conformational+adaptation+drives+potent%2C+selective+and+durable+inhibition+of+the+human+protein+methyltransferase+dot1l&doi=10.1111%2Fcbdd.12050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L</span></div><div class="casAuthors">Basavapathruni, Aravind; Jin, Lei; Daigle, Scott R.; Majer, Christina R. A.; Therkelsen, Carly A.; Wigle, Tim J.; Kuntz, Kevin W.; Chesworth, Richard; Pollock, Roy M.; Scott, Margaret P.; Moyer, Mikel P.; Richon, Victoria M.; Copeland, Robert A.; Olhava, Edward J.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Biology & Drug Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">80</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">971-980</span>CODEN:
                <span class="NLM_cas:coden">CBDDAL</span>;
        ISSN:<span class="NLM_cas:issn">1747-0277</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">DOT1L is the human protein methyltransferase responsible for catalyzing the methylation of histone H3 on lysine 79 (H3K79).  The ectopic activity of DOT1L, assocd. with the chromosomal translocation that is a universal hallmark of MLL-rearranged leukemia, is a required driver of leukemogenesis in this malignancy.  Here, we present studies on the structure-activity relation of aminonucleoside-based DOT1L inhibitors.  Within this series, we find that improvements in target enzyme affinity and selectivity are driven entirely by diminution of the dissocn. rate const. for the enzyme-inhibitor complex, leading to long residence times for the binary complex.  The biochem. Ki and residence times measured for these inhibitors correlate well with their effects on intracellular H3K79 methylation and MLL-rearranged leukemic cell killing.  Crystallog. studies reveal a conformational adaptation mechanism assocd. with high-affinity inhibitor binding and prolonged residence time; these studies also suggest that conformational adaptation likewise plays a crit. role in natural ligand interactions with the enzyme, hence, facilitating enzyme turnover.  These results provide crit. insights into the role of conformational adaptation in the enzymic mechanism of catalysis and in pharmacol. intervention for DOT1L and other members of this enzyme class.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJm_d3iX3p77Vg90H21EOLACvtfcHk0lj7ZoUIe1HzDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhslClsr7O&md5=de628fcd2c37b5f6496cc3b483125309</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1111%2Fcbdd.12050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fcbdd.12050%26sid%3Dliteratum%253Aachs%26aulast%3DBasavapathruni%26aufirst%3DA.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DDaigle%26aufirst%3DS.%2BR.%26aulast%3DMajer%26aufirst%3DC.%2BR.%26aulast%3DTherkelsen%26aufirst%3DC.%2BA.%26aulast%3DWigle%26aufirst%3DT.%2BJ.%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26aulast%3DChesworth%26aufirst%3DR.%26aulast%3DPollock%26aufirst%3DR.%2BM.%26aulast%3DScott%26aufirst%3DM.%2BP.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DRichon%26aufirst%3DV.%2BM.%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26aulast%3DOlhava%26aufirst%3DE.%2BJ.%26atitle%3DConformational%2520adaptation%2520drives%2520potent%252C%2520selective%2520and%2520durable%2520inhibition%2520of%2520the%2520human%2520protein%2520methyltransferase%2520dot1l%26jtitle%3DChem.%2520Biol.%2520Drug%2520Des.%26date%3D2012%26volume%3D80%26spage%3D971%26epage%3D980%26doi%3D10.1111%2Fcbdd.12050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Chang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiebel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bommineni, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Khanna, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sotriffer, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kisker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonge, P. J.</span><span> </span><span class="NLM_article-title">Rational optimization of drug-target residence time: Insights from inhibitor binding to the staphylococcus aureus fabi enzyme-product complex</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">4217</span><span class="NLM_x">–</span> <span class="NLM_lpage">4228</span><span class="refDoi"> DOI: 10.1021/bi400413c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi400413c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotVSlsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=4217-4228&author=A.+Changauthor=J.+Schiebelauthor=W.+Yuauthor=G.+R.+Bommineniauthor=P.+Panauthor=M.+V.+Baxterauthor=A.+Khannaauthor=C.+A.+Sotrifferauthor=C.+Kiskerauthor=P.+J.+Tonge&title=Rational+optimization+of+drug-target+residence+time%3A+Insights+from+inhibitor+binding+to+the+staphylococcus+aureus+fabi+enzyme-product+complex&doi=10.1021%2Fbi400413c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Rational Optimization of Drug-Target Residence Time: Insights from Inhibitor Binding to the Staphylococcus aureus FabI Enzyme-Product Complex</span></div><div class="casAuthors">Chang, Andrew; Schiebel, Johannes; Yu, Weixuan; Bommineni, Gopal R.; Pan, Pan; Baxter, Michael V.; Khanna, Avinash; Sotriffer, Christoph A.; Kisker, Caroline; Tonge, Peter J.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">4217-4228</span>CODEN:
                <span class="NLM_cas:coden">BICHAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-2960</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Drug-target kinetics has recently emerged as an esp. important facet of the drug discovery process.  In particular, prolonged drug-target residence times may confer enhanced efficacy and selectivity in the open in vivo system.  However, the lack of accurate kinetic and structural data for a series of congeneric compds. hinders the rational design of inhibitors with decreased off-rates.  Therefore, we chose the Staphylococcus aureus enoyl-ACP reductase (saFabI) - an important target for the development of new anti-staphylococcal drugs - as a model system to rationalize and optimize the drug-target residence time on a structural basis.  Using our new, efficient, and widely applicable mechanistically informed kinetic approach, we obtained a full characterization of saFabI inhibition by a series of 20 di-Ph ethers complemented by a collection of 9 saFabI-inhibitor crystal structures.  We identified a strong correlation between the affinities of the investigated saFabI di-Ph ether inhibitors and their corresponding residence times, which can be rationalized on a structural basis.  Because of its favorable interactions with the enzyme, the residence time of our most potent compd. exceeds 10 h.  In addn., we found that affinity and residence time in this system can be significantly enhanced by modifications predictable by a careful consideration of catalysis.  Our study provides a blueprint for investigating and prolonging drug-target kinetics and may aid in the rational design of long-residence-time inhibitors targeting the essential saFabI enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVCwUUpjx2QrVg90H21EOLACvtfcHk0lj7ZoUIe1HzDw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotVSlsLo%253D&md5=bc06231375d06e4e58772f4afc7f8829</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fbi400413c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi400413c%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DA.%26aulast%3DSchiebel%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DW.%26aulast%3DBommineni%26aufirst%3DG.%2BR.%26aulast%3DPan%26aufirst%3DP.%26aulast%3DBaxter%26aufirst%3DM.%2BV.%26aulast%3DKhanna%26aufirst%3DA.%26aulast%3DSotriffer%26aufirst%3DC.%2BA.%26aulast%3DKisker%26aufirst%3DC.%26aulast%3DTonge%26aufirst%3DP.%2BJ.%26atitle%3DRational%2520optimization%2520of%2520drug-target%2520residence%2520time%253A%2520Insights%2520from%2520inhibitor%2520binding%2520to%2520the%2520staphylococcus%2520aureus%2520fabi%2520enzyme-product%2520complex%26jtitle%3DBiochemistry%26date%3D2013%26volume%3D52%26spage%3D4217%26epage%3D4228%26doi%3D10.1021%2Fbi400413c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Meharena, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keshwani, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oruganty, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nene, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kannan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornev, A. P.</span><span> </span><span class="NLM_article-title">Deciphering the structural basis of eukaryotic protein kinase regulation</span> <span class="citation_source-journal">PLoS Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">e1001680</span><span class="refDoi"> DOI: 10.1371/journal.pbio.1001680</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1371%2Fjournal.pbio.1001680" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=24143133" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslags7bM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2013&pages=e1001680&author=H.+S.+Meharenaauthor=P.+Changauthor=M.+M.+Keshwaniauthor=K.+Orugantyauthor=A.+K.+Neneauthor=N.+Kannanauthor=S.+S.+Taylorauthor=A.+P.+Kornev&title=Deciphering+the+structural+basis+of+eukaryotic+protein+kinase+regulation&doi=10.1371%2Fjournal.pbio.1001680"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Deciphering the structural basis of Eukaryotic protein kinase regulation</span></div><div class="casAuthors">Meharena, Hiruy S.; Chang, Philip; Keshwani, Malik M.; Oruganty, Krishnadev; Nene, Aishwarya K.; Kannan, Natarajan; Taylor, Susan S.; Kornev, Alexandr P.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e1001680</span>CODEN:
                <span class="NLM_cas:coden">PBLIBG</span>;
        ISSN:<span class="NLM_cas:issn">1545-7885</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Eukaryotic protein kinases (EPKs) regulate numerous signaling processes by phosphorylating targeted substrates through the highly conserved catalytic domain.  Our previous computational studies proposed a model stating that a properly assembled nonlinear motif termed the Regulatory (R) spine is essential for catalytic activity of EPKs.  Here we define the required intramol. interactions and biochem. properties of the R-spine and the newly identified "Shell" that surrounds the R-spine using site-directed mutagenesis and various in vitro phosphoryl transfer assays using cAMP-dependent protein kinase (PKA) as a representative of the entire kinome.  Anal. of the 172 available Apo EPK structures in the protein data bank (PDB) revealed four unique structural conformations of the R-spine that correspond with catalytic inactivation of various EPKs.  Elucidating the mol. entities required for the catalytic activation of EPKs and the identification of these inactive conformations opens new avenues for the design of efficient therapeutic EPK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwdeD18CvhBLVg90H21EOLACvtfcHk0lge5tZwrCLk-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslags7bM&md5=fa8a4d5a9383bca04d15f017b4cc9194</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pbio.1001680&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pbio.1001680%26sid%3Dliteratum%253Aachs%26aulast%3DMeharena%26aufirst%3DH.%2BS.%26aulast%3DChang%26aufirst%3DP.%26aulast%3DKeshwani%26aufirst%3DM.%2BM.%26aulast%3DOruganty%26aufirst%3DK.%26aulast%3DNene%26aufirst%3DA.%2BK.%26aulast%3DKannan%26aufirst%3DN.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DKornev%26aufirst%3DA.%2BP.%26atitle%3DDeciphering%2520the%2520structural%2520basis%2520of%2520eukaryotic%2520protein%2520kinase%2520regulation%26jtitle%3DPLoS%2520Biol.%26date%3D2013%26volume%3D11%26spage%3De1001680%26doi%3D10.1371%2Fjournal.pbio.1001680" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Hu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahuja, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meharena, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kannan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornev, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. S.</span><span> </span><span class="NLM_article-title">Kinase regulation by hydrophobic spine assembly in cancer</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">264</span><span class="NLM_x">–</span> <span class="NLM_lpage">276</span><span class="refDoi"> DOI: 10.1128/MCB.00943-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1128%2FMCB.00943-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=25348715" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFerurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2015&pages=264-276&author=J.+Huauthor=L.+G.+Ahujaauthor=H.+S.+Meharenaauthor=N.+Kannanauthor=A.+P.+Kornevauthor=S.+S.+Taylorauthor=A.+S.+Shaw&title=Kinase+regulation+by+hydrophobic+spine+assembly+in+cancer&doi=10.1128%2FMCB.00943-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Kinase regulation by hydrophobic spine assembly in cancer</span></div><div class="casAuthors">Hu, Jiancheng; Ahuja, Lalima G.; Meharena, Hiruy S.; Kannan, Natarajan; Kornev, Alexandr P.; Taylor, Susan S.; Shaw, Andrey S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">264-276/1-264-276/13, 13 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">A new model of kinase regulation based on the assembly of hydrophobic spines has been proposed.  Changes in their positions can explain the mechanism of kinase activation.  Here, we examd. mutations in human cancer for clues about the regulation of the hydrophobic spines by focusing initially on mutations to Phe.  We identified a selected no. of Phe mutations in a small group of kinases that included BRAF, ABL1, and the epidermal growth factor receptor.  Testing some of these mutations in BRAF, we found that one of the mutations impaired ATP binding and catalytic activity but promoted noncatalytic allosteric functions.  Other Phe mutations functioned to promote constitutive catalytic activity.  One of these mutations revealed a previously underappreciated hydrophobic surface that functions to position the dynamic regulatory αC-helix.  This supports the key role of the C-helix as a signal integration motif for coordinating multiple elements of the kinase to create an active conformation.  The importance of the hydrophobic space around the αC-helix was further tested by studying a V600F mutant, which was constitutively active in the absence of the neg. charge that is assocd. with the common V600E mutation.  Many hydrophobic mutations strategically localized along the C-helix can thus drive kinase activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRC2fQzzavjrVg90H21EOLACvtfcHk0lge5tZwrCLk-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFerurY%253D&md5=94b744e5233f1afd640d67fb2355a569</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1128%2FMCB.00943-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00943-14%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DJ.%26aulast%3DAhuja%26aufirst%3DL.%2BG.%26aulast%3DMeharena%26aufirst%3DH.%2BS.%26aulast%3DKannan%26aufirst%3DN.%26aulast%3DKornev%26aufirst%3DA.%2BP.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DShaw%26aufirst%3DA.%2BS.%26atitle%3DKinase%2520regulation%2520by%2520hydrophobic%2520spine%2520assembly%2520in%2520cancer%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2015%26volume%3D35%26spage%3D264%26epage%3D276%26doi%3D10.1128%2FMCB.00943-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Yurtsever, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheaffer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Romero, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holtzman, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brett, T. J.</span><span> </span><span class="NLM_article-title">The crystal structure of phosphorylated mapk13 reveals common structural features and differences in p38 mapk family activation</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D: Biol. Crystallogr.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">790</span><span class="NLM_x">–</span> <span class="NLM_lpage">799</span><span class="refDoi"> DOI: 10.1107/S1399004715001212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1107%2FS1399004715001212" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2015&pages=790-799&author=Z.+Yurtseverauthor=S.+M.+Scheafferauthor=A.+G.+Romeroauthor=M.+J.+Holtzmanauthor=T.+J.+Brett&title=The+crystal+structure+of+phosphorylated+mapk13+reveals+common+structural+features+and+differences+in+p38+mapk+family+activation&doi=10.1107%2FS1399004715001212"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1107%2FS1399004715001212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS1399004715001212%26sid%3Dliteratum%253Aachs%26aulast%3DYurtsever%26aufirst%3DZ.%26aulast%3DScheaffer%26aufirst%3DS.%2BM.%26aulast%3DRomero%26aufirst%3DA.%2BG.%26aulast%3DHoltzman%26aufirst%3DM.%2BJ.%26aulast%3DBrett%26aufirst%3DT.%2BJ.%26atitle%3DThe%2520crystal%2520structure%2520of%2520phosphorylated%2520mapk13%2520reveals%2520common%2520structural%2520features%2520and%2520differences%2520in%2520p38%2520mapk%2520family%2520activation%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2015%26volume%3D71%26spage%3D790%26epage%3D799%26doi%3D10.1107%2FS1399004715001212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Kornev, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ten Eyck, L. F.</span><span> </span><span class="NLM_article-title">A helix scaffold for the assembly of active protein kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">14377</span><span class="NLM_x">–</span> <span class="NLM_lpage">14382</span><span class="refDoi"> DOI: 10.1073/pnas.0807988105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1073%2Fpnas.0807988105" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=14377-14382&author=A.+P.+Kornevauthor=S.+S.+Taylorauthor=L.+F.+Ten+Eyck&title=A+helix+scaffold+for+the+assembly+of+active+protein+kinases&doi=10.1073%2Fpnas.0807988105"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0807988105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0807988105%26sid%3Dliteratum%253Aachs%26aulast%3DKornev%26aufirst%3DA.%2BP.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DTen%2BEyck%26aufirst%3DL.%2BF.%26atitle%3DA%2520helix%2520scaffold%2520for%2520the%2520assembly%2520of%2520active%2520protein%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D14377%26epage%3D14382%26doi%3D10.1073%2Fpnas.0807988105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Francis, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rozycki, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koveal, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hummer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Page, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peti, W.</span><span> </span><span class="NLM_article-title">Structural basis of p38 alpha regulation by hematopoietic tyrosine phosphatase</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">916</span><span class="NLM_x">–</span> <span class="NLM_lpage">924</span><span class="refDoi"> DOI: 10.1038/nchembio.707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1038%2Fnchembio.707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=22057126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsVagtL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=916-924&author=D.+M.+Francisauthor=B.+Rozyckiauthor=D.+Kovealauthor=G.+Hummerauthor=R.+Pageauthor=W.+Peti&title=Structural+basis+of+p38+alpha+regulation+by+hematopoietic+tyrosine+phosphatase&doi=10.1038%2Fnchembio.707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of p38α regulation by hematopoietic tyrosine phosphatase</span></div><div class="casAuthors">Francis, Dana M.; Rozycki, Bartosz; Koveal, Dorothy; Hummer, Gerhard; Page, Rebecca; Peti, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">916-924</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">MAP kinases regulate essential cellular events, including cell growth, differentiation and inflammation.  The soln. structure of a complete MAPK-MAPK-regulatory protein complex, p38α-HePTP, was detd., enabling a comprehensive investigation of the mol. basis of specificity and fidelity in MAPK regulation.  Structure detn. was achieved by combining NMR spectroscopy and small-angle X-ray scattering data with a new ensemble calcn.-refinement procedure.  We identified 25 residues outside of the HePTP kinase interaction motif necessary for p38α recognition.  The complex adopts an extended conformation in soln. and rarely samples the conformation necessary for kinase deactivation.  Complex formation also does not affect the N-terminal lobe, the activation loop of p38α or the catalytic domain of HePTP.  Together, these results show how the downstream tyrosine phosphatase HePTP regulates p38α and provide for fundamentally new insights into MAPK regulation and specificity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh8OtxlNaLJrVg90H21EOLACvtfcHk0ljLzVyUEFjDWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsVagtL3L&md5=bde10f5d0142704475ba8fd390598c99</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.707%26sid%3Dliteratum%253Aachs%26aulast%3DFrancis%26aufirst%3DD.%2BM.%26aulast%3DRozycki%26aufirst%3DB.%26aulast%3DKoveal%26aufirst%3DD.%26aulast%3DHummer%26aufirst%3DG.%26aulast%3DPage%26aufirst%3DR.%26aulast%3DPeti%26aufirst%3DW.%26atitle%3DStructural%2520basis%2520of%2520p38%2520alpha%2520regulation%2520by%2520hematopoietic%2520tyrosine%2520phosphatase%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D916%26epage%3D924%26doi%3D10.1038%2Fnchembio.707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Bukhtiyarova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karpusas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Northrop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Namboodiri, H. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springman, E. B.</span><span> </span><span class="NLM_article-title">Mutagenesis of p38alpha map kinase establishes key roles of phe169 in function and structural dynamics and reveals a novel dfg-out state</span> <span class="citation_source-journal">Biochemistry</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">5687</span><span class="NLM_x">–</span> <span class="NLM_lpage">5696</span><span class="refDoi"> DOI: 10.1021/bi0622221</span> </span><div class="citationLinks">[<a href="/doi/10.1021/bi0622221" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=5687-5696&author=M.+Bukhtiyarovaauthor=M.+Karpusasauthor=K.+Northropauthor=H.+V.+Namboodiriauthor=E.+B.+Springman&title=Mutagenesis+of+p38alpha+map+kinase+establishes+key+roles+of+phe169+in+function+and+structural+dynamics+and+reveals+a+novel+dfg-out+state&doi=10.1021%2Fbi0622221"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Fbi0622221&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fbi0622221%26sid%3Dliteratum%253Aachs%26aulast%3DBukhtiyarova%26aufirst%3DM.%26aulast%3DKarpusas%26aufirst%3DM.%26aulast%3DNorthrop%26aufirst%3DK.%26aulast%3DNamboodiri%26aufirst%3DH.%2BV.%26aulast%3DSpringman%26aufirst%3DE.%2BB.%26atitle%3DMutagenesis%2520of%2520p38alpha%2520map%2520kinase%2520establishes%2520key%2520roles%2520of%2520phe169%2520in%2520function%2520and%2520structural%2520dynamics%2520and%2520reveals%2520a%2520novel%2520dfg-out%2520state%26jtitle%3DBiochemistry%26date%3D2007%26volume%3D46%26spage%3D5687%26epage%3D5696%26doi%3D10.1021%2Fbi0622221" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Wentsch, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walter, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhrmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer-Wrangowski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaman, G. J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willemsen-Seegers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buijsman, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henning, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dauch, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zender, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">Optimized target residence time: Type i1/2 inhibitors for p38alpha map kinase with improved binding kinetics through direct interaction with the r-spine</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">5363</span><span class="NLM_x">–</span> <span class="NLM_lpage">5367</span><span class="refDoi"> DOI: 10.1002/anie.201701185</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1002%2Fanie.201701185" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVCmu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=5363-5367&author=H.+K.+Wentschauthor=N.+M.+Walterauthor=M.+Buhrmannauthor=S.+Mayer-Wrangowskiauthor=D.+Rauhauthor=G.+J.+R.+Zamanauthor=N.+Willemsen-Seegersauthor=R.+C.+Buijsmanauthor=M.+Henningauthor=D.+Dauchauthor=L.+Zenderauthor=S.+Laufer&title=Optimized+target+residence+time%3A+Type+i1%2F2+inhibitors+for+p38alpha+map+kinase+with+improved+binding+kinetics+through+direct+interaction+with+the+r-spine&doi=10.1002%2Fanie.201701185"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Optimized Target Residence Time: Type I1/2 Inhibitors for p38α MAP Kinase with Improved Binding Kinetics through Direct Interaction with the R-Spine</span></div><div class="casAuthors">Wentsch, Heike K.; Walter, Niklas M.; Buehrmann, Mike; Mayer-Wrangowski, Svenja; Rauh, Daniel; Zaman, Guido J. R.; Willemsen-Seegers, Nicole; Buijsman, Rogier C.; Henning, Melanie; Dauch, Daniel; Zender, Lars; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">5363-5367</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Skepinone-L was recently reported to be a p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo.  However, this class of compds. still act as fully ATP-competitive Type I binders which, furthermore, suffer from short residence times at the enzyme.  We herein describe a further development with the first Type I1/2 binders for p38α MAP kinase.  Type I1/2 inhibitors interfere with the R-spine, inducing a glycine flip and occupying both hydrophobic regions I and II.  This design approach leads to prolonged target residence time, binding to both the active and inactive states of the kinase, excellent selectivity, excellent potency on the enzyme level, and low nanomolar activity in a human whole blood assay.  This promising binding mode is proven by X-ray crystallog.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO3M43Sl8vibVg90H21EOLACvtfcHk0ljLzVyUEFjDWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVCmu70%253D&md5=c4a1f981eaf8a2146f758fe4e71ac8b5</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fanie.201701185&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201701185%26sid%3Dliteratum%253Aachs%26aulast%3DWentsch%26aufirst%3DH.%2BK.%26aulast%3DWalter%26aufirst%3DN.%2BM.%26aulast%3DBuhrmann%26aufirst%3DM.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%2BR.%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3DBuijsman%26aufirst%3DR.%2BC.%26aulast%3DHenning%26aufirst%3DM.%26aulast%3DDauch%26aufirst%3DD.%26aulast%3DZender%26aufirst%3DL.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DOptimized%2520target%2520residence%2520time%253A%2520Type%2520i1%252F2%2520inhibitors%2520for%2520p38alpha%2520map%2520kinase%2520with%2520improved%2520binding%2520kinetics%2520through%2520direct%2520interaction%2520with%2520the%2520r-spine%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D5363%26epage%3D5367%26doi%3D10.1002%2Fanie.201701185" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Seo, Y.</span><span> </span><span class="NLM_article-title">Novel isoindolinone derivatives having inhibitory activity against t-type calcium channel and method for preparation</span>. U.S. Patent US 2010/0004286 A1,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=Y.+Seo&title=Novel+isoindolinone+derivatives+having+inhibitory+activity+against+t-type+calcium+channel+and+method+for+preparation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSeo%26aufirst%3DY.%26atitle%3DNovel%2520isoindolinone%2520derivatives%2520having%2520inhibitory%2520activity%2520against%2520t-type%2520calcium%2520channel%2520and%2520method%2520for%2520preparation%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Surry, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Dialkylbiaryl phosphines in pd-catalyzed amination: A user’s guide</span> <span class="citation_source-journal">Chem. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">27</span><span class="NLM_x">–</span> <span class="NLM_lpage">50</span><span class="refDoi"> DOI: 10.1039/C0SC00331J</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1039%2FC0SC00331J" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=22432049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFWqsbnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=27-50&author=D.+S.+Surryauthor=S.+L.+Buchwald&title=Dialkylbiaryl+phosphines+in+pd-catalyzed+amination%3A+A+user%E2%80%99s+guide&doi=10.1039%2FC0SC00331J"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Dialkylbiaryl phosphines in Pd-catalyzed amination: a user's guide</span></div><div class="casAuthors">Surry, David S.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Science</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-50</span>CODEN:
                <span class="NLM_cas:coden">CSHCCN</span>;
        ISSN:<span class="NLM_cas:issn">2041-6520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A review.  Dialkylbiaryl phosphines are a valuable class of ligand for Pd-catalyzed amination reactions and have been applied in a range of contexts.  This perspective attempts to aid the reader in the selection of the best choice of reaction conditions and ligand of this class for the most commonly encountered and practically important substrate combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrY0vbHHdx-_rVg90H21EOLACvtfcHk0lgexKlYp2EUjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFWqsbnM&md5=8743358f11af138189d106c51b5942b9</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1039%2FC0SC00331J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252FC0SC00331J%26sid%3Dliteratum%253Aachs%26aulast%3DSurry%26aufirst%3DD.%2BS.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DDialkylbiaryl%2520phosphines%2520in%2520pd-catalyzed%2520amination%253A%2520A%2520user%25E2%2580%2599s%2520guide%26jtitle%3DChem.%2520Sci.%26date%3D2011%26volume%3D2%26spage%3D27%26epage%3D50%26doi%3D10.1039%2FC0SC00331J" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Hill, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dabbagh, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Phippard, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suttmann, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Welch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papp, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Song, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, K. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leaffer, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, Y. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zabka, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aud, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dal Porto, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldstein, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B. R.</span><span> </span><span class="NLM_article-title">Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: Preclinical analysis of efficacy and selectivity</span> <span class="citation_source-journal">J. Pharmacol. Exp. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">327</span><span class="NLM_x">, </span> <span class="NLM_fpage">610</span><span class="NLM_x">–</span> <span class="NLM_lpage">619</span><span class="refDoi"> DOI: 10.1124/jpet.108.139006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1124%2Fjpet.108.139006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=18776065" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVCjtL3F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=327&publication_year=2008&pages=610-619&author=R.+J.+Hillauthor=K.+Dabbaghauthor=D.+Phippardauthor=C.+Liauthor=R.+T.+Suttmannauthor=M.+Welchauthor=E.+Pappauthor=K.+W.+Songauthor=K.+C.+Changauthor=D.+Leafferauthor=Y.+N.+Kimauthor=R.+T.+Robertsauthor=T.+S.+Zabkaauthor=D.+Audauthor=J.+Dal+Portoauthor=A.+M.+Manningauthor=S.+L.+Pengauthor=D.+M.+Goldsteinauthor=B.+R.+Wong&title=Pamapimod%2C+a+novel+p38+mitogen-activated+protein+kinase+inhibitor%3A+Preclinical+analysis+of+efficacy+and+selectivity&doi=10.1124%2Fjpet.108.139006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity</span></div><div class="casAuthors">Hill, Ronald J.; Dabbagh, Karim; Phippard, Deborah; Li, Ching; Suttmann, Rebecca T.; Welch, Mary; Papp, Eva; Song, Kyung W.; Chang, Kung-ching; Leaffer, David; Kim, Yong-Nam; Roberts, Richard T.; Zabka, Tanja S.; Aud, Dee; Dal Porto, Joseph; Manning, Anthony M.; Peng, Stanford L.; Goldstein, David M.; Wong, Brian R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">327</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">610-619</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">P38α is a protein kinase that regulates the expression of inflammatory cytokines, suggesting a role in the pathogenesis of diseases such as rheumatoid arthritis (RA) or systemic lupus erythematosus.  Here, we describe the preclin. pharmacol. of pamapimod, a novel p38 mitogen-activated protein kinase inhibitor.  Pamapimod inhibited p38α and p38β enzymic activity, with IC50 values of 0.014±0.002 and 0.48±0.04 μM, resp.  There was no activity against p38δ or p38γ isoforms.  When profiled across 350 kinases, pamapimod bound only to four kinases in addn. to p38.  Cellular potency was assessed using phosphorylation of heat shock protein-27 and c-Jun as selective readouts for p38 and c-Jun NH2-terminal kinase (JNK), resp.  Pamapimod inhibited p38 (IC50, 0.06 μM), but inhibition of JNK was not detected.  Pamapimod also inhibited lipopolysaccharide (LPS)-stimulated tumor necrosis factor (TNF) α prodn. by monocytes, interleukin (IL)-1β prodn. in human whole blood, and spontaneous TNFα prodn. by synovial explants from RA patients.  LPS- and TNFα-stimulated prodn. of TNFα and IL-6 in rodents also was inhibited by pamapimod.  In murine collagen-induced arthritis, pamapimod reduced clin. signs of inflammation and bone loss at 50 mg/kg or greater.  In a rat model of hyperalgesia, pamapimod increased tolerance to pressure in a dose-dependent manner, suggesting an important role of p38 in pain assocd. with inflammation.  Finally, an analog of pamapimod that has equiv. potency and selectivity inhibited renal disease in lupus-prone MRL/lpr mice.  Our study demonstrates that pamapimod is a potent, selective inhibitor of p38α with the ability to inhibit the signs and symptoms of RA and other autoimmune diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoImm011NnzW7Vg90H21EOLACvtfcHk0lgexKlYp2EUjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVCjtL3F&md5=9311aa6b1a51544ac755d1cc77cdd92f</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1124%2Fjpet.108.139006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.108.139006%26sid%3Dliteratum%253Aachs%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DDabbagh%26aufirst%3DK.%26aulast%3DPhippard%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DSuttmann%26aufirst%3DR.%2BT.%26aulast%3DWelch%26aufirst%3DM.%26aulast%3DPapp%26aufirst%3DE.%26aulast%3DSong%26aufirst%3DK.%2BW.%26aulast%3DChang%26aufirst%3DK.%2BC.%26aulast%3DLeaffer%26aufirst%3DD.%26aulast%3DKim%26aufirst%3DY.%2BN.%26aulast%3DRoberts%26aufirst%3DR.%2BT.%26aulast%3DZabka%26aufirst%3DT.%2BS.%26aulast%3DAud%26aufirst%3DD.%26aulast%3DDal%2BPorto%26aufirst%3DJ.%26aulast%3DManning%26aufirst%3DA.%2BM.%26aulast%3DPeng%26aufirst%3DS.%2BL.%26aulast%3DGoldstein%26aufirst%3DD.%2BM.%26aulast%3DWong%26aufirst%3DB.%2BR.%26atitle%3DPamapimod%252C%2520a%2520novel%2520p38%2520mitogen-activated%2520protein%2520kinase%2520inhibitor%253A%2520Preclinical%2520analysis%2520of%2520efficacy%2520and%2520selectivity%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2008%26volume%3D327%26spage%3D610%26epage%3D619%26doi%3D10.1124%2Fjpet.108.139006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Goettert, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graeser, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S. A.</span><span> </span><span class="NLM_article-title">Optimization of a nonradioactive immunosorbent assay for p38alpha mitogen-activated protein kinase activity</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">406</span><span class="NLM_x">, </span> <span class="NLM_fpage">233</span><span class="NLM_x">–</span> <span class="NLM_lpage">234</span><span class="refDoi"> DOI: 10.1016/j.ab.2010.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1016%2Fj.ab.2010.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=20638357" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFamu7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=406&publication_year=2010&pages=233-234&author=M.+Goettertauthor=R.+Graeserauthor=S.+A.+Laufer&title=Optimization+of+a+nonradioactive+immunosorbent+assay+for+p38alpha+mitogen-activated+protein+kinase+activity&doi=10.1016%2Fj.ab.2010.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of a nonradioactive immunosorbent assay for p38α mitogen-activated protein kinase activity</span></div><div class="casAuthors">Goettert, Marcia; Graeser, Ralph; Laufer, Stefan A.</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">406</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">233-234</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Here, the authors describe the optimization of a nonradioactive immunosorbent p38α-MAP kinase (MAPK) activity assay to det. the inhibitory potency of small mol. inhibitors.  The assay omitted the secondary antibody and, therefore, was shorter, more accurate, and easier to handle (total assay time of 3 h).  This direct assay used a new monoclonal anti-phospho-ATF-2 (Thr69/71) peroxidase-conjugated antibody, increasing the specificity and eliminating problems with cross-reactivities of secondary antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXu4ELn6_1brVg90H21EOLACvtfcHk0lgexKlYp2EUjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFamu7zP&md5=23b6434a50195acd27895d7d2205556c</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.ab.2010.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ab.2010.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DGoettert%26aufirst%3DM.%26aulast%3DGraeser%26aufirst%3DR.%26aulast%3DLaufer%26aufirst%3DS.%2BA.%26atitle%3DOptimization%2520of%2520a%2520nonradioactive%2520immunosorbent%2520assay%2520for%2520p38alpha%2520mitogen-activated%2520protein%2520kinase%2520activity%26jtitle%3DAnal.%2520Biochem.%26date%3D2010%26volume%3D406%26spage%3D233%26epage%3D234%26doi%3D10.1016%2Fj.ab.2010.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Bauer, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kubiak, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothbauer, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laufer, S.</span><span> </span><span class="NLM_article-title">From enzyme to whole blood: Sequential screening procedure for identification and evaluation of p38 mapk inhibitors</span> <span class="citation_source-journal">Methods Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">1360</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">148</span><span class="refDoi"> DOI: 10.1007/978-1-4939-3073-9_10</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1007%2F978-1-4939-3073-9_10" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=26501907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC2sXntVenu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1360&publication_year=2016&pages=123-148&author=S.+M.+Bauerauthor=J.+M.+Kubiakauthor=U.+Rothbauerauthor=S.+Laufer&title=From+enzyme+to+whole+blood%3A+Sequential+screening+procedure+for+identification+and+evaluation+of+p38+mapk+inhibitors&doi=10.1007%2F978-1-4939-3073-9_10"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">From Enzyme to Whole Blood: Sequential Screening Procedure for Identification and Evaluation of p38 MAPK Inhibitors</span></div><div class="casAuthors">Bauer, Silke M.; Kubiak, Jakub M.; Rothbauer, Ulrich; Laufer, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Molecular Biology (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">1360</span>
        (<span class="NLM_cas:issue">Kinase Screening and Profiling</span>),
    <span class="NLM_cas:pages">123-148</span>CODEN:
                <span class="NLM_cas:coden">MMBIED</span>;
        ISSN:<span class="NLM_cas:issn">1940-6029</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">P38 mitogen-activated protein kinase (MAPK) is a pivotal enzyme in the biosynthesis of pro-inflammatory cytokines like IL-1 and TNF.  Therefore, the success of anti-cytokine therapy for treatment of inflammatory processes qualified p38-MAPK as a solid target in drug research concerning chronic inflammatory diseases including infectious vascular, neurobiol., and autoimmune disorders.  However, the discovery of new kinase inhibitors is limited by the need for a high biol. activity combined with restricted activity to the target enzyme or pathway interaction.  As a consequence, no p38 MAPK inhibitor has been introduced to the market so far, although several p38 inhibitors have proceeded into clin. trials.  The development of novel inhibitor types and optimization of already known structural classes of MAPK inhibitors require appropriate testing systems reaching across these crucial parameters.  As a new approach, we describe the sequential arrangement of three testing systems custom-tailored to the requirements of drug discovery programs with focus on p38 inhibition.  Integrated anal. of the obtained results enables a concerted step-by-step selection of tested mols. in order to screen a compd. library for the most suitable inhibitor.  First, evaluation of the inhibitor's activity on the isolated p38 MAPK enzyme via an ELISA assay gives a first idea about the inhibitory potency of the mol.  Moreover, structure-activity relationships can be elucidated when comparing mols. within inhibitor series.  Second, screening in living cells via a p38 substrate-specific MK2-EGFP translocation assay supplies further information about efficacy, but provides also a first notion concerning selectivity and toxicity.  Third, efficacy is evaluated more specifically in vivo in LPS-stimulated human whole blood with regard to in vivo parameters, e.g., pharmacokinetic characteristics like plasma protein binding and cellular permeability.  These three testing systems complement one another synergistically by providing a high overlap and predictability.  Clear advantages of all presented systems are their realizability in an academic environment as well as their applicability for high-throughput screenings on a larger scale.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpzgA7iA4wN77Vg90H21EOLACvtfcHk0lg0AwjT1yGNdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXntVenu7Y%253D&md5=3b170d3e07e05e52d383d2acf1525b02</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1007%2F978-1-4939-3073-9_10&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252F978-1-4939-3073-9_10%26sid%3Dliteratum%253Aachs%26aulast%3DBauer%26aufirst%3DS.%2BM.%26aulast%3DKubiak%26aufirst%3DJ.%2BM.%26aulast%3DRothbauer%26aufirst%3DU.%26aulast%3DLaufer%26aufirst%3DS.%26atitle%3DFrom%2520enzyme%2520to%2520whole%2520blood%253A%2520Sequential%2520screening%2520procedure%2520for%2520identification%2520and%2520evaluation%2520of%2520p38%2520mapk%2520inhibitors%26jtitle%3DMethods%2520Mol.%2520Biol.%26date%3D2016%26volume%3D1360%26spage%3D123%26epage%3D148%26doi%3D10.1007%2F978-1-4939-3073-9_10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Liu, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrobleski, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hynes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyckman, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wityak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gillooly, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIntyre, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salter-Cid, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuster, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doweyko, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiefer, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kish, K. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newitt, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McKinnon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schieven, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leftheris, K.</span><span> </span><span class="NLM_article-title">Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-n-propylpyrrolo[1,2-f][ 1,2,4]triazine-6-carboxamide (bms-582949), a clinical p38alpha map kinase inhibitor for the treatment of inflammatory diseases</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">6629</span><span class="NLM_x">–</span> <span class="NLM_lpage">6639</span><span class="refDoi"> DOI: 10.1021/jm100540x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100540x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=6629-6639&author=C.+Liuauthor=J.+Linauthor=S.+T.+Wrobleskiauthor=S.+Linauthor=J.+Hynesauthor=H.+Wuauthor=A.+J.+Dyckmanauthor=T.+Liauthor=J.+Wityakauthor=K.+M.+Gilloolyauthor=S.+Pittauthor=D.+R.+Shenauthor=R.+F.+Zhangauthor=K.+W.+McIntyreauthor=L.+Salter-Cidauthor=D.+J.+Shusterauthor=H.+Zhangauthor=P.+H.+Maratheauthor=A.+M.+Doweykoauthor=J.+S.+Sackauthor=S.+E.+Kieferauthor=K.+F.+Kishauthor=J.+A.+Newittauthor=M.+McKinnonauthor=J.+H.+Doddauthor=J.+C.+Barrishauthor=G.+L.+Schievenauthor=K.+Leftheris&title=Discovery+of+4-%285-%28cyclopropylcarbamoyl%29-2-methylphenylamino%29-5-methyl-n-propylpyrrolo%5B1%2C2-f%5D%5B+1%2C2%2C4%5Dtriazine-6-carboxamide+%28bms-582949%29%2C+a+clinical+p38alpha+map+kinase+inhibitor+for+the+treatment+of+inflammatory+diseases&doi=10.1021%2Fjm100540x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1021%2Fjm100540x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100540x%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DJ.%26aulast%3DWrobleski%26aufirst%3DS.%2BT.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DHynes%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DDyckman%26aufirst%3DA.%2BJ.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DWityak%26aufirst%3DJ.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DPitt%26aufirst%3DS.%26aulast%3DShen%26aufirst%3DD.%2BR.%26aulast%3DZhang%26aufirst%3DR.%2BF.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DShuster%26aufirst%3DD.%2BJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DMarathe%26aufirst%3DP.%2BH.%26aulast%3DDoweyko%26aufirst%3DA.%2BM.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DKiefer%26aufirst%3DS.%2BE.%26aulast%3DKish%26aufirst%3DK.%2BF.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26aulast%3DMcKinnon%26aufirst%3DM.%26aulast%3DDodd%26aufirst%3DJ.%2BH.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DSchieven%26aufirst%3DG.%2BL.%26aulast%3DLeftheris%26aufirst%3DK.%26atitle%3DDiscovery%2520of%25204-%25285-%2528cyclopropylcarbamoyl%2529-2-methylphenylamino%2529-5-methyl-n-propylpyrrolo%255B1%252C2-f%255D%255B%25201%252C2%252C4%255Dtriazine-6-carboxamide%2520%2528bms-582949%2529%252C%2520a%2520clinical%2520p38alpha%2520map%2520kinase%2520inhibitor%2520for%2520the%2520treatment%2520of%2520inflammatory%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D6629%26epage%3D6639%26doi%3D10.1021%2Fjm100540x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Chin, N. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neu, H. C.</span><span> </span><span class="NLM_article-title">Ciprofloxacin, a quinolone carboxylic acid compound active against aerobic and anaerobic bacteria</span> <span class="citation_source-journal">Antimicrob. Agents Chemother.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">25</span><span class="NLM_x">, </span> <span class="NLM_fpage">319</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span><span class="refDoi"> DOI: 10.1128/AAC.25.3.319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1128%2FAAC.25.3.319" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1984&pages=319-326&author=N.+X.+Chinauthor=H.+C.+Neu&title=Ciprofloxacin%2C+a+quinolone+carboxylic+acid+compound+active+against+aerobic+and+anaerobic+bacteria&doi=10.1128%2FAAC.25.3.319"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1128%2FAAC.25.3.319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.25.3.319%26sid%3Dliteratum%253Aachs%26aulast%3DChin%26aufirst%3DN.%2BX.%26aulast%3DNeu%26aufirst%3DH.%2BC.%26atitle%3DCiprofloxacin%252C%2520a%2520quinolone%2520carboxylic%2520acid%2520compound%2520active%2520against%2520aerobic%2520and%2520anaerobic%2520bacteria%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1984%26volume%3D25%26spage%3D319%26epage%3D326%26doi%3D10.1128%2FAAC.25.3.319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Willemsen-Seegers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uitdehaag, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prinsen, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Vetter, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Man, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawase, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buijsman, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaman, G. J.</span><span> </span><span class="NLM_article-title">Compound selectivity and target residence time of kinase inhibitors studied with surface plasmon resonance</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2017</span><span class="NLM_x">, </span> <span class="NLM_volume">429</span><span class="NLM_x">, </span> <span class="NLM_fpage">574</span><span class="NLM_x">–</span> <span class="NLM_lpage">586</span><span class="refDoi"> DOI: 10.1016/j.jmb.2016.12.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1016%2Fj.jmb.2016.12.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=28043854" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlt12ltw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=429&publication_year=2017&pages=574-586&author=N.+Willemsen-Seegersauthor=J.+C.+Uitdehaagauthor=M.+B.+Prinsenauthor=J.+R.+de+Vetterauthor=J.+de+Manauthor=M.+Sawaauthor=Y.+Kawaseauthor=R.+C.+Buijsmanauthor=G.+J.+Zaman&title=Compound+selectivity+and+target+residence+time+of+kinase+inhibitors+studied+with+surface+plasmon+resonance&doi=10.1016%2Fj.jmb.2016.12.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Compound Selectivity and Target Residence Time of Kinase Inhibitors Studied with Surface Plasmon Resonance</span></div><div class="casAuthors">Willemsen-Seegers, Nicole; Uitdehaag, Joost C. M.; Prinsen, Martine B. W.; de Vetter, Judith R. F.; de Man, Jos; Sawa, Masaaki; Kawase, Yusuke; Buijsman, Rogier C.; Zaman, Guido J. R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">429</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">574-586</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Target residence time (τ) has been suggested to be a better predictor of the biol. activity of kinase inhibitors than inhibitory potency (IC50) in enzyme assays.  Surface plasmon resonance binding assays for 46 human protein and lipid kinases were developed.  The assocn. and dissocn. consts. of 80 kinase inhibitor interactions were detd. τ and equil. affinity consts. (KD) were calcd. to det. kinetic selectivity.  Comparison of τ and KD or IC50 values revealed a strikingly different view on the selectivity of several kinase inhibitors, including the multi-kinase inhibitor ponatinib, which was tested on 10 different kinases.  In addn., known pan-Aurora inhibitors resided much longer on Aurora B than on Aurora A, despite having comparable affinity for Aurora A and B.  Furthermore, the γ/δ-selective PI3K inhibitor duvelisib and the δ-selective drug idelalisib had similar 20-fold selectivity for δ- over γ-isoform but duvelisib resided much longer on both targets.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8CehT0ysswLVg90H21EOLACvtfcHk0lg0AwjT1yGNdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlt12ltw%253D%253D&md5=3970beac9a1fcdcfe013f6750b6537b5</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.jmb.2016.12.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jmb.2016.12.019%26sid%3Dliteratum%253Aachs%26aulast%3DWillemsen-Seegers%26aufirst%3DN.%26aulast%3DUitdehaag%26aufirst%3DJ.%2BC.%26aulast%3DPrinsen%26aufirst%3DM.%2BB.%26aulast%3Dde%2BVetter%26aufirst%3DJ.%2BR.%26aulast%3Dde%2BMan%26aufirst%3DJ.%26aulast%3DSawa%26aufirst%3DM.%26aulast%3DKawase%26aufirst%3DY.%26aulast%3DBuijsman%26aufirst%3DR.%2BC.%26aulast%3DZaman%26aufirst%3DG.%2BJ.%26atitle%3DCompound%2520selectivity%2520and%2520target%2520residence%2520time%2520of%2520kinase%2520inhibitors%2520studied%2520with%2520surface%2520plasmon%2520resonance%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2017%26volume%3D429%26spage%3D574%26epage%3D586%26doi%3D10.1016%2Fj.jmb.2016.12.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Xing, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devadas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Devraj, R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selness, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shieh, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mao, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messing, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Samas, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, G. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Webb, E. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Monahan, J. B.</span><span> </span><span class="NLM_article-title">Discovery and characterization of atropisomer ph-797804, a p38 map kinase inhibitor, as a clinical drug candidate</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span><span class="refDoi"> DOI: 10.1002/cmdc.201100439</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;key=10.1002%2Fcmdc.201100439" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=273-280&author=L.+Xingauthor=B.+Devadasauthor=R.+V.+Devrajauthor=S.+R.+Selnessauthor=H.+Shiehauthor=J.+K.+Walkerauthor=M.+Maoauthor=D.+Messingauthor=B.+Samasauthor=J.+Z.+Yangauthor=G.+D.+Andersonauthor=E.+G.+Webbauthor=J.+B.+Monahan&title=Discovery+and+characterization+of+atropisomer+ph-797804%2C+a+p38+map+kinase+inhibitor%2C+as+a+clinical+drug+candidate&doi=10.1002%2Fcmdc.201100439"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201100439&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201100439%26sid%3Dliteratum%253Aachs%26aulast%3DXing%26aufirst%3DL.%26aulast%3DDevadas%26aufirst%3DB.%26aulast%3DDevraj%26aufirst%3DR.%2BV.%26aulast%3DSelness%26aufirst%3DS.%2BR.%26aulast%3DShieh%26aufirst%3DH.%26aulast%3DWalker%26aufirst%3DJ.%2BK.%26aulast%3DMao%26aufirst%3DM.%26aulast%3DMessing%26aufirst%3DD.%26aulast%3DSamas%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DJ.%2BZ.%26aulast%3DAnderson%26aufirst%3DG.%2BD.%26aulast%3DWebb%26aufirst%3DE.%2BG.%26aulast%3DMonahan%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520atropisomer%2520ph-797804%252C%2520a%2520p38%2520map%2520kinase%2520inhibitor%252C%2520as%2520a%2520clinical%2520drug%2520candidate%26jtitle%3DChemMedChem%26date%3D2012%26volume%3D7%26spage%3D273%26epage%3D280%26doi%3D10.1002%2Fcmdc.201100439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QUE" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3QUE','PDB','3QUE'); return false;">PDB: 3QUE</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1KV2','PDB','1KV2'); return false;">PDB: 1KV2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HV7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3HV7','PDB','3HV7'); return false;">PDB: 3HV7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UVQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UVQ','PDB','3UVQ'); return false;">PDB: 3UVQ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MTY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MTY','PDB','5MTY'); return false;">PDB: 5MTY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MTX" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MTX','PDB','5MTX'); return false;">PDB: 5MTX</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i131"><a href="/doi/suppl/10.1021/acs.jmedchem.7b00745">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_74184"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.7b00745">10.1021/acs.jmedchem.7b00745</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">SMILES and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00745/suppl_file/jm7b00745_si_001.csv">CSV</a>)</p></li><li><p class="inline">Experimental and analytical data, including HPLC purity, (HR)MS, and NMR data of compounds <b>2</b>–<b>60</b>; additional characterization of binding kinetics; all general methods; experimental section for materials and intermediates; X-ray crystallography; metabolic stability determination in vitro (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.7b00745/suppl_file/jm7b00745_si_002.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00745/suppl_file/jm7b00745_si_001.csv">jm7b00745_si_001.csv (6.93 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.7b00745/suppl_file/jm7b00745_si_002.pdf">jm7b00745_si_002.pdf (626.26 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Cocrystal structures of the human p38α MAP kinase in complex with <b>6j</b> and <b>8m</b>, respectively, are deposited under the accession codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MTY">5MTY</a> and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5MTX">5MTX</a> in the Protein Data Bank. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.7b00745&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-19%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.7b00745" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.7b00745" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799d9325ee83d18","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
